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Over the last twenty years, many prescribing tools have been developed and 
validated to identify inappropriate prescribing (IP) in older adults and assist 
physicians in medication optimisation. However, these prescribing tools have 
predominantly focused on identifying IP in the general older adult population, rather 
than targeting the population cohort that is growing at the fastest rate and that is at 
the highest risk of IP and adverse drug reactions (ADRs) i.e. older frailer multimorbid 
patients with a poor survival prognosis.  
Extensive research on the prevalence of ADRs has been published. However 
many different definitions of ADRs and many different ADR causality tools have been 
employed across different studies, making it difficult to compare the results of 
studies. To confound this area of investigation further, many ADR causality tools are 
not appropriate to use in older frail multimorbid adults. In addition, a limited amount 
of research has occurred identifying the morbidity associated with ADRs in older 
adults. To date, there is no standardized approach to identifying, assessing and 
reporting ADRs in older adults. 
This doctoral thesis was designed to (i) standardise the identification, 
assessment and reporting of ADRs in older adults, (ii) assess ADRs using this new 
methodology in high risk populations, and (iii) develop and validate a new usable set 
of criteria called STOPPFrail (Screening Tool of Older Persons Prescriptions in Frail 
adults with limited life expectancy) to assist deprescribing in older frail multimorbid 
adults with a poor survival prognosis i.e. patients where the role of preventative 
therapy is questionable.  
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This thesis comprises eleven chapters. The first chapter is an introduction, 
divided into four sections i.e. (i) demographic changes and the proportional increase 
in high risk older adults, (ii) prescribing considerations for older adults, (iii) 
consequences of IP including ADRs and (iv) potential targets for intervention. The 
second chapter proposes a methodologically robust way of identifying, assigning 
causality and reporting ADRs and tests this theory on physicians, pharmacists, 
biomedical scientists and nurses. The third chapter uses this new ADR methodology 
to identify the prevalence of ADRs in older adults presenting to hospital. The fourth 
chapter compares older and younger adults with cancer in terms of multimorbidity, 
medication use and ADRs using the same methodology proposed in Chapter 2. The 
fifth chapter develops and validates STOPPFrail criteria, an explicit prescribing tool 
to assist deprescribing in frail older adults with a poor one year survival prognosis. 
The sixth chapter describes the inter-rater reliability (IRR) of STOPPFrail criteria 
between physicians. The seventh chapter, applies STOPPFrail criteria to two 
representative populations i.e. a proportion of older adults deemed suitable for 
nursing home care and a proportion of older adults presenting for hospitalisation. 
Chapter eight considers the relevance of the research data developed in this thesis 
as well as questions any issues arising from these research studies. Chapter nine 
contains peer-reviewed articles that were published and awards received during the 
writing of this thesis. Finally, chapters ten and eleven list the references and 
appendices, respectively. 
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CHAPTER 1: 
Introduction 
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1.1  AGEING DEMOGRAPHICS & MULTIMORBIDITY 
1.1.1 Predicted demographic changes nationally and internationally 
The United Nations (UN) defines an older person as ≥ 60 years and the oldest old as 
≥ 80 years of age (1). In well-resourced developed countries transition to older age is 
generally accepted as occurring at the age of retirement. Therefore, older age is often 
defined as ≥ 65 years. More people are now reaching older age than ever before due 
to improvements in nutrition, drinking water and sanitation, as well as improvements 
in the treatment of infectious diseases and overall improvements in healthcare. In 
addition to increasing life expectancy, fertility rates have dropped which has led to a 
shift in the population demographics of developed countries where there are now 
more adults ≥ 65 years than there are children under 10 years.  
The National Clinical Program for Older People (NCPOP), a joint initiative by 
the Health Service Executive (HSE) and the Royal College of Physicians Ireland (RCPI), 
highlights that, in Ireland, those ≥ 65 years of age are predicted to increase from 
11.4% in 2012 to 18% in 2042 (2). In addition, those ≥ 85 years are expected to 
increase by 150% by 2031 (2). At a European level, Eurostat foresees that those ≥ 65 
years will continue to increase in the coming years and that those ≥ 80 years will likely 
double (3). The World Health Organisation (WHO) predicts that the global population 
of those aged ≥ 60 years will increase from 11.3% in 2013 to 21.2% in 2050, with 
those ≥ 80 years expected to quadruple (4). Overall, the absolute increase in those ≥ 
65 years is expected to increase by 976 million internationally, between 2010 and 
2050, with the largest increase in older adults expected in developing countries.  
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1.1.2 Multimorbidity in high risk older adults 
With ageing comes an increase in the number and severity of medical conditions (5), 
functional impairment, cognitive impairment (6) and frailty (7). Thus, the evolving 
demographic changes in the population pyramid will have a very large impact on 
healthcare delivery.  Comorbidity was the original term used to define the occurrence 
of medical conditions in addition to an index disease (8). Subsequently, in 1976, the 
term multimorbidity was introduced by Brandlmeier to capture the co-existence of 
two or more diseases, rather than the focus being on one primary condition (9). 
However, the most widely used and accepted definition is that of the WHO i.e. the 
co-occurrence of two or more chronic medical conditions in one person (10).  
As a result of different definitions of multimorbidity being employed across 
different studies, the prevalence of multimorbidity can be difficult to truly ascertain. 
To date, observational studies and systematic reviews have focused on the 
prevalence of multimorbidity in community dwelling older adults, with no study to 
date focusing primarily on hospitalised older adults. In primary care, two systematic 
reviews by Violan et al. and Fortin et al. have reported multimorbidity prevalence 
rates of 12.9 – 95.1% (11) and 13.1 – 71.8% (12), respectively.  A United States (US) 
population-focused systematic review, based on Medicare data, reports a 
multimorbidity prevalence rate of 67% with this rate increasing with advancing age 
i.e. 50% for persons under age 65 years, 62% for those aged 65–74 years and 81.5% 
for those aged ≥ 85 years (13). At age 85 compared to age 70, the prevalence of 
chronic multimorbidity has been reported to increase 3-fold (14).  Older age, female 
gender and lower socio-economic status are factors known to be independently 
associated with multimorbidity (5) 
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Multimorbidity has been linked to increased mortality, with one study 
reporting a 73% increase in death for adults with 2 conditions or more compared to 
those without multimorbidity (Odds ratio 1.73 [95%CI: 1.41 - 2.13]) and a 172% 
increase in the mortality rate for those with 3 conditions or more compared to those 
without (Odds ratio 2.72 [95%CI: 1.81 - 4.08] (15). Multimorbidity, will certainly 
increase in prevalence in tandem with the ageing of populations globally.   
 
1.1.3 Specific population changes 
Populations at highest risk of multimorbidity are increasing at a very rapid rate i.e. 
persons aged ≥ 80 years will account for 19% of the total international population in 
2050 and 28% in 2100. This means that there will be seven times as many persons ≥ 
80 years at the end of the century compared to 2013 (1). For adults aged ≥ 85 years, 
approximately 1 in every 5 persons has chronic cognitive impairment, 2 in every 5 
persons have urinary incontinence and 1 in every 2 persons are dependant in basic 
and instrumental activities of daily living (14). In such multimorbid patients, the final 
months of life are commonly characterised by frailty and increased dependency with 
many patients requiring nursing home care (16, 17). In Ireland, 4.5% of adults’ ≥ 65 
years reside in nursing homes, increasing to 49% for females’ ≥ 95 years and 26% for 
males’ ≥ 95 years (18). In the US, approximately 5% of adults aged ≥ 67 years reside 
in residential care facilities (19). Therefore, with the predicted demographic shifts, 
the number of frailer multimorbid older adults will very likely increase, as will the 
demand for nursing home care.  
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 Another population that will increase substantially over the coming decades 
is older adults with a diagnosis of cancer. Between 2010 and 2030, the incidence of 
cancer in older adults is expected to increase from 61% to 70% (20), coinciding with 
the ageing population (1, 3, 21). Thus, the demand for cancer treatment services in 
older patients is likely to increase concomitantly. However, as outlined above, 
multimorbidity increases with age so cancer may be only one of several complex 
diagnoses in an older individual. A diagnosis of cancer, coupled with co-existing 
polypharmacy, cognitive impairment and functional impairment can present the 
treating clinician with challenging pharmacotherapeutic and ethical dilemmas. High 
risk populations such as multimorbid frailer older adults and multimorbid older 
adults with cancer will increase in numbers which will inevitably lead to an increase 
in medication use, presenting many unique challenges for the prescriber. 
 
1.2  PRESCRIBING FOR OLDER ADULTS; CONSIDERATION AND CHALLENGES 
1.2.1 Prescribing for older adults: general considerations 
Prescribing for the heterogeneous older adult population is challenging, in particular 
prescribing for frail older adults with multiple medical conditions. Prescribers need 
to be cognizant of age-related anatomical, biochemical and physiological changes 
that affect pharmacokinetics and pharmacodynamics. They also must be aware of 
the potential for important drug-drug interactions as well as drug-disease 
interactions with concurrently prescribed drugs and co-existing disease states. 
Prescribers should have an appreciation of the potentially low therapeutic yield in 
very frail older patients with poor life expectancy where the risk of certain treatments 
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can exceed the potential clinical benefit. These important tenets of appropriate 
prescribing for older patients are briefly summarised below. 
 
1.2.2 Pharmacokinetics and pharmacodynamics 
The key pharmacokinetic changes commonly associated with ageing are summarized 
in Table 1.1.  
Table 1.1: Pharmacokinetics and ageing: important changes associated with old age 
compared to young adulthood (22) 
Absorption Distribution Metabolic Excretion 
↓ amount of saliva 
↓ gastric acid 
secretion 
↓ gastric surface area 
↓ gastrointestinal 
motility 
↓ active transport 
mechanisms 
↑ gastric pH 
↑ gastric emptying 
↓ cardiac output 
↑ Peripheral vascular 
resistance 
↓ renal blood flow 
↓ hepatic blood flow 
↓ body water 
↑ body fat tissue 
↓ serum albumin 
levels 
↑ for lipid soluble 
and decrease for 
water soluble drugs 
↓ microsomal hepatic 
oxidation 
↓ clearance 
↑ steady state levels 
↑ half lives 
↑ levels of active 
metabolites 
↓ first pass 
metabolism due to 
reduced ↓ blood flow 
↓ renal perfusion 
↓ renal size 
↓ glomerular 
filtration rate 
↓ tubular secretion 
↓ tubular 
reabsorption 
Legend: ↑ = increased, ↓ = decreased 
Older people also experience significantly different pharmacodynamic responses to 
similar drug concentrations than their younger counterparts. Differences can be 
caused by a shift in receptor affinity, density, post receptor events at the cellular 
level, or in adaptive homeostatic response mechanisms. Pathologic organ changes 
may also affect pharmacodynamic responses, particularly in frail older patients. 
Prescribers should be aware of commonly encountered age-related 
pharmacodynamic differences as listed in Table 1.2. Generally, it is recommended to 
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initiate medications at the smallest possible dose and titrate slowly according to 
response. 
Table 1.2: Age associated changes in pharmacodynamic responses to commonly 
prescribed drugs (22) 
Drug type Specific drug Pharmacodynamic 
response in an 
older person 
Potential clinical consequence 
Analgesia Morphine ↑ Excessive sedation, confusion, 
constipation, respiratory 
depression 
Anticoagulants Warfarin     
Dabigatran             
(≥75 years, <50kg) 
↑                            
↑ 
Bleeding                                
Bleeding 
ACE inhibitor Enalapril ↑ Hypotension 
CCB Diltiazem ↑ Hypotension 
Diuretic Furosemide,   
Bumetanide 
↓                            
↓ 
Reduced diuretic effect at a 
standard dose 
Psychoactive 
drugs 
Diazepam, 
Temazepam, 
Triazolam,   
Midazolam 
↑ Excessive sedation, confusion, 
postural sway, falls 
Psychoactive 
drugs 
Haloperidol ↑ Excessive sedation, confusion, 
postural sway, falls 
Legend: ACE = angiotensin converting enzyme, CCB = calcium channel blocker, ↑ = increased 
pharmacodynamics response, ↓ = decreased pharmacodynamics response, Kg = Kilogram 
 
1.2.3 Medication use and polypharmacy 
Over recent decades, the incidence and prevalence of polypharmacy has been 
increasing steadily due to a rapidly increasing ageing population experiencing 
multimorbid illness and advances in the treatment of chronic diseases. Various 
definitions of polypharmacy have been employed in research studies (23). 
Historically, polypharmacy has been defined in two ways. The first definition is 
‘concomitant use of multiple drugs, which is measured by a simple count of 
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medications’, with many using 3-5 medications as a cut-off point (24). The second 
definition is the daily intake of 6 or more drugs (25). High level polypharmacy has 
been proposed to encompass the daily consumption of ≥ 11 prescription drugs. It is 
a characteristic feature of multimorbid older people and is likely to increase markedly 
in prevalence as a by-product of global ageing in the 21st century. Another definition 
of polypharmacy is ‘the administration of one medication or more that is not clinically 
indicated’ (24).  
Recently, a clear distinction has emerged to differentiate between 
appropriate and inappropriate or problematic polypharmacy (26). Appropriate 
polypharmacy has been defined as ‘prescribing for an individual with complex or 
multiple conditions in circumstances where medicine use has been optimised and 
the medicines are prescribed according to best evidence’ (26). Maintaining good 
quality of life, improving life-span and minimising drug related harm are the aims of 
appropriate polypharmacy (26). Problematic, or inappropriate polypharmacy occurs 
when ‘multiple medications are prescribed inappropriately, or where the intended 
benefit of the medication is not realised’ (26). The causes of inappropriate 
polypharmacy are several, principally the lack of an evidence base for particular 
prescriptions and an unfavourable risk/benefit ratio from particular drugs in 
individual patients.  On other occasions, the demands of taking multiple medications 
compromise adherence. Finally, inappropriate polypharmacy can result from so-
called ‘prescribing cascades’ i.e. the prescribing of additional drugs to counteract 
symptoms that are not recognised as adverse effects of other drugs taken by the 
same patient (27). 
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Currently, the highest rates of polypharmacy are seen in older people (28). In 
the UK, approximately 20% of the population is aged over 65 years, but receive 45% 
of all dispensed drugs (29). Similarly in the US, people aged 65 to 79 years 
proportionately take five times more medication than young adults aged 19 to 25, 
with those over 80 years remaining the largest per person users of prescription drugs 
(30). Inappropriate polypharmacy exists to similar degrees in the community and 
hospital settings. In nursing home residents, approximately 15 – 40% of residents 
take ≥ 9 medications and approximately 1 in 2 older persons take one or more 
medications that aren’t medically indicated (28).  
Prescription of multiple drugs impacts negatively on adherence and 
compliance. Clinicians are sometimes unaware of their patients complete 
prescription record, sometimes because of multiple prescribers or under reporting 
of medication intake by patients at time of consultation. Frank et al. reported that 
almost 40% of patients were taking drugs without the knowledge of their doctors, 
and approximately 1 out of 20 patients were not taking medications listed on their 
prescription record (31). Prescribers should make every effort to obtain an accurate 
medication list and pharmacy reconciliation protocols are useful for this purpose in 
hospital environments. Tools to facilitate medication reconciliation such as the 
Structured History of Medications use (SHiM) can also be very useful (32). 
 
1.2.4 Potentially inappropriate prescribing 
Inappropriate prescribing (IP) refers to use of medications that may cause more harm 
than good and, of equal importance, the under-prescription of clinically indicated 
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medications (33). There is firm evidence of substantially high prevalence rates of IP 
in older people in a variety of clinical settings (34, 35). Recent data from southern 
Ireland using STOPP (Screening Tool of Older Persons potentially inappropriate 
Prescriptions) criteria (36, 37), an explicit prescribing tool, are illustrated in Table 1.3. 
Not surprisingly, identification of potentially inappropriate medications (PIMs) 
increases steadily from primary care through secondary acute hospital care to long 
term nursing home care. 
Table 1.3: Reported inappropriate prescribing rates according STOPP criteria in 
Ireland 
Cohort ≥ 1 daily STOPP 
medication  
 
Population based (n = 3454) (38) 
 
14.6% 
Population based (n = 121,454) (39) 36% 
Population based (n = 539,792) (40) 37.3% 
Primary care (n = 1329) (41) 21.4% 
Primary care (n = 931) (42) 42% 
Community dwelling (n = 2051) (43) 52.7% 
Community dwelling (n = 931) (44) 42% 
Older adults presenting with acute illness to hospital (n = 715) (45) 35% 
Older adults presenting with acute illness to hospital (n = 600) (46) 56.2% 
Older adults presenting to ED with a fall (n = 1016) (47) 53.1% 
Nursing home residents attending ED (n = 195) (48) 84.8% 
Nursing home residents (n = 313) (49) 59.8% 
Nursing home residents (n = 514) (50) 70% 
 
Legend: ED = Emergency department 
 
Clinical judgments of prescribing appropriateness with respect to therapeutic benefit 
can be difficult to make because of insufficient scientific evidence for the older 
population. Those with multiple co-morbidities and multiple medications are often 
poorly represented in clinical trials (51) and physicians often have to extrapolate 
scientific evidence from the use of medications in younger, unrepresentative patient 
populations, with fewer illnesses and fewer concurrent medications.  
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 Under-prescribing of essential medication, particularly for preventive benefit, 
is perhaps an even bigger concern than misuse of medications in older patients (52). 
The risk of cardio-embolic stroke in those with atrial fibrillation increases with age 
i.e. 1.2% - 2.5% annual risk in persons aged 60-69 years versus 7.3%-13.7% annual 
risk in persons aged 80 years and over (53-55). Despite this age-related risk, many do 
not receive evidence-based preventative anticoagulation (56). The Irish Longitudinal 
stuDy on Ageing (TILDA) recently reported that 30% of patients had a potential 
prescribing omission (PPO), most commonly appropriate anti-hypertensive therapy 
(38). Even greater proportions of hospitalised older patients are reported to have 
PPOs. Barry et al. reported a 57% prevalence of prescribing omissions in one 
prospective study of 600 hospitalised older adults in Ireland (57).   
Prescribing appropriateness must also take into consideration a patient’s 
ability to comply with the prescription as well as their physical ability to take the 
prescribed medication. In older adults following coronary artery bypass surgery, one 
study found that in-hospital education was paramount in helping patients adhere to 
their medication regimens (58). However, almost 25% of patients aged ≥ 80 years will 
have significant cognitive and memory deficits, which can often contribute to 
suboptimal medication use (59). Patients may also take multiple doses concurrently, 
thus placing them at an increased risk of ADRs (60). Physical impairments such as 
hearing loss, visual loss and impaired manual dexterity can also impact on adherence 
to prescribed medications, contributing to reduced therapeutic impact and 
consequently poorer treatment outcomes in some cases. 
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1.2.5 Current prescribing assessment tools 
Prescribing tools have been developed to help prescribers identify inappropriate 
prescribing and avoid the unintended negative consequences of same. Prescribing 
tools can be implicit (e.g. Medication Appropriate Index (MAI) (61, 62)), explicit (e.g. 
Beers criteria (63-67), STOPP/START (Screening Tool of Older Persons 
Prescriptions/Screening Tool to Alert doctors to the Right Treatment) criteria (36, 
37), FORTA criteria (68, 69)) or a combination of both (Australian prescribing 
indicators tool (70)). 
 Explicit criteria are developed from literature reviews, expert opinions and 
often use consensus techniques for their development. They consist of list of drugs 
or drug classes with or without doses that are known to cause harm in specific 
circumstances or in conjunction with specific diseases. They can be applied with 
limited clinical judgement and are generally time efficient. Limitations of explicit 
criteria are that they often don’t take into consideration patient preferences, they 
require regular updating with advances in evidence-based medicine and can be 
country specific.  In contrast, implicit criteria rely on expert professional judgement, 
focus on the patient in question and address the entire medication regimen. 
However, implicit criteria are generally highly time-consuming and have low inter-
rater reliability (IRR) as they are based on the judgement of the clinician in question. 
 In 2013, Kauffman et al., completed a comprehensive and structured 
systematic review of existing prescribing tools to assess appropriate prescribing (71). 
They identified 46 tools, of which 28 (61%) used an explicit approach, 8 (17%) used 
implicit approach and 10 (22%) used a mixed approach. Thirty six tools (89%) focused 
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on older adults, 19 (41%) were designed to detect IP in a specific healthcare setting 
and 6 (13%) were specific to nursing home residents.  
 The most frequently cited and applied explicit criteria are Beers criteria (62-
66), and STOPP/START criteria (36, 37). Potentially inappropriate medications (PIMs) 
listed in STOPP criteria, have been shown to be significantly associated with 
avoidable adverse drug events (ADEs) in older people that cause or contribute to 
hospitalisation (odds ratio 1.8; 95% confidence interval (CI) 1.5–2.3) (46). In addition, 
the application of STOPP/START criteria has been shown to improve prescribing 
appropriateness (34, 72) and reduce falls in nursing home residents (73). A recently 
published randomized control trial (RCT) by O’Connor et al., showed that the 
application of STOPP/START criteria by an experienced physician within 48 hours of 
admission reduced ADRs occurring in hospital from 21.0% to 11.7% (74). 
 Prescribing tools have allowed researchers to identify and report potentially 
inappropriate prescribing (PIP) in a structured fashion and subsequently complete 
RCTs to see if their application can improve patients’ outcomes. 
 
1.3  CONSEQUENCES OF INAPPROPRIATE PRESCRIBING 
 1.3.1 Adverse drug reactions 
There is an intimate link between polypharmacy, IP and ADR risk. Many different 
definitions of an ADR and ADEs exist (Table 1.4), with clear limitations associated 
with each definition. The WHO (75) and Laurence et al. (76) definitions do not 
incorporate administration errors (under or over-dosing), withdrawal of medications 
or reactions to inactive components of drugs. Similarly, minor unwanted reactions 
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are not included. In the Bates et al. definition (77, 78), the word “injury” is ambiguous 
and leaves ADR assessment open to subjectivity. Despite differences in these 
definitions, they have been used interchangeably, which has led to difficulty with 
reporting, interpreting and comparing observational and interventional studies. The 
definition of an ADR proposed by Edwards and Aronson (79) is the most 
comprehensive and incorporates what other definitions have lacked. Thus, it is the 
most all-encompassing and appropriate to use, particularly when assessing ADRs in 
older adults.  
Table 1.4: Definitions of ADRs and ADEs 
Author Year Definition 
 
WHO (75) 
 
1972 
 
ADR – A response to a drug that is noxious and unintended and 
occurs at doses normally used in man for the prophylaxis, 
diagnosis or therapy of disease, or for modification of 
physiological function. 
Bates et al. (77, 
78) 
1995 ADE - An injury resulting from medical intervention related to a 
drug. 
Laurence et al. 
(76) 
1998 ADR - A harmful or significantly unpleasant effect caused by a 
drug at doses intended for therapeutic effect (or prophylaxis or 
diagnosis) which warrants reduction of dose or withdrawal of the 
drug and/or foretells hazard from future administration. 
Edwards and 
Aronson (79) 
2000 ADR - An appreciably harmful or unpleasant reaction, resulting 
from an intervention related to the use of a medicinal product, 
which predicts hazard from future administration and warrants 
prevention or specific treatment, or alteration of the dosage 
regimen, or withdrawal of the product. 
Nebeker et al. 
(80) 
2004 ADE - Any physical or mental harm resulting from medication use 
be it misuse, under-dosing or overdosing 
Legend: ADR = adverse drug reaction, ADE = adverse drug event 
 
Furthermore, ADRs were traditionally classified as either “type A” (typically dose 
related, predictable, and accounting for approximately 80% of ADRs) or “Type B” 
(non-dose related and unpredictable) (81). This classification has subsequently 
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broadened into 6 categories defined by Edwards and Aronson i.e. (i) dose related 
(augmented), (ii) non-dose related (bizarre), (iii) dose related and time related 
(chronic), (iv) time related (delayed), (v) withdrawal related (end of use) and (vi) 
failure of therapy (failure) (78). Examples are listed in Table 1.5. Edwards and 
Aronson’s classification is also most appropriate to use when assessing older adults. 
Table 1.5: Examples of different categories of ADRs per Edwards and Aronson (79) 
ADR type Drug involved ADR 
 
Dose related (augmented) 
 
Warfarin 
 
Bleeding 
Bizarre (non-dose related) NSAIDs Interstitial nephritis 
Dose related and time related (chronic) Neuroleptics Tardive dyskinesia 
Time related (delayed) Immunosuppressant therapy Lymphoma 
Withdrawal (end of use) Benzodiazepines Seizure 
Failure of therapy (failure) Warfarin and carbamazepine ↓anti-coagulant effect 
Legend: ADR = adverse drug reaction, NSAIDs = non-steroidal anti-inflammatories, ↓ = reduced 
 
 1.3.2 Prevalence of ADRs in different populations 
ADRs are a common cause of hospitalisation and their incidence increases with 
ageing (82). A meta-analysis by Kongkaew et al. reported that 6.3% (IQR 3.9-9%) of 
all adult admissions are secondary to ADRs and that this proportion increases to 
10.7% (IQR 9.3-13.3%) for older adults (83). A meta-analysis, by Lazarou et al. 
concluded that on average 10.9% (CI 7.9-13.9%) of adults experience an ADR during 
hospitalisation, with 2.1% reported to be clinically serious (84). A more recent meta-
analysis by Alhawassi et al. found that ADRs cause hospitalisation in 10% (CI 7.2-
12.8%) and occur during hospitalisation in 11.5% (CI 0-27.7%) of adults aged 65 years 
and older.  
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 Fewer studies have been undertaken on both community dwelling older 
adults and nursing home residents such that to date there is no systematic review to 
report same. Hanlon et al. reported that 35% of high risk older adults, defined as 
those on ≥ 5 medications, living in the community experienced an ADR over a 1 year 
period (85).  In addition, Cooper et al. reported that 217 out of 332 older people 
(67.4%) living in nursing homes experienced an ADR over a 2 year period (86).  
 
1.3.3 ADR risk factors in older people   
Polypharmacy is strongly predictive of ADRs (87, 88) which is linked to increased 
frequency of hospitalisation, negative health outcomes and increased healthcare 
resource utilisation (89-93). The risk of an ADR when taking two concurrent 
medications is 13%. This risk rises to 38% in patients taking 4 medications and to 82% 
in those taking ≥ 7 medications (94). This is a cause of concern because the risk of 
clinically significant ADRs increases in a linear fashion in proportion to the number of 
daily prescription medicines taken by hospitalised patients (95).  The highest rate of 
polypharmacy occurs in nursing home residents (28), so it is not surprising that ADRs 
are more prevalent in this group (96). 
IP is highly prevalent in older patients. The association between IP and ADRs 
is well established with Lindley et al. showing that 50% of ADRs in older adults are 
caused by IP (60). A significant association has also been found between IP, ADRs, 
acute hospitalization, death (97, 98) and higher healthcare costs (99). The association 
between IP and negative clinical outcomes has been shown in numerous studies in 
Europe (46, 60, 100) the US (101-103) and Asia (104). 
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Women have a 1.5 to 1.7 fold increased risk of ADRs compared with men 
(105). This can be attributed to gender differences in immunological and hormonal 
physiology which influence pharmacodynamics and pharmacokinetic response, 
particularly in relation to cardiac and psychotropic medications (106). Genetic factors 
are thought to play a role in serious ADRs that have been traditionally classified as 
idiosyncratic, for example drug-induced liver injury, statin-induced myotoxicity and 
macrolide-induced long QT syndrome (107). Genotyping at an individual level has the 
potential to optimize drug therapy thereby reducing ADRs (108).  
 
1.3.4 Effects of ADRs 
ADRs have major clinical and economic consequences. They prolong hospital stay 
(109), increase resource utilisation (110), can be fatal (111) and are costly (112). IP 
and related ADRs represent a major drain on health budgets. One study estimated 
that 5 - 9% of all hospital costs were related to ADRs (113). In 2004, Pirmohamed et 
al. (114) estimated that ADRs were costing the United Kingdom (UK) National Health 
Service approximately €700 million per annum. The HARM study in the Netherlands 
estimated that the average cost of preventable medication related acute 
hospitalisation was €6009 (115). This figure was calculated by adding the direct 
medical costs and the productive losses of all preventable admission. The authors 
extrapolated this average cost to represent approximately 0.5% of the total national 
Dutch hospital budget (115). The median length of stay of patients hospitalised as a 
result of medication adversity in the HARM study was the same as that recorded by 
Pirmohamed et al. (114) in the earlier UK study i.e. 8 days. In another recent German 
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study, Rottenkolber et al. (116) calculated that approximately 3.25% of all acute 
hospital admissions were directly related to ADRs. In that study, the median age of 
affected patients was 74 years, the median length of stay was once again 8 days and 
the extrapolated cost to the national exchequer was €434 million i.e. approximately 
€650 million in 2015 terms. These European studies indicate a consistent level of 
ADRs resulting directly in acute hospitalisation, affecting older people in the majority 
and imposing very serious strain on healthcare budgets. 
The mortality rate attributable to ADRs in hospitalised patients is reported to 
be between 0.14% and 4.7% (84, 114). In the US, annual mortality rates of 0.08–
0.12/100,000 have been reported, with this rate significantly increasing over the last 
7 years (111), with those at greatest risk being aged ≥ 75 years. Mortality associated 
with ADRs is due to commonly prescribed drugs with predictable side effects such as 
anticoagulants, opioids and immunosuppressant drugs (111). In the future, the 
demand for these drugs will increase as the incidence and prevalence of illness 
requiring these drug treatments increases with age i.e. atrial fibrillation, stroke, 
cancer and arthritis. In the US, the overall incidence of serious and fatal ADRs are 
reported as 6.7% and 0.32% respectively during a hospital episode, such that ADRs 
are now listed as fifth leading cause of death (114). The implication from all these 
studies is that whilst ADRs are highly prevalent in older sicker patients, they are also 
predictable and therefore preventable in most cases. 
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 1.3.5 Current difficulties in ADR reporting 
Identifying and reporting of ADRs can be challenging in older adults. Older adults are 
a heterogeneous population, with high levels of multimorbidity and polypharmacy. 
Therefore, the ADR risk varies considerably between different older patient groups 
e.g. nursing home patients are at the highest risk. Older adults experiencing ADRs 
often present with nonspecific symptoms such as cognitive decline, recurrent falls 
and reduced mobility, such that it can be difficult to discern whether medications 
have been implicated or not.  
Many definitions for ADRs exist (75, 76, 78-80) and variability in ADR 
definitions means that identification and reporting of ADRs can also vary depending 
on the definition being employed. Variability in defining ADRs also makes it difficult 
to compare published studies. Similarly, several standardized methods of assessing 
ADR causality exist, the advantages and disadvantages of each being summarised in 
Table 1.6. None of the ADR causality tools is universally used or accepted in everyday 
clinical practice and no method is specifically validated for use in older adults with 
multimorbidity and polypharmacy. 
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Table 1.6: Adverse drug reaction (ADR) causality assessment tools (117) 
Causality Assessment Tool Year  Tool Description Advantages Disadvantages 
1. Expert Judgement / Global Introspection Methods 
Swedish method (Wilholm et 
al.) (118) 
1984 Seven factors for a clinician to assess. 
Events classified as probably, possible, non-accessible 
or unlikely. 
Quick to use. There are only a small number of categories into which 
causality can be placed. Causality can overlap into more 
than one of these categories and thus ADRs can be 
wrongly classified. 
WHO-UMC criteria (119)  Six different categories for causality: certain, probable, 
possible, unlikely, conditional, unclassifiable 
Clinical and pharmacological aspect of a case and 
drug-drug interactions taken into consideration. 
Knowledge about medical conditions and diseases 
required. 
2. Algorithms 
Dangaumou’s French 
method (120) 
1977 Seven criteria for assessment. Allows certain drugs taken at the same time with the 
‘suspect’ drug to be excluded because each drug is 
assessed separately. 
More time consuming than other algorithms. 
Kramer method (121) 1979 Assesses a single clinical manifestation occurring after 
administration of a single suspect drug.  
Transparent method. Certain levels of expertise, experience required for use. 
Time consuming to apply. If multiple drugs are involved, 
each is assessed separately. 
Naranjo method (Naranjo et 
al.) (122) 
1981 Can assess causality in a variety of clinical situations 
using the conventional categories. It comprises ten 
questions. 
Shown to be reliable in prospective studies. Intended to assess the likelihood of a reaction from one 
drug not drug-drug interactions. 
Requires the user to have knowledge of the literature. 
Balanced assessment 
method (Lagier et al.) (123) 
1983 It evaluates cases on a series of visual analogue scales. It considers the possibility of an alternative to 
causation for each of the factors. 
The assessor needs to be knowledgeable for it to be 
reliable, 
Summary time plot (Castle et 
al.) (124) 
1984 Identifies patterns of ADRs in the industry setting. Time efficient to use. 
Applicable even with minimal information. 
Does not lead to a conclusion on causality. It examines 
factors that are relevant to the drug-event relationship 
e.g. time. 
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Ciba Geigy method (Venulet 
et al.) (125) 
1980 Derived from a number of expert consensus meetings. 
Causality is assessed by visual analogue scales. 
High degree of agreement (62%) between users. User knowledge and experience required. 
Loupi et al.  method (126) 1986 Developed to assess teratogenicity of a drug. Alternative aetiologies considered. Requires the user to have knowledge about the drug in 
question. 
Roussel Uclaf Causality 
Assessment Method 
(RUCAM) (127) 
1993 Designed for predetermined diseases and illnesses. Easy to use. The range of agreement between users is 37 – 99%. 
Organ specific and currently not validated for every 
organ system. 
Maria and Victorino (M & V) 
scale (128) 
1997 Scale for diagnosing drug induced liver injury (DILI). High level of validity and inter-rater reliability. Specifically for diagnosing DILI. 
Physicians need to be experienced to use. 
Where more than one drug is suspected, the scale needs 
to be computed for individual drugs. 
Some questions on the scale only apply to immune-
allergic hepatitis, making it difficult for scores to be 
generated. 
Drug Interaction Probability 
Scale (DIPS) (129) 
2007 Ten questions scale to evaluated drug interaction 
cases. 
Easy to use. Requires the user to have accurate knowledge of the 
drug involved and the interactions. 
3. Probabilistic methods (Bayesian approaches) 
Bayesian Adverse Reaction 
Diagnostic Instrument 
(BARDI) (130) 
1992 Developed to overcome the limitations associated with 
expert judgements and algorithms. The odds in favour 
of a particular drug causing an adverse event are 
compared with an alternative cause. 
It can evaluate more than 2 possible causes at a 
time. 
Quick to apply, 
Requires expertise to operate. 
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The World Health Organization–Uppsala Monitoring Center (WHO-UMC) criteria 
(119) (Table 1.7) and the Naranjo criteria (122) (Table 1.8) are the most frequently 
cited ADR causality tools in the literature. However, some of the variables required 
by the Naranjo criteria are difficult to apply to older patients with suspected ADRs. 
For example, it may be unethical to rechallenge if there is a high index of suspicion 
of ADR and risk of recurrence or harm is high. In addition, the Naranjo criteria do not 
allow for drug–drug interactions as a cause of an ADR. Often, many of the required 
variables cannot be completed, thus making it unlikely for any older patient to score 
higher than ‘possible or probable’ in this causality system, thereby limiting its utility.  
Table 1.7: WHO-UMC causality criteria (119) 
Causality Conditions (All conditions need to be complied with for each causality 
criteria) 
Certain Event / laboratory test abnormality with plausible time relationship to intake of 
a drug 
Cannot be explained by disease or other drugs  
Response to withdrawal plausible 
Event definitive pharmacologically or phenomenologically 
Rechallenge satisfactory, if necessary 
 
Probable Event or laboratory test abnormality, with reasonable time relationship to drug 
intake Unlikely to be attributed to disease or other drugs  
Response to withdrawal clinically reasonable  
Rechallenge not required 
Possible Event or laboratory test abnormality, with reasonable time relationship to drug 
intake Could also be explained by disease or other drugs  
Information on drug withdrawal may be lacking or unclear 
Unlikely Event or laboratory test abnormality, with a time to drug intake that makes a 
relationship improbable 
Disease or other drugs provide plausible explanations 
 
Conditional/ 
Unclassified  
 
Event or laboratory test abnormality  
More data for proper assessment needed, or  
Additional data under examination  
Unassessable/ 
Unclassifiable  
 
Report suggesting an adverse reaction  
Cannot be judged because information is insufficient or contradictory  
Data cannot be supplemented or verified 
 
 
53 
 
Table 1.8: The Naranjo ADR causality criteria (122) 
 
Yes No Don’t 
Know 
Are there previous conclusive reports on this reaction? +1 0 0 
 
Did the adverse event occur after the suspected drug 
was administered? 
 
+2 -1 0 
Did the adverse reaction improve when the drug was 
discontinued or an antagonist was administered? 
 
+1 0 0 
Did the adverse reaction reappear when the drug was 
re-administered? 
 
+2 -1 0 
 
Are there alternative causes (other than the drug) that 
could have on their own caused the reaction? 
 
-1 +2 0 
Did the reaction reappear when a placebo was given? 
 
-1 +1 0 
Was the drug detected in the blood (or other fluids) in 
concentrations known to be toxic? 
 
+1 0 0 
Was the reaction more severe when the drug was 
increased or less severe when the drug was 
decreased? 
 
+1 0 0 
Did the patient have a similar reaction to the same or 
similar drugs in any previous exposure? 
 
+1 0 0 
Was the adverse event confirmed by any objective 
evidence? 
+1 0 0 
Legend: Total scores range from -4 to +13; ≥9 indicates a definite adverse drug reaction 
(ADR); a score of 5 to 8 indicates a probable ADR; a score of 1 to 4 indicates a possible 
ADR; a score of ≤ 0 indicates that an ADR is doubtful 
 
A standardized method to identify, classify and assess causality of ADRs in older 
adults is required for future research in order to enhance the accuracy of ADR 
reporting. Rigorous ADR reporting would greatly improve the accuracy and quality of 
ADR prevalence and incidence data. In addition, it would allow direct comparisons 
between studies completed by different research groups and would contribute to 
interventional studies being more methodologically robust in the future. 
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1.4  TARGETS FOR INTERVENTION IN POPULATIONS AT HIGH RISK OF ADRS  
 1.4.1  Deprescribing  
Deprescribing is defined as “the process of withdrawal of an inappropriate 
medication, supervised by a health care professional with the goal of managing 
polypharmacy and improving outcomes” (131). It involves (i) reviewing all 
medications prescribed, (ii) identifying those medications that are inappropriate, (iii) 
deciding when and how these medications should be reduced or stopped and (iv) 
arranging adequate monitoring and follow-up (132). Many physicians, healthcare 
professionals, patients and their relatives all acknowledge the burden of 
polypharmacy for older frail adults, yet all groups display passivity towards 
deprescribing (133) with less than half of attending clinicians use a consistent 
approach to deprescribing (134) and many clinicians avoid it completely. 
 
1.4.2 Need for new deprescribing tools  
To date, numerous prescribing tools have been developed to guide physicians with 
cessation of PIMs in the general older adult population. However, comprehensive 
tools such as Beers criteria (63-67), STOPP/START criteria (36, 37) and FORTA criteria 
(68, 69) were not developed to specifically address IP in frail multimorbid older adults 
with a poor survival prognosis. Prescribing needs for these patients differ from those 
of the general older population. For instance, patients with limited life expectancy 
(LLE) would be unlikely to survive long enough to derive benefit from most 
medications listed in the START criteria. Furthermore, STOPP criteria do not suggest 
discontinuing major drugs classes that are least likely to have benefits in the last year 
of life, e.g. statins. Therefore, the population at the highest risk of IP and ADRs that 
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is growing most rapidly is the one where there is the least clear guidance on 
prescribing and deprescribing for physicians. To date, no explicit guidelines exist for 
deprescribing in frailer older people with LLE, other than NORGEP-NH criteria, which 
are specific to the older nursing home population (135). Therefore, with the accepted 
need for deprescribing in frailer older persons with LLE, there is a clear associated 
need for specific explicit deprescribing criteria. 
 
1.4.3 Limited life expectancy 
LLE is defined in most studies as a life expectancy of one year or less (136-138). 
Recognition of a LLE can be challenging for less experienced physicians. However 
there are some simple mortality predictive tools available that can help guide and 
support junior physicians in assessing this e.g. Walter Index (139). However, 
deprescribing in older frailer adults is usually undertaken by patients’ General 
Practitioners (GPs) or senior hospital physicians with high-level prognostic 
knowledge. The literature to date indicates that co-morbidities and functional 
impairment are the most consistent predictors of mortality (140). 
 
1.4.4 Frailty 
Many older adults with LLE are not clinically frail. Conversely, some older adults who 
are clinically frail do not have a poor one year survival prognosis. However, in most 
instances, frailty and poor survival prognosis do co-exist. Frailty in some 
circumstances can be reversible, but in patients where there is an irreversible, end-
stage diagnosis e.g. dementia or disseminated progressive malignancy with 
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associated severe functional impairment, frailty is implicit and prognosis is usually 
poor. 
 Many different frailty assessment tools are available which have been 
validated across many different healthcare settings and applied to various age 
groups. In addition, many frailty tools use different criteria. Of 79 frailty instruments 
recently systematically reviewed by Azzopardi et al. (141), 24 included physical 
characteristic components alone, with all other instruments consisting of two or 
more components from the following domains: medical, physical, functional and 
cognitive. Some components were self-reported, others were based on objective 
measures and in those remaining, a combination of both were employed. Frailty 
indices are used to assist identification and diagnosis of frailty and are not intended 
to supersede clinical judgement but rather guide physicians in clinical decision 
making. The prevalence of frailty in older adults is reported to be 10.7% in the 
community (7), 14% in hospitals (142) and 52.3% in nursing homes (143).  
 
1.5 CONCLUSIONS  
Prescribing for frail multimorbid older patients is often complex and time-consuming, 
particularly when all of the patients’ variables are considered. In addition, older 
people are a heterogeneous population, with a wide variation in physical, cognitive 
and functional status. Prescribing appropriately and safely for frail older multimorbid 
adults with a poor survival prognosis is often highly challenging, particularly when 
considering the many preventative therapies that may carry greater risk than a clear 
benefit.  
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Older frail multimorbid adults surviving with complex clinical conditions 
contribute to the population that is growing at the fastest rate and will continue to 
grow for several decades to come. Therefore, research needs to focus on identifying 
potentially adverse polypharmacy and IP in these multimorbid patients as well as 
interventions to improve prescribing appropriateness and safety. ADRs need to be 
identified speedily and accurately, correctly classified and reported in a standardized 
manner to assist best clinical practice and ensure that research studies are 
methodologically robust. 
Evaluation of the therapeutic goal must take into account the scientific 
rationale of using a drug as well as the potential benefit to the patient. There is a lack 
of guidance on deprescribing in older frail multimorbid patients for present day 
physicians. Explicit deprescribing criteria are required so that the evidence base for 
deprescribing in this growing population can develop and support physicians in their 
routine clinical decision making. 
 
1.6  OBJECTIVES OF THIS THESIS 
The objectives of this thesis were to: 
(i) Develop a standardized method of assessing, classifying and reporting 
ADRs in older people. 
(ii) Identify multimorbidity, medication use and IP in older adults with 
unselected acute illness presenting to hospital for admission. 
(iii) To assess the prevalence of ADRs causing hospitalisation in an acutely ill 
general older unselected population using this new ADR assessment 
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methodology and to compare these rates to those reported in the 
literature to date. 
(iv) Identify multimorbidity, medication use and IP in older adults with cancer 
using the same ADR methodology in order to determine the prevalence 
of ADRs causing hospitalisation in this cohort. 
(v) Develop a new explicit prescribing tool to address deprescribing in older 
frail multimorbid patients with a poor one year survival prognosis. 
(vi) Determine the inter-rater reliability of this newly developed deprescribing 
tool and apply it to a representative population of frail, multimorbid older 
people.
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CHAPTER 2: 
Development and validation of an adverse drug reaction (ADR) trigger list 
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2.1  INTRODUCTION 
Adverse drug reactions (ADRs) are common and their incidence increases with ageing 
(82). A recent meta-analysis reported that ADRs cause or contribute to 
hospitalisation in approximately 10% of older adults (83, 144). Furthermore, ADRs 
occur in approximately 11.5% of older adults during their hospital admission (84, 
144). However, it is often difficult to compare individual studies because of 
considerable heterogeneity in (i) definition of ADRs, (ii) identification of causality and 
(iii) variations in population cohorts studied.  
 The economic burden of ADRs in terms of healthcare resource consumption 
(99, 113-116, 145) and mortality (84, 111, 114) is well established and has been 
discussed in Chapter 1. However, the clinical nature and severity of ADRs is often 
poorly described. More specifically, differences in drug-related morbidity between 
older and younger patients are rarely investigated or compared. Recognition and 
diagnosis of ADRs can be challenging in everyday clinical practice, particularly in older 
patients with multiple symptoms that may feasibly be attributed to multiple co-
morbid illnesses e.g. falls, cognitive decline, fatigue or constipation. ADRs that 
require intensive medical input are generally identified and managed accordingly e.g. 
acute liver injury secondary to a statin or clinically significant bleeding secondary to 
an anticoagulant. However, in cases where symptomatology is milder, or viewed as 
non-life threatening e.g. severe constipation, drug causation is often under-
recognised. Older adults often experience a large burden of co-morbid illnesses and 
frequently present with non-specific symptoms such as falls, delirium and dizziness, 
most of which have several causative factors. A fall may occur in a patient with visual 
impairment and gait instability attributable to severe osteoarthritis, but that same 
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patient may also fall because of postural hypotension attributable to a new 
antihypertensive agent. All factors may have contributed to the fall, thus making it 
difficult to precisely conclude that the event was caused by a drug.  
 Ideally, a standardized approach should be employed to accurately identify 
and classify suspected ADRs, in order to minimise associated morbidity and prevent 
recurrence.  One such approach would be to determine an individual’s risk of 
developing an ADR using a tool such as the GerontoNet ADR risk prediction score 
(146). This tool considers an individual’s risk of developing an ADR according to the 
presence or absence of variables including increasing numbers of medications, 
presence of liver dysfunction and renal dysfunction. This approach, though 
promising, is not universally applicable, with one study (outside of the original 
research validation exercise) showing poor predictive ability in correctly identifying 
ADRs, thus limiting the clinical applicability of GerontoNet as a reliable ADR 
prediction tool (146).   
 Another approach would be to focus on the most common adverse clinical 
syndromes attributable to medications in older patients e.g. falls, bleeding, 
electrolyte disturbance and cognitive dysfunction. The presence of such symptoms 
in an older person should prompt a medication review to investigate whether or not 
such symptoms could be caused by a prescribed medication i.e. these symptoms 
should “trigger” further investigation of the adverse event (AE) in question and 
determine whether a drug is implicated i.e. an “AE trigger”. This would require a 
standardized definition of an ADR and a robust and valid process of determining 
whether or not a drug contributed to the clinical event. Accordingly, the aim of this 
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study was to develop and validate a new Trigger List of clinical symptoms and 
syndromes that may herald the presence of an ADR and to devise a robust, 
standardized process of assessing these symptoms to determine whether or not a 
drug is culprit. The specific study objectives are detailed below. 
 
 2.1.1  Objectives 
The objectives of this study were: 
(i) To develop a Trigger List of clinical symptoms or events to identify 
potential ADRs in older patients. 
(ii) To develop and validate a standardized investigative process for each 
event on the Trigger List in order to ascertain whether or not the event 
was an ADR.  
(iii) To develop a standardized approach to assessing the morbidity associated 
with ADRs. 
(iv) To determine the inter-rater reliability (IRR) of this new methodology 
amongst physicians, pharmacists, nurses and biomedical scientists, all of 
whom are working as researchers on a multi-centred RCT investigating 
the role of medication optimisation software on ADRs that occur during 
hospital stay. 
 
The work in this chapter was undertaken with support and input from the SENATOR 
(Software ENgine for the Assessment and optimisation of drug and non-drug 
Therapies in Older peRsons) consortium (147). 
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2.2  METHODS 
This study involved four distinct phases: (i) development of a list of common potential 
ADRs in older patients i.e. the AE Trigger List; (ii) development of a standardized 
investigative process for each AE on the Trigger List in order to ascertain whether or 
not the event was an ADR, (iii) development of a standardized process for 
ascertaining ADR-related morbidity i.e. inter-dependent relationships between AE 
Trigger List symptoms deemed ADRs i.e. Sequence of Events, and (iv) conduct of a 
study to test the IRR of the process between doctors, nurses, pharmacists and 
biomedical scientists using clinical cases. Each of these phases is described in more 
detail below. 
 
2.2.1  Development of the AE Trigger List  
Each AE on the Trigger List should be a clinical symptom or syndrome that may be 
indicative of an ADR and requires investigation using a standardized process to 
determine if this is the case. The Trigger List must (i) incorporate the most common 
ADRs reported in older adults and (ii) include clear definitions of all AEs to avoid any 
ambiguity around whether the event in question occurred or not.  
 As discussed in Chapter 1, the definition of an ADR proposed by Edwards and 
Aronson (79) is the most comprehensive definition and incorporates what other 
definitions lack. Thus, it is the most all-encompassing and appropriate to use, 
particularly when assessing ADRs in older adults. Therefore it will be the definition 
used going forward for this thesis i.e. “An appreciably harmful or unpleasant 
reaction, resulting from an intervention related to the use of a medicinal product, 
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which predicts hazard from future administration and warrants prevention or specific 
treatment, or alteration of the dosage regimen, or withdrawal of the product.” 
 The AE Trigger List was composed by incorporating the most common ADRs 
identified in an earlier observational study at Cork University Hospital (CUH); an 
observational study in which the clinical manifestations of the most common ADRs 
were defined in a robust manner (148) (Table 2.1). A large study by Budnitz et al 
looked at national data in America and identified that warfarin, insulin, anti-platelets 
and oral hypoglycaemic agents were the most common drug classes implicated in 
ADRs and that bleeding and hypoglycaemia events dominated ADRs in older adults 
(149). It was decided not to base our trigger list on this study as there was detection 
bias. Firstly many ADRs that occur in older patients were not listed for coders who 
inputted data into the hospitals electronic system, therefore this study was not an 
accurate representation of all ADRs in older adults. 
Table 2.1: Most common ADRs identified by O’Connor MN et al. (148) 
Drug/Drug Class Adverse Drug Event Number (%) 
 
Diuretics 
 
AKI/electrolyte disturbance 
 
45 (25%) 
Benzodiazepines Falls 32 (18%) 
Opiates Delirium/falls/sedation/constipation 32 (18%) 
Beta blockers Symptomatic bradycardia/OH 16 (9%) 
Anti-hypertensives OH/AKI/hyperkalaemia 14 (7.8%) 
NSAIDs Gastritis/peptic ulceration/AKI 10 (5.6%) 
Warfarin Haemorrhage 8 (4.5%) 
Anti-platelets Haemorrhage 6 (3.3%) 
Neuroleptics Falls/parkinsonism 3 (1.6%) 
SSRIs Hyponatraemia 3 (1.6%) 
Antibiotics Clostridium difficile colitis 3 (1.6%) 
   
Legend: AKI = Acute kidney injury, OH = Orthostatic hypotension, NSAIDs = Non-steroidal anti-
inflammatories, SSRIs = Selective serotonin re-uptake inhibitors 
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In this prospective observational study, ADRs were defined rigorously according to 
the World Health Organisation-Uppsala Monitoring Center (WHO-UMC) causality 
criteria (119), a causality assessment tool that has been discussed in Chapter 1. Two 
physicians jointly reviewed all ADRs and only included those where there was 
consensus between them that a probable/certain ADR had occurred. The 10 ADRs 
most commonly reported were (i) acute kidney injury (AKI), (ii) electrolyte 
disturbance, (iii) falls, (iv) delirium, (v) constipation, (vi) orthostatic hypotension (OH), 
(vii) dyspepsia, (viii) bleeding (ix) diarrhoea and (x) symptomatic bradycardia. These 
ADRs formed the basis of the AE Trigger List of potential ADRs i.e. AEs requiring 
further investigation.  
 The SENATOR consortium (of which I am a member), is a European group 
comprising of renowned researchers from across Europe that has a strong clinical 
and research background in Geriatric Pharmacotherapy. Although I was funded by 
the SENATOR project, this chapter is the only part of my PhD that is linked to the 
consortium.  The SENATOR group discussed this AE Trigger List. On the basis of 
clinical experience, two additional AEs were proposed for inclusion i.e. gait 
disturbance and symptomatic hypoglycaemia. Their inclusion was agreed by 
consensus. The result, a 12 AE Trigger List, to assist in the unbiased reporting of 
ADRs. It was acknowledged that not all potential ADRs were included on the 12 point 
Trigger List e.g. anaphylaxis, but those not included were those that were more likely 
to have severe symptomatology and consequently less likely to be missed; an 
“unspecified AE” was added to the AE Trigger List to capture these. 
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 2.2.2 Development of a standardized investigative process for each AE on
  the trigger list in order to ascertain whether or not the event was an 
  ADR 
As I worked as a primary researcher on the SENATOR feasibility study (150), the first 
study to employ the AE Trigger List, it became evident that there was huge variability 
in AE assessments between researchers. This was due to the subjective nature in 
assessing a drug’s role in symptomatology, lack of clarity around the timing of events, 
lack of clarity around the duration of events and in general the unstandardized 
approach employed to assessing whether an ADR occurred. This inevitably can lead 
to the inaccurate reporting of ADRs.  
 Therefore after developing the AE Trigger List, I set out to develop a robust 
and valid process, of determining whether or not a drug contributed to clinical AEs 
that could be used by researchers going forward. The aim was to remove the current 
subjective nature of this process, thus ensuring accurate capture and reporting of 
ADRs.  This work was undertaken by me under the guidance of Prof. Denis O’Mahony 
(senior academic consultant/geriatrician, University College Cork), Dr. Paul Gallagher 
(senior academic consultant/geriatrician, University College Cork) and Prof. Joseph 
Eustace (senior academic consultant/nephrologist/Director of the Health Research 
Board Clinical Research Facility (HRB-CRF), University College Cork (UCC)).  
 This involved (i) each AE on the Trigger List having a clear definition, (ii) a 
clear definition around the timing and duration of each AE, (iii) a clear standardized 
approach to assessing whether a drug was involved using both direct focused 
questions and the WHO-UMC causality criteria (119) and ensuring a structured scale 
67 
 
to apply severity was employed if an AE was deemed an ADR i.e. Hartwig & Siegel 
Scale (151) and lastly (iv) the use of an independent adjudication process to confirm 
the presence of an ADR. Each of these phases is described in more detail below. 
 
(i) AE Trigger List definitions 
Each of the 12 AEs on the AE Trigger List were given a clear definition based on what 
was deemed clinically significant e.g. it was proposed that the definition for 
symptomatic bradycardia be “a heart rate of < 50 beats/minute with symptoms”. 
Definitions were included to ensure that a drug cause was investigated only for 
clinically significant AEs.  Older adults can often present to hospital with an acute 
illness, such as a urinary tract infection, and incidentally be found to have for example 
bradycardia but are asymptomatic and don’t require intervention. I wanted to ensure 
that clinically asymptomatic AEs were not being investigated inappropriately and 
consequently ADRs were not being over reported. Each definition was proposed 
based on clinical experience and subsequently agreed upon by consensus by the 
SENATOR consortium.  
 
(ii) Timing and duration of AEs 
The SENATOR feasibility study also highlighted the inability, in most cases, for 
researchers to reliably and reproducibly separate prolonged or repeated occurrences 
of the same ADR into separate discrete events e.g. if a persons had 3 falls (AEs) and 
it is discovered that there was a drug cause (ADR), this had the potential to be 
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reported as either 3 ADRs or 1 ADR. Lack of clarity as to what precisely defines an AE 
leads to subjectivity in ADR reporting and can lead to over-estimation of ADRs. I 
proposed that AEs and subsequently ADRs should be viewed as processes rather than 
discrete events i.e. in the example case above, falling occurs secondary to a 
medication. The only time a second ADR should be declared is if a second drug 
becomes implicated after the first original drug and is felt to cause re-emergence of 
the same symptoms or worsening of current symptoms. For example, if a person 
developed hyponatraemia secondary to a thiazide diuretic, which was subsequently 
stopped and the hyponatraemia resolved and then the same person was prescribed 
an selective serotonin reuptake inhibitor (SSRI) and a further substantial drop in Na+ 
(sodium) occurred then this would be classified as two separate ADRs.  
 In addition, it became apparent that there was confusion around the timing 
of AEs, which subsequently led to inaccurate reporting of the timing of ADRs. As a 
result I proposed that ADRs occurring pre-hospital should be distinct from those 
occurring during hospitalisation i.e. “prevalent” ADRs and “incident” ADRs. A 
prevalent event is one which commences pre hospital and an incident event is one 
which commences post admission to hospital. This distinction between prevalent 
and incident ADRs is paramount to assess ADRs in order to prevent future ADRs. 
 
(iii) Development of a standardized approach to causality and severity  
As discussed in detail in Chapter 1, in 2015, I completed a review looking at ADR 
causality tools (152). I reviewed 13 tools, and concluded that the WHO-UMC causality 
assessment tool was the most appropriate to apply to older adults (119). As a tool, it 
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takes into consideration the clinical and pharmacological aspects of a drug, as well as 
ensuring drug-drug interactions are not overlooked. It offers clear guidance on the 
likelihood of an AE being an ADR and is easy to apply. It does not require rechallenge 
with the culprit medication, which can often be unsafe in older adults and in general 
is very easy to understand and apply. In addition, the Hartwig & Siegel scale robustly 
categorise ADR severity into seven groups according to clinical consequences, 
including resultant harm and the intensity of medical intervention required (Table 
2.2) (151). These tools are most appropriate to use to assess causality and severity 
of ADRs in older adults. 
Table 2.2: Hartwig & Siegel Severity Scale (151) 
Severity Grade 
 
1 
 
An ADR occurred but no change in treatment with suspected drug 
2 The ADR required that treatment with the suspected drug be held, 
discontinued or otherwise changes. No antidote or other treatment required. 
No increase in length of stay. 
3 The ADR required that treatment with the suspected drug be held, 
discontinued or otherwise changed, or an antidote or other treatment. No 
increase in length of stay. 
4 Any level 3 ADR which increases length of stay by at least one day or the ADR 
was the reason for admission. 
5 Any level 4 ADR which required intensive medical care. 
6 Any ADR causing permanent harm to the patient. 
7a The ADR was indirectly linked to the death of the patient. 
7b The ADR was directly linked to the death of the patients 
  
Legend: ADR = adverse drug reaction. 
 
(iv) Development of an independent adjudication process 
To avoid unbiased reporting of ADRs, all AEs assessed on the AE Trigger List, should 
be forwarded to an adjudication committee, regardless of the probability that the AE 
in question is an ADR. This will ensure that ADRs are not under or over reported. The 
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evidence for each AE must be presented in a standardized fashion to those involved 
in the adjudication committee. Evidence that indicates causality (temporal 
relationship, appropriate time line in resolution or recurrence etc.) must be stated 
along with additional qualifying explanatory text. To ensure this information was 
presented in a standardized format, a form for each AE, incorporating all the 
components as discussed above, was compiled. This standardised AE form is present 
in Table 2.5, page 80. 
 2.2.3 Development of a standardized process for ascertaining ADR-related 
  morbidity  
It also was apparent from the SENATOR feasibility study that for many patients there 
was an interrelationship between different types of AEs that were deemed ADRs e.g. 
a patient could present with diarrhoea secondary to an antibiotic, leading to fluid 
depletion and subsequently orthostatic hypotension, which subsequently leads to a 
fall and injury. Data collection processes to date have not captured this associated 
morbidity, but rather report the starting event or the event causing hospitalisation 
i.e. in the example given above, diarrhoea or a fall would be reported.   
 In order to capture the morbidity associated with ADRs, I proposed that the 
Sequence of Events surrounding an ADR should be evaluated. AEs that are deemed 
drug-related, as determined by the WHO-UMC causality tool (119), should have their 
inter-dependent relationships captured to ensure the associated morbidity is not 
missed.  The use of the AE Trigger List and determination of the inter-dependant 
relationships between events will capture this morbidity prospectively i.e. Sequence 
of Events. 
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 2.2.4  Conduct of a study to test the IRR of the process between doctors, 
  nurses, pharmacists and biomedical scientists using clinical cases 
(i) Application of AE Trigger List process to clinical cases 
The aim was to determine the inter-rater reliability (IRR) of the AE process between 
healthcare professionals. Eight clinical cases histories were selected from a cohort of 
240 consecutive patients, aged ≥ 65 years, who were admitted with an acute medical 
(i.e. non-surgical) illness to the general medical services at Cork University Hospital, 
between August 2014 and July 2016. The purpose of this observational study was to 
determine ADR incidence causing hospitalisation. This study will be discussed in 
Chapter 3, however for the purpose of this IRR exercise, participants included in this 
observational study had their medical conditions, concurrent medications, cognitive 
and functional impairment documented. The eight cases were selected based on 
case complexity to ensure a variety of clinical scenarios were presented to 
participants.  The details of these 8 clinical cases can be found in Appendix 1.   
 Each clinical case was presented in the same format with an appropriate 
amount of information to make an ADR assessment i.e. medical diagnoses, 
concurrent medications, allergies, laboratory tests, electrocardiogram (ECG), 
functional status and cognitive status. Participants were also given information 
regarding what occurred during hospitalisation to assist their assessments. Survey 
Monkey© was the platform used to distribute this information to participants. An 
example of one clinical case is presented in Figure 2.1 and the questions asked, 
incorporating the key concepts as discussed above to guide ADR assessment of the 
AEs, is presented in Figure 2.2.  
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Figure 2.1: Example of a clinical case. 
Patient & symptoms:  66 year old male presented with a 3 day history of new painless jaundice.  
HPC:  He presented with cellulitis of his right leg to his GP 5 days earlier. At this time he was commenced on 
Flucloxacillin. After 2 days of treatment a yellow discoloration of his skin occurred which became worse over 
the following days. After 5 days of treatment he stopped taking the antibiotics and presented to the 
emergency department. No nausea, no diarrhoea, no constipation, no vomiting, on confusion, no falls. 
Medical History:  
1. Varicose veins 
2. Gastro-oesophageal reflux disease (GORD)  
3. Hiatus hernia – Gastroscopy 6 months ago 
4. Hypertension 
Medications (regular): 
 Drug Name Dose Route Frequency Duration 
1 Tramadol 50mg Oral Once a day 2 weeks 
2 Diclofenac gel One application Topical Three times a day 2 weeks 
3 Esomeprazole 40mg Oral Once a day 6 months – 1 yr 
4 Bisoprolol 5mg Oral Once a day >5 years 
5 Ramipril 10mg Oral Once a day >5 years 
6 Paracetamol  1g Oral  As required (last took 6 weeks ago) >5 years 
 
Recent short courses of treatment: 
 Drug Name Dose Route Frequency Duration 
1 Flucloxacillin 500mg Oral Four times a day 5 days 
Courses was started 5 days prior to admission  
 
Allergies: Amoxicillin/clavulanate – history of jaundice  
Social History: Ex-smoker, no alcohol, lives with wife, fully independent of ADLs 
Barthel Index score: 20/20, MMSE score: 30/30, 4AT score: 0 
Blood results (at admission): Serum creatinine 70 µmol/l, eGFR 104 ml/min/1.72m2, Na+ 137, K+ 4.8, 
Haemoglobin 12.8g/l, WCC 9.8, Neutrophils 5.4, Platelets 304, Albumin 36 g/l, Bilirubin 242 µmol/l ↑, Ca++ 
(corrected) 2.30 mmol/l, ALT 40, ALP 753↑, GGT 152 
ECG:  Normal sinus rhythm, 65 bpm, no conduction blocks 
Course of events in hospital: 
- Diagnosis made by attending team: Acute Liver Failure 
- The patient spent a total of 6 weeks in hospital 
- His liver function recovered with monitoring. 
- It took 6 weeks until liver function tests were within normal limits. 
- During the hospitalisation he had no falls, no nausea, no vomiting, no diarrhoea, no constipation. 
Medication changes during admission: 
1. Tramadol stopped 
2. Flucloxacillin stopped by the patient the day before admission 
Legend: MMSE = Mini mental state examination, 4AT = Screening test for delirium (≥4 possible delirium +/- 
cognitive impairment, 1-2 possible cognitive impairment, 0 = delirium or severe cognitive impairment) 
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Figure 2.2: Questions asked on each clinical case. 
Did this patients have any AE: yes or no 
If yes: 
 Event 
y/n 
Prevalent 
or incident 
Drug implicated 
y/n 
Drug 
1 
WHO 
causality 
Drug 
2 
WHO 
causality 
New onset fall        
New unsteady gait        
Acute kidney injury        
Symptomatic 
orthostatic 
hypotension 
       
Severe electrolyte 
disturbance 
       
Symptomatic 
bradycardia 
       
New major 
constipation 
       
Acute bleeding         
Dyspepsia, nausea or 
vomiting 
       
Acute diarrhoea        
Delirium        
Symptomatic 
hypoglycaemia 
       
Unspecified        
 
If an ADR occurred, grade severity according to Hartwig and Siegel? 1 – 7  ____________ 
Was there a Sequence of Events? If yes list order: 
 Order of events  Order of events 
New onset fall  New major constipation  
New unsteady gait  Acute bleeding   
Acute kidney injury  Dyspepsia, nausea or vomiting  
Symptomatic orthostatic 
hypotension 
 Acute diarrhoea  
Severe electrolyte disturbance  Delirium  
Symptomatic bradycardia  Symptomatic hypoglycaemia  
  Unspecified  
 
Narrative: 
 
Legend: AE = adverse event 
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The median age of patients in the 8 clinical cases was 77 (IQR 69 – 24) years. Four of 
eight patients were male. The median number of active medical conditions was 10 
10 (IQR 7.5 – 11.75) and the median number of prescribed medications was 9 (IQR 
6.25 – 10) regular medications. Their median Barthel score was 18/20 (IQR 17.25 – 
20) and their median MMSE was 26 (IQR 18.5 – 29.75). Four patients experienced an 
ADR; there were four prevalent ADRs and one of these patients had an incident ADR 
during the acute hospitalisation. 
 
(ii) Participant recruitment and training  
Twenty one persons, across 6 European centres, were asked to participate, all of 
whom accepted. Participants were selected on the basis of their recognised academic 
credentials, clinical practice, experience and geographical diversity. All participants 
were researchers, either primary investigators or primary researchers, for an 
observational study determining ADR incidence during hospitalisation across 6 
European sites (SENATOR) (150). Participants consisted of physicians (Consultant 
Geriatricians, Consultant Clinical Pharmacologists and registrars training in Geriatric 
Medicine), clinical pharmacists, biomedical scientists and nurses (Table 2.3). 
Participants were invited to attend a training session. This training was offered during 
one afternoon and encompassed training on ADR identification, classification and 
their associated morbidity. Following training, 4 cases experiencing AEs, 
incorporating the key concepts highlighted above, were discussed.  
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Table 2.3: Participants in the ADR assessment inter-rater reliability exercise 
Name Discipline Place of practice 
Dr. Roy Soiza Geriatric Medicine 
(Consultant) 
Grampian Health Board  
(Aberdeen, Scotland) 
Prof. Alfonso Cruz-Jentoft Geriatric Medicine 
(Consultant) 
Hospital Universitario Ramón y Cajal 
(IRYCIS) 
(Madrid, Spain) 
Prof. Mirko Petrovic Clinical Pharmacology & 
Geriatric Medicine 
(Consultant) 
Universiteit Gent 
(Gent, Belgium) 
Dr. Aðalsteinn Guðmundsson Geriatric Medicine 
(Consultant) 
Landspitali University Hospital  
(Reykjavik, Iceland) 
Prof. Denis O’Mahony Geriatric Medicine 
(Consultant) 
Cork University Hospital 
(Cork, Ireland) 
 
Prof. Antonio Cherubini Geriatric Medicine 
(Consultant) 
 
Geriatria ed Accettazione Geriatrica 
d’urgenza, IRCCS-INRCA, 
(Ancona, Italy) 
Dr. Selvarani Subbarayan Research fellow 
 
Grampian Health Board  
(Aberdeen, Scotland) 
Dr. Denis Curtin Geriatric Medicine 
(specialist registrar) and 
research fellow 
Cork University Hospital 
(Cork, Ireland) 
Dr. Anna Cerenzia Geriatric Medicine 
(registrar) and research 
fellow 
Geriatria ed Accettazione Geriatrica 
d’urgenza, IRCCS-INRCA, 
(Ancona, Italy) 
Dr. Marisol Cotourello 
Ferreiro 
Geriatric Medicine 
(registrar) and research 
fellow 
Geriatria ed Accettazione Geriatrica 
d’urgenza, IRCCS-INRCA, 
(Ancona, Italy) 
Dr. Ólafur Samúelsson Geriatric Medicine 
(Consultant) 
Landspitali University Hospital  
(Reykjavik, Iceland) 
Mr. Michael McCarthy Pharmacist and research 
fellow 
Cork University Hospital 
(Cork, Ireland) 
Mr. Kieran Dalton Pharmacist and research 
fellow 
Cork University Hospital 
(Cork, Ireland) 
Ms. Andrea Resi Pharmacist  Hospital Universitario Ramón y Cajal 
(IRYCIS) 
(Madrid, Spain) 
Ms. Lore Vandaele Biomedical scientist  
 
Universiteit Gent 
(Gent, Belgium) 
Ms. Eline Meireson Biomedical scientist 
 
Universiteit Gent 
(Gent, Belgium) 
Ms. Sirjana Devkota Nurse 
 
Grampian Health Board  
(Aberdeen, Scotland) 
Ms. Sandra Nelson Nurse Grampian Health Board  
(Aberdeen, Scotland) 
Ms. Pamela Paton Nurse Grampian Health Board  
(Aberdeen, Scotland) 
Ms. Ástrós Sverrisdóttir Nurse 
 
Landspitali University Hospital  
(Reykjavik, Iceland) 
Ms. Védís Húnbogadóttir Nurse 
 
Landspitali University Hospital  
(Reykjavik, Iceland) 
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(iii) Expert Gold Standard (GS) Assessment of ADRs according to the AE 
Trigger List 
Two trained physicians (Dr. Paul Gallagher and I) assessed each of the 8 clinical cases. 
It was first ascertained if the patient described was experiencing any AEs on the AE 
Trigger List. Each of these AEs was then assessed for a possible drug cause using the 
WHO-UMC casualty tool. Once potential ADRs were identified, their timing, whether 
prevalent or incident, was determined. Finally, morbidity was identified by 
ascertaining the Sequence of Events, and the ADR severity was assessed using the 
Hartwig & Siegel rating scale (151). Complete agreement, in terms of all ADR 
assessments, was reached between the two assessors. This combined level of 
agreement (labelled “rater 1”) was set as the gold standard (GS), against which other 
participants’ assessments were compared.  
 
 2.2.5 Statistical analysis 
For the purpose of this study, physician responses were dichotomized into whether 
each clinical case experienced an ADR or not.  The responses of raters were cross-
tabulated with those of the GS assessment. Statistical analysis was performed using 
IBM SPSS® Statistics version 22. Cohen’s Kappa Statistic was used to determine the 
level of agreement between each rater and the GS. This was also a chance-corrected 
measure of agreement on how raters classify individual items into the same category, 
in this instance the presence or absence of an ADR. The calculation of the kappa 
statistic is detailed in Figure 2.3. The kappa statistic was interpreted as poor if ≤ 0.2, 
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fair if 0.21–0.40, moderate if 0.51–0.6, substantial if 0.61–0.8 and good if 0.81–1.00 
(153). 
Figure 2.3: Calculation of the kappa statistic and proportions of positive and 
negative agreement between raters 1 and 3 
 
 
Kappa co-efficient = (observed agreement – chance agreement) / (1 – chance 
agreement) 
Observed agreement = (4 + 3) / 8 = 0.875 
Chance agreement = (0.625 x 0.500 ) + (0.500 x 0.375 ) = 0.500 
Kappa = (0.875 – 0.500 ) / (1 – 0.500) = 0.750 
Proportion of positive agreement (ppos) = 2 (4) / (8 + 4 – 3) = 0.89 
Proportion of negative agreement (pneg) = 2 (3) / (8 – 4 + 3) = 0.86 
     
    ADR ascertainment 
 
Rater 1 (GS)  
ADR occurred    No ADR Total 
 
Rater 3 
ADR occurred 4 (50%) 1 (12.5%) 5 (62.5%) 
No ADR 0 (0%) 3 (37.5%) 3(37.5%) 
Total 4 (50%) 4 (50%) 8 
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2.3 RESULTS 
 2.3.1 The AE Trigger List 
The 12 AE Trigger List and the definitions agreed upon by consensus are displayed in 
Table 2.4. 
Table 2.4: Adverse event (AE) Trigger List.  
Event Definition 
 
New onset fall/s 
 
New fall 
New onset of unsteady gait New onset of unsteady gait that results in poor mobility and 
unsteady balance 
Acute kidney injury An increase in serum creatinine by 0.3mg/dl (26.5 μmol/l) within 
48 hours or an increase in serum creatinine by 1.5 baseline, which 
is known or presumed to have occurred within the prior 7 day 
 
Symptomatic orthostatic 
hypotension 
A systolic blood pressure drop ≥20 mmHg ± diastolic blood 
pressure drop ≥10mmHg within 3 minutes of standing from the 
lying or sitting posture associated with symptoms 
Major serum electrolyte 
disturbance 
A sodium (Na+) of < 130 mmol/l or > 145 mmol/l  and/or a 
potassium (K+) < 3.5 mmol/l or > 5.2 mmol/l and/or a corrected 
calcium (Ca++) < 2.1 mmol/l or > 2.7 mmol/l 
 
Symptomatic bradycardia Heart rate of < 50 beats/minute with symptoms 
New major constipation Subjective symptoms of hard stools and/or less than 3 bowel 
movements per week and/or supported by nursing records 
Acute bleeding Malaena or haematuria or haematemesis or haemoptysis with or 
without a drop in haemoglobin level >2g/dl (not due to 
rehydration) or associated symptoms (hypotension, tachycardia, 
pallor) or secondary renal failure 
 
Acute 
dyspepsia/nausea/vomiting 
Subjective symptoms of acute ‘indigestion’/’upset stomach’ or 
acute abdominal pain or acute refusal to eat or acute 
heartburn/acid reflux or acute nausea/vomiting 
Acute diarrhoea New liquid stools reported by the patient or the nursing staff or 
new liquid stools detected by medical staff on physical 
examination or new liquid (non-solid) stools occurring more than 
3 times in 24 hours 
Acute delirium Confirmed by a reliable witness and the DSM-V criteria. 
Supported by a 4AT ≥ 4 and/or MMSE < 23/30 
 
Symptomatic hypoglycaemia Symptoms with a blood glucose of < 3.5 mmol/L or < 63 mg/dl 
Legend: MMSE = Mini mental state examination, 4AT = Screening test for delirium 
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 2.3.2 A standardized investigative process for each AE on the Trigger List 
  to ascertain whether an ADR occurred and assessment of the  
  associated morbidity. 
A standardized AE assessment form was developed to incorporate all the key 
concepts that were discussed above (Table 2.5). This standardized form includes 
asking questions above the timing of the AE, the duration of the AE and key questions 
to guide the likelihood of a drug being involved e.g. “is the event a known reaction 
to the drug in question?”. If an AE is found to be an ADR then the Hartwig & Siegel 
scale must to be completed. Every AE should be assessed in the same robust manner. 
If an ADR occurs, the Sequence of Events should to be recorded to robustly assess 
morbidity. 
 Once an AE is recorded and the below form completed, this form should then 
be sent to an adjudication committee for assessment. The structured process put 
forward to assist this robust process portrayed in Figure 2.4. An ADR is confirmed if 
two persons agreed that a probable or certain ADR, as per the WHO-UMC causality 
assessment has occurred.  
 
 
 
 
 
80 
 
Table 2.5: Standardized AE assessment form 
Event = [name event type] 
Did the event occur: 
1. Pre hospital (prevalent) 
2. Occurred in hospital (incident) 
 
 
 
Approximate duration of the process: 
1. Discrete event 
2. < 1 day 
3. 1 – 3 days 
4. 4 – 7 days 
5. 8 – 10 days 
6. ≥ 11 days 
 
 
 
 
 
 
Were drug(s) the exclusive/predominant cause of the event? Y/N 
If no possible culprit drug implicated in the process, tick here and skip the below questions and 
process to narrative box at the end of the form 
 
Name drug implicated:  
(a list of drugs commonly implicated in the above event is listed here) 
Regarding drug named: 
 
Is the event a known reaction/adverse effect to the drug in questions? 
Did this reaction/event previously occur in this patient secondary to this drug? 
Was the medication changed in a potentially deleterious fashion (↑, ↓ or abruptly stopped) prior 
to event? 
Was the medication changed in a potentially corrective fashion post event? 
Was the corrective change in medication post event associated with resolution? 
Is there an additional medication involved? If yes answer the above questions for this drug?  
 
 
 
 
 
 
Did any of the following conditions contribute to the event? 
(a list of conditions commonly implicated in the above event is listed here) 
Did the environment contributed to the event?   Specify:____________  
Evidence for event/process (tick all that apply) 
Physician narrative 
Nursing narrative 
Radiology evidence 
Laboratory/blood evidence 
Other:__________ 
 
 
 
 
 
Did the team implicate a medication in the event Y or 
N 
Drug (name) Causality (WHO-UMC) Severity (Hartwig & Siegel) 
 Certain 
Probable 
Possible 
Unlikely 
 0       1       2       3       4       5       6       7  
  
         
 
 
Did process/event occur as part of a sequel? Y or 
N 
If yes, list sequel order 
Example: A patient began VOMITING because of clarithromycin which subsequently caused an ACUTE 
KIDNEY INJURY which then led to a FALL. [Vomiting = 1, AKI = 2, Fall = 3] 
Narrative 
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Figure 2.4: Adjudication Process 
  
 
 2.3.3 The IRR of this new ADR process 
 (i)  Participants and training 
The 21 participants included 11 physicians, 5 nurses, 3 pharmacists, and 2 biomedical 
scientists, of whom 12 attended the training session i.e. 4 of 11 physicians, 2 of 3 
pharmacists, 2 of 2 biomedical scientists and 4 of 5 nurses. There was no significant 
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difference in the numbers attending training from each group, Χ2 (3) = 4.617, p = 
0.062, however there was a trend towards more physicians not attending training 
than all other groups, Χ2 (1) = 4.073, p = 0.056.  
 
(v) GS assessment of ADR occurrence in the eight clinical cases 
All 8 clinical cases experienced AEs, with four experiencing ADRs (Table 2.6). Eight of 
the twelve AEs listed on the Trigger List occurred and required assessment. One 
patient had an ADR that was not listed on the AE Trigger List i.e. drug-induced liver 
injury (DILI). Excluding the DILI, 16 AEs were identified of which 8 AEs were identified 
as ADRs with inter-dependent relationships identified between events. 
 
Table 2.6: Answers to the eight clinical cases in the inter-rater reliability exercise 
Case Name and Number of 
prevalent AEs 
Prevalent ADRs Name and Number 
of incident AEs 
Incident ADRs 
1 DILI 1 DILI 1  0  0 
2 Constipation 
Nausea/vomiting 
2 Constipation 
Nausea/vomiting 
2  0  0 
3 AKI 
Elect disturbance 
2  0  0  0 
4 Delirium 1 Delirium 1 AKI 
Diarrhoea 
2 AKI 
Diarrhoea 
2 
5 Constipation 
Nausea/vomiting 
2  0  0  0 
6 Fall 
Elect disturbance 
Delirium 
3  0  0  0 
7 Fall 
OH 
2 Fall 
OH 
2 Constipation 1  0 
8 Acute kidney 
injury 
Elect disturbance 
2  0  0  0 
Legend: AEs = adverse events, ADRs = adverse drug reactions, DILI = drug induced liver injury, AKI = 
acute kidney injury, elect = electrolyte, OH = orthostatic hypotension 
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(i) Inter-rater reliability (IRR) 
Table 2.7 displays the kappa co-efficient for all raters compared to the GS for 
determining the presence or absence of ADRs. Columns A, B, C and D indicate the 
status of agreement between raters and the GS. For example, rater 1 (GS) and rater 
2 agreed that ADRs were not identified in 4 clinical cases (column A). There were no 
instances in which rater 1 did not identify an ADR but rater 2 did so (column B). 
Similarly, there were no instances where rater 2 identified an ADR that rater 1 did 
not (column C). In 4 instances, both rater 1 and rater 3 identified an ADR (column D). 
 The overall median IRR was 0.750 (IQR 0.750 – 0.875); for physicians, the IRR 
was 0.75 (IQR 0.500 – 1.000), for pharmacists, the IRR was 0.750 (IQR 0.750 – 1.000), 
for biomedical scientists, the IRR was 0.750 (SD 0.750 – 0.750) and for nurses, the IRR 
was 0.750 (SD 0.750 – 0.750). The IRR of those who attended training was 0.750 (IQR 
0.562 – 0.750), whilst among those that did not attend training, the IRR was 0.750 
(IQR 0.750 – 1.00), with no significant difference identified between these two 
groups, U = 42, p = 0.422. Four physicians and 1 pharmacist obtained a perfect kappa 
score of 1.  
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Table 2.7: Inter-rater reliability (IRR) of the presence of ADRs 
Kappa Co-efficient  Level of agreement to gold standard identifying 
out of 8 patients how many had ADRs 
Rater  A B C D Kappa 
Gold standard * Rater 2 – physician 4 0 0 4 1.000 
Gold standard * Rater 3 – physician 3 1 0 4 0.750 
Gold standard * Rater 4 – physician 4 0 0 4 1.000 
Gold standard * Rater 5 – physician 3 1 0 4 0.750 
Gold standard * Rater 6 – physician 3 1 0 4 0.750 
Gold standard * Rater 7 – physician 4 0 0 4 1.000 
Gold standard * Rater 8 – physician 2 2 1 3 0.250 
Gold standard * Rater 9 – physician 4 0 0 4 1.000 
Gold standard * Rater 10 – physician 4 0 2 2 0.500 
Gold standard * Rater 11 – physician 4 0 2 2 0.500 
Gold standard * Rater 12 - physician 1 3 0 4 0.250 
Gold standard * Rater 13 - pharmacist 4 0 0 4 1.000 
Gold standard * Rater 14 - pharmacist 4 0 1 3 0.750 
Gold standard * Rater 15 - pharmacist 4 0 1 3 0.750 
Gold standard * Rater 16 – Biomedical 
scientist 
4 0 1 3 0.750 
Gold standard * Rater 17 - Biomedical 
scientist 
4 0 1 3 0.750 
Gold standard * Rater 18 – nurse 4 0 1 3 0.750 
Gold standard * Rater 19 – nurse  4 0 1 3 0.750 
Gold standard * Rater 20  - nurse     4 0 1 3 0.750 
Gold standard * Rater 21 – nurse  3 1 0 4 0.750 
Gold standard * Rater 22 – nurse  4 0 1 3 0.750 
Median Kappa     0.750 
(IQR0.750 –
0.875) 
A – Both the gold standard and rater in question agreed no ADR occurred 
B – Gold standard concluded an ADR did not occur / rater in question concluded an ADR did occur 
C – Gold standard concluded an ADR occur / rater in question concluded an ADR did not occur 
D –  Both the gold standard and rater in question agreed an ADR occurred 
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Table 2.8 displays the kappa co-efficient for all raters compared to the GS for 
determining whether a patient had a prevalent or an incident ADR.  For each case, a 
prevalent ADR could or could not occur and similarly an incident ADR could or could 
not occur. Columns A, B, C and D indicate the status of agreement between raters 
and the GS. For example, rater 1 (GS) and rater 2 agreed that no prevalent or incident 
ADR occurred in 11 instances (column A). In 0 instances, rater 1 did not identify a 
prevalent or incident ADR but rater 2 did so (column B). There was one instance 
where rater 2 identified a prevalent or an incident ADR that rater 1 did not (column 
C). In 4 instances, both rater 1 and rater 2 identified prevalent or incident ADR 
correctly in 4 cases an ADR (column D).  
 The median kappa was 0.673 (IQR 0.478 – 0.846); for physicians 0.625 (0.478 
– 0.846), for pharmacists 0.673 (IQR 0.204 – 0.846), for biomedical scientists 0.846 
(0.846 – 0.846) and for nurses 0.586 (IQR 0.412 – 0.673). The IRR of those who 
attended training was 0.673 (IQR 0.478 – 0.846), compared to 0.625 (IQR 0.466 – 
0.750) among those who did not, i.e. no significant difference identified between the 
two groups, U = 49, p = 0.754. One physician scored a perfect kappa score of 1.  
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Table 2.8: Inter-rater reliability of whether prevalent or incident events occurred 
Kappa Co-efficient Agreement with prevalent and incident ADRs   
Rater  A B C D Kappa 
Gold standard * Rater 2 – physician 11 0 1 4 0.846 
Gold standard * Rater 3 – physician 10 1 0 5 0.862 
Gold standard * Rater 4 – physician 11 0 1 4 0.846 
Gold standard * Rater 5 – physician 9 2 1 4 0.586 
Gold standard * Rater 6 – physician 9 2 1 4 0.586 
Gold standard * Rater 7 – physician 11 0 1 4 0.846 
Gold standard * Rater 8 – physician 8 3 2 3 0.310 
Gold standard * Rater 9 – physician 11 0 0 5 1.000 
Gold standard * Rater 10 – physician 11 0 3 2 0.478 
Gold standard * Rater 11 – physician 11 0 3 2 0.478 
Gold standard * Rater 12 - physician 8 3 0 5 0.625 
Gold standard * Rater 13 - pharmacist 11 0 1 4 0.846 
Gold standard * Rater 14 - pharmacist 11 0 2 3 0.204 
Gold standard * Rater 15 - pharmacist 11 0 2 3 0.673 
Gold standard * Rater 16 – Biomedical scientist 11 0 1 4 0.846 
Gold standard * Rater 17 - Biomedical scientist 11 0 1 4 0.846 
Gold standard * Rater 18 – nurse 11 0 2 3 0.673 
Gold standard * Rater 19 – nurse  11 0 2 3 0.673 
Gold standard * Rater 20  - nurse     11 0 3 2 0.478 
Gold standard * Rater 21 – nurse  9 2 1 4 0.586 
Gold standard * Rater 22 – nurse  10 1 3 2 0.347 
Median Kappa     0.673 
(IQR0.478 –
0.846) 
A – Both the gold standard and rater in question agreed no prevalent or incident ADR occurred 
B – Gold standard concluded a prevalent or incident ADR did not occur / rater in question concluded  
a prevalent or incident ADR did occur 
C – Gold standard concluded  a prevalent or incident  ADR occur / rater in question concluded  a 
prevalent or incident  ADR did not occur 
D –  Both the gold standard and rater in question agreed a prevalent or incident ADR occurred 
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(ii) Variability between raters 
The level of agreement between raters and the GS for each individual case with 
regards to causality, severity and Sequence of Events are displayed in Table 2.9. 
 Variability was identified between the various raters and the GS assessment 
when assigning severity scores to ADRs as per Hartwig & Siegel severity scale; 
agreement rates varying between 9.5% and 52.4% were identified.  
 Additionally, raters’ responses varied when determining whether events 
were inter-dependent or completely independent ADRs.  Three cases contained a 
recognizable Sequence of Events i.e. case 2, case 4 and case 7. For case 2, 17 of the 
21 raters identified that constipation occurred secondary to a drug in case 2, 
however, just 5 raters identified nausea and vomiting as a drug-related event. For 
case 4, 15 of the 21 raters identified that diarrhoea occurred secondary to a 
medication, however just 3 raters correctly determined that this led to acute kidney 
injury.  Lastly for case 7, 7 of the 21 raters identified a fall occurred secondary to a 
drug, however 6 identified a fall as a sequence to orthostatic hypotension (OH). 
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Table 2.9: Percentage of agreement for each case with the gold standard i.e. correct answer. 
Variable  Gold standard PIs (n=6) PR (phys) 
(n=5) 
PR (pharm) 
(n=3) 
PR (biomed) 
(n=2) 
PR (nurses) 
(n=5) 
Total (n=21) 
Case 1         
ADR type N (%) Liver failure 6 (100%) 5 (100%) 3 (100%) 2 (100%) 5 (100%) 21 (100%) 
Prevalent or incident N (%) Prevalent 6 (100%) 5 (100%) 3 (100%) 2 (100%) 5 (100%) 21 (100%) 
Causative Drug (probable/certain) N (%) Flucloxacillin 6 (100%) 5 (100%) 3 (100%) 2 (100%) 5 (100%) 21 (100%) 
Extra drug (tramadol) N (%) No 1 (16.7%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 1 (4.76%) 
Extra drug (paracetamol) N (%) No 0 (0%) 1 (20%) 0 (0%) 0 (0%) 0 (0%) 1 (4.76%) 
H and S N (%) 5 0 (0%) 1 (20%) 1 (33.3%) 0 (0%) 0 (0%) 2 (9.5%) 
Case 2         
ADR type 1 N (%) Constipation 6 (100%) 3 (60%) 3 (100%) 2 (100%) 3 (60%) 17 (81%) 
ADR sequence 2 N (%) Dyspepsia / nausea / 
vomiting 
2 (33.3%) 0 (0%) 2 (66.66%) 0 (0%) 1 (20%) 5 (23.8%) 
Prevalent or incident N (%) Prevalent  6 (100%) 3 (60%) 3 (100%) 2 (100%) 3 (60%) 17 (81%) 
Causative drug 1 (probable/certain) N (%) Oxycodone 6 (100%) 3 (60%) 3 (100%) 2 (100%) 3 (60%) 17 (81%) 
H and S N (%) 4 4 (66.7%) 3 (60%) 2 (66.66%) 0 (0%) 2 (40%) 11 (52.4%) 
Case 3         
ADR type  N (%) No ADR 5 (83.3%) 3 (60%) 3 (100%) 2 (100%) 1 (20%) 17 (81%) 
Case 4         
ADR type 1  N (%) Delirium 4 (66.7%) 3 (60%) 2 (66.7%) 2 (100%) 2 (40%) 13 (61.9%) 
Prevalent or incident N (%) Prevalent  4 (66.7%) 3 (60%) 2 (66.7%) 2 (100%) 2 (40%) 13 (61.9%) 
Causative drug (probable/certain) N (%) oxycodone 4 (66.7%) 3 (60%) 2 (66.7%) 2 (100%) 2 (40%) 13 (61.9%) 
Extra drug (tramadol) N (%) No 3 (50%) 2 (40%) 2 (66.7%) 2 (100%) 1 (20%) 10 (47.6%) 
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H and S N (%) 4 3 (50%) 2 (40%) 2 (66.7%) 1 (50%) 1 (20%) 9 (42.9%) 
ADR type 2 N (%) Diarrhoea 5 (83.3%) 4 (80%) 0 (0%) 2 (100%) 4 (80%) 15 (71.4%) 
ADR type 3  N (%) AKI 2 (33.3%) 1 (20%) 0 (0%) 0 (0%) 0 (0%) 3 (14.3%) 
Prevalent or incident N (%) Incident 5 (83.3%) 4 (80%) 0 (0%) 2 (100%) 4 (80%) 15 (71.4%) 
Causative drug (probable/certain) N (%) Piperacillin / tazobactam 4 (66.7%) 4 (80%) 0 (0%) 2 (100%) 3 (60%) 13 (61.9%) 
Extra drug (cefuroxime) N (%) No 1 (16.7%) 0 (0%) 0 (0%) 0 (0%) 1 (20%) 2 (9.5%) 
H and S N (%) 4 3 (50%) 3 (60%) 0 (0%) 1 (50%) 4 (80%) 11 (52.4%) 
Case 5         
ADR type N (%) No ADR 6 (100%) 4 (80%) 3 (100%) 2 (100%) 5 (100%) 20 (85.2%) 
Case 6         
ADR type N (%) No ADR 5 (83.3%) 4 (80%) 3 (100%) 2 (100%) 5 (100%) 19 (90.5%) 
Case 7         
ADR type 1 N (%) OH 1 (16.7%) 1 (20%) 2 (66.6%) 0 (0%) 0 (0%) 6 (28.6%) 
ADR type 2  N (%) Fall 3 (50%) 2 (40%) 2 (66.6%) 0 (0%) 0 (0%) 7 (33.3%) 
Prevalent or incident N (%) Prevalent 4 (66.7%) 2 (40%) 2 (66.6%) 0 (0%) 0 (0%) 7 (33.3%) 
Causative drug (probable/certain) N (%) furosemide 4 (66.7%) 1 (20%) 2 (66.6%) 0 (0%) 0 (0%) 7 (33.3%) 
Extra drug (Dosulepin) N (%) No 0 (0%) 1 (20%) 0 (0%) 0 (0%) 0 (0%) 1 (4.8%) 
Extra drug (Diltiazem) N (%) No 0 (0%) 1 (20%) 0 (0%) 0 (0%) 0 (0%) 1 (4.8%) 
H and S N (%)  2 (33.3%) 2 (40%) 1 (33.3%) 0 (0%) 0 (0%) 5 (23.8%) 
Case 8         
ADR type N (%) No ADR 6 (100%) 4 (80%) 3 (100%) 2 (100%) 5 (100%) 20 (95.2%) 
Legend: PI = principal investigator, PR = primary researcher, phys = physicians, pharm = pharmacists, biomed = biomedical scientist 
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2.4 DISCUSSION 
An AE Trigger List, based on the 12 most common ADRs that occur in older adults, 
was developed and validated for application in older adults. Each AE on the Trigger 
List was given a clear definition to ensure accurate capture of clinically significant AEs 
and thus clinically significant ADRs. ADRs should be clearly classified as occurring 
prehospital, prevalent ADRs, or during hospitalisation, incident ADRs. To avoid over-
reporting of ADRs, all AEs and ADRs should be viewed as processes rather than 
discrete events.  To capture the morbidity associated with ADRs, the inter-dependent 
relationship between AEs on the Trigger list, if deemed drug related, should be 
recorded i.e. Sequence of Events. Lastly to further strengthened ADR assessments, 
all AEs assessed for a drug cause should be sent to an adjudication committee to 
ensure 2 people agree on the final causality per the WHO-UMC causality criteria.  
 The above proposed approach to ADR assessments has the potential to 
standardise the identification, classification and reporting of ADRs. ADR assessments 
approached in this manner has the potential to allow comparisons between future 
observational studies. In addition, where ADRs are the primary endpoints in 
interventional studies, it will ensure ADRs are captured in a clear and robust manner 
and thus, interventions to reduce same are appropriately assessed. Using this 
approach may also mean that more ADRs are identified and therefore the offending 
drug is stopped earlier and the associated morbidity and mortality avoided. To date, 
economic consequences and mortality associated with ADRs has been captured but 
the true morbidity associated has not. The role of Sequence of Events will be 
paramount going forward. 
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 The IRR of ascertaining ADRs using this 12 point AE Trigger List and the IRR of 
ascertaining the of the timing of ADRs (prevalent vs incident) was found to be 
substantial with median values of 0.750 (IQR 0.750 – 0.875) and 0.673 (IQR 0.478 – 
0.846) respectively. Disagreements were identified regarding the grading of ADR 
severity using the standardized Hartwig & Siegel scale (151). In addition, variations 
were identified when identifying the Sequence of Events. Overall, the kappa co-
efficient indicate that the common reading and interpretation of the above proposed 
methodology was good. 
 However, there were limitations identified for the IRR exercise. Firstly, not all 
participants attended the training session, notably fewer physicians attended, 
presumably because they considered themselves already proficient in ADR 
ascertainment. Furthermore, for those that did attend the ADR ascertainment 
training, there was no pre-training exercise with which to compare their post training 
answers i.e. to determine if the training exercise improved their ADR ascertainment 
capabilities. It is speculative whether improvements in kappa co-efficient would have 
been observed if all participants had attended the training exercise and all 
participants completed this assessment pre- and post-training. This study could have 
benefited from participants applying the methodology to more than 8 clinical cases. 
Kappa coefficient results for physicians for ADR identifications were skewed, with 
two physicians scoring 0.250 and two others scoring 0.500. This may relate to the 
fact that English was not the first language among the first pair of physicians. This 
fact may have resulted in limited value for them from the training exercise.  
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 This research was completed as part of the SENATOR (Development and 
clinical trials of a new Software ENgine for the Assessment and optimization of drug 
and non-drug Therapy in Older peRsons) clinical trial feasibility study (150), which 
examined the prevalent rates of incident ADRs in older hospitalised adults. This study 
highlighted many challenges with assessing ADRs as discussed through the chapter 
and instigated the proposed methodology for the SENATOR RCT. The SENATOR RCT 
is looking at a software intervention advising on medication optimisation at reducing 
in hospital ADRs and will be using the methodology proposed in this chapter.  
 Since this research, two further ADR trigger lists have been developed (154, 
155).  Both differ from the trigger list proposed in this chapter. The trigger list by Silva 
et al. does not incorporate clinical symptoms of ADRs but rather looks at triggers such 
as abrupt medication withdrawal or the prescription of specific drug classes (154). 
This trigger list has been tested and has been found to identify ADRs in only 53.3% of 
patients. The later, by Guzmán et al. comprises a much larger 51 point trigger list. 
Triggers here are based on medications and their concentrations, antidotes and 
abnormal lab values. This trigger list has yet to be tested in an observational study. 
 The ADR ascertainment methodology described in this study, along with the 
ADR adjudication process could be used to standardize the reporting of ADRs in 
future ADR studies. This would greatly help with assessment and comparison of ADR 
attenuating interventions.  The next two chapters will report on (i) prevalent ADRs in 
the acute unselected older hospitalised patients and (ii) prevalent ADRs in 
hospitalised adults with cancer, using the above methodology. 
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CHAPTER 3: 
Prevalence of adverse drug reactions (ADRs) in an acute unselected hospital 
population as determined by new ADR ascertainment methodology 
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3.1  INTRODUCTION 
The lack of studies examining the prevalence of multimorbidity in hospitalised older 
adults was discussed in Chapter 1. The subjective nature of ADR identification, 
classification and reporting was discussed in Chapter 2, in which a novel approach to 
ADR ascertainment was described and validated. ADRs are reported to cause 
hospitalisation in approximately 10% of older adults by two large meta-analyses (83, 
144), however more recent observational studies report higher prevalent ADR rates 
of 21% to 26.3% (46, 74). 
 
 3.1.1  Objectives 
The objectives of this study were: 
(i) To investigate and describe the burden of multimorbidity in unselected 
older (≥ 65 years) adults presenting to hospital with an acute illness. 
(ii) To use the newly developed AE Trigger List to determine the prevalence 
of ADRs causing or contributing significantly to hospital admission in an 
acute unselected older (≥ 65 years) adult population. 
(iii) To classify the identified ADRs according to type, causality, associated 
morbidity, severity, predictability and preventability. 
(iv) To identify risk factors for ADRs in this patient cohort. 
 
The work undertaken in this chapter, including study design, data collection and 
statistical analysis, is entirely my own. 
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3.2  METHODS 
 3.2.1 Study setting and design 
This prospective observational study was conducted at Cork University Hospital 
(CUH), an academic teaching hospitals in southern Ireland, over 107 days between 
August 2014 and March 2017. CUH is a major university teaching hospital with 850 
inpatient beds and over 25,000 emergency admissions per year. In 2016, there were 
approximately 65,000 emergency department presentations, approximately 210,000 
outpatient attendances and just over 45,000 inpatient discharges. 
 
 3.2.2 Patient eligibility and consent 
All patients’ aged ≥ 65 years admitted as emergency cases under the care of any 
medical or surgical speciality were eligible for inclusion. Exclusion criteria were as 
follows: (i) patients who had already enrolled in the study on a previous hospital 
admission, (ii) patients deemed to be actively dying by the attending physician, at the 
point of admission, and (iii) patients who declined to participate. 
 The study’s objectives were explained to patients. If they agreed to 
participate, patients provided written informed consent. In circumstances where 
patients were unable to give consent due to reduced decision making ability e.g. 
delirium or advanced dementia, consent was obtained from their legal 
representative. Inclusion in the study was documented in patients’ medical records. 
The study protocol was assessed and approved by the local research ethics 
committees at University College Cork (Appendix 2).
96 
 
3.2.3 Study population and sample size calculation 
Using an estimated ADR prevalence rate of 20%, with a margin of error of 5% and a 
95% confidence limit, a minimum sample of 251 patients was required for this study. 
This power calculation was based on the formula outlined in Figure 3.1 and adjusted 
using admission data from 2015 i.e. the total number of patients admitted to Cork 
University Hospital (CUH) ≥65 years old between January 1st and December 31st 2015.  
Table 3.1: Sample size calculation 
Hospital admission rates between January and 
December 2015 (excluding repeat admissions) 
Sample Size calculation 
Cardiology 1656 Formula 
n = Z2 x P (1 – P) 
D2 
n = sample size 
Z = Z statistic for the level of confidence 
(1.96) 
P = Expected prevalence (20% or 0.20) 
D = margin of error (5% or 0.05)  
 
n = (1.96)2 x (0.20) (1 – 0.2) = 246 
0.052 
 
Adjusted for population available: 
 
Formula  
n0 X N 
N0 + (N – 1) 
 
n0 = population available to recruit from 
N = sample size calculation 
             
 8945 x 246 = 239 (+ 5%) + 12 = 251 
      8945 + (246 – 1)                                                             
 
Endocrinology 61 
Diabetes Mellitus 70 
Gastroenterology 85 
Geriatric Medicine 1035 
Haematology 123 
Neurology 109 
Neurosurgery 152 
Orthopaedics 834 
Plastic surgery 120 
Maxillary facial 8 
Renal Medicine 257 
Respiratory Medicine 450 
Rheumatology 109 
General Surgery 480 
Hepato-biliary Surgery 1 
Vascular Surgery 60 
Breast Surgery 5 
Infectious Diseases 116 
General Medicine 2970 
Cardiothoracic Surgery 168 
Urology  76 
Total 8945 
 
 3.2.4 Data collection 
All participants and patients’ medical notes were reviewed within 24 hours of 
admission. Each morning, a list of admissions from the previous 24 hours was 
compiled. To avoid any bias, patients were enrolled according to the time of 
presentation to the hospital.  
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 The following data were extracted and transferred onto a standardized 
proforma (Appendix 3): (i) demographic details, (ii) medical co-morbidities (in order 
to calculate Cumulative Illness Rating Scale (CIRS) scores) (156), (iii) concurrent 
medications, (iv) functional ability (Barthel Index) (157), (v) cognitive ability (Mini-
mental state examination – MMSE), in those ≥ 65 years (158), 4-At (159) and the 
Diagnostic and Statistical Manual of Mental Disorders V (DSM-V) to assess for 
delirium (160), (vi) laboratory values, and (vii) electrocardiogram (ECG) data. 
Medication reconciliation was completed using the Structured History taking of 
Medication use (SHiM) (32).  These validated tools are described in brief below. 
 
(i) Cumulative Illness Rating Scale (CIRS) 
The CIRS (156) is a scoring system that measures the burden of chronic medical 
illnesses by considering the severity of each illness (Figure 3.1). It does this by ranking 
the severity of each disease on a scale of 0 to 4; 14 categories of illness are 
represented according to various physiological systems. A score of 0 represents no 
active illness, whereas 4 represents an extremely severe problem. The higher a 
patient’s score, the higher the morbidity burden; CIRS scores range from 0 to 56. CIRS 
was developed to assist physicians in quantifying medical problems and allowing 
meaningful comparison of medical burden between patients. CIRS is applicable to 
patients of all ages. 
 A comprehensive medical history, and relevant laboratory values are required 
to apply the CIRS tool.  CIRS was chosen for this study instead of the more commonly 
used Charlson Comorbidity Index (161) because the disease weighting system in the 
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Charlson Comorbidity Index was felt to be outdated e.g. metastatic disease is 
weighted with a maximum score of 6. This does not reflect the many advances that 
have occurred in the treatment of metastatic cancer since the original Charlson Index 
was published in 1987.  
Figure 3.1: Cumulative illness rating scale (CIRS) scoring system 
Body system Score 
 
  
Cardiac 0  –  1  –  2  –  3  –  4  
Vascular 0  –  1  –  2  –  3  –  4  
Haemapoetic 0  –  1  –  2  –  3  –  4  
Respiratory 0  –  1  –  2  –  3  –  4  
ENT (eye, ear, throat, larynx) 0  –  1  –  2  –  3  –  4  
Upper GI 0  –  1  –  2  –  3  –  4  
Lower GI 0  –  1  –  2  –  3  –  4  
Hepatic 0  –  1  –  2  –  3  –  4  
Renal 0  –  1  –  2  –  3  –  4  
Other GU 0  –  1  –  2  –  3  –  4  
Musculoskeletal 0  –  1  –  2  –  3  –  4  
Neurological 0  –  1  –  2  –  3  –  4  
Endocrine-metabolic 0  –  1  –  2  –  3  –  4  
Psychiatric/Behavioural 0  –  1  –  2  –  3  –  4  
  
Score (range 0 – 56)  
 
Scoring  
0 = no problem 
1=  current mild problem/past significant problem 
2 = moderate disability or morbidity and/or requires first line treatment 
3 =  Severe problem and/or constant and significant disability and/or difficult to control chronic problems 
4 = Extremely severe problem and/or immediate treatment required and/or organ failure and/or severe 
functional impairment 
 
If scoring malignancy 
0 = no cancer 
1 = cancer diagnosed in the remote past without evidence of recurrence or sequelae in the past 10 years 
2 = cancer diagnosed in the past without evidence of recurrence or sequelae in the past five years 
3 = required chemotherapy, radiation, hormonal therapy or surgical procedure for cancer in the past five 
years 
4 = Recurrent malignancy of life threatening potential/failed containment of the primary 
malignancy/palliative treatment stage 
Legend: GI = Gastrointestinal; GU = genitourinary 
 
(ii) Barthel Index 
The Barthel Index (157) (Appendix 4) classifies functional status by measuring 
activities of daily living (ADLs). It consists of 10 parameters describing ADLs and 
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mobility. Each parameter can be scored a 0 or 1 and for some parameters a score 2 
can be given. The maximum score is 20 i.e. fully independent in personal activities of 
daily living. The lower the score, the more dependent a person is. To apply the 
Barthel Index, patients or caregivers need to be able to answer questions on 
functional ability. 
  
(iii) Mini Mental State Examination (MMSE) 
The MMSE is a validated tool designed to assess cognitive status in patients aged ≥65 
years old (Appendix 5) (158). This 30 item questionnaire is widely used to identify 
cognitive impairment in both the clinical and research settings. It is a poor 
discriminator of mild cognitive impairment from dementia, in which case the 
Montreal Cognitive Assessment (MOCA) is more frequently deployed instead (162). 
 
(iv) 4-AT Test 
The 4-AT test is a validated tool to assess for the prevalence of delirium (159). It 
assesses 4 components (Figure 3.2): alertness, orientation, attention and fluctuating 
consciousness. It incorporates the Months Backwards Test (MBT). It is quick and easy 
to use. The maximum score on the 4-AT is 14. A score of ≥ 4 suggests a possible 
delirium with or without an underlying cognitive impairment, a score of 1 or 2 
suggested possible cognitive impairment and a score of 0 indicates that delirium or 
severe cognitive impairment is unlikely. 
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Figure 3.2: 4-AT delirium screening test 
 Score 
 
 
Alertness 
Normal (fully alert, but not agitated, throughout assessment) 
Mild sleepiness for <10 seconds after waking, then normal 
Clearly abnormal 
 
0 
0 
4 
  
AMT4 
Age, date of birth, place, current year 
No mistakes 
1 or more mistakes 
2 or more mistakes 
 
 
0 
1 
2 
  
Attention 
“Please tell me the months backwards, starting at December?” 
Achieves 7 or more correctly 
Starts and scores <7/ refuses to start 
Untestable (cannot start because unwell, drowsy, inattentive) 
 
 
 
0 
1 
2 
Acute Change of fluctuating course 
Evidence of significant change/fluctuation in: alertness, cognition, other mental function  
(e.g. paranoia, hallucinations) arising over the last 2 weeks and still evident in last 24hrs 
No or yes 
 
0 
4 
Total Score  
 
 
(v) Structured History of Medications (SHiM) 
The SHiM (Appendix 6) is a structured method that aims to assist physicians with 
verifying all medications a patient is taking and thus aid with medication 
reconciliation (32). It comprises 16 questions which ensures, as much as possible, 
that an accurate account of all medication use, including over the counter 
medications (OTC) and recent short course treatments, occurs. It also defines 
adherence to medications, previous side effects and ADRs, as well as patients’ 
concerns regarding their medications. 
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(vi) Rockwood’s Clinical Frailty Scale (CFS) 
The Rockwood Clinical Frailty Scale (Appendix 7) is a 9 point scale that was developed 
to help classify patients according to their level of frailty (163). A score of 1 implies a 
patient is very fit, whereas a score of 8 indicates high level dependency and 
impending end-of-life status. Persons receive a score of 9 if they have a terminal 
diagnosis with a known life expectancy of ≤ 6 months. This tool, although primarily 
developed for use in classifying frailty in patients with dementia, is now used to 
identify and classify frailty in all patients. It usually takes less than 30 seconds to 
apply. 
 
 3.2.5 Potentially inappropriate prescribing 
Potentially inappropriate prescribing was assessed using STOPP/START criteria (37) 
(Appendix 8). STOPP/START criteria were originally developed and validated through 
Delphi technique in 2008 (36) and further updated in 2014 (37). STOPP/START is an 
explicit prescribing tool that aims to highlight common instances of potentially 
inappropriate prescribing and potentially prescribing omissions (PPOs) in adults 65 
years and older. It consists of 80 potentially inappropriate prescriptions (PIPs) and 34 
PPOs and is divided according to physiological system. For their application, a 
physician requires an up to date list of all medical diagnoses, concurrent medications, 
baseline laboratory values and an ECG. STOPP/START criteria have been used to 
identify potentially inappropriate medication (PIM) use in multiple studies of older 
adults, both in Ireland (41, 45, 50) and Europe (34, 164) and elsewhere. PIMs listed 
in STOPP/START criteria are significantly associated with ADRs (46). The application 
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of STOPP/START criteria has been shown by way of RCTs to result in sustained 
improvement in various domains of medication appropriateness (72, 165), and 
reductions in incident ADRs in hospitalised older patients (74) as well as fewer 
incident falls in nursing home residents (73). The presence or absence of a PIM, 
according to STOPP/START criteria, was categorised as a dichotomous variable. 
Where there was uncertainty regarding appropriateness of a prescription this was 
treated conservatively i.e. the prescription was deemed appropriate.  
 
3.2.6 Adverse drug reactions 
The proportion of patients experiencing one or more non-trivial, probable or certain, 
ADR causing or contributing significantly to hospital admission was also recorded. For 
this study, Edwards and Aronson’s definition of an ADR was applied i.e. “An 
appreciably harmful or unpleasant reaction, resulting from an intervention related to 
the use of a medicinal product, which predicts hazard from future administration and 
warrants prevention or specific treatment, or alteration of the dosage regimen, or 
withdrawal of the product” (79). 
 To limit potential bias from selective ADR reporting and to ensure ADRs were 
not missed, the validated AE Trigger List of the 12 most common ADRs, as discussed 
in Chapter 2, was used. Data on any ADR not listed in the AE Trigger List was also 
collected e.g. acute liver injury. All AEs representing potential ADRs were recorded 
prospectively and subsequently reviewed to assess the causative role of current 
medications. The morbidity associated with ADRs was captured using the Sequence 
of Events. 
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 3.2.7 ADR causality, severity, predictability and preventability 
Causality was assessed using the World Health Organisation Uppsala Monitoring 
Centre (WHO-UMC) criteria (119). ADR severity was assessed using the Hartwig & 
Siegel scale, as discussed in Chapter 2 (151). ADR preventability was assessed using 
Hallas criteria i.e. definitely avoidable, possibly avoidable, unavoidable and 
unclassifiable (166). ADR predictability was assessed using the summary of product 
characteristics (SPC) (Table 3.2). ADRs were deemed predictable if they commonly 
(≥1/100 and <1/10) or very commonly (≥1/10) occurred in patients prescribed the 
medication in question. 
Table 3.2: ADR predictability 
Incident rate 
 
Incident description Predictability 
 
≥1/10 
≥1/100 and < 1/10 
≥1/1000 and < 1/100 
≥1/10,000 and < 1/1000 
< 1/10,000 
 
Very common 
Common 
Uncommon 
Rare 
Very rare 
 
Predictable 
Predictable 
Unpredictable 
Unpredictable 
Unpredictable 
 
 
 3.2.8 Statistical analysis 
Statistical analysis was performed using SPSS® version 22 for windows. Descriptive 
data were reported using the mean and standard deviation (SD) for variables that 
were normally distributed and median and interquartile range (IQR) for non-
parametric variables.  Differences in the distribution of categorical variables were 
compared using Pearson’s Chi-square (Χ2) test and continuous variables using the 
independent t test. The Mann Whitney U and Kruskal-Wallis tests were used to 
determine independence of two or more non-parametric variables respectively. 
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Pearson’s kappa coefficient was used to assess correlation between variables. 
Multivariable logistic regression was used to examine the influence of gender, age, 
number of medications and burden of co-morbidity on potentially inappropriate 
prescribing practices. One-way ANOVA was used to determine the difference in the 
mean of a dependent variable when there were 3 or more categories to the 
independent variable. The Hosmer & Lemeshow statistic was used to test the 
goodness-of-fit of the regression model. A probability value of less than 0.05 was 
considered statistically significant. 
 
3.3 RESULTS 
 3.3.1 Screening 
Between August 2014 and March 2017, a total of 274 emergency admissions were 
screened for study inclusion. Of these, 240 patients agreed to participate, 81.7% 
(n=196) of whom were medical patients and 18.3% (n=44) were surgical patients. 
These data are summarised in Figure 3.3 together with reasons for study exclusion. 
The distribution of admissions according to specialty are summarised in Figure 3.4. 
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Figure 3.3: Participant screening, exclusion and enrolment 
 
 
Figure 3.4: Distribution of admissions according to specialty  
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3.3.2 Population characteristics 
Baseline characteristics are displayed in Table 3.3. Similar numbers of males and 
females participated in this study (50.4% vs 49.6%). The mean age was 78.0 (SD 7.6) 
years. Almost half of the patients (44.2%) were ≥ 80 years old and approximately 1 in 
5 (22.5%) were ≥ 85 years old. Most patients were functionally independent, with 
71.4% (n=171) being categorised as independent or low level dependency (Barthel 
Index scores ≥16). Eighty three percent of patients (n=199) completed the MMSE. 
From these scores, normal cognition and mild cognitive impairment were identified 
in 57.9% and 15% respectively. Approximately 1 in every 5 patients had moderate or 
severe cognitive impairment. It must be mentioned that acutely ill patients can 
underperform on a MMSE due to delirium and thus mild cognitive impairment and 
dementia may be over-estimated. Delirium was identified in 19.6% (n=47) using the 
4-AT test and DSM-5 criteria. Collateral history was taken to confirm the presence of 
delirium. No differences in Rockwood Clinical Frailty Scale scores were identified 
between genders (Χ2 (8) = 12.018, p = 0.150).  Differences in the level of frailty were 
identified between age groups (Χ2 (16) = 37.662, p = 0.002) (Figure 3.5). 
One in four (25.4%) participants consumed alcohol on a weekly basis. Men 
were significantly more likely to do so (33.9% vs 16.8%, Χ2 (1) = 9.034, p = 0.003) and 
significantly more likely to drink more than the recommended weekly allowance 
(10.7% vs 1.7%, Χ2 (1) = 3.416, p = 0.004). Eight (3.3%) older adults drank more than 
25 units per week. Collateral history was obtained to confirm alcohol intake. One 
hundred and nineteen (49.6%) patients had a history of smoking and 10.4% (n=25) 
were current smokers.  
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Table 3.3: Characteristics of study population according to gender (n = 240) 
Variable Male 
n = 121   
Female 
n = 119  
Total 
n = 240 
P-value 
 
     
Age distribution     
Mean (SD) 75.6 (7.6) 78.6 (7.7) 78 (7.6) 0.986 
65 – 74 42 (34.7%) 38 (31.9%) 80 (33.3%) 0.648 
75 – 84 52 (43%) 54 (45.4%) 106 (44.2%) 0.708 
≥ 85 27 (22.3%) 27 (22.7%) 54 (22.5%) 0.945 
     
Functional ability (Barthel Index)     
Median (IQR) 20 (14 – 20) 19 (15 – 20) 19 (15 – 20) 0.655 
Range 2 – 20 6 – 20 2 – 20  
Independent (≥ 20) 63 (52.1%) 54 (45.4%) 117 (48.9) 0.300 
Low dependency (16 – 19) 24 (19.8%) 30 (25.2%) 54 (22.5%) 0.319 
Moderate dependency (11 – 15) 20 (16.5%) 22 (18.5%) 42 (17.5%) 0.690 
High dependency (6 – 10) 9 (7.4%) 13 (10.9%) 22 (9.2%) 0.349 
Maximum dependency (0 – 5) 5 (4.1%) 0 (0%) 5 (2.1%) 0.025* 
     
Cognitive ability (MMSE)     
Number that completed MMSE 98 (81%) 101 (84.9%) 199 (83%) 0.424 
Median (IQR) 26.5 (23 – 28) 26 (22 – 28) 26 (22-28) 0.439 
Range 9 – 30 8 – 30 8 – 30  
MMSE score 25 – 30 70 (57.9%) 69 (58%) 139 (57.9%) 0.632 
MMSE score 20 – 24 suggesting MCI 17 (14%) 19 (16%) 36 (15%) 0.788 
MMSE score 11 – 19 suggesting 
moderate cognitive impairment  
10 (8.3%) 11 (9.2%) 21 (8.8%) 0.875 
MMSE score 0 – 10 suggesting Severe 
cognitive impairment  
1 (0.8%) 2 (1.7%) 3 (1.3%) 0.579 
Severe cognitive impairment (unable to 
complete MMSE) 
11 (9.1%) 4 (3.4%) 15 (6.25%)  
     
Clinical Frailty Scale     
Mean (SD) 5 (2.1) 5 (1.9) 5 (2) 0.751 
     
Alcohol and Smoking     
Consumes alcohol weekly 41 (33.9%) 20 (16.8%) 61 (25.4%) 0.003* 
Consume ≥ recommended weekly 
limit** 
13 (10.7%) 2 (1.7%) 15 (6.3%) 0.004* 
History of smoking 79 (65.3%) 40 (33.6%) 119 (49.6%) <0.001* 
Current smokers 17 (14%) 8 (6.7%) 25 (10.4%) 0.063 
     
Legend: SD = standard deviation, IQR = inter-quartile range, MMSE = mini-metal state examination, 
MCI = mild cognitive impairment** ≥ 11 units for females, ≥ 17 units for males 
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Figure 3.5: Frailty according to age category 
 
 
Key Findings 1: 
 Approximately 1 in 3 had a moderate to high level of functional 
dependency. 
 Approximately 1 in 5 had a moderate to severe dementia. 
 Approximately 1 in 5 experienced delirium. 
 Approximately 1 in 4 were very fit, well or managing well per Rockwood’s 
frailty scale 
 Approximately 1 in 4 were severely frail, very severely frail or terminally ill 
per Rockwood’s frailty scale 
 
3.3.3 Level of morbidity  
The level of morbidity in this population was measured by the total number of 
chronic conditions, the number of chronic conditions requiring regular medications 
and the CIRS score. These data are summarised in Table 3.4.  
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Table 3.4: Level of morbidity according to gender 
Variable Male 
n = 121   
Female 
n = 119  
Total 
n = 240 
P-value 
 
 
Multi-morbidity 
    
≥2 conditions 120 (99.2%) 117 (99.3%) 237 (98.8%) 0.551 
≥3 conditions 117 (96.7%) 114 (95.8%) 231 (96.3%) 0.715 
≥4 conditions 106 (87.6%) 111 (93.3%) 217 (90.4%) 0.135 
≥5 conditions 103 (85.1%) 100 (84%) 203 (84.6%) 0.815 
 
Conditions 
    
Mean (SD) 8.8 (4.1) 9 (4.1) 8.9 (4.1) 0.647 
range 1 - 20 1 – 19 1 – 20  
 
Conditions  
(on regularly medications) 
    
Mean (SD) 5.6 (2.9) 6 (3.2) 5.8 (3.1) 0.539 
range 0 - 12 0 – 17 0 - 17  
 
CIRS 
    
Mean (SD) 15.8 (6.3) 14.8 (5.9) 15.3 (6.1) 0.889 
range 0 - 30 0 - 30 0 - 30  
Legend: CIRS = Cumulative illness rating scale, SD = standard deviation 
 
 
Almost all participants (98.8%) were multi-morbid, with 84.6% having ≥ 5 chronic 
conditions. There was no significant difference between the number of conditions in 
patients aged 65 – 74 year, 75 – 84 years and those ≥ 85 years, (F (2, 237) = 2.529, p 
= 0.082 (Figure 3.6). The mean CIRS score was 15.3 (SD 6.1), with no significant 
difference between genders (15.8 (SD 6.3) vs 14.8 (SD 5.9), t238 = 1.228, p = 0.889).  
Significant differences in CIRS scores were identified according to patients’ age (F (2, 
237) = 3.634, p = 0.028 (Figure 3.7). A Tukey post hoc test revealed that the CIRS 
rating was statistically lower in those aged 65 – 74 years compared to those aged ≥ 
85 years i.e. 14.0 (SD 6.3) vs 16.7 (SD 6.1), p = 0.026. There was no difference 
identified between those aged 75 – 84 years and those aged 65 – 74 years (15.6 (SD 
5.7) vs 14 (SD 6.3), p = 0.157) or between those aged 75 – 84 years those aged ≥ 85 
years (15.6 (SD 5.7) vs 16.7 (SD 6.1), p = 0.506) (Figure 3.7). 
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Figure 3.6: Number of chronic 
conditions according to age category 
 
Figure 3.7: Mean (SD) CIRS scores 
according to age category 
 
  
 
Figure 3.8 illustrates the percentage of participants that rated at least one system 
with either a 0, 1, 2, 3 or 4 according to age. Approximately 32.5% (n=78) of 
participants rated at least one illness with a “4” for one physiological system 
(indicating extremely severe disease requiring immediate treatment or contributing 
to severe impairment in function), 78.8% (n=189) rated at least one illness with a “3” 
(indicating a severe condition that is uncontrollable), 94.6% (n=227) at least one “2” 
(indicating a disease requiring first line treatment or causing moderate disability) and 
78.8% (n=189) rated at least at least one “1” (indicating a mild current problem or 
past significant problem).  
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Figure 3.8: The number of participants that rated at least one system a 0, 1, 2, 3 or 
4 according to age (n=240) 
 
Key Findings 2: 
 Multimorbidity was identified in 98.8% of patients. 
 More than 8 out of every 10 participants (84.6%) had ≥ 5 conditions. 
 Adults’ ≥ 85 years had a significantly higher burden of illness compared to 
those 65 – 74 years as determined by their CIRS score. 
 
 3.3.4 Diagnoses 
The most common diagnoses identified are displayed in Table 3.5. Approximately 
two thirds of participants had a diagnosis of hypertension and dyslipidaemia. 
Approximately two fifths of participants had a diagnosis of atrial fibrillation and 
ischaemic heart disease (IHD). Approximately 1 in 3 participants had a diagnosis or 
osteoarthritis or constipation. Approximately 1 in 4 patients had a diagnosis of heart 
failure, diabetes mellitus, chronic obstructive pulmonary disease, anaemia or chronic 
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kidney disease. Approximately 1 in 5 participants had a diagnosis of osteoporosis, 
hypothyroidism and urinary incontinence. 
Table 3.5: Diagnoses according to gender 
Variable Male 
n = 121   
Female 
n = 119  
Total 
n = 240 
P-value 
 
 
Diagnoses (in order of frequency) 
    
1. Hypertension 88 (66.1%) 86 (72.3%) 166 (69.2%) 0.302 
2. Dyslipidaemia 64 (52.9%) 80 (67.2%) 144 (60%) 0.023* 
3. Atrial fibrillation 50 (41.3%) 45 (37.8%) 95 (39.6%) 0.579 
4. IHD 62 (51.2%) 30 (25.2%) 92 (38.3%) <0.001* 
PCI 14 (11.6%) 9 (7.6%) 23 (9.6%) 0.292 
MI 23 (19%) 10 (8.4%) 33 (13.8%) 0.017* 
CABG 24 (19.8%) 6 (5%) 30 (12.5%) 0.001* 
Angina 9 (7.4%) 7 (5.9%) 16 (6.7%) 0.629 
5. Osteoarthritis 45 (37.5%) 44 (37%) 89 (37.1%) 0.972 
6. Anaemia 48 (39.7%) 32 (26.9%) 80 (33.3%) 0.036* 
7. Chronic constipation 36 (29.8%) 37 (31.1%) 73 (30.4%) 0.821 
8. Heart Failure 30 (12.5%) 28 (23.5%) 64 (26.7%) 0.276 
9. Diabetes Mellitus 31 (25.6%) 29 (24.4%) 60 (25%) 0.823 
10. COPD 36 (29.8%) 21 (17.6%) 57 (23.8%) 0.028* 
11. GORD 25 (20.7%) 32 (26.9%) 57 (23.8%) 0.257 
Previous GI bleed 4 (3.3%) 8 (6.7%) 12 (5%) 0.225 
Previous ulcer 4 (3.3%) 5 (4.2%) 9 (3.8%) 0.715 
Oesophagitis/gastritis/duodenitis 10 (8.3%) 11 (9.2%) 21 (88%) 0.788 
12. Chronic kidney disease 30 (24.8%) 26 (21.8%) 56 (23.3%) 0.590 
13. Previous fracture 17 (14%) 38 (31.9%) 55 (22.9%) 0.001* 
14. Depression with/without Anxiety 21 (17.4%) 32 (26.9%) 53 (22.1%) 0.075 
15. Osteoporosis 12 (9.9%) 36 (30.3%) 48 (20%) <0.001* 
16. Hypothyroidism 17 (14%) 30 (25.2%) 47 (19.6%) 0.029* 
17. Urinary incontinence 17 (14%) 30 (25.2%) 47 (19.6%) 0.029* 
18. Stroke 14 (11.6%) 25 (21%) 39 (16.3%) 0.048* 
19. Benign prostatic hypertrophy 37 (30.6%) 0 (0%) 37 (15.4%) <0.001* 
20. Dementia 18 (14.9%) 18 (15.1%) 36 (15%) 0.957 
21. Insomnia 16 (13.2%) 20 (16.8%) 36 (15%) 0.437 
22. Falls 17 (14%) 16 (13.4%) 33 (13.8%) 0.892 
23. Diverticular disease 17 (14%) 15 (12.6%) 32 (13.3%) 0.742 
24. Peripheral vascular disease 23 (19%) 7 (5.9%) 30 (12.5%) 0.002* 
25. Gout 13 (10.7%) 17 (14.3%) 30 (12.5%) 0.407 
26. History of cancer 15 (12.4%) 6 (5%) 28 (11.7%) 0.044* 
27. Current active cancer 13 (10.7%) 15 (12.6%) 21 (8.8%) 0.653 
 
Legend: GORD = gastro-oesophageal reflux disease, IHD = Ischaemic heart disease, PCI = 
percutaneous coronary intervention (Stents), MI = myocardial infarction, CABG = coronary artery 
bypass graft, HF = heart failure, COPD = chronic obstructive pulmonary disease 
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Women were significantly more likely to have osteoporosis (Χ2 (1) = 15.505, p < 
0.001), urinary incontinence (Χ2 (1) = 4.745, p = 0.029), a history of fractures (Χ2 (1) = 
10.862, p = 0.001), hypothyroidism (Χ2 (1) = 4.745, p = 0.029), dyslipidaemia (Χ2 (1) = 
5.136, p = 0.023) and a history of stroke (Χ2 (1) = 3.927, p = 0.048). Men were 
significantly more likely to have IHD (Χ2 (1) = 17.196, p <0.001), peripheral vascular 
disease (Χ2 (1) = 9.451, p = 0.002) and COPD (Χ2 (1) = 4.855, p = 0.028).  
 
 3.3.5 Prescription medications 
A total of 2,110 medications were prescribed regularly to this cohort of 240 patients, 
with a mean of 8.7 (SD 4.6), range of 0 - 23. Approximately 98% of all participants 
were prescribed ≥ 1 medication (Table 3.6). Polypharmacy (≥ 6 daily medications) 
and high level polypharmacy (≥ 11 daily medications) were identified in 76.7% and 
32.5% respectively. There was no significant difference between the mean number 
of medications prescribed to men and women, i.e. 8.3 (4.4) and 9.1 (4.7) respectively, 
t238 = 1.484, p = 0.037. As expected, the number of medications prescribed 
significantly increased with the level of comorbidity (CIRS), r-statistic 0.582, p < 0.001. 
Table 3.6: Prescribing according to gender (n=240) 
Variable Male 
n = 121   
Female 
n = 119  
Total 
n = 240 
P-value 
 
 
Patients taking at least 1 medication 
 
120 (99.2%) 
 
116 (97.5%) 
 
236 (98.3%) 
 
0.305 
 
Medications (regular) 
    
Mean (SD) 8.3 (4.4) 9.1 (4.7) 8.7 (4.6) 0.637 
Range 0 - 23 0 -23 0 - 23  
1 – 5 medications 32 (26.4%) 21 (17.6%) 53 (22.1%) 0.100 
6 – 10 medications 53 (43.8%) 52 (43.7%) 105 (43.8%) 0.987 
≥ 11 medications 35 (28.9%) 43 (36.1%) 78 (32.5%) 0.233 
≥ 6 medications 
 
88 (72.7%) 96 (80.7%) 184 (76.7%) 0.146 
Legend: SD = standard deviation 
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 3.3.6 Medication use according to age 
There was no significant difference between the numbers of medications prescribed 
to patients age 65 – 74 years, 75 – 84 years and those ≥ 85 years, (Χ2 (4) = 6.914, p = 
0.141) (Figure 3.9). There was no significant difference between the proportions of 
patients that experienced polypharmacy, (Χ2 (2) = 1.318, p = 0.517) and high level 
polypharmacy, (Χ2 (2) = 5.149, p = 0.076) according to age groups (Figure 3.10). 
Figure 3.9: Medication use according to age group 
 
 
Figure 3.10: Prevalence of polypharmacy and high level polypharmacy according to 
age 
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Key Findings 3: 
 Approximately 3 of every 4 (76.7%) patients experienced polypharmacy. 
 Approximately 1 of every 3 (32.5%) patients experienced high level 
polypharmacy. 
 
 3.3.7 Medication use according to drug class 
The most common medications prescribed are displayed in Figure 3.11. 
Approximately 1 in 2 participants were prescribed proton pump inhibitors (PPIs), 
statins, beta blockers and anti-platelets. Approximately 1 in 3 were prescribed loop 
diuretics. Approximately 1 in 4 were prescribed vitamin d, anti-coagulation and anti-
depressants. Approximately 1 in 5 were prescribed ace inhibitors, calcium channel 
blockers, angiotensin receptor blockers (ARBs), calcium and benzodiazepines.  
 
Figure 3.11 Drug classes most commonly prescribed (n=240) 
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 3.3.8 Drug class use according to gender 
Differences in drug class prescriptions between genders are displayed in Table 3.7.   
Table 3.7: Most common prescription medications (n=240) 
Variable Male 
n = 121   
Female 
n = 119  
Total 
n = 240 
P-value 
 
 
Regular prescriptions (in order of 
frequency) 
    
1. Proton pump inhibitors 87 (55.4%) 75 (63%) 142 (59.2%) 0.228 
2. Statins 89 (57%) 63 (52.9%) 132 (55%) 0.525 
3. Beta blockers 58 (47.9%) 66 (50.4%) 118 (49.2%) 0.700 
4. Anti-platelets 63 (52.1%) 44 (37%) 107 (44.6%) 0.019* 
5. Loop diuretics 39 (32.2%) 36 (30.3%) 75 (31.3%) 0.741 
6. Vitamin D 19 (15.7%) 47 (39.5%) 66 (27.5%) <0.001* 
7. Anticoagulants 
Warfarin 
Direct oral anti-coagulants 
30 (24.8%) 
13 (10.7%) 
17 (14%) 
35 (29.4%) 
21 (17.6%) 
14 (11.1%) 
65 (27.1%) 
34 (14.2%) 
31 (12.9%) 
0.421 
0.125 
0.598 
8. Anti-depressants 26 (21.5%) 36 (30.3%) 62 (25.8%) 0.121 
SSRIs 17 (14%) 18 (15.1%) 35 (14.6%) 0.813 
Tricyclic anti-depressants 6 (5%) 14 (11.8%) 20 (8.3%) 0.056 
NASSas 3 (2.5%) 14 (11.8%) 17 (7.1%) 0.005* 
9. ACE inhibitors 32 (26.4%) 19 (16%) 51 (21.3%) 0.047* 
10. Calcium channel blockers 20 (16.5%) 29 (24.4%) 49 (20.4%) 0.132 
11. Angiotensin receptor blockers  20 (16.5%) 29 (24.4%) 49 (20.4%) 0.132 
12. Calcium supplements 14 (11.6%) 34 (28.6%) 48 (20%) 0.001* 
13. Benzodiazepines 17 (14%) 30 (25.2%) 47 (19.6%) 0.029* 
14. Laxatives 21 (17.4%) 24 (20.2%) 45 (18.8%) 0.577 
Osmotic 7 (5.8%) 5 (4.2%) 36 (15%) 0.255 
Stimulant 15 (12.4%) 21 (17.6%) 12 (5%) 0.574 
Bulk forming 1 (0.8%) 1 (0.8%) 2 (0.8%) 0.991 
15. Paracetamol 16 (13.2%) 28 (23.5%) 44 (18.3%) 0.039* 
16. Inhaled anti-muscarinics 26 (21.5%) 16 (13.4%) 42 (17.5%) 0.101 
17. levothyroxine 15 (12.4%) 27 (22.7%) 42 (17.5%) 0.036* 
18. inhaled beta agonists 10 (8.3%) 10 (8.4%) 39 (16.3%) 0.969 
19. Alpha blockers 29 (24%) 4 (3.4%) 33 (13.8%) <0.001* 
20. Neuropathic agents 18 (14.9%) 14 (11.8) 32 (13.3%) 0.478 
21. Metformin 15 (12.4%) 18 (15.1%) 33 (13.8%) 0.538 
22. Hypnotic Z drugs 13 (10.7%) 16 (13.4%) 29 (12.1%) 0.521 
23. Opioids 10 (8.3%) 16 (13.4%) 26 (10.8%) 0.197 
Weak opioid 21 (17.4%) 21 (17.6%) 26 (10.8%) 0.953 
Strong opioid 12 (9.9%) 7 (5.9%) 19 (7.9%) 0.247 
24. Oral corticosteroids 
 
8 (6.6%) 16 (13.4%) 24 (10%) 0.079 
Legend: SSRIs = selective serotonin reuptake inhibitors; NASSas = Noradrenergic and specific 
serotonergic anti-depressants;  
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Men were prescribed significantly more angiotensin converting enzymes (ACE) 
inhibitors (26.4% vs 16%, Χ2 (1) = 3.938, p = 0.047), angiotensin receptor blockers 
(ARBs) (24.0% vs 3.4%, Χ2 (1) = 2.270, p <0.001) and anti-platelets (52.1% vs 37.0%, 
Χ2 (1) = 5.530, p = 0.019). Women were more commonly prescribed levothyroxine 
(22.7% vs 12.4%, Χ2 (1) = 4.402, p = 0.036), benzodiazepines (25.2% vs 14.0%, Χ2 (1) = 
4.745, p = 0.029), paracetamol (23.5%) vs 13.2%, Χ2(1) = 4.256 p = 0.039), calcium 
(28.6% vs 11.6%, Χ2 (1) = 10.838, p = 0.001),  vitamin d (39.5% vs 15.7%, Χ2 (1) = 
17.036, p <0.001) and NASSa (11.8% vs 2.5%, Χ2 (1) = 7.859, p = 0.005. 
 
3.3.9 Drug class use according to age category 
Differences identified in drug class prescriptions between the different age 
categories are displayed in Figure 3.12. The only drug class in which a significant 
difference in prescribing rate was shown between the 3 age groups was anti-
coagulants, (i.e. 16.3% vs 34% vs 29.6%, Χ2 (2) =7.471, p = 0.024),  reflecting 
significantly higher prevalence of atrial fibrillation in the older age groups compared 
to patients aged 65 to 74 years. 
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Figure 3.12 Drug classes most commonly prescribed according to age (n=240) 
 
 
 3.3.10  Medication adherence 
Sixty nine percent of patients managed their medications alone, with 46.3% using a 
blister pack. Nine percent participants admitted to problems of various kinds taking 
their daily medications, with approximately 15.4% forgetting to take some or all of 
their medications at least once in the preceding month.  
 
 3.3.11  Potentially inappropriate prescriptions as determined by STOPP  
  criteria 
STOPP criteria for potentially inappropriate medication (PIM) use were applied to all 
240 patients. Four hundred and five prescriptions (19.2%) out of the total of 2,110 
prescriptions were potentially inappropriate according to STOPP criteria. These were 
0.0%
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40.0%
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distributed amongst 67.5% (n=162) of the study population with 53 patients (22.1%) 
receiving 1 PIM, 43 patients (17.9%) receiving 2 PIMs and 66 patients (27.5%) 
receiving ≥3 PIMs. An increasing number of daily medications number was 
significantly associated with increasing PIM number (R = 0.644, p < 0.001). 
 The most frequently encountered PIMs identified by STOPP criteria are listed 
in order of descending frequency in Table 3.8. More than 1 in 3 participants (41.3%) 
were prescribed a drug beyond the recommended duration. Approximately 1 in 4 
(24.8%) participants were prescribed a PPI for uncomplicated PUD/erosive 
oesophagitis at full therapeutic dosage for more than 8 weeks. One in five (20%) 
participants were prescribed a drug without an evidence-based clinical indication. 
Over 1 in 6 participants (17.6%) were prescribed a benzodiazepine for ≥ 4 weeks. A 
similar proportion of patients who were at risk of falls were prescribed a 
benzodiazepine (15.4%). Table 3.8 displays the most prevalent PIMs in the patient as 
a whole and also according to gender. Females were more likely than males to be 
inappropriately prescribed anti-cholinergic drugs in the context of delirium or 
dementia i.e. 6.7% vs 1.7%, Χ2 (1) = 3.862, p = 0.049. Criteria STOPP A2 (Any drug 
prescribed beyond the recommended duration) was based on BNF indications and 
up to date clinical guidelines. 
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Table 3.8: Most common potentially inappropriate medications (PIMs) according to 
STOPP criteria according to gender 
STOPP criteria (code & descriptor) Male 
n = 121   
Female 
n = 119  
Total 
n = 240 
P-value 
 
 
A2: Any drug prescribed beyond 
recommended duration 
 
 
50 (41.3%) 
 
49 (41.2%) 
 
99 (41.3%) 
 
0.982 
F2: PPI for uncomplicated PUD/erosive 
peptic oesophagitis at full therapeutic 
dosage for > 8 weeks 
 
33 (27.3%) 26 (21.8%) 59 (24.6%) 0.329 
A1: Any drug prescribed without an 
evidence-based clinical indication 
 
24 (19.8%) 24 (20.2%) 48 (20%) 0.949 
D5: Benzodiazepines for ≥ 4 weeks 
 
16 (13.2%) 27 (22.7%) 43 (17.9%) 0.056 
K1: Benzodiazepines (those at ↑risk of 
falls) 
 
15 (12.4%) 22 (18.5%) 37 (15.4%) 0.191 
L2: Use of regular opioids without 
concomitant laxative 
 
12 (9.9%) 15 (12.6%) 27 (11.3%) 0.510 
K4: Hypnotic Z-drugs (those at ↑risk of 
falls) 
 
13 (10.7%) 13 (10.9%) 26 (11.3%) 0.964 
A3: Any duplicate drug prescription 
 
11 (9.1%) 14 (11.8%) 25 (10.4%) 0.498 
F3: Drugs likely to cause constipation in 
patients with chronic constipation 
 
10 (8.3%) 7 (5.9%) 17 (7.1%) 0.472 
B6: Loop diuretic as first-line treatment 
for HTN 
 
5 (4.1%) 8 (6.7%) 13 (5.4%) 0.375 
D2: Initiation of TCAs as first-line 
antidepressant treatment 
 
6 (5%) 10 (8.4%) 16 (6.7%) 0.285 
D14: First generation anti-histamines 
 
7 (5.8%) 7 (5.9%) 14 (5.8%) 0.974 
D10: Neuroleptics as hypnotics 8 (6.6%) 4 (3.4%) 12 (5%) 0.248 
 
K2: Neuroleptic drugs (those at ↑risk of 
falls) 
 
6 (5%) 5 (4.2%) 11 (4.6%) 0.779 
 
D8: Anti-cholinergic drugs in patients with 
delirium or dementia 
2 (1.7%) 8 (6.7%) 10 (4.2%) 0.049* 
     
K3: Vasodilator drugs (with persistent 
postural hypotension) 
 
7 (5.8%) 3 (2.5%) 10 (4.2%) 0.206 
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 3.3.12  Risk Factors for receiving a potentially inappropriate medication 
  according to STOPP criteria. 
Differences were identified between participants who were prescribed PIMs and 
those who were not prescribed PIMs (Table 3.9). Males and females were equally 
likely to be prescribed a PIM (Χ2 (1) = 0.544, p = 0.461), as were all age groups (Χ2 (2) 
= 1.373, p = 0.503). Patients prescribed PIMs had more chronic conditions (median 
9.5 (IQR7-12) vs median 6 (IQR3.75-9), U = 3987, p < 0.001), a higher median CIRS 
score (17 (13-21) vs 11 (8 – 17), U = 3638.5, p <0.001) and were prescribed a high 
median number of daily medications (10 (IQR7-13) vs 5 (IQR2-7), U = 2254, p <0.001). 
As expected, the number of PIMs significantly increased with the number of treated 
conditions (R = 0.455, p <0.001), the number of daily prescription medications (R = 
0.644, p <0.001) and with the CIRS score (R = 0.318 p <0.001). 
 
Table 3.9: Comparison between older adults prescribed at least 1 potentially 
inappropriate medication (PIM) and older adults prescribed no PIM 
Variable PIMs 
(n=162) 
No PIMs 
(n=78) 
Total 
n = 240 
P-value 
 
 
Gender (female) 
 
85 (51.8%) 
 
36 (46.2%) 
 
119 (49.6%) 
 
0.461 
Age, median (IQR) 
Range 
78 (73-84) 
65 - 99 
76 (70-84) 
65 - 93 
78 (72-80) 
65 - 99 
0.270 
Chronic conditions, median (IQR) 9.5 (7-12) 6 (3.75-9) 8 (6-12) <0.001* 
Range 1 - 20 1 - 18 1 - 20  
Treated chronic conditions, median 
(IQR) 
6 (5-8) 4 (2-6) 6 (4-8) <0.001* 
Range 1 - 17 0 - 12 0 - 17  
CIRS score, median (IQR) 17 (13-21) 11 (8-17) 16 (11 – 19.75) <0.001* 
Range 0 - 30 0 -28 0 -30  
Medications, median (IQR) 10 (7-13) 5 (2-7) 8.5 (9-12) <0.001* 
Range 1 - 23 0 - 15 0 - 23  
     
Legend: IQR = Inter quartile range, CIRS = Cumulative Illness rating scale 
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Logistic regression was used to determine the influence of age, gender, chronic 
conditions, burden of co-morbidities as defined by CIRS score and number of 
medications on the likelihood of receiving a STOPP-defined PIM; the results are 
detailed in Table 3.10.  
Table 3.10: Risk factors for receiving a PIM according to STOPP criteria 
 
      95% CI for Exp (B) 
Variable B (SE) Wald df p-value Exp (B) Lower Upper 
        
Female   .101 (.350) .083 1 0.773 1.106 0.557 2.196 
Age .033 (.023) 2.112 1 0.146 1.034 0.988 1.081 
Meds .347 (.069) 25.536 1 <0.001* 1.415 1.237 1.619 
Cond .065 (.077) .707 1 0.400 1.067 0.917 1.242 
CIRS -.023 (.051) .206 1 0.650 0.977 0.885 1.079 
Constant -4.784 
(1.872) 
6.528 1 0.011 0.008   
Legend: Hosmer and Lemeshow, Χ2(8) ≥9.918, p=0.552; B = beta value; Snell R2=0.285; Nagelkerke R2 
= 0.398; SE = standard error; df = degrees of freedom; Exp (B) = Odds ratio; meds = number of daily 
prescription medications; cond = conditions, CIRS = cumulative index rating scale. 
 
The only factor associated with a significantly increased risk of receiving a PIM was 
the number of daily prescribed medications, when all other variables are kept at a 
constant. For every additional medication prescribed, the odds of receiving a PIM 
increased by 41.5% (Odds ratio 1.415, 95% CI 1.237 – 1.619, p <0.001). 
Key Findings 4: 
 Two out of every three (67.5%) adults’ ≥ 65 years were prescribed at least 
one PIM according to STOPP criteria. 
 Adults’ receiving at least 1 PIM had a significantly higher number of 
conditions, had a significantly higher burden of co-morbidities and were 
prescribed a higher number of medications. 
 For every one medication prescribed, the odds of receiving a PIM 
increased by 41.5%. 
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 3.3.13  Potentially prescribing omissions as determined by START criteria 
START criteria were applicable to 170 of the 240 participants (70.8%). For the 
remaining 80 participants, a more palliative approach to pharmacotherapy was 
appropriate i.e. starting medications would have been inappropriate. Over 1 in 2 
(52.9%) of participants were identified as having a potentially prescribing omissions 
(PPO), with 53 patients (31.2%) having 1 PPO, 24 patients (14.1%) having 2 PPOs and 
13 patients (7.6%) having ≥3 PPOs. There was no significant difference identified 
between the numbers of PPOs according to gender (Χ2 (3) = 3.435, p = 0.329). The 
most frequently encountered PPOs identified by START criteria are listed in Table 
3.11.   
 Approximately 1 in 8 patients (12.4%) were not prescribed ACE inhibitors with 
systolic heart failure and/or coronary artery disease. Approximately 1 in 12 (8.4%) 
were not prescribed bone anti-resorptive or anabolic therapy with known 
osteoporosis. Approximately 1 in 13 patients (7.6%) were not prescribed vitamin D 
and calcium with known osteoporosis or vitamin D when housebound or 
experiencing falls. Approximately 1 in 16 (6.5%) were not prescribed beta blockers 
with known ischaemic heart disease.  
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Table 3.11: Most common PPOs according to START criteria 
START criterion  Male 
n = 80 
Female 
n = 90 
Total 
n = 170 
P-value 
 
A6: ACE inhibitor with systolic heart failure and/or 
coronary artery disease 
 
13 (16.3%) 8 (8.9%) 21 (12.4%) 0.145 
E4: Bone anti-resorptive or anabolic therapy in 
patients with osteoporosis 
 
6 (7.5%) 8 (8.9%) 14 (8.2%) 0.742 
E3: Vitamin D and calcium in patients with known 
osteoporosis 
 
5 (6.3%) 8 (8.9%) 13 (7.6%) 0.518 
E5: Vitamin D in older adults who are housebound 
or experiencing falls 
 
7 (8.8%) 6 (6.7%) 13 (7.6%) 0.610 
A7: Beta blocker with ischaemic heart disease 
 
7 (8.8%) 4 (4.4%) 11 (6.5%) 0.255 
A1: Vitamin K antagonists or DOACs in the present 
of atrial fibrillation 
 
5 (6.3%) 5 (5.6%) 10 (5.9%) 0.848 
A5: Statin therapy with a history of coronary, 
cerebral or peripheral vascular disease 
 
6 (7.5%) 2 (2.2%) 8 (4.7%) 0.105 
D2: Fibre supplements for diverticulosis with a 
history of constipation 
 
2 (2.5%) 6 (6.7%) 8 (4.7%) 0.200 
F1: ACE inhibitor or Angiotensin Receptor Blocker 
in diabetes with evidence of renal disease with or 
without serum biochemical renal impairment 
 
5 (6.3%) 3 (3.3%) 8 (4.7%) 0.370 
E6: Xanthine-oxidase inhibitors with a history of 
recurrent episodes of gout 
 
3 (3.8%) 4 (4.4%) 7 (4.1%) 0.820 
A8: Appropriate beta blockade with stable systolic 
heart failure 
 
3 (3.8%) 3 (3.3%) 6 (3.5%) 0.883 
B1: Regular inhaled 2 agonist or anti-muscarinic 
bronchodilator for mild to moderate asthma or 
COPD 
 
3 (3.8%) 3 (3.3%) 6 (3.5%) 0.883 
G2: 5-alpha reductase inhibitor with symptomatic 
prostatism, where prostatectomy unnecessary 
5 (6.3%) 0 (0%) 5 (2.9%) N/A 
     
H2: Laxatives in patients receiving opioids 
regularly 
 
1 (1.3%) 4 (4.4%) 5 (2.9%) 0.219 
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 3.3.14 Risk factors for potentially prescribing omissions according to START 
  criteria 
No significant differences were identified between participants who had a PPO and 
those who did not (Table 3.12).  
Table 3.12: Comparison between older adults experiencing one potential 
prescribing omission according to START criteria and older adults not 
Variable PPOs 
(n=90) 
No PPO 
(n=80) 
Total 
n = 170 
P-
value 
     
Gender (female) 44 (48.9%) 46 (57.5%) 119 (49.6%) 0.725 
Age, median (IQR) 
Range 
76 (70.75-84) 
65 - 93 
77 (70.25-81.25) 
65 – 99 
78 (72-84) 
65 - 99 
0.858 
Chronic conditions, median (IQR) 
Range 
8 (6-11) 
1 - 18 
6 (4–9) 
1 – 16 
8 (6-12) 
1 - 20 
0.215 
CIRS score, median (IQR) 
Range 
15 (10-18) 
0 - 29 
11.5 (9-15) 
1 – 27 
16 (11-19.75) 
0 - 30 
0.498 
Medications, median (IQR) 
Range 
8 (4.75-11) 
0 - 19 
7 (5-11) 
0 – 18 
8.5 (8-12) 
0 - 23 
0.228 
     
 
Key findings 5: 
 Approximately 1 of every 2 (52.9%) adults’ ≥ 65 years were identified as 
having one PPO as determined by START criteria.   
 No significant differences were identified between adults having a PPO 
and those not. 
 
  3.3.15 Adverse drug reactions (ADR) prevalence rates 
A total of 284 adverse events (AEs) were identified in 161 (67.1%) of the 240 patients. 
One hundred and two AEs were drug-related in 53 (22.1%) of the 240 patients 
enrolled (Table 3.13). ADRs directly caused hospitalisation in 17.1% (n=41) and 
contributed significantly for 5% (n=12) of all patients enrolled. The AE Trigger List 
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identified 79.3% (n = 43) of all ADRs. The remaining 11 ADRs are shown in Table 3.14. 
As discussed in Chapter 2, all ADRs were viewed as processes rather than discrete 
events e.g. a person who fell more than once as a result of adverse medication was 
classified as having had one ADR only.   
Table 3.13: Adverse event (AE) conversion to adverse drug reaction (ADR) 
AE description AE incidence  
(% of total) 
Number of ADRs 
represented by AE 
   
New onset fall/s 55 (19/4%) 16 (5.6%) 
New onset unsteady gait 1 (0.4%) 1 (0.4%) 
Acute kidney injury 32 (11.3%) 12 (4.2%) 
Symptomatic orthostatic hypotension 7 (2.5%) 6 (2.1%) 
Major serum electrolyte disturbance 44 (15.5%) 14 (5%) 
Symptomatic bradycardia 2 (0.7%) 1 (0.4%) 
New major constipation 11 (3/9%) 2 (0.7%) 
Acute bleeding 20 (7%) 10 (3.5%) 
Acute dyspepsia / nausea / vomiting 33 (11.6%) 11 (3.9%) 
Acute diarrhoea 16 (5.6%) 2 (0.8%) 
Acute delirium 48 (16.9%) 15 (5.3%) 
Symptomatic hypoglycaemia 2 (0.7%) 1 (0.4%) 
Other (unspecified) 13 (4.6%) 11 (3.9%) 
   
   
Total Number 284 102 
Number of patients involved 161 53 
   
 
 
Table 3.14: ADRs not identified by the 12 point AE Trigger List 
ADRs not identified by the Trigger List (n=11) 
 
Seizure following withdrawal of anti-epileptic drugs (carbamazepine and 
levetiracetam) 
2 
Parkinsonism following recently introduced haloperidol 1 
Diabetic ketoacidosis secondary to cessation of long acting insulin (levemir) 1 
Anaphylaxis following moxifloxacin  1 
Exacerbation of cardiac failure following withdrawal of furosemide 1 
Chest pain and atrial fibrillation following ingestion of supra-therapeutic daily dose of 
pseudoephedrine for 3 days 
1 
Extreme pain following abrupt withdrawal of fentanyl 1 
Urinary retention following withdrawal of tamsulosin 1 
Type two respiratory failure and pneumonia following commencement of daily 
alprazolam that caused drowsiness 
1 
Relapse of unstable angina following aspirin cessation 1 
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Key Findings 6: 
 Approximately 1 in 5 (22.1%) adults’ ≥ 65 years are admitted secondary to 
an ADR. 
 For approximately 1 in 6 (17.1%) an ADR directly causes admission. 
 For approximately 1 in 20 (5%) an ADR contributes significantly to 
admission. 
 The 12 point AE Trigger List identified 79.3% (4 in every 5) ADRs. 
 
 3.3.16 Type of adverse drug reactions 
The primary ADRs, as defined by the AE Trigger List, are displayed in Table 3.15.  
Table 3.15: Types of primary ADR in order of frequency. 
Variable Male 
n = 121   
Female 
n = 119  
Total 
n = 240 
P-value 
 
     
    0.266 
1. Unspecified 7 (5.9%) 4 (3.4%) 11 (4.6%)  
2. Bleeding 4 (3.3%) 4 (3.4%) 8 ((3.3%)  
3. New onset fall/s 5 (4.1%) 1 (0.8%) 6 (2.5%)  
4. Severe electrolyte disturbance 2 (1.7%) 4 (3.4%) 6 (2.5%)  
5. Delirium 2 (1.7%) 4 (3.4%) 6 (2.5%)  
6. Dyspepsia/nausea/vomiting 1 (0.8%) 4 (3.4%) 5 (2.1%)  
7. Symptomatic orthostatic hypotension 1 (0.8%) 4 (3.4%) 5 (2.1%)  
8. Severe constipation 1 (0.8%) 1 (0.8%) 2 (0.8%)  
9. Acute kidney injury 2 (1.7%) 0 (0%) 2 (0.8%)  
10. Diarrhoea 0 (0%) 1 (0.8%) 1 (0.4%)  
11. Symptomatic bradycardia 0 (0%) 1 (0.8%) 1 (0.4%)  
     
 
Twenty nine of the 53 participants (54.7%) who experienced an ADR experienced a 
Sequence of Events e.g. severe vomiting leading to an acute kidney injury and severe 
electrolyte disturbance. The number of patients who experienced Sequence of 
Events can be seen in Figure 3.13. Women were significantly more likely to 
experience Sequence of Events as a consequence of a medications, (67.9% vs 40%, 
Χ2 (1) = 4.137, p = 0.042). Men and women were equally likely to experience the same 
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type of ADRs (Χ2 (10) = 12.288, p = 0.266). There was no significant difference in the 
prevalence rate of ADRs experienced across the 3 age groups of 65 – 74 years, 75 – 
84 years and 85 years and older, (Χ2(20) = 20.809, p = 0.408). 
Figure 3.13: Percentage of patients who experienced ADRs who had a sequence of 
one or more adverse events (n=53). 
 
 
Key findings 7: 
 The three most common ADRs experienced were bleeding, falls and 
electrolyte disturbances. 
 Approximately 1 in 2 participants (54.7%) who experienced an ADR had a 
Sequence of Events. 
 Women were significantly more likely to experience a Sequence of Events 
  
 3.3.17 Adverse drug reaction causality 
As per the WHO-UMC causality criteria, medication probably/certainly caused or 
contributed significantly to admission in 53 (22.1%) cases. The medications 
implicated are listed, in order of frequency, in table 3.16. 
≥ 1 ≥ 2 ≥ 3 ≥ 4 ≥ 5
Total 100.0% 54.7% 15.1% 7.5% 1.9%
Male 100.0% 40.0% 12.0% 8.0% 0.0%
Female 100.0% 67.9% 17.9% 7.1% 3.6%
0.0%
20.0%
40.0%
60.0%
80.0%
100.0%
120.0%
Total Male Female
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Table 3.16: Drug classes involved in ADRs 
Drug class Total (n=53) 
 
1 
 
Opioids 
 
7 (13.2%) 
2 Direct oral anti-coagulants (DOACs) 6 (11.3%) 
3 Benzodiazepines 4 (7.5%) 
4 Aldosterone antagonists 3 (5.7%) 
5 Antibiotics 3 (5.7%) 
6 Neuroleptics 3 (5.7%) 
7 Loop diuretics 3 (5.7%) 
8 Anti-epileptic drugs 3 (5.7%) 
9 Selective α1- alpha blockers 2 (3.8%) 
10 Thiazide diuretic 2 (3.8%) 
11 Anti-platelets 2 (3.8%) 
12 Non-adrenergic and specific serotonergic anti-depressants 2 (3.8%) 
13 Z-drug (hypnotics) 1 (1.9%) 
14 Anti-cholinergic 1 (1.9%) 
15 Selective serotonin reuptake inhibitors 1 (1.9%) 
16 Anti-coagulants (warfarin) 1 (1.9%) 
17 Corticosteroids 1 (1.9%) 
18 Insulin 1 (1.9%) 
19 Non-steroidal anti-inflammatories 1 (1.9%) 
20 Metformin 1 (1.9%) 
21 Beta blocker 1 (1.9%) 
22 Angiotensin converting enzyme-inhibitors 1 (1.9%) 
23 Anti-histamines 1 (1.9%) 
24 Decongestant (pseudoephedrine) 1 (1.9%) 
25 Laxatives 1 (1.9%) 
 
 
 
 
 3.3.18 Adverse drug reaction severity, predictability and preventability 
Of the 53 ADRs causing or contributing significantly to acute index admission, 6 ADRs 
(11.3%) were grade 5 on the Hartwig & Siegel scale of severity i.e. they required 
intensive medical treatment. The remaining 47 ADRs (88.7%) were Hartwig & Siegel 
graded 4 i.e. for the direct cause of the admission or increased length of stay by ≥ 1 
day. Forty-five (84.9%) of the ADRs were predictable according to the SPC guidelines 
of the individual medications in question. Using Hallas ADR avoidability criteria, 24 
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ADRs (45.3%) were definitely avoidable, 24 ADRs (45.3%) possibly avoidable and 5 
ADRs (9.4%) unavoidable. 
 
 3.3.19 Adverse drug reaction risk factors and outcomes 
A comparison of patients who did and did not experience ADRs is shown in Table 
3.17. Adults who experienced ADRs had a higher burden of co-morbid illness as 
defined by their CIRS scores (U = 4069.5, p = 0.047), were prescribed a higher number 
of medications (U = 3751, p = 0.007) and were more likely to die during the index 
admission (Χ2 (1) = 6.05, p = 0.014). 
Table 3.17: Comparison between older patients experiencing ADRs and patients 
not experiencing ADRs 
Variable ADRs 
(n=53) 
No ADRs 
(n=187) 
Total 
n = 240 
P-value 
 
 
Gender (female) 
 
28 (52.8%) 
 
91 (48.7%) 
 
119 (49.6) 
 
0.592 
Age, median (IQR) 81 (72.5-84.5) 77 (72.84) 78 (72-84) 0.329 
Range 65 - 94 65 - 99 65 – 99  
Chronic conditions, median 
(IQR) 
10 (7-12) 8 (6-12) 8 (6-12) 0.107 
Range 3 - 18 1 - 20 1 – 20  
CIRS score, median (IQR) 18 (12 – 21) 15 (10-18) 16 (11-19.75) 0.047* 
Range 3 - 30 0 - 30 0 - 30  
Medications, median (IQR) 10 (7-13) 8 (5-11) 8.5 (6-12) 0.007* 
Range 2 - 30 0 – 23 0 – 23  
Length of stay, median (IQR) 8 (4.5-14.5) 7 (3-14) 8 (3-13.75) 0.279 
Range 1 - 43 0 – 101 0 – 101  
Death during index hospital 
admission 
5 (12.2%) 4 (2.8%) 9 (4.9%) 0.014* 
     
 
Logistic regression analysis was used to determine the influence of age, gender, 
number of conditions, burden of co-morbid illness and number of medications on the 
risk of experiencing an ADR. The results are detailed in Table 3.18. 
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Table 3.18: Risk factors for experiencing an ADR 
      95% CI for Exp (B) 
Variable B (SE) Wald df p-value Exp (B) Lower Upper 
        
Female   -.091 (.325) .078 1 0.780 .913 .913 1.726 
Age .023 (.022) 1.155 1 0.282 1.024 .981 1.068 
Meds .098 (.047) 4.399 1 0.036* 1.103 1.006 1.210 
Cond -.037 (.065) .326 1 0.568 .964 .849 1.094 
CIRS .018 (.041) .197 1 0.657 1.018 .936 1.104 
Constant -3.893 
(1.755) 
4.921 1 0.027    
Legend: Hosmer and Lemeshow, Χ2(5) ≥9.704, p=0.271; B = beta value; Snell R2=0.034; Nagelkerke R2 
= 0.053; SE = standard error; df = degrees of freedom; Exp (B) = Odds ratio; Meds = medications; Cond 
= number of conditions; CIRS = cumulative index rating scale 
The only factor significantly and independently associated with an increased risk of 
ADRs was the number of medications a patient was prescribed, when all other 
variables are kept at a constant. For every extra medication prescribed, the odds of 
experiencing an ADR increased by 10.3% (Odds ratio 1.103, 95% CI 1.006 – 1.210, p 
<0.001). 
 
3.4 DISCUSSION 
The present study is one of the first to use this novel standardized approach to 
identifying, classifying and reporting ADRs in older people. This study has also 
characterized the current older adult population presenting with acute unselected 
illness to hospital in terms of multimorbidity, medication use and potentially 
inappropriate prescribing. 
 Almost half (44.2%) of these older adults presenting to hospital were ≥ 80 
years old and more than 1 in 5 (22.5%) were aged ≥ 85 years old. Approximately 1 in 
3 older adults had a moderate to high level functional dependency. In addition, 
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approximately 1 in 5 had moderate to severe dementia and in a further 1 in 5 
patients, delirium was evident at the time of presentation to hospital. Applying the 
Rockwood Clinical Frailty Scale, approximately 1 in 4 patients were severely frail, very 
severely frail or terminally ill. 
 Multimorbidity was identified in almost all patients (98.8%), with 84% of 
patients having ≥ 5 chronic medical conditions. Two in five older adults had atrial 
fibrillation and IHD, 1 in 3 had symptomatic osteoarthritis and constipation, 1 in 4 
had heart failure, diabetes mellitus, COPD or chronic kidney disease and 1 in 5 had 
osteoporosis, hypothyroidism or urinary incontinence. These result illustrate the 
higher rates of multimorbidity encountered in hospitalised older adults compared to 
clinically stable older adults living in the community. 
 Approximately 3 out of 4 (76.7%) patients experienced polypharmacy (≥ 6 
medications) and 1 in 3 (32.5%) experienced high level polypharmacy (≥ 11 
medications). Further analysis shows that approximately 1 in 2 patients were 
prescribed a PPI, statin, beta blocker or loop diuretic. One in four were prescribed 
vitamin D, anti-coagulants and anti-depressants. Lastly, 1 in 5 were prescribed an 
ACE-inhibitor, ARB, calcium channel blocker or benzodiazepine. One in 10 (9%) 
patients had problems taking their daily medications and 1 in 3 required another 
person to oversee the management of same. 1 in 6 (15.4%) had forgotten to take 
some or all of their daily medications in the month preceding admission.  Considering 
the extent of multimorbidity generally and cognitive impairment specifically in this 
patient cohort, these findings of problematic or impaired medication adherence are 
not surprising. 
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 Potentially inappropriate prescribing was evident in two-thirds (67.5%) of the 
patients studied. Less than half (41.3%) of the patients were taking at least one drug 
beyond the recommended duration, 24.8% of patients were on a potentially 
inappropriate high dose of PPI drug for 8 weeks or more with uncomplicated disease 
and 20% of patients were prescribed a drug without any clear clinical indication. In 
addition, 17.6% of patients were prescribed a benzodiazepine for ≥ 4 weeks and 
15.4% of patients were prescribed a benzodiazepines whilst simultaneously being at 
risk of falls. Those who were prescribed at least 1 PIM had a higher burden of co-
morbid illness and were prescribed a higher number of medications than patients 
who were not prescribed PIMs. For every extra medication prescribed, the odds of 
receiving a PIM increased by 41.5%.  
Approximately 1 in every 2 (52.9%) patients were prescribed ≥ 1 PPO. One in 
eight (12.4%) patients were not prescribed an ACE inhibitor with a known diagnosis 
of heart failure of coronary heart disease and 1 in 12 (8.4%) were not prescribed anti-
resorptive medication with known osteoporosis, where no contraindications to these 
medications existed. 
ADRs caused or contributed to acute admission in approximately 1 in 5 
(22.1%) older adults. The AE Trigger List identified 79.3% of all verified ADRs. The 
most common ADRs reported were bleeding, falls and electrolyte disturbances. 
Approximately 1 in 2 (54.7%) patients who experienced an ADR had a Sequence of 
Events, with women significantly more likely to experience this adverse sequence 
than their male counterparts (67.9% vs 40%). This is the first time this AE Trigger List 
approach has been used to classify ADR morbidity.  
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The three drugs most commonly implicated in ADRs were opioids (13.2%), 
direct oral anti-coagulants (11.7%) and benzodiazepines (7.5%). Forty-five (84.9%) of 
ADRs were predictable, with 45.3% (n = 24) ADRs definitely avoidable and 45.3% (n = 
24) possibly avoidable. Those who experienced ADRs had a higher burden of co-
morbid illness, were prescribed more medications and more likely to die during the 
index admission than patients who did not experience ADRs. For every extra 
medication prescribed, the odds of experiencing an ADR increased by 10.3%. 
These results demonstrate that a significant proportion of older adults 
presenting with acute unselected illness to hospital for admission are over 80 years 
and are often highly frail and multimorbid with cognitive and functional impairment, 
consistent with the changing population demographic profile,  as predicted by the 
NCPOP (2), Eurostat (3) and WHO (4). Importantly, despite most of these older adults 
being multimorbid and having significant complex care needs, just 1 in 8 (12.5%) 
were admitted to the specialist Geriatric Medicine service. This emphasizes the need 
for all doctors practising in all specialties who care for acutely ill older patients to 
have continued postgraduate education in managing the pharmacotherapy of older 
adults. This education need is likely to grow as the general population in Ireland and 
elsewhere expands. 
 This study confirms what has already been reported in other studies in Ireland 
(45-47, 167) i.e. that many older adults presenting to hospital are prescribed at least 
one PIM and thus at risk of ADRs. Hospitalisation is an opportune time to optimise 
prescribing in a high risk population, through comprehensive geriatric assessment 
(CGA) and IP screening tools. However, there are currently no explicit IP criteria 
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designed to guide prescribing in frail multimorbid adults with a poor one year survival 
prognosis.  
 The ability of patients to adhere to prescribed medications is a key 
consideration in medication review of frailer, multimorbid older people. The present 
study identified that at least 1 in 10 older adults experience serious problems taking 
their medications according to SHiM assessment and are therefore likely to have 
reduced medication benefit. This is not a new finding, but it is consistent with 
previous studies of medication adherence in the multimorbid older patient 
population (168, 169). 
The ADR prevalence rate at admission to hospital reported here (22.1%) is 
consistent with the most recent observational studies on ADRs causing 
hospitalisation conducted at CUH, in which the reported prevalence rate ranges from 
21.0% to 26.3% (46, 74). The ADR prevalence in multimorbid acutely ill older people 
reported in the CUH studies is significantly higher than in most other studies. A recent 
systematic review by Alhawassi et al. (144) of the prevalence and risk factors for ADRs 
in older people in the acute care setting indicated a median ADR prevalence of 10%. 
Using the AE Trigger List in the present study, as well as rigorous approach to ADR 
assessment, resulted in detection of approximately twice as many prevalent ADRs as 
reported by Alhawassi et al. Serious under detection of ADRs in acutely ill frailer 
multimorbid older people has serious clinical ramifications and supports the case for 
routine scrutiny of AE Trigger List events as possible ADRs and follow-up rigorous 
structured medication review by appropriately trained medical and pharmacist staff 
in the hospital setting. 
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The AE Trigger List highlighted 4 in 5 verified ADRs in the present study. The 
AE Trigger List also allowed capture of sequential morbidity associated with ADRs i.e. 
one Trigger List ADR leading to further Trigger List ADRs. The present study shows 
that in more than half (54.7%) of the patients who experience a primary ADR, there 
were ≥ 1 further ADR that was directly related to the primary ADR. For 1 in 7 patients 
(15.1%), there was a sequence of 3 events and for 1 in 13 (7.5%), this progressed to 
4 sequential, related ADRs. Women are more prone to this sequence phenomenon 
than men, highlighting the importance of early detection of ADRs early to prevent 
further ADR-related problems. 
There were some limitations with this study. Firstly, patients were only 
recruited to the study on one admission, and thus it is possible that ADRs causing 
readmission were missed. Secondly, only one person assessed patients, their case 
records and laboratory data for evidence of ADR occurrence. Ideally, all putative 
ADRs would be corroborated by a second trained assessor in an unbiased manner as 
suggested in Chapter 2.  Thirdly, prevalent ADR assessment took place in one clinical 
setting only. Evaluation of older frailer multimorbid patients in other settings, such 
as ambulatory assessment units, primary care and nursing home care would be 
important for comparison with similar older patients in the acute hospital setting. 
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CHAPTER 4: 
Prevalence of multimorbidity, potentially inappropriate prescribing and 
adverse drug reactions (ADRs) in patients with cancer  
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4.1 INTRODUCTION 
Between 2010 and 2030, the incidence of cancer in older adults is expected to 
increase from 61% to 70% (20), coinciding with an ageing population (2-4). The 
demand for cancer treatment services in older patients is also likely to increase 
concomitantly. However, cancer may be only one of several complex diagnoses in an 
older individual. These, coupled with co-existing polypharmacy, cognitive and 
functional impairments can present the treating clinician with challenging 
therapeutic and ethical dilemmas.  
 
 4.1.1  Multimorbidity in patients with cancer 
Multimorbidity, defined as the co-occurrence of two or more chronic medication 
conditions in one person (10), is highly prevalent in the general (non-cancer) older 
population; prevalence rates of 50% in those aged ≤65 years and 80% in those ≥80 
years have been reported (13). To date, there has been a relative paucity of research 
into the burden of co-morbid illnesses in patients with cancer. Wedding et al. 
reported multimorbidity rates of 51% in patients with cancer aged < 65 years and 
76% in patients with cancer aged ≥ 65 years (170).  
 Data from insurance company databases identifies multimorbidity in two 
thirds of patients with cancer, with older adults with cancer having a higher rate of 
co-morbid illness than their age-matched controls (171-173). However, the reliability 
of these data is likely to be limited by the accuracy of patient recall and precision of 
data input. Studies of medication use in patients with cancer have identified a high 
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prevalence of co-morbid illnesses (see Table 4.1). However, specific prospective 
studies investigating the burden of multimorbidity in older patients are lacking.  
Table 4.1: Multimorbidity in patients with cancer 
Author Year Country n Age (years) Clinical conditions 
Riechelmann RP et al (174) 2007 Canada 405 Median 58 
(IQR 21-88) 
Median 1    (IQR0-
5) 
Sokol KC et al (175) 2007 US 100 Mean 78        
(r 70-90) 
Mean 3  
Puts MT et al (176) 2009 Canada 112 Mean 74.2 
(SD6) 
48.2% 1 or 2 31.2% 
≥3 
Prithviraj GK et al (177) 2012 Canada 117 Mean 74.6 
(SD6.9) 
0 – 4 (55%)       ≥5 
(45%) 
Saarelainen LK et al (178) 2014 Australia 385 Mean 76.7 
(SD4.8)         All 
≥70 years 
CCI 0 -2 (66.5%)  
CCI ≥3 (33.5%) 
Nightingale G et al (179) 2015 US 234 Mean 80  Mean 7.69 
Alkan A et al (180) 2017 Turkey 445 Mean            
75 (SD60-89) 
All ≥65 years 
76.6%           multi-
morbid 
Legend: IQR = Interquartile range; SD = Standard deviation; CCI = Charlson Co-morbidity Index. 
 
 4.1.2 Medication use in patients with cancer 
It is well established that increasing levels of co-morbid illness correlates with 
increasing numbers of prescribed medications (181). Unsurprisingly, polypharmacy, 
commonly defined as ≥ 5 or (23) ≥ 6 medications (25), is reported to be as frequent 
in patients with cancer as those without (182), though robust data on the prevalence 
and impact of polypharmacy in older patients with cancer are limited. Table 4.2 
highlights studies of medication use, including the prevalence of potentially 
inappropriate medications (PIMs) in older patients with cancer. The prevalence of 
polypharmacy in patients with cancer is reported to range from 35% to 80%. The 
proportions of patients prescribed at least one PIM is reported to be between 21% 
and 41%,  Beers criteria being used most commonly to identify PIMs (65, 66). 
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Table 4.2: Medication use and prevalence of PIMs in patients with cancer 
Author Year Country n Age (years) Medications PIMs 
Riechelmann RP et al. 
(174) 
2007 Canada 405 Median 58 
(IQR 21-88) 
Median 5              
(r 0 -23) 
- 
Sokol KC et al. (175) 2007 US 100 Mean 78     
(r 70-90) 
Mean 9 - 
Puts MT et al. (176) 2009 Canada 112 Mean 74.2 
(SD6) 
Median 5          
(IQR 3-9) 
47.6% moderate 
or severe DIs 
Flood KL et al. (173) 2009 US 47 Mean 73.5 - 21% ≥1 PIM 
(Beers) (64) 
Cashman et al. (184) 2010 UK 100 Median 73.5 
(IQR65-88) 
Median 7         
(IQR 1-17) 
- 
Jorgensen TL et al. 
(185) 
2012 Denmark 24,808 47% ≥70  ≥5 meds           
35% ≥70, 39% ≥80         
41% ≥90  
- 
Prithviraj GK et al. 
(177) 
2012 Canada 117 Mean 74.6 
(SD6.9) 
Mean 7 (r 0 -17) 
80% ≥5 meds 
41% ≥1 PIM 
(Beers) (64) 
Saarelainen LK et al. 
(178) 
2014 Australia 385 Mean 76.7 
(SD4.8)       
Mean 5.7    
(SD3.7) 
26.5% ≥1 PIM 
(Beers) (182) 
Kotlinska-Lemieszek 
A et al. (186) 
2014 Europe 2282 Mean 62.3 
(SD12.3) 
Mean 7.8 (SD3.2) 
25% ≥10 meds 
- 
Maggiore RJ et al. 
(187) 
2014 US 500 Mean 73      
All ≥65 years 
Mean 5 (SD4) 
 
29% ≥1 PIM 
(Beers) (182) 
Nightingale G et al. 
(179) 
2015 US 234 Mean 80  Mean 9.23 
(SD4.29)          
41% ≥5 meds   
43% ≥10 meds 
40% ≥1 PIM 
(Beers) (182)     
38% ≥1 PIM 
(STOPP) (35) 
Samuelsson et al. 
(188) 
2016 Sweden 7279 All ≥75 years 
 
No PIMs        
Mean 3.5 (SD2.7)  
≥1 PIM          
Mean 6.5 (SD 3.3) 
22.5% ≥1 PIM         
(National Board 
of Health & 
Welfare) (186) 
Leger DY et al. (189) 2017 France 122 Mean 81.5 
All ≥75 years 
Mean 6.6      
75.4% ≥5 meds 
34.4% ≥1 PIM 
Alkan A et al. (180) 2017 Turkey 445 Mean 75 
(SD60-89)   
Median 3 (0-14) 
30.8% ≥5 meds 
26.6 % ≥1 PIM 
(Beers) (182) 
Legend: PIM = potentially inappropriate medication, DI = drug interaction, r = range 
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 4.1.3 Adverse drug reactions in patients with cancer 
Polypharmacy (144) and IP (35) contribute to ADRs. ADRs are common, the 
prevalence in the general older adult population at time of hospital admission being 
as high as 20% depending on the definitions and methodologies used to identify 
ADRs. ADRs associated specifically with chemotherapy have been well studied. 
Indeed, potential toxicities are well documented in medications’ summary of product 
characteristics (SPCs) e.g. neutropenia can occur in 30% of patients receiving 
chemotherapy (190). In addition, multiple online educational resources exist e.g. 
http\\:www.chemocare.com and http\\:www.MacMillan.com. These clearly list, 
classify and risk stratify potential ADRs of chemotherapy so that patients, and clinical 
practitioners can be aware of, and vigilant for ADRs prior to and during treatment. 
However, little is known about the prevalence rates of non-chemotherapy related 
ADRs in patients with cancer and whether or not older patients with cancer are more 
vulnerable to ADRs than their younger counterparts. 
 Lau et al. investigated the potential for cancer specific treatments as well non-
cancer specific treatments to cause ADRs during hospitalisation in patients with 
cancer and reported that the following ADRs were most commonly experienced by 
patients: (i) constipation, (ii) nausea/vomiting, (iii) fatigue, (iv) alopecia, (v) 
drowsiness, (vi) myelosuppression, (vii) skin reactions, (viii) anorexia, (ix) mucositis 
and (x) diarrhoea, with 74.3% of patients experiencing at least 1 ADR during 
hospitalisation (191). This study population had a mean age of 59 years (range 20 – 
92), however no comparisons were made between the prevalence and nature of 
ADRs in younger versus older patients.  
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 There is relative paucity of research on the prevalence and impact of 
multimorbidity, IP and ADRs in older patients with cancer. Studies to date that report 
on this weren’t all designed to capture multimorbidity, IP and ADRs in older patient 
with cancer and for some data is from large databases where the precision of data 
input may not accurate.  Medical and radiation oncologists are managing and treating 
cancer in a heterogeneous group of older patients, many of whom have age-related 
physiological change, complex co-morbidities, complex polypharmacy as well as 
functional and cognitive impairments. The burden of multimorbidity, prevalence of 
medication use and related ADRs has not been studied in older patients with cancer 
in Ireland, nor has there been an investigation into the differences between older 
and younger patients with cancer in Ireland. With a rapidly changing demographic 
distribution, more older patients are expected to be diagnosed with cancer in the 
coming decades. This will require more complex and multidisciplinary clinical and 
social care. More robust data are required about this patient group in order to 
effectively design and administer appropriate interventions.  
 
 4.1.4 Objectives 
The specific objectives of this study were: 
(i) To investigate and describe the burden of multimorbidity in patients 
attending a tertiary specialist oncology unit, comparing younger and older 
adults. 
(ii) To assess the pattern of prescription drug use in these patients, both 
oncological and non-oncological. 
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(iii) To determine the prevalence of polypharmacy (≥ 6 medications) and high 
level polypharmacy (≥ 11 medications) in patients attending a specialist 
oncology unit. 
(iv) To determine the prevalence of potentially inappropriate prescribing, 
where applicable, using STOPP (Screening Tool of Older Person’s 
potentially inappropriate Prescriptions) criteria (Appendix 8) (36) and 
OncPal (Oncological palliative care deprescribing guideline) (Appendix 9) 
(190). 
(v) To determine the incidence of ADRs causing or contributing significantly 
to hospital admission in patients with cancer. 
(vi) To classify ADRs according to type, causality, associated morbidity, 
severity, predictability and preventability. 
(vii) To identify risk factors for ADRs in older and younger patients with cancer. 
(viii) To analyse the outcomes for patients who experience ADRs. 
 
The work undertaken in this chapter, including study design, data collection and 
statistical analysis, is entirely my own. 
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4.2 METHODS 
 4.2.1 Study setting and design 
This prospective observational study was conducted in two academic teaching 
hospitals in the Republic of Ireland; Cork University Hospital (CUH) and Mercy 
University Hospital (MUH). It was conducted over a 12 month period (January 1st 
2016 – December 31st 2016), following a one month pilot in which study procedures 
and logistics were refined and finalised.   
 CUH is a level 4 University Teaching Hospital with 850 inpatients beds and 
over 25,000 emergency admissions per year. It caters for approximately 5300 
medical oncology admissions per year comprising 4500 day cases, 500 emergency 
inpatient admissions and 300 elective inpatient admissions. In addition, there are 
approximately 30,000 day unit radiation oncology admissions per year. MUH is a 300 
bed level 3 University Teaching Hospital, with a smaller medical oncology service 
catering for 4400 admissions per year. This comprises 4000 day cases, 300 emergency 
inpatient admissions and 100 elective inpatient admissions. MUH has no radiation 
oncology service. Both hospitals serve a population of over 800,000 people and 
together form one of the eight regional cancer centres in the Republic of Ireland.  
 
 4.2.2  Patient eligibility and consent 
All patients’ aged 16 years and older, admitted under the medical oncology or 
radiation oncology services in CUH and MUH, were eligible for inclusion in this 
prospective study. For the purpose of this study older adults were defined as being 
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aged ≥70 years. Participants were enrolled from three different admission pathways; 
emergency, elective and medical oncology day unit admissions. Radiation oncology 
day unit admissions were excluded due to logistical difficulties noted during the 1 
month pilot phase, principally due to rapid treatment turnover times and lack of 
appropriate office space to conduct patient interviews in the radiation oncology 
centre. 
 Emergency and elective admissions to the medical oncology service were 
recruited within 72 hours of presentation to hospital. Chemotherapy day unit 
admissions i.e. patients attending for daily treatment on a regular basis, were 
reviewed over a two week period (March 28th to April 8th 2016); one week being 
allocated to each hospital. Day unit admissions encompass patients undergoing 
regular cycles of cancer treatment and therefore the same patients attend weekly 
for a defined period of time. Exclusion criteria were as follows: (i) patients already 
enrolled in the study on a previous hospital admission and (ii) patients deemed to be 
actively dying by the attending physician, at the point of admission. 
 The study’s objectives were explained to patients. If agreeable, patients 
provided written consent to participate. In circumstances where patients were 
unable to give consent due to reduced decision making ability e.g. delirium or 
advanced dementia, consent was obtained from their legal representative. Inclusion 
in the study was voluntary and was clearly documented in patients’ medical records. 
The study protocol was assessed and approved by the local Clinical Research Ethics 
Committees at University College Cork (Appendix 2). 
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4.2.3 Study population and sample size calculation 
 
 (i) Sample size required to determine the prevalence of potentially 
 inappropriate prescribing 
Using an estimated prevalence of potentially inappropriate prescribing (PIP) of 20%, 
a margin of error of 4% and 95% level of confidence, a minimum sample of 322 
patients was required for this study. This power calculation was based on the formula 
outlined in Table 4.3 and adjusted using oncology service admissions data from 2015.  
 
(ii) Sample size required to determine the prevalence of adverse drug 
reactions 
In the acute unselected population of all ages, the reported ADR rate is 
approximately 7%, therefore this study was powered to record an ADR rate of 7% 
with a margin of error of 2% with 95% confidence. This determined that a minimum 
sample of 333 patients was required (Table 4.3).  
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Table 4.3: Sample size calculation 
Hospital admission rates: January to  December 2015 Sample size calculation 
Potentially Inappropriate Prescribing 
Sample size calculation  
Adverse Drug Reactions 
All admission episodes (including multiple/repeat 
admissions) 
Formula 
n = Z2 x P (1 – P) 
D2 
 
n = sample size 
Z = Z statistic for the level of confidence (1.96) 
P = Expected prevalence (20% or 0.20) 
D = margin of error (4% or 0.04)  
 
n = (1.96)2 x (0.20) (1 – 0.2) = 384 
0.042 
 
Adjusted for population available: 
 
Formula  
n0 X N 
N0 + (N – 1) 
 
n0 = population available to recruit from 
N = sample size calculation 
             
 1538 x 384 = 307 (+ 5%) + 15 = 322 
        1538 + (384 – 1)                                                             
Formula 
n = Z2 x P (1 – P) 
D2 
 
n = sample size 
Z = Z statistic for the level of confidence (1.96) 
P = Expected prevalence (7% or 0.07) 
D = margin of error (2% or 0.02)  
 
n = (1.96) x (0.07) (1 – 0.07) = 625 
0.022 
 
Adjusted for population available 
Formula  
n0 X N 
N0 + (N – 1) 
 
 
n0 = population available to recruit from 
N = sample size calculation 
                                            _   
644 x 625__ = 317 (+ 5%) + 16 = 333 
     644 + (625 – 1)               
 Emergency Elective Day unit  Total 
CUH (MO) 482 313 4538 5333 
MUH (MO) 235 109 3956 4300 
CUH (RO) 117 126  243 
Total 834 548 8494 9633 
Numbers of individual patients admitted at least once in 2015 
 Emergency Elective Day unit  Total 
CUH (MO) 237 101 457 795 
MUH (MO) 107 32 437 576 
CUH (RO) 83 84  167 
 427 217 894 1538 
Legend: MO = medical oncology; RO = radiation oncology; CUH = Cork University Hospital; MUH = Mercy University Hospital
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 4.2.4 Data collection 
All participants were reviewed within 72 hours of admission. Each morning, a list of 
admissions from the previous 72 hours was compiled. To avoid any bias, patients 
were enrolled in chronological order of admission i.e. those in hospital the longest 
were recruited first.  
 The following data were abstracted onto a standardized proforma (Appendix 
3): (i) demographic details, (ii) medical co-morbidities using the Cumulative Illness 
Rating Scale – CIRS (156), (iii) concurrent medications, (iv) functional ability using the 
Barthel Index (157), (v) cognitive status using a standardized Mini-mental state 
examination – MMSE), in those ≥ 65 years (158), the 4-AT  (159) and the Diagnostic 
and Statistical Manual of Mental Disorders V - DSM-V to assess for delirium (160), (vi) 
laboratory values, and (vii) electrocardiogram (ECG). Medication reconciliation was 
completed using the Structured History taking of Medication use (SHiM) (32). These 
tools have been described in detail in Chapter 3. 
 Potentially inappropriate prescribing (PIP) was assessed using STOPP criteria 
(Appendix 8) (37) and OncPal (Appendix 9) (192). A brief description of STOPP criteria 
has been presented in chapter 3. A brief description of the development and validity 
of OncPal follows. OncPal (192) is an explicit prescribing tool, developed and 
validated in Australia, to assist physicians with deprescribing for patients with cancer 
and a poor survival prognosis. It aims to highlight medications that are of limited 
benefit in this patient group. Similar to STOPP criteria it is divided into physiological 
systems. It focuses primarily on preventative therapy e.g. aspirin for primary 
prevention and anti-hypertensives. To date, only one study has been published that 
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used OncPal (192). This prospective study of 61 patients (mean age 66 (range 23 - 93) 
showed that 70% of patients with cancer and a limited life expectancy were 
prescribed at least one potentially inappropriate medication (PIM) and that 21.4% of 
all medications prescribed to this population were potentially inappropriate (192). 
 
 4.2.5 Potentially inappropriate prescribing 
STOPP criteria (Appendix 8) (37) were applied to the abstracted data of all patients 
≥ 65 years. OncPal criteria (Appendix 9) (192) were applied to the abstracted data on 
participants who died within 6 months of enrolment. The presence or absence of a 
PIM, according to STOPP and OncPal criteria, was categorised as a dichotomous 
variable. Where there was uncertainty regarding appropriateness of a prescription 
this was treated conservatively i.e. the medication was deemed appropriate.  
 
4.2.6 Adverse drug reactions (ADRs) 
The proportion of patients experiencing one or more non-trivial, probable or certain, 
ADR causing or contributing significantly to hospital admission was determined using 
Edwards and Aronson’s definition of an ADR i.e. “An appreciably harmful or 
unpleasant reaction, resulting from an intervention related to the use of a medicinal 
product, which predicts hazard from future administration and warrants prevention 
or specific treatment, or alteration of the dosage regimen, or withdrawal of the 
product” (79). 
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 To limit potential bias from selective ADR reporting and to ensure ADRs were 
not missed, the AE Trigger List of the 12 most common adverse events (AEs) linked 
to ADRs was used, as previously discussed in Chapter 2, data on any ADR not listed 
in the AE Trigger List were also collected e.g. drug anaphylaxis. All AEs including 
potential ADRs were recorded and subsequently reviewed to assess the causative 
role of prescribed medications. ADRs were assessed prospectively at the time of 
enrolment.  
 
 4.2.7 ADR causality, severity, predictability and preventability 
Causality was assessed using the World Health Organisation Uppsala Monitoring 
Centre (WHO-UMC) criteria whereby the likelihood of a drug causing the adverse 
event is classified as either certain, probable, possible, unlikely or unrelated (119). 
ADR severity was assessed using the Hartwig & Siegel scale. This grades ADR severity 
according to clinical consequence on a scale of 1 to 7 with a grade 1 ADR being trivial 
and requiring no medical intervention and a grade 7 ADR representing a fatal event 
(151). Preventability of the ADR was assessed using Hallas criteria i.e. definitely 
avoidable, possibly avoidable, unavoidable and unclassifiable (166). Predictability 
was assessed using the summary of product characteristics (SPC) (Table 4.4). ADRs 
were deemed predictable if they were listed in the relevant SPC as occurring 
commonly (≥1/100 and <1/10) or very commonly (≥1/10). 
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Table 4.4: Adverse drug reaction predictability 
Incident rate 
 
Incident description Predictability 
 
≥1/10 
≥1/100 and < 1/10 
≥1/1000 and < 1/100 
≥1/10,000 and < 1/1000 
< 1/10,000 
 
Very common 
Common 
Uncommon 
Rare 
Very rare 
 
Predictable 
Predictable 
Unpredictable 
Unpredictable 
Unpredictable 
 
 
 4.2.8  Statistical analysis 
Statistical analysis was performed using IBM SPSS® Statistics version 22 for windows. 
Descriptive data were reported using the mean and standard deviation (SD) for 
variables that were normally distributed and median and interquartile range (IQR) 
for non-parametric variables.  Differences in the distribution of categorical variables 
were compared using the Pearsons Chi-square (Χ2) test and continuous variables 
using the independent t-test. The Mann Whitney U and Kruskal-Wallis tests were 
used to determine independence of two or more non-parametric variables 
respectively. Pearson’s kappa coefficient was used to assess correlation between 
variables. Logistic regression was used to examine the influence of gender, age, 
number of medications and burden of co-morbidity on PIP practices. The Hosmer and 
Lemeshow statistic was used to test the goodness of fit of the regression model. A 
probability value of less than 0.05 was considered statistically significant. 
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4.3  RESULTS 
 4.3.1 Screening 
A total of 408 emergency and elective admissions to the medical and radiation 
oncology services in CUH and MUH were screened for study inclusion between the 
1st of January 2016 and the 31st December 2016. Of these, 265 patients agreed to 
participate of whom 201 were admitted emergently (57.4% of total study sample) 
and 64 were admitted electively (18.3% of total study sample). Ninety patients 
attending the Oncology Chemotherapy Day Unit treatment were screened for 
eligibility, of whom 85 agreed to participate (24.3% of total study sample). These data 
are summarised in Figure 4.1, together with reasons for study exclusion. Overall, 350 
patients attending the oncology services were enrolled in this study. 
Figure 4.1: Participant screening, exclusion and enrolment 
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 4.3.2 Population characteristics 
Baseline characteristics are displayed in Table 4.5. The mean age was 63.6 (SD12.1) 
years, range 16 – 90. Males were significantly older than females (65.4 (SD10.7) vs 
61.9 (SD13) years, t345.954 = 2.731, p = 0.005). Accordingly, 37.1% of males and 32.2% 
of females were ≥ 70 years (Χ2 (1) = 0.921, p = 0.198). Most patients were functionally 
independent with 95.5% (n=334) being categorised as independent or being of low 
dependency using the Barthel Index (scores ≥ 16). The MMSE was applied to 
participants ≥ 65 years to assess cognitive ability, 88.3% (n=165) of whom completed 
this assessment. In participants who completed the MMSE, normal cognition and 
mild cognitive impairment were identified in 87.3% and 8.5% respectively. Delirium 
was identified in 6.3% (n=22) at the point of admission using the 4-AT and DSM-V. 
 One in four (25.4%) participants consumed alcohol on a weekly basis with 
6.9% drinking more than the recommended weekly allowance. One hundred and 
ninety five (65.7%) patients had a history of smoking and 10% (n=35) continued to 
smoke. Differences identified between older and younger adults are displayed in 
Table 4.6. The key findings with regard to population demographics are presented in 
Key findings box 1. 
Key Findings 1: 
 One in three (34.5%) patients attending a regional oncology unit were ≥70 years. 
 One in twenty (6.5%) patients were aged ≥ 80 years. 
 Functional independence was identified in 95.5%. 
 The majority of patients with cancer aged ≥ 65 years had normal (87.3%) or mild 
cognitive impairment (8.5%) as determined by the MMSE. 
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Table 4.5: Characteristics of study population according to gender (n = 350) 
Variable Male 
n = 167 
Female 
n = 183 
Total 
n = 350 
P-value 
 
     
Age distribution (years)     
Mean (SD) 65.4 (10.7) 61.9 (13) 63.6 (12.1) 0.005* 
≤ 64  67 (40%) 97 (53%) 164 (46.9%) 0.016* 
65 – 74 73 (43.7%) 59 (32.2%) 132 (37.7%) 0.027* 
75 – 84 23 (13.9%) 24 (13%) 47 (13.4%) 0.857 
≥ 85 4 (2.4%) 3 (1.6%) 7 (2%) 0.614 
     
Functional ability (Barthel Index)     
Median (IQR) 20 (20 – 20) 20 (20 – 20) 20 (20 – 20) 0.006* 
Range 11 - 20 7 - 20 7 - 20  
Independent (≥ 20) 141 (84.4%) 130 (71%) 271 (77.4%) 0.003* 
Low dependency (16 – 19) 21 (12.7%) 42 (22.7%) 63 (18%) 0.012* 
Moderate dependency (11 – 15) 6 (3.6%) 8 (4.3%) 14 (4%) 0.710 
High dependency (6 – 10) 0 (0%) 3 (1.6%) 3 (0.9%) 0.097 
Maximum dependency (0 – 5) 0 (0%) 0 (0%) 0 (0%) NA 
     
Driving     
Ability to drive 150 (90.4%) 129 (71.7%) 279 (80.6%) <0.001* 
Actively still driving 111 (66.9%) 87 (47.5%) 198 (57.2%) <0.001* 
     
Cognitive ability (MMSE)     
Number of patients ≥65 years 101 (60.5%) 86 (47%) 187 (53.5%) 0.012* 
Number ≥65 that completed MMSE 88 (87.2%) 77 (89.5%) 165 (88.3%) 0.742 
Median (IQR) 28 (26 – 29) 28 (26 -29) 28 (26 – 29) 0.610 
Range 14 - 30 12 - 30 12 - 30  
Normal MMSE score (24 – 30) 81 (92%) 63 (81.8%) 144 (87.3%) 0.049* 
Mild cognitive impairment (19 - 23) 5 (3%) 9 (11.7%) 14 (8.5%) 0.167 
Moderate cognitive impairment (10 – 18) 2 (1.2%) 5 (6.5%) 7 (4.2%) 0.180 
Severe cognitive impairment (0 – 9) 0 (0%) 0 (0%) 0 (0%) NA 
     
Alcohol and Smoking     
Consumes alcohol weekly 54 (32.7%) 35 (19.4%) 89 (25.4%) 0.005* 
Consume ≥ recommended weekly limit 14 (8.4%) 10 (5.5%) 24 (6.9%) 0.285 
History of smoking 105 (63.9%) 90 (49.2%) 195 (55.7%) 0.010* 
Current smokers 18 (10.8%) 17 (9.3%) 35 (10%) 0.643 
     
Legend: SD = standard deviation; IQR = inter-quartile range; MMSE = mini-metal state examination, 
** ≥11 units for females, ≥17 units for male
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Table 4.6: Characteristics of study population according to age category (n = 350) 
Variable  < 70 years  
n=229 (65.5%) 
≥ 70 years  
n=121 (34.5%) 
p-value < 80 years 
n=327 (93.5%) 
≥ 80 years  
n=23 (6.5%) 
p-value 
        
Functional ability         
Barthel Index Med (IQR) 20  (20-20) 20 (18-20) <0.001* 20 (20-20) 19 (17-20) <0.001* 
Independent (≥ 20) n (%) 191 (83.4%) 80 (66.1%) <0.001* 262 (80.1%) 9 (39.1%) <0.001* 
Low dependency (16 – 19) n (%) 32 (14%) 31 (25.6%) 0.007* 52 (15.9%) 11 (47.8%) <0.001* 
Moderate dependency (11 – 15) n (%) 6 (2.6%) 8 (6.6%) 0.070 13 (4%) 1 (4.3%) 0.930 
High dependency (6 – 10) n (%) 0 (0%) 0 (0%) 0.017 1 (0.3%) 2 (8.7%) <0.001* 
Maximum dependency (0 – 5) n (%) 0 (0%) 0 (0%) NA 0 (0%) 0 (0%) NA 
        
Driving        
History of driving n (%) 187 (82.4%) 92 (77.3%) 0.257 264 (81.7%) 15 (65.2%) 0.053 
Current driving n (%) 130 (57.3%) 68 (57.1%) 0.982 190 (58.8%) 8 (34.8%) 0.024* 
        
Cognitive ability         
MMSE Med (IQR) 28 (26-30) 27 (25-29) 0.029* 28 (26-29) 26 (21.75-27) <0.001* 
Number of patients completed MMSE (≥65years) n (%) 56 (86.2%) 109 (90.1%) 0.420 143 (87.7%) 22 (95.7%) 0.261 
Normal cognition (25 – 30) n (%) 49 (87.5%) 89 (81.7%) 0.336 126 (88.1%) 12 (54.5%) <0.001* 
Mild cognitive impairment (20 – 24) n (%) 4 (7.1%) 15 (13.8%) 0.207 12 (8.4%) 7 (31.8%) <0.001* 
Moderate cognitive impairment (10 – 19) n (%) 3 (5.4%) 5 (4.6%) 0.827 5 (3.5%) 3 (13.6%) 0.039* 
Severe cognitive impairment (0 – 10) n (%) 0 (0%) 0 (0%)  0 (0%) 0 (0%)  
        
Alcohol and smoking        
Consumes alcohol weekly n (%) 62 (27.7%) 27 (22.3%) 0.277 86 (26.7%) 3 (13%) 0.148 
Consume ≥ recommended weekly limit n (%) 14 (6.3%) 10 (8.3%) 0.483 24 (7.5%) 0 (0%) 0.175 
History of smoking n (%) 129 (56.3%) 66 (54.5%) 0.749 186 (56.9%) 9 (39.1%) 0.098 
Current smokers n (%) 30 (13.1%) 5 (4.1%) 0.008* 33 (10.1%) 2 (8.7%) 0.829 
        
Legend: IQR = Inter-quartile range; MMSE = Mini mental state examination. 
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 4.3.3 Level of morbidity 
The level of morbidity in this population was measured by the total number of 
chronic conditions, the number of chronic conditions requiring regular drug 
treatment and the CIRS score. These data are summarised in Table 4.7.  
 Most participants (96.9%) were multimorbid, with almost 7 out of every 10 
patients (68%) having 5 or more chronic conditions.  Older adults (≥ 70 years) were 
significantly more likely to be multimorbid than younger adults, 100% vs 95.2%, Χ2 
(1) = 6.001, p = 0.014 (Figure 4.2). Older adults (≥ 70 years) were also significantly 
more likely to have 5 or more chronic conditions than younger adults, 81.1% vs 
60.7%, Χ2 (1) = 16.228, p < 0.001.  
 Participants had a median of 6 (IQR 4-8) clinical conditions, with a median of 
3 (IQR2-5) requiring regular medication use.  Older adults (≥ 70 years) had a 
significantly higher number of conditions compared to younger adults, median of 7 
(IQR 5-10) vs 5 (IQR 3-7) U = 8168.5, p <0.001 (Figure 4.3). Additionally they had a 
significantly higher number of conditions requiring regular medication use, 4 (IQR 3-
6) vs 3 (IQR 2-4) U = 8827, p <0.001.  
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Table 4.7: Level and severity of co-morbid illnesses according to age category 
Variable < 70 years  
n=229 (65.5%) 
≥ 70 years 
n=121 (34.5%) 
p-value < 80 years 
n=327 (93.5%) 
≥ 80 years 
n=23 (6.5%) 
p-value Total 
N = 350 
        
Multi-morbidity        
≥2 conditions 218 (95.2%) 121 (100%) 0.014* 316 (96.6%) 23 (100%) 0.371 339 (96.9%) 
≥3 conditions 201 (87.8%) 119 (98.3%) 0.001* 297 (90.8%) 23 (100%) 0.129 320 (91.4%) 
≥4 conditions 171 (74.4%) 110 (90.9%) <0.001* 260 (79.5%) 21 (91.3%) 0.169 281 (80.3%) 
≥5 conditions 139 (60.7%) 99 (81.1%) <0.001* 219 (67%) 19 (82.6%) 0.120 238 (68%) 
        
Total conditions        
Median (IQR) 5 (3-7) 7 (5-10) <0.001* 6 (4-8) 8 (5-9) 0.018* 6 (4-8) 
Range 1-17) 2-18  1-18 3-15  1-18 
        
Conditions  
(requiring regular 
meds) 
       
Median (IQR) 3 (2-4) 4 (3-6) <0.001* 3 (2-5) 4 (3-8) 0.030* 3 (2-5) 
Range 1-12 0-14  0-14 1-12  0-14 
        
CIRS        
Median (IQR) 
Range 
11 (9-14.5) 
2-26 
15 (11-19) 
6-30 
<0.001* 
 
12 (9-16)  
2-30 
16(13-19) 
6-29 
0.004* 13 (9-16) 
2-30 
        
Legend: CIRS = Cumulative illness rating scale, IQR = inter-quartile range, meds = medications, SD = standard deviation 
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Figure 4.2: Prevalence of multimorbidity according to age category 
 
 
 
Figure 4.3: Number of chronic conditions according to age category 
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 4.3.4  Cumulative Illness Rating Scale (CIRS) scores 
The median CIRS score was 13 (IQR 9-16), with adults 70 years and older having a 
significantly higher CIRS score than those < 70 years (15 (IQR 11-19) vs 11 (IQR 9-
14.5), U = 8511.5, p <0.001. Adults aged 80 years and older also had a significantly 
higher CIRS score than those aged < 80 years (16 (IQR 13-19) vs 12 (IQR 9-16), U = 
2416, p = 0.004 (Figure 4.4). 
Figure 4.4: CIRS score according to age category 
 
Figure 4.5 illustrates the CIRS ratings of system-based illnesses. Approximately 81% 
(n=283) of participants rated at least one illness with a “4” for one physiological 
system (indicating extremely severe disease requiring immediate treatment or 
contributing to severe impairment in function), 48.6% (n=170) rated at least one 
illness with a “3” (indicating a severe condition that is uncontrollable), 85.4% (n=299) 
at least one “2” (indicating a disease requiring first line treatment or causing 
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moderate disability) and 76.9% rated at least (n=269) at least one “1” (indicating a 
mild current problem or past significant problem).  
 
Figure 4.5: The number of participants according to age that rated at least one 
system with a score of 0, 1, 2, 3 or 4 (n = 350) 
 
 
Key Findings 2: 
 Older adults (≥ 70 years) had a higher cumulative index rating score (CIRS) 
than younger comparators, 15 (IQR 11-19) vs 11 (IQR 9-14.5). 
 
 4.3.5 Cancer diagnoses 
The most common primary cancer sites in this population were (i) breast, (li) lung 
and (iii) colorectal (see Table 4.8). Older adults (≥ 70 years) were significantly more 
likely to have a primary lung cancer diagnosis (22.3% vs 13.5%, Χ2 (1) = 4.411, p = 
0.036), whereas younger adults (< 70 years) were significantly more likely to have a 
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primary breast cancer diagnosis (21.4% vs 12.4%, Χ2 (1) = 4.292, p = 0.038). 
Additionally, adults ≥80 years were significantly more likely to have a primary lung 
cancer diagnosis than their younger counter parts (100% vs 17.7%, Χ2 (1) = 4.411, p = 
0.027). There was no significant difference according to age for all other primary 
cancer diagnoses. Approximately 17% (n=28) men had a history of another cancer or 
a concurrent cancer diagnosis compared to 9.9% (n=18) of females (Χ2 (1) = 4.988, p 
= 0.026).  
Table 4.8: Primary cancer diagnoses 
Variable Male 
n = 167 
Female 
n = 183 
Total P-value 
 
     
Primary cancer diagnosis  
(in order of frequency) 
    
1. Breast 4 (2.4%) 60 (32.4%) 64 (18.3%) <0.001* 
2. Lung 35 (21%) 23 (12.6%) 58 (16.6%) 0.035* 
3. Colorectal 31 (18.6%) 15 (8.2%) 46 (13.1%) 0.004* 
4. Lymphoma 15 (9%) 15 (8.2%) 30 (8.6%) 0.793 
5. Ovarian 0 (0%) 15 (8.2%) 15 (4.3%) <0.001* 
6. Pancreatic 7 (4.2%) 8 (4.4%) 15 (4.3%) 0.934 
7. Prostate 14 (8.4%) 0 (0%) 14 (4%) <0.001* 
8. Oesophageal 10 (6%) 4 (2.2%) 14 (4%) 0.070 
9. Melanoma 7 (4.2%) 6 (3.3%) 13 (3.7%) 0.652 
10. Gastric 4 (2.4%) 7 (3.8%) 11 (3.1%) 0.444 
     
 
 4.3.6 Non-cancer diagnoses 
The most common non-cancer diagnosis in this population were (i) hypertension (ii) 
dyslipidaemia and (iii) gastro-oesophageal reflux disease (GORD) (see Table 4.9). 
Females were significantly more likely to have hypothyroidism (Χ2 (1) = 8.034, p = 
0.038), and thromboembolic disease (Χ2 (1) = 6.696, p = 0.010). Men were 
significantly more likely to have ischaemic heart disease (Χ2 (1) = 9.398, p = 0.002) 
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and diabetes mellitus (Χ2 (1) = 4.258, p = 0.039). The key findings with regard to 
diagnoses are presented in Key Findings 4. 
Table 4.9: Non-cancer diagnoses 
Variable Male 
n = 167 
Female 
n = 183 
Total P-value 
 
 
Non-cancer diagnosis (in order of frequency)     
1. Hypertension 75 (44.9%) 64 (35%) 139 (39.7%) 0.058 
2. Dyslipidaemia 68 (40.7%) 65 (35.5%) 133 (38%) 0.317 
3. Gastro-oesophageal reflux disease 45 (26.9%) 50 (27.3%) 95 (27.1%) 0.937 
4. Depression/Anxiety 
Depression 
Anxiety 
35 (21%) 
26 (15.6%) 
14 (8.4%) 
46 (25.1%) 
32 (17.5%) 
25 (13.7%) 
81 (23.1%) 
58 (16.6%) 
39 (11.1%) 
0.355 
0.630 
0.117 
5. Osteoarthritis 25 (15%) 32 (17%) 57 (16.3%) 0.524 
6. Ischaemic heart disease 
Percutaneous coronary intervention  
Myocardial Infarction 
Coronary artery bypass graft 
35 (21%) 
17 (10.2%) 
16 (9.6%) 
10 (6%) 
17 (9.3%) 
3 (1.6%) 
6 (3.3%) 
2 (1.1%) 
52 (14.9%) 
20 (5.7%) 
22 (6.3%) 
12 (3.4%) 
0.002* 
0.001* 
0.015* 
0.012* 
Heart Failure 5 (3%) 3 (1.6%) 8 (2.3%) 0.397 
7. Diabetes Mellitus 29 (17.4%) 18 (9.8%) 47 (13.4%) 0.039* 
8. Hypothyroidism 13 (7.8%) 33 (18%) 46 (13.1%) 0.005* 
9. Chronic obstructive pulmonary 
disease 
22 (13.2%) 21 (11.5%) 43 (12.3%) 0.629 
10. Thromboembolic disease 11 (6.6%) 28 (15.3%) 39 (11.1%) 0.010* 
11. Atrial fibrillation 
 
21 (12.6%) 17 (9.3%) 38 (10.9%) 0.324 
 
Older adults (≥ 70 years) were significantly more likely to have a diagnosis of 
hypertension (62.8% vs 27.5%, Χ2 (1) = 41.202,  p <0.001), dyslipidaemia (51.2% vs 
31%, Χ2 (1) = 13.769, p <0.001), osteoarthritis (24% vs 12.2%, Χ2 (1) = 8.003, p = 0.005), 
ischaemic heart disease (26.4% vs 8.7%, Χ2 (1) = 19.635, p <0.001), heart failure (5.1% 
vs 0.9%, Χ2 (1) = 5.916, p = 0.015), diabetes mellitus (19.8% vs 10%, Χ2 (1) = 6.528, p 
= 0.011), hypothyroidism (18.2% vs 10.5%, Χ2 (1) = 4.113, p = 0.043) and atrial 
fibrillation (22.3% vs 4.8%, Χ2 (1) = 25.081, p <0.001) than their younger counterparts 
(see Table 4.10). Adults aged 80 years and older were significantly more likely to have 
a diagnosis of hypertension (78.3% vs 37%, Χ2 (1) = 15.278, p <0.001) and 
osteoarthritis (34.6% vs 15%, Χ2 (1) = 6,178, p = 0.013) than those aged < 80 years. 
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Table 4.10: Non-cancer diagnoses according to age  
Variable  < 70 
n=229 
(65.5%) 
≥ 70 
n=121 
(34.5%) 
p-
value 
< 80  
n=327 
(93.5%) 
≥ 80  
n=23 
(6.5%) 
p-value 
        
Non-cancer 
diagnosis 
       
Hypertension n (%) 63 (27.5%) 76 (62.8%) <0.001 121 (37%) 18 (78.3%) <0.001* 
Dyslipidaemia n (%) 71 (31%) 65 (51.2%) <0.001 122 (37.3%) 11 (47.8%) 0.315 
GORD n (%) 62 (27.1%) 33 (27.3%) 0.968 90 (27.5%) 5 (21.7%) 0.547 
Depression/Anxiet
y 
    Depression 
    Anxiety 
n (%) 
n (%) 
n (%) 
51 (22.3%) 
35 (15.3%) 
27 (11.9%) 
30 (24.8%) 
23 (19%) 
12 (9.9%) 
0.595 
0.373 
0.596 
77 (23.5%) 
55 (16.8%) 
37 (11.3%) 
5 (17.4%) 
3 (13%) 
2 (8.7%) 
0.499 
0.638 
0.700 
Osteoarthritis n (%) 28 (12.2%) 29 (24%) 0.005 49 (15%) 8 (34.6%) 0.013 
IHD n (%) 20 (8.7%) 32 (26.4%) <0.001 46 (14.1%) 6 (26.1%) 0.117 
    PCI n (%) 10 (4.4%) 10 (8.3%) 0.135 19 (5.8%) 1 (4.3%) 0.770 
    MI n (%) 11 (4.8%) 11 (9.1%) 0.116 19 (5.8%) 3 (13%) 0.180 
    CABG n (%) 6 (2/6%) 6 (5%) 0.253 11 (3.4%) 1 (4.3%) 0.807 
    HF n (%) 2 (0.9%) 6 (5%) 0.015 7 (2.1%) 1 (4.3%) 0.499 
Diabetes Mellitus n (%) 23 (10%) 24 (19.8%) 0.011 43 (13.1%) 4 (17.4%) 0.564 
Hypothyroidism n (%) 24 (10.5%) 22 (18.2%) 0.043 42 (12.8%) 4 (17.4%) 0.533 
COPD n (%) 23 (10%) 20 (16.5%) 0.079 43 (13.1%) 0 (0%) 0.063 
Thromboembolic 
dx 
n (%) 25 (10.9%) 14 (11.6%) 0.853 38 (11.6%) 1 (4.3%) 0.284 
Atrial fibrillation n (%) 11 (4.8%) 27 (22.3%) <0.001 34 (10.4%) 4 (17.4%) 0.297 
        
Legend: GORD = gastro-oesophageal reflux disease, IHD = ischaemic heart disease, PCI = percutaneous 
coronary intervention (stents), MI = myocardial infarction, CABG = coronary artery bypass graft, HF = heart 
failure, COPD = chronic obstructive pulmonary disease, dx = disease 
 
 
Key Findings 3: 
 The three most common cancer sites were breast, lung and colorectal. 
 The three most common non-cancer diagnoses were hypertension (HTN), 
dyslipidaemia and gastro-oesophageal reflux disease (GORD). 
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 4.3.7 Prescription medications  
A total of 2,575 medications were prescribed regularly to 326 (93.1%) patients, 6.9% 
(n=24) were not prescribed medications. Additionally, 491 medications were 
prescribed “as required” to 280 (80%) patients. The median number of medications 
prescribed per patient was 5 (IQR 3-8), range 0 - 24, with 47.1% (almost 1 in 2 
patients) experiencing polypharmacy and 11.4% (almost 1 in 9 patients) experiencing 
high level polypharmacy (table 4.11). There was no significant difference between 
the numbers of medications prescribed to males and females (Χ2 (3) = 3.619, p = 
0.306). 
Table 4.11: Prescribing according to gender (n=350) 
Variable Male 
n = 167 
Female 
n = 183 
Total 
n = 350 
P-value 
 
 
Medications (regular) 
    
Median (IQR) 5 (3-8) 5 (3-8) 5 (3-8) 0.658 
Range 
 
0 - 24 0 - 17 0 - 24  
Medications (as required)     
Median (IQR) 1 (0-2) 1 (0-2) 1 (0-2) 0.012* 
Range 
 
 
0 - 6 0 - 12 0 - 12  
Patients taking at least 1 medication 152 (91%) 174 (95.1%) 326 (93.1%) 0.133 
1 – 5 medications 72 (43.1%) 89 (48.6%) 161 (46%) 0.301 
6 – 10 medications 58 (34.7%) 67 (36.6%) 125 (35.7%) 0.714 
≥ 11 medications 22 (13.2%) 18 (9.8%) 40 (11.4%) 0.327 
≥ 6 medications 
 
80 (47.9%) 85 (46.4%) 165 (47.1%) 0.785 
Legend: IQR = inter quartile range 
 
 4.3.8 Medication use according to age category 
Adults aged ≥ 70 years were prescribed more medications than those aged < 70 years 
(median 7 (IQR4-9) vs 4(IQR2-7), U = 9379.5, p<0.001) (Table 4.12) with 
polypharmacy and high level polypharmacy significantly higher in those ≥ 70 years, 
Χ2 (1) = 20.189, p <0.001 and Χ2 (1) = 10.496, p = 0.001 respectively (Figure 4.6). 
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Table 4.12: Distribution of prescription medications according to age category 
(n=350) 
Variable < 70 years 
n=229 
(65.5%) 
≥ 70 years 
n=121 
(34.5%) 
p-value < 80 years 
n=327 
(93.5%) 
≥ 80 years 
n=23 
(6.5%) 
p-value 
       
Medications 
(regular) 
      
Median (IQR) 4 (2-7) 7 (4-9) <0.001* 5 (3-8) 7 (4-9) 0.063 
Range 0-24 0-18  0-24 0-16  
       
Medications 
(as required) 
      
Median (IQR) 1 (0-2) 1 (0-2) 0.744 1 (0-2) 1 (0-2) 0.669 
Range 0-6 0-12  0-8 0-12  
       
Patients taking at 
least 1 med 
208 (90.8%) 118 (97.5%) 0.018* 304 (93%) 22 (95.7%) 0.622 
1 – 5 medications 120 (52.4%) 41 (33.9%) 0.001* 153 (46.8%) 8 (34.8%) 0.264 
6 – 10 medications 71 (31%) 54 (44.6%) 0.010* 114 (34.9%) 11 (47.8%) 0.210 
≥ 11 medications 17 (7.4%) 23 (19%) 0.001* 37 (11.3%) 3 (13%) 0.801 
≥ 6 medications 88 (38.4%) 77 (63.6%) <0.001* 151 (46.2%) 14 (60.9%) 0.172 
       
*Statistically significant difference (higher proportions of patients aged >70 prescribed medications in 
these categories) 
 
Figure 4.6: Polypharmacy and high level polypharmacy according to age (n=350) 
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There was a significant difference between the numbers of medications prescribed 
to patients from different age groups (Χ2 (9) = 39.527, p <0.001) (Figure 4.7). All age 
groups were equally likely to be prescribed no medications (Χ2 (3) = 4.818, p = 0.186), 
however significant differences were seen for the other 3 medication categories 1-5 
medications (Χ2 (3) = 20.958, p <0.001), 6-10 medications (Χ2 (3) = 13.694, p = 0.003) 
and ≥11 medications (Χ2 (3) = 16.843, p <0.001) (Figure 4.7).  
Figure 4.7: Numbers of prescribed medications according to age groups 
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 4.3.9  Medication use according to drug class 
The most common non-cancer drug therapies prescribed are displayed in Figure 4.8. 
Almost 6 in 10 (58.3%) were prescribed proton pump inhibitors (PPIs), 1 in 3 (30.9%) 
were prescribed opioids and 1 in 3 (29.1%) were prescribed statins. Approximately 1 
in 5 (19.7%) patients were prescribed anti-depressant medications and 1 in 7 (13.4%) 
were prescribed regular benzodiazepines. Increasing prevalence of co-morbid illness 
substantially correlated to increasing medication number with an r-statistic of 0.678, 
p<0.001. 
Figure 4.8 Drug classes most commonly prescribed (n=350) 
 
Legend: PPI = proton pump inhibitor, ARBs = angiotensin II receptor blockers 
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 4.3.10  Drug class use according to gender 
Differences identified in drug class prescriptions between genders are displayed in 
Figure 4.9. Men were prescribed more angiotensin receptor blockers (ARBs) (19.2% 
vs 7.7%, Χ2 (1) = 10.136, p = 0.001), anti-platelets (25.7% vs 12.6%, Χ2 (1) = 9.913, p = 
0.002), statins (34.7% vs 24%, Χ2 (1) = 4.829, p = 0.028) and alpha-adrenergic blockers 
(17.4% vs 1.6%, Χ2 (1) = 25.995, p= <0.001) than women (Figure 4.8). Conversely, 
women were more commonly prescribed levothyroxine (18% vs 7.2%, Χ2 (1) = 9.170, 
p = 0.002). This is in accordance with the differences identified in co-morbid illnesses 
above. Benign Prostatic Hypertrophy (BPH) was present in one in five men (n=31) and 
accounts for the significantly higher proportion of men on alpha-adrenergic 
blockade. 
Figure 4.9 Drug classes most commonly prescribed according to gender (n=350) 
 
Legend: PPI = proton pump inhibitor, ARBs = angiotensin II receptor blockers 
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 4.3.11  Drug class use according to age 
Differences identified in drug class prescriptions between older adults (≥70 years) 
and younger comparators are displayed in figure 4.10. Older adults were more 
commonly prescribed anti-platelet therapy (32.2% vs 11.8%, Χ2 (1) = 21.619. p < 
0.001), statins (43.8% vs 21.4%, Χ2 (1) = 19.244, p < 0.001), ARBs (23.1% vs 7.9%, Χ2 
(1) = 16.193, p < 0.001) and beta-blockers (37.2% vs 16.2%, Χ2 (1) = 19.523, p < 0.001) 
than younger comparators, 
Figure 4.10 Drug classes most commonly prescribed according to age category 
(n=350) 
 
Legend: PPI = proton pump inhibitor, ARBs = angiotensin II receptor blockers 
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4.3.12 Prescription of chemotherapy and radiation therapy for cancer 
Older adults were less likely to be receiving chemotherapy at the time of enrolment 
(56.2% vs 75%, Χ2 (1) = 14.524, p <0.001). They were also less likely to have received 
chemotherapy in the past (38.8% vs 52.8%, Χ2 (1) = 6.213, p = 0.013). This was not 
the case for radiation therapy, with both ages equally likely to be receiving radiation 
therapy (23.1% vs 17%, Χ2 (1) = 1.909, p=0.167) and equally likely to have received 
same in the past (29.8% vs 31.9%, Χ2 (1) = 0.719, p = 0.698) (Figure 4.11). 
Figure 4.11: Chemotherapy and radiation therapy according to age (n=350) 
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diagnosis.  Doxorubicin (12.2% vs 1.7%, Χ2 (1) = 11.296, p = 0.001) and oxaliplatin 
(10.9% vs 3.3%, Χ2 (1) = 6.035,  p = 0.014) were prescribed significantly more 
frequently to younger than older adults (Table 4.14).  
Table 4.13: Most common cancer specific therapies according to gender 
Variable Male 
n = 167 
Female 
n = 183 
Total 
n = 350 
P-value 
 
     
Number of patients on chemotherapy 114 
(68.3%) 
128 
(69.9%) 
242 
(69.1%) 
0.734 
     
Chemotherapeutic agents     
1. 5-fluorouracil 30 (18%) 14 (7.7%) 44 (18.2%) 0.004* 
2. Doxorubicin 11 (6.6%) 19 (10.4%) 30 (12.4%) 0.205 
3. Oxaliplatin 21 (12.6%) 8 (4.4%) 29 (12%) 0.005* 
4. Cyclophosphamide 9 (5.4%) 20 (10.9%) 29 (12%) 0.060 
5. Gemcitabine 9 (5.4%) 14 (7.7%) 23 (9.5%) 0.394 
6. Paclitaxel 3 (1.8%) 20 (10.9%) 23 (9.5%) 0.001* 
7. Irinotecan 11 (6.6%) 8 (4.4%) 19 (7.9%) 0.361 
8. Pemetrexed 7 (4.2%) 7 (3.8%) 14 (5.8%) 0.861 
9. Etoposide 12 (7.2%) 2 (1.1%) 14 (5.8%) 0.004* 
10. Carboplatin 15 (9%) 14 (7.7%) 14 (5.8%) 0.652 
     
 
Table 4.14: Most common cancer specific therapies according to age 
Variable < 70  
n=229  
≥ 70  
n=121  
Total 
n = 350 
P-value 
 
     
Number of patients on chemotherapy 174 (76%)  68 (56.2%) 242 (69.1%) <0.001* 
     
Chemotherapeutic agents     
1. 5-fluorouracil 31 (13.5%) 13 (10.7%) 44 (18.2%) 0.453 
2. Doxorubicin 28 (12.2%) 2 (1.7%) 30 (12.4%) 0.001* 
3. Oxaliplatin 25 (10.9%) 4 (3.3%) 29 (12%) 0.014* 
4. cyclophosphamide 23 (10%) 6 (5%) 29 (12%) 0.101 
5. Gemcitabine 18 (7.9%) 5 (4.1%) 23 (9.5%) 0.181 
6. Paclitaxel 18 (7.9%) 5 (4.1%) 23 (9.5%) 0.181 
7. Irinotecan 14 (6.1%) 5 (4.1%) 19 (7.9%) 0.437 
8. Pemetrexed 9 (3.9%) 5 (4.1%) 14 (5.8%) 0.927 
9. Etoposide 11 (4.8%) 3 (2.5%) 14 (5.8%) 0.291 
10. Carboplatin 18 (7.8%) 11 (9.1%) 14 (5.8%) 0.691 
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4.3.13 Potentially inappropriate prescribing as determined by STOPP 
criteria 
STOPP criteria for potentially inappropriate medication (PIM) use were applied to 
186 patients who were ≥65 years (53.1% of study population). PIMs were observed 
in 136 patients, giving a prevalence rate of 73.1%. Of these, 54 (29%) patients were 
prescribed 1 PIM, 35 (18.8%) were prescribed 2 PIMs, 26 (14%) were prescribed 3 
PIMs, 13 (7%) were prescribed 4 PIMs, 4 (2.2%) patients were prescribed 5 PIMs, 4 
(2.2%) patients were prescribed 6 PIMs and 1 (0.5%) patient was prescribed 7 PIMs. 
Men and women were equally likely to receive 0, 1, 2 or ≥3 PIMs (Χ2 (3) = 6.671, p = 
0.083). Increasing medication number, medical conditions and reducing function 
according to Barthel were substantially correlated to increasing PIM number with r-
statistics of 0.622, p < 0.001, 0.490, p < 0.001 and 0.452, p <0.001 respectively. 
 The most common PIMs identified are detailed in descending order in table 
4.15. Almost 1 in 2 (46.8%) participants 65 years and older with a cancer diagnosis 
were prescribed drugs beyond their recommended duration.  Approximately 1 in 3 
were prescribed a PPI for uncomplicated PUD/erosive peptic oesophagitis at full 
therapeutic dosage for > 8 weeks and 1 in 5 were prescribed regular opioids without 
concomitant laxatives. Both genders were equally likely to be on the above PIMs. 
One PIM was prescribed more commonly in men i.e. vasodilator drugs with 
persistent hypotension (10% vs 1.2%, Χ2 (1) = 6.489 p=0.011). 
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Table 4.15: Most common PIMs according to STOPP criteria 
Variable Male 
n = 100 
Female 
n = 86 
Total 
n = 186 
P-value 
 
STOPP criteria     
A2: Any drug prescribed beyond recommended 
duration 
 
45 (45%) 42 (48.8%) 87 (46.8%) 0.601 
F2: PPI for uncomplicated PUD/erosive peptic 
oesophagitis at full therapeutic dosage for > 8 weeks 
 
35 (35%) 30 (34.9%) 65 (34.9%) 0.987 
L2: Use of regular opioids without concomitant 
laxative 
 
21 (21%) 17 (19.8%) 38 (20.4%) 0.835 
K4: Hypnotic Z-drugs (↑risk of falls) 
 
16 (16%) 13 (15.1%) 29 (15.6%) 0.868 
A1: Any drug prescribed without an evidence-based 
clinical indication 
 
13 (13%) 15 (17.4%) 28 (15.1%) 0.398 
K1: Benzodiazepines (↑risk of falls) 
 
9 (9%) 14 (16.3%) 23 (12.4%) 0.133 
D5: Benzodiazepines for ≥ 4 weeks 
 
9 (9%) 12 (14%) 21 (11.3%) 0.287 
B6: Loop diuretic as first-line treatment for HTN 
 
8 (8%) 7 (8.1%) 15 (8.1%) 0.972 
D2: Initiation of TCAs as first-line antidepressant 
treatment 
 
6 (6%) 7 (8.1%) 13 (7%) 0.568 
L3: Long-acting opioids without short-acting opioids 
for break-through pain 
 
7 (7%) 5 (5.8%) 12 (6.5%) 0.743 
K3: Vasodilator drugs (with persistent postural 
hypotension) 
 
10 (10%) 1 (1.2%) 11 (5.9%) 0.011* 
A3: Any duplicate drug prescription 
 
7 (7%) 4 (4.7%) 11 (5.9%) 0.498 
Legend: PPI = Proton pump inhibitor; TCAs = tricyclic anti-depressants, HTN = hypertension 
 
4.3.14 Risk factors for receiving a potentially inappropriate medication 
according to STOPP criteria 
Differences were identified between participants who were prescribed at least 1 PIM 
and who were not (Table 4.16). Patients prescribed at least 1 PIM had more chronic 
conditions (8.4 (SD3.4) vs 5.2 (SD2.4), t126.266= 7.13, p < 0.001), a higher CIRS score 
(18 (12-20) vs 11 (10 - 14), U = 1724, p <0.001) and were prescribed a high number 
of regular medications (8 (IQR6-10) vs 3 (IQR1-4.25), U = 757.5, p <0.001). 
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Table 4.16: Comparison between adults prescribed at least 1 potentially 
inappropriate medication according to STOPP criteria and adults not 
Variable PIMs 
(n=136) 
No PIMs 
(n=50) 
Total 
n = 196 
P-value 
 
     
Gender (female) 66 (48.5%) 20 (40%) 86 (43.9%) 0.301 
Age, median (IQR) 
Range 
71 (68 – 76) 
65 - 90 
71.5 (67.75-75.25) 
65 - 90 
71 (68-76) 
65 – 90 
0.833 
Chronic conditions, mean (SD) 
Range 
8.38 (3.4) 
2 - 18 
5.22 (2.4) 
2 – 13 
7.53 (3.4) 
2 – 18 
<0.001* 
CIRS score, median (IQR) 
Range 
18 (12-20) 
2 - 30 
11 (10-14) 
6 – 21 
14 (11-19) 
2 – 30 
<0.001* 
Medications, median (IQR) 
Range 
8 (6-10) 
0 - 24 
3 (1-4.25) 
0 - 9 
7 (4 – 9) 
0 -24 
<0.001* 
     
 
Logistic regression was used to determine the influence of age, gender, burden of co-
morbidities as defined by CIRS and number of medications on the likelihood of 
receiving a PIM, as defined by STOPP criteria. The results are detailed in Table 4.17. 
The only factor significantly associated with an increased risk was the number of 
medications a patient was prescribed, taking into consideration a patient’s gender, 
age and level of morbidity. For every one extra medication prescribed, the odds of 
receiving a PIM increased by 79.2% (Odds ratio 1.792, 95% CI 1.459 – 2.02, P <0.001). 
 
Table 4.17: Risk factors for receiving a PIM according to STOPP criteria 
      95% CI for Exp (B) 
Variable B (SE) Wald df p-value Exp (B) Lower Upper 
        
Gender -.285 (.443) 0.414 1 0.520 0.752 0.216 1.791 
Age -.044 (.038) 1.353 1 0.245 0.957 0.888 1.031 
Meds .584 (.105) .105 1 <0.001* 1.792 1.459 2.202 
CIRS .025 (.057) .194 1 0.660 1.026 0.917 1.147 
Constan
t 
.927 
(2.695) 
.118 1 0.731 2.527   
Legend: Hosmer and Lemeshow Χ2 (8) ≥4.185, p=0.840; B = beta value; Snell R2=0.356; Nagelkerke R2 
= 0.518; SE = standard error; df = degrees of freedom; Exp (B) = Odds ratio; CIRS = cumulative index 
rating scale 
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Key Findings 5: 
 Three of every four (73.1%) adults’ ≥ 65 years were prescribed at least one 
potentially inappropriate medication (PIM) according to STOPP criteria. 
 For every one extra medication prescribed, the odds of receiving a PIM increased 
by 79.2%. 
 
 
4.3.15 Potentially inappropriate prescribing as determined by OncPal 
criteria 
Sixteen patients (4.6%) died during their index admission, with a further 111 (31.7%) 
dying within 6 months of enrolment. In total, 39.1% (n=127) of the total population 
cohort died. Since these were the patients that preventative therapy was least likely 
to be of benefit, OncPal criteria were applied to their prescription and clinical data. 
Both genders were equally likely to die during admission, Χ2 (1) = 0.035, p = 0.831, 
but males were more likely to die within 6 months of enrolment, Χ2 (1) = 5.001, p = 
0.025. 
 PIMs (according to OncPal) were observed in 90 patients, giving a prevalence 
rate of 70.8%. Of these 90 patients, 32 (25.2%) patients received 1 PIM, 19 (15%) 2 
PIMs, 20 (15.7%) 3 PIMs, 11 (8.7%) 4 PIMs, 6 (4.7 %) 5 PIMs, 0 (0%) 6 PIMs and 2 
(1.6%) 7 PIMs. Men and women were equally likely to receive 0, 1, 2 or ≥ 3 PIMs (Χ2 
(3) = 3.759,  p = 0.289) (see Figure 4.12). Similarly, older adults (≥ 70 years) were 
equally likely to receive 0, 1, 2 or ≥3 PIMs (Χ2 (3) = 3.919, p = 0.270) (see Figure 4.13).  
 The most common PIMs identified by OncPal were intended for treatment of 
primary or secondary cardiovascular diseases (Table 4.18). The three most common 
drug classes were (i) statins (ii) beta blockers and (iii) PPIs. These were equally 
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distributed between males and females. One PIM was prescribed more commonly in 
men i.e. angiotensin receptor blockers (ARBs) (18.6% vs 1.8%, Χ2 (1) = 9.059 p=0.003). 
Figure 4.12: Percentage of patients with potentially inappropriate medications 
as determined by OncPal criteria according to gender 
 
 
 
Figure 4.13: Proportions of patients with potentially inappropriate medications 
as determined by OncPal criteria according to age 
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Table 4.18: Most common PIMs according to OncPal criteria in 127 patients 
Variable Male 
n = 70 
Female 
n = 57 
Total 
n = 127 
P-value 
 
OncPal criteria     
Cardiovascular System  37 (52.9%) 22 (38.6%) 59 (46.5%) 0.109 
Statins 23 (32.9%) 12 (21.1%) 35 (27.6%) 0.139 
Beta blockers 21 (12.6%) 10 (17.5%) 31 (24.4%) 0.104 
ARBs 13 (18.6%) 1 (1.8%) 14 (11%) 0.003* 
CCB 9 (12.9%) 4 (7%) 13 (10.2%) 0.280 
ACE inhibitors 6 (8.6%) 5 (8.8%) 11 (8.7%) 0.968 
Thiazides 5 (7.1%) 1 (1.8%) 6 (4.7%) 0.155 
Ezetimibe 0 (0%) 2 (3.5%) 2 (1.6%) 0.114 
     
Vitamins (if plasma level not low) 14 (20%) 17 (29.8%) 31 (24.4%) 0.200 
Vitamin d 6 (3.6%) 9 (15.8%) 15 (11.8%) 0.210 
Folate 7 (4.2%) 6 (10.5%) 13 (10.2%) 0.922 
Vitamin b12 2 (2.9%) 4 (7%) 6 (4.7%) 0.272 
Multivitamin 1 (1.4%) 2 (3.5%) 3 (3.4%) 0.443 
Vitamin c 0 (0%) 2 (3.5%) 2 (1.6%) 0.114 
Vitamin b1 1 (1.4%) 0 (0%) 1 (0.8%) 0.365 
     
Alimentary tract and metabolism 
(prophylaxis of peptic ulcer disease) 
19 (27.1%) 10 (17.5%) 29 (22.8%) 0.200 
PPIs 19 (27.1%) 10 (17.5%) 29 (22.8%) 0.200 
H2 Antagonists 1 (1.4%) 0 (0%) 1 (0.8%) 0.365 
     
Minerals  
(if plasma level not low) 
6 (8.6%) 9 (15.8%) 15 (11.8%) 0.210 
Calcium 6 (8.6%) 7 (3.8%) 13 (10.2%) 0.493 
Iron 0 (0%) 2 (3.5%) 2 (1.6%) 0.114 
     
Oral Hypoglycaemics 6 (8.6%) 5 (8.8%) 11 (8.7%) 0.968 
Sulphonylureas 5 (7.1%) 2 (2.5%) 7 (5.5%) 0.372 
Metformin 2 (2.9%) 3 (1.6%) 5 (3.9%) 0.481 
DPP4-inhibitors 0 (0%) 2 (2.5%) 2 (1.6%) 0.114 
     
Bloods and blood forming organs 
(for primary prevention) 
2 (2.9%) 3 (5.3%) 5 (3.9%) 0.488 
Aspirin  2 (2.9%) (5.3%) 5 (3.9%) 0.488 
     
Musculoskeletal system  
(for osteoporosis) 
1 (1.4%) 2 (3.5%) 3 (2.4%) 0.443 
Bisphosphonates 1 (0.6%) 1 (1.8%) 2 (1.6%) 0.883 
Denosumab 0 (0%) 1 (1.8%) 1 (0.8%) 0.266 
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4.3.16 Risk factors for receiving a potentially inappropriate medication 
according to OncPal criteria 
Differences were identified between participants who were prescribed at least 1 PIM 
and who were not (Table 4.19). Patients prescribed at least 1 PIM according to 
OncPal criteria were older (69 years vs 57 years, U = 974, p <0.001), had more chronic 
conditions (7.4 (SD3.6) vs 5.8 (SD5.5), t128= 2.43, p = 0.017), a higher CIRS score (15 
(12-19) vs 12 (10 – 15.5), U = 1106.5, p = 0.00s) and were prescribed a high number 
of regular medications (6.5 (IQR4.75-10) vs 5 (IQR2.5-7.5), U = 1002.5, p < 0.001). 
Table 4.19: Comparison between adults prescribed at least one PIM according to 
OncPal criteria and adults without PIMs 
Variable PIMs 
(n=136) 
No PIMs 
(n=50) 
Total 
n = 196 
P-value 
 
     
Gender (female) 40 (44.4%) 17 (45.9%) 57 (44.9%) 0.877 
Age, median (IQR) 
Range 
69 (59.75-73) 
43 - 90 
57 (50-70) 
40 - 79 
67 (57-72) 
40 - 90 
<0.001* 
Chronic conditions, mean (SD) 
Range 
7.4 (3.6) 
2 - 17 
5.8 (5.5) 
1 - 16 
7 (3.6) 
1 – 17) 
0.017* 
CIRS score, median (IQR) 
Range 
15 (12-19) 
8 - 30 
12 (10-15.5) 
2 - 27 
14 (11-19) 
21 - 30 
0.003* 
Medications, median (IQR) 
Range 
6.5 (4.75- 10) 
1 - 24 
5 (2.5-7.5) 
0 - 11 
6 (4-9) 
0 - 24 
<0.001* 
     
Legend: PIMs = potentially inappropriate medications, IQR = inter-quartile range, CIRS = cumulative 
illness rating scale 
 
Logistic regression was used to determine the influence of age, gender, burden of co-
morbidities as defined by CIRS and number of medications on the likelihood of 
receiving a PIP as defined by OncPal criteria. The results are detailed in Table 4.20. 
Both age and number of medications were significantly and positively associated with 
an increased risk of being prescribed a PIM according to OncPal criteria, taking into 
consideration the patients’ gender and level of morbidity. For every one extra 
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medication prescribed, the odds of being prescribed a PIM increased by 21.4% (Odds 
ratio 1.214, 95% CI 1.038 – 1.420, P =0.015). For every one year increase in age, the 
odds of receiving a PIM increased by 7.3% (Odds ratio 1.073, 95% CI 1.023 – 1.126, P 
=0.004). 
Table 4.20: Risk factors for receiving a potentially inappropriate medication 
according to OncPal criteria 
      95% CI for Exp (B) 
Variabl
e 
B (SE) Wald df p-value Exp (B) Lower Upper 
        
Gender -.309 (.463) 0.447 1 0.504 0.734 0.296 1.819 
Age -.071 (.024) 8.387 1 0.004* 1.073 1.023 1.126 
Meds .194 (.080) 5.863 1 0.015* 1.214 1.038 1.420 
CIRS .009 (.059) .023 1 0.879 1.009 0.900 1.132 
Consta
nt 
.4.681 
(1.458) 
10.30
2 
1 0.001 0.009   
Legend: Hosmer and Lemeshow Χ2(8) ≥12.563, p=128 0; B = beta value; Snell R2=0.176; Nagelkerke 
R2 = 0.253; SE = standard error; df = degrees of freedom; Exp (B) = Odds ratio; CIRS = cumulative 
index rating scale 
 
 
Key Findings 6: 
 Three of every four (70.8%) adults’ who died within 6 months of enrolment were 
prescribed at least one potentially inappropriate medication (PIM) according to 
OncPal criteria. 
 For every one extra medication prescribed, the odds of being prescribed a PIM 
increased by 21.4%. 
 For every one year increase in age, the odds of receiving a PIM increased by 
7.3%. 
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4.3.17 Patients in whom both STOPP and OncPal criteria were applied 
One in five patients (n=77) were aged ≥ 65 years and died within six months of 
enrolment. These patients were therefore eligible for the application of both STOPP 
and OncPal criteria. Sixty six of these 77 patients (85.7%) were prescribed at least 1 
PIM as per STOPP criteria and 83.1% (n=64) and at least 1 PIM as per OncPal criteria. 
On further analysis, these patients, were more likely to be on more PIMs according 
to OncPal than those patients who met the criteria for OncPal alone and not STOPP 
criteria (U = 1243, p = 0.001). This was also the case for STOPP criteria (U = 2742, p 
<0.001) 
 
 4.3.18 Adverse Drug Reactions in patients with cancer 
A total of 274 adverse events (AEs) were identified in 166 (47.4%) participants, of 
which 139 were identified as being drug related in 90 (25.7%) participants (Table 
4.21). For 15 of these 90 participants, ADRs did not cause or contribute significantly 
to admission and were thought to be an incidental findings and therefore trivial. 
Accordingly, for 75 (21.5%) patients, an ADR caused or contributed significantly to 
hospital admission (Figure 4.14). Of these 75 ADRs, 72 (35.8%) presented as 
emergency admissions, whereas 3 (4.7%) presented electively i.e. one out of every 
three emergency oncological admissions were drug related and one out of every 
twenty elective oncological admissions were drug related. 
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Table 4.21: Adverse events (AE) and adverse drug reactions (ADR) 
 
AE name AE 
 
All ADR 
 
ADR  
(causing / 
contributing to 
admission) 
    
New onset fall/s 16 (4.6%) 6 (1.7%) 5 (1.4%) 
New onset unsteady gait 9 (2.6%) 3 (0.9%) 2 (0.6%) 
Acute kidney injury 26 (7.4%) 5 (1.4%) 5 (1.4%) 
Symptomatic orthostatic hypotension 4 (1.1%) 3 (0.9%) 3 (0.9%) 
Major serum electrolyte disturbance 49 (14%) 13 (3.7%) 12 (3.4%) 
Symptomatic bradycardia 1 (0.3%) 1 (0.3%) 1 (0.3%) 
New major constipation 30 (8.6%) 19 (5.4%) 14 (4%) 
Acute bleeding 13 (3.7%) 6 (1.7%) 6 (1.7%) 
Acute dyspepsia / nausea / vomiting 52 (14.9%) 30 (8.6%) 29 (8.3%) 
Acute diarrheoa 25 (7.1%) 17 (4.9%) 10 (2.9%) 
Acute delirium 21 (6%) 8 (2.3%) 8 (2.3%) 
Symptomatic hypoglycaemia 0 (0%) 0 (0%) 0 (0%) 
Other 
 
28 (8%) 28 (8%) 28 (8%) 
    
Total Number 274 139 123 
Number of patients involved 166 90 75 
    
 
Figure 4.14: Adverse drug reactions classification 
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4.3.19 Types of adverse drug reactions 
The primary ADR symptoms causing clinical presentation are listed in table 4.22. The 
12 point AE Trigger List identified 64% (n=48) of all ADRs. Older and younger adults 
were equally like to experience the same type of ADRs (Χ2 (17) = 16.434, p = 0.493), 
as were men and women (Χ2 (17) = 23.230, p = 0.142). 
Table 4.22: Types of ADRs in order of frequency and according to age 
Variable < 70 years 
n=229 
≥ 70 years 
n=121 
Total 
n = 350 
P-value 
 
    0.493 
Neutropenia with infection 15 (6.6%) 3 (2.5%) 19 (5.1%)  
Acute dyspepsia / nausea / vomiting 10 (4.4%) 5 (4.1%) 15 (4.3%)  
New major constipation 10 (4.4%) 2 (1.7%) 12 (3.4%)  
Acute diarrhea 5 (2.2%) 3 (2.5%) 8 (2.8%)  
Acute bleeding 3 (1.3%) 3 (2.5%) 6 (1.7%)  
Acute delirium 0 (0%) 2 (1.7%) 2 (0.6%)  
Symptomatic orthostatic hypotension 1 (0.4%) 1 (0.8%) 2 (0.6%)  
New unsteady gait 1 (0.4%) 1 (0.8%) 2 (0.6%)  
Steroid induced hyperglycaemia 1 (0.4%) 1 (0.8%) 2 (0.6%)  
Steroid induced insomnia 1 (0.4%) 0 (0%) 1 (0.3%)  
Symptomatic bradycardia 1 (0.4%) 0 (0%) 1 (0.3%)  
Electrolyte disturbance 0 (0%) 1 (0.8%) 1 (0.3%)  
Acute liver failure 1 (0.4%) 0 (0%) 1 (0.3%)  
Pancreatitis 1 (0.4%) 0 (0%) 1 (0.3%)  
Urinary retention 0 (0%) 1 (0.8%) 1 (0.3%)  
Anxiety secondary to levothyroxine 1 (0.4%) 0 (0%) 1 (0.3%)  
Mouth sores and neutropenia 
 
1 (0.4%) 0 (0%) 1 (0.3%)  
 
 
Thirty two (42.7%) of participants that experienced an ADR had a Sequence of events 
e.g. one patient that presented with new major constipation had associated vomiting 
and acute kidney injury. Men and women were equally likely to experience a 
Sequence of Events, 43.8% vs 41.9%, Χ2 (1) = 0.027, p = 0.870, as were all age groups, 
Χ2(3) = 1.423, p = 0.700 (Figure 4.15). 
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Figure 4.15: Percentage of patients who experienced adverse drug reactions 
who had a Sequence of Events (n=75) 
 
 
 
Key Findings 7: 
 The three most common ADRs experienced by participants were neutropenia 
with infection, nausea and vomiting and major constipation. 
 Less than 1 in 2 (42.5%) participants who experienced an ADR had a Sequence of 
Events. 
 
 4.3.20  Adverse drug reaction causality  
As per the WHO causality criteria, medication probably/certainly caused or 
contributed significantly to admission in 75 (21.5%) cases. ADRs occurred in similar 
frequencies for older and younger secondary to cancer specific treatment (Χ2 (1) = 
1.292, p = 0.295), non-cancer specific treatments (Χ2 (1) = 2.603, p = 0.107) and a 
combination of both (Χ2 (1) = 1.382, p = 0.240) (Table 4.23). Women were more likely 
to experience an ADR secondary to cancer specific treatment (15.8 vs 6.6%, Χ2 (1) = 
8.060, p = 0.005) and men secondary to non-cancer specific treatment (10.8 vs 7.7%, 
≥ 1 ≥ 2 ≥ 3 ≥ 4 ≥ 5
Total 100.0% 42.7% 12.0% 1.3% 1.3%
Male 100.0% 43.8% 6.3% 0.0% 0.0%
Female 100.0% 41.9% 16.3% 2.3% 2.3%
0.0%
20.0%
40.0%
60.0%
80.0%
100.0%
120.0%
Total Male Female
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Χ2 (1) = 4.210, p = 0.040) or a combination of both (1.8 vs 0%, Χ2 (1) = 4.199, p = 0.040) 
(Table 4.24). The specific drug classes involved in ADRs are listed in Table 4.25. 
Table 4.23: ADR causality according to age 
Variable < 70 years 
n=229 
≥ 70 years 
n=121 
Total 
n = 350 
P-value 
ADRs secondary to cancer specific treatments 
 
30 (13.1%) 10 (8.3%) 40 (11.4%) 0.295 
ADRs secondary to non-cancer specific 
treatment 
 
19 (8.3%) 13 (10.7%) 32 (9.1%) 0.107 
ADRs secondary to a combination of both 
 
3 (1.3%) 0 (0%) 3 (0.9%) 0.240 
 
Table 4.24: ADR causality according to gender 
Variable Male 
n = 167 
Female 
n = 183 
Total 
n = 350 
P-value 
 
ADRs secondary to cancer specific treatments 
 
11 (6.6%) 29 (15.8%) 40 (11.4%) 0.005 
ADRs secondary to non-cancer specific 
treatment 
 
18 (10.8%) 14 (7.7%) 32 (9.1%) 0.040 
ADRs secondary to a combination of both 
 
3 (1.8%) 0 (0%) 3 (0.9%) 0.040 
 
Table 4.25: Drug classes involved in ADRs 
Drug class Total 
n=75 
 
1 
 
Cancer specific treatments 
 
40 (53.3%) 
2 Opioids 13 (17.3%) 
3 Steroids 5 (6.7%) 
4 Non-steroidal anti-inflammatories 4 (5.3%) 
5 Antibiotics 2 (2.7%) 
6 Diuretics 2 (2.7%) 
7 Thyroid hormone 1 (1.3%) 
8 DMARD 1 (1.3%) 
9 Anti-cholinergic 1 (1.3%) 
10 Alpha blocker 1 (1.3%) 
11 Proton pump inhibitor 1 (1.3%) 
12 Laxative 1 (1.3%) 
13 Cancer specific treatment and anti-emetic 1 (1.3%) 
14 Benzodiazepine and opioid 1 (1.3%) 
15 
 
Warfarin and DOAC 1 (1.3%) 
Legend: DMARD  = Disease modifying anti-rheumatic drug, DOAC = Direct-oral anti-coagulants 
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Key Findings 8: 
 ADRs were equally likely to be caused by cancer specific treatment as 
non-cancer specific treatment in both younger and older (≥70 years) 
 The three most common drug implicated were cancer specific treatments, 
opioids and steroids. 
 
4.3.21 Adverse drug reaction severity, predictability and preventability 
Of the 75 ADRs causing or contributing significantly to admission 73 (97.3%) were 
graded as “four” on the Hartwig and Siegel severity scale i.e. any ADR which was the 
reason for the admission or increased the length of stay by at least 1 day. Two ADRS 
(2.7%) required intensive medical input (grade 5 on Hartwig and Siegel severity 
scale). Of 75 ADRs, 67 (89.3%) were predictable i.e. were listed in the ‘drugs' 
summary of product characteristics of the drugs as being common or very common 
adverse effect. Using Hallas criteria of avoidability, 22 of 75 ADRs (29.3%) were 
definitely avoidable, 25 (33.3%) possibly avoidable and 28 (37.4%) unavoidable i.e. 2 
out of every 3 ADRs were potentially avoidable. 
 
 4.3.22 ADR Risk factors and Outcomes 
There were no differences between participants who experience ADRs and those 
who did not (Table 4.26). However, when day unit admissions (patients who 
attended for a couple of hours for treatment) were removed from analysis, all of 
whom had no significant ADR, it was identified that patients on chemotherapy had a 
significantly higher chance of experiencing an ADR than those not currently receiving 
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chemotherapy (Χ2 (1) = 7.749, p = 0.005) (Table 4.27). There was no significant 
difference between patients who experienced an ADR and those who did not in 
relation to the length of stay (5 (3-10) vs 6 (4-11), U = 6642, p = 0.389), incidence of 
death during the index admission (8% vs 5.3%, Χ2 (1) = 0.088, p = 0.339) and incidence 
of death during the 6 months following admission (43.9% vs 44.2%, Χ2 (1) = 0.361, p 
= 0.0.548). 
Table 4.26: Comparisons between those who experienced ADRs and those who did 
not 
Variable ADRs 
(n = 75) 
No ADRs 
(n=275) 
Total 
n = 350 
P-value 
 
 
Gender (female) 
 
47 (57.3%) 
 
140 (50.9%) 
 
183 (52.3%) 
 
0.323 
Age, median (IQR) 
range 
65 (56 – 70) 
16 - 89 
66 (57-72) 
18 - 90 
65.5 (57-72) 
16 - 90 
0.599 
Chronic conditions, median (IQR) 
range 
6 (4-8) 
1 - 15 
6 (4-8) 
1 - 18 
6 (4-8) 
1 - 18 
0.816 
CIRS score, median (IQR) 
range 
13 (10-17) 
4 - 29 
12 (9-16) 
2 - 30 
13 (9-16) 
2 - 30 
0.292 
Medications, median (IQR) 
range 
5 (3-8) 
0 - 24 
5 (3-8) 
0 - 22 
5 (3-8) 
0 - 24 
0.502 
Length of stay, median (IQR) 5 (3-10) 6 (4-11) 6 (3-10) 0.389 
RIP during index admission 6 (8%) 10 (3.6%) 16 (4.6%) 0.109 
RIP within 6 months of enrolment 29 (38.7%) 99 (36%) 127 (39.1%) 0.364 
Currently on chemotherapy 55 (73.3%) 187 (68%) 242 (69.1%) 0.375 
 
Table 4.27: Risk factors associated with ADRs (Day unit patients excluded) 
Variable ADRs 
n = 75 
No ADRs 
n=190 
Total 
n = 265 
P-value 
 
 
Gender (female) 
 
43 (57.2%) 
 
99 (52.1%) 
 
142 (53.6%) 
 
0.442 
Age, median (IQR) 
range 
65 (56-70) 
16 - 89 
66 (57-72) 
18 - 90 
66 (57-72) 
16 - 90 
0.494 
Chronic conditions, median (IQR) 
range 
6 (4-8) 
1 - 15 
6 (4-8.25) 
1 - 18 
6 (4-8) 
1 - 18 
0.753 
CIRS score, median (IQR) 
range 
14 (10-18) 
2 - 30 
13 (10-17) 
4 - 29 
14 (10-17.5) 
2 - 30 
0.503 
Medications, median (IQR) 
range 
5 (3-8) 
0 - 24 
6 (3-9) 
0 - 18 
6 (3-9) 
0 - 24 
0.637 
Length of stay, median (IQR) 
range 
5 (3-10) 
0 - 41 
6 (4-11) 
0 - 68 
6 (3-10) 
0 - 69 
0.389 
Death during index admission 6 (8%) 10 (5.3%) 16 (6%) 0.399 
Death within 6 months of enrolment 29 (43.9%) 84 (44.2%) 113 (47.1%) 0.548 
Currently on chemotherapy 55 (73.3%) 104 (54.7%) 157 (60%) 0.005* 
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Logistic regression was used to determine the influence of age, gender, 
chemotherapy, number of conditions and number of medications on the risk of 
experiencing an ADR (Table 4.28). No predictor variables were identified. 
Table 4.28: Risk factors for experiencing an ADR 
 
 
      95% CI for Exp (B) 
Variable  B (SE) Wald df p-value Exp (B) Lower Upper 
         
Gender Female -.255 (.267) .913 1 .339 .775 .459 1.307 
Age  -.004 (.012) .104 1 .747 .996 .973 1.020 
chemo  -.297 (.307) .939 1 .333 .743 .407 1.356 
Medications  .007 (.057) .017 1 .897 1.007 .901 1.127 
Conditions  -.028 (.043) .430 1 .512 1.029 .945 1.120 
Constant  . -1.061 (.698) 2.310 1 .339 .775 .459 1.307 
         
Homer and Lemeshow Χ2 (8) ≥5.054, p=0.752, Model Χ2 = 361.003, Cox and Snell R2 = 0.008, Nagelkerke 
R2 = 0.012, B = beta-value, SE = standard error, df = degrees of freedom, CI = confidence interval, Exp (B) 
= Odds ratio, Medications = number of medications, Conditions = number of conditions 
 
 
 
Key Findings 9: 
 Nine of every ten (89.3%) ADRs were predictable. 
 Twenty two (29.3%) of ADRs were definitely avoidable. 
 Twenty five (33.3%) were possibly avoidable. 
 
4.4 DISCUSSION 
This is the first study in Ireland to identify and classify patients with cancer according 
to age, morbidity burden, medication and PIM use. It is also the first study 
internationally to assess ADRs in a robust manner in this population.  
 This study identified that 1 in 3 (34.5%) patients attending oncologists are 70 
year and older. It also identified that nearly all patients (96.9%) attending oncologists 
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are multimorbid with 68% of participants having ≥ 5 chronic conditions. Four in every 
five (81.1%) older adults (≥ 70 years) have ≥ 5 chronic conditions compared to more 
than one in every two (60.7%) younger adults. Older adults had a significantly higher 
burden of comorbidity as determined by their CIRS scores. Cardiovascular conditions 
were highly prevalent with approximately 1 in 2 having a diagnosis of hypertension 
and dyslipidaemia, 1 in 7 having a diagnosis of IHD and DM and 1 in 10 having a 
diagnosis of atrial fibrillation.  
 Polypharmacy and high level polypharmacy were identified in 47.1% and 
11.4% respectively. Their prevalence was significantly higher in older adults 
compared to younger adults, 63.6% vs 38.4% and 19% vs 7.4% respectively. Older 
adults were less likely to be prescribed chemotherapy and less likely to have received 
chemotherapy in the past. Three out of every four (73.1%) adults’ ≥ 65 years were 
prescribed at least one PIM according to STOPP criteria, one in four received ≥ 3 PIMs. 
This was also the case for those eligible for the application of OncPal criteria; 3 in 
every 4 (70.8%) were prescribed at least 1 PIM and 1 in every 3 received ≥ 3 PIMs.  
 Ninety (25.7%) patients experienced an ADR. For 75 (21.5%) patients 
admissions to the oncology service (emergency, elective or day unit), ADRs caused or 
contributed significantly to hospital admission. ADRs were more prevalent in those 
presenting as emergency admissions i.e. ADRs cause/significantly contributed to 1 in 
3 (35.8%) emergency admissions. ADRs were equally likely to be caused by cancer 
specific treatment as non-cancer specific treatment with no difference in rates 
identified between older and younger adults. Of these ADRs, 89.3% were predictable 
and 62.6% possibly or definitely avoidable i.e. approximately 2 of every 3 were 
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potentially avoidable. Chemotherapy, opioids, steroids and NSAIDs were the most 
common drugs implicated. One in twenty (4.6%) patients enrolled died during the 
index admission with 4 out of 10 (39.1%) dying within the following 6 months. 
 As predicted for patients with cancer, cancer is often one of several 
diagnoses. This has implications for the management and treatment of cancer as 
many of the medications involved in cancer treatment regimens have the potential 
to worsen other diagnoses e.g. corticosteroid use in diabetes mellitus. Despite their 
multimorbidity, these patients were almost exclusively functionally independently 
and cognitively intact, with a lower average age then expected of 63.6 years. This 
suggests that perhaps older adults with medium to severe level dependency or 
moderate to severe cognitive impairment either (i) do not get referred to oncology 
specialists for assessment or (ii) do but they are not put forward for intensive 
treatment regimens. This could mean that appropriate patient selection occurs, 
however we have to ensure that patients who could benefit from treatment, have a 
discussion regarding this with a thorough risk benefit assessment.  
 In accordance with earlier studies the prevalence of polypharmacy and high 
level polypharmacy was high. Approximately every second patient (47.1%) was 
prescribed 6 or more medications and 1 out of every 10 (11.4%) were prescribed ≥ 
11 medications. Some of the most commonly prescribed drugs identified in this study 
have the potential to interact with chemotherapy e.g. 5-fluorouracil increases the 
level of warfarin. During treatment with chemotherapeutic agents up to 30% will 
experience nausea, vomiting or diarrhoea. This can have implications for other 
medications specifically antihypertensive agents, which when fluid depleted, could 
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provoke dizziness and falls. Ongoing diuretic use in this context could increase the 
risk of a patient developing an acute kidney injury with continued use. The vast 
majority of cancer drugs, as expected, are prescribed by oncologists but the vast 
majority of other drugs are prescribed by patients’ General Practitioners (GP) or 
other hospital specialists. It is pertinent that there is clear communication between 
these specialists. An extensive knowledge of chemotherapeutic agents and 
medications required to treat other conditions is required to assess risk and adjust 
medications accordingly. At present, this is not the sole responsibility of any one 
doctor. Often once a cancer diagnosis is made, patients and other doctors defer to 
the treating oncologist for treatment of all ailments. 
 Similar to other patient populations, PIM prescription was highly prevalent in 
this cohort. This increases medication burden and places patients at an increased risk 
of ADRs. Additionally, this can place a financial burden on an already stretched 
healthcare system. The discussion around deprescribing of medications with patients 
with cancer is challenging. Deprescribing of medications, even if inappropriate, can 
be viewed by patients as withdrawal of care, in a time that presents many 
psychological difficulties. This is supported by the findings of this study that identified 
that 1 in 4 patients had a diagnosis of depression or anxiety and that 13.4% of 
patients were prescribed benzodiazepines on a daily basis. Tapering or stopping of 
medications can often lead to a discussion around end of life care. It is important a 
clear discussion is had with patients regarding medication use addressing the risks of 
continued use so that patients understand that it is not withdrawing of care, but 
rather the optimisation of prescribing to reduce potential risks e.g. interactions 
between a regular medication and chemotherapy. 
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 Worryingly, 1 in 10 patients continued to smoke despite their cancer 
diagnosis and 1 in 10 continued to drink more than the recommended weekly alcohol 
allowance. Alcohol in small amounts can be good for patients (e.g. appetite 
stimulation), but in excess can be harmful and can interact with chemotherapy. Its 
use in patients who are already on many high risk medications i.e. chemotherapy 
(69.1%), anticoagulation (14%), opioids (30%), steroids (12.3%), benzodiazepines 
(3.4%), z-drugs (11.1%) and neuroleptics (5.1%), potentially places these patients at 
a higher risk of ADRs.  
 The most common non-cancer specific treatments implicated in ADRs were 
medications that are commonly implicated in ADRs in the acute (non-cancer) 
population i.e. opioids, steroids and NSAIDs. This highlights that the high risk 
medicines, regardless of the patient population, are the ones that most likely cause 
ADRs. This offers an opportunity to intervene in prescribing practices early and thus 
either avoid ADRs or improve their recognition so that they can be identified early 
and adverse consequences can be minimised or avoided. 
 This study has some limitations. Firstly it was limited by the small sample size. 
For the sample size calculation at the start of the study, it was predicted that 313 
older adults would be required to estimate the true prevalence of PIM according to 
STOPP criteria in this population. Unfortunately, this was not feasible for two 
reasons; (i) time allocated to the study and (ii) inability to recruit from the radiation 
oncology day unit. In total, 186 older adults were enrolled i.e. 59% of the target 
amount required. In the pilot phase of this study, the logistics of recruiting radiation 
oncology patients was identified as challenging secondary to (i) limited space and (ii) 
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the time patients spend in hospital undergoing treatment. Space was allocated to 
this research for one afternoon a week. Frequently patients attend for radiation 
treatment weekly at the same day, with patients with the same cancer diagnoses 
allocated the same time slots. This would have biased our sample. Additionally, 
patients spend a short time receiving radiotherapy (i.e. approximately 10 -15 
minutes), and are therefore eager to receive treatment and leave. Perhaps if the 
radiation oncology day unit had been included in this study our overall sample 
population would have been older, more functionally and cognitively impaired and 
on more medications. Even so, our results are consistent with the rates of PIM 
identified by the Nightingale study (179), supporting this high PIM prevalent rate. 
 Another limitation of this study was the exclusion criteria i.e. the ability to 
only recruit patients on one admission. Prevalence rates of multimorbidity, 
medication use and PIM are accurate because of this, however it is possible that ADRs 
were missed due to the exclusion of repeat admissions. 
 This study highlights the importance of an integrated care approach for 
patients with cancer, particularly older adults. Older adults could benefit from 
gerontology input, as well as ongoing GP input at the time of cancer diagnosis as well 
as during treatment. During treatment for cancer, the risk of drug-drug and drug-
disease interactions is likely at its highest. This is a key time for comprehensive 
geriatric assessment to (i) adjust medications, (ii) optimise other chronic conditions 
and (iii) optimise both cognitive and functional ability through a multi-disciplinary 
approach. The application of prescribing tools such as STOPP and OncPal could assist 
in reducing medication burden in a structure fashion as well as avoiding ADRs. Going 
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forward medication reviews are an important part of the treatment of cancer and 
both oncologists and GPs need to be educated regarding their potentially for harm 
during this high risk time. The use of the ADR trigger list could assist oncologists to 
identify ADRs and in doing so deprescribe or adjust medications accordingly, so that 
repeated ADRs do not occur.  
 The prescription of preventative medications, as determined by OncPal 
criteria, in patients with cancer and a poor prognosis, was highly prevalent. The 
prescription of preventative medications in the acute (non-cancer) older frailer 
population with a poor survival prognosis is an evolving entity with limited evidence 
available to guide best practice. On reviewing all common explicit prescribing tools 
to date, none address this. STOPP (36, 37), Beers (63-67) and FORTA (68, 69) criteria 
all look at PIMs in the general older population and NORGEP-NH (135) criteria 
addresses PIMs in the nursing home population. However no prescribing tool to date 
addresses the deprescription of preventative medications in older frailer 
multimorbid patients with a poor survival prognosis, regardless of place of residence. 
NORGEP-NH addresses prescribing in nursing homes, but fundamentally doesn’t 
acknowledge that not all patients living in residential care are frail, multimorbid with 
a poor survival prognosis. The following chapters will discuss the development, 
validation and inter-rater reliability (IRR) of a new explicit prescribing tool 
(STOPPFrail criteria) to address this. The final chapter will apply STOPPFrail criteria to 
a representative population. 
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CHAPTER 5: 
STOPPFrail (Screening Tool of Older Persons Prescriptions in Frail adults with limited 
life expectancy): Consensus validation 
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5.1 INTRODUCTION 
Many explicit prescribing tools have been developed to guide clinicians on cessation 
of potentially inappropriate medications (PIMs) in older adults; the most commonly 
cited are Beers criteria (63-67), STOPP (Screening Tool of Older Persons’ 
Prescriptions)/START (Screening Tool to Alert doctors to Right Treatment) criteria 
(36, 37) and FORTA (Fit FOR The Aged) criteria (68, 69). These explicit tools are 
designed to detect common instances of potentially inappropriate medication (PIM) 
use in the general older population. In chapters 3, I reported PIM prevalence 
according to STOPP/START criteria (36, 37) in an unselected population of older 
adults presenting with acute illness and requiring hospital admission. Similarly, in 
chapter 4, I reported on the prevalence of PIMs in patients attending a medical 
oncology service using STOPP/START criteria (36, 37) and OncPal (Oncological 
palliative care deprescribing guideline) (192). It is evident that existing explicit criteria 
for PIM identification are unsuitable for older frail adults with multiple co-
morbidities, high levels of functional dependency and a poor survival prognosis, a 
population which is becoming increasingly prevalent and is increasingly encountered 
in clinical practice (3).  
 Older patients are now surviving longer with complex co-morbid illnesses 
including cancer, dementia, chronic kidney disease, cardiovascular disease, 
cerebrovascular disease and chronic lung disease, many of which contribute to frailty 
and poor survival prognosis (193, 194). Chronic illnesses, together with the effects of 
physiological ageing can impact negatively on cognitive and physical functional 
ability. In such patients, the final months of life are often characterised by frailty and 
increased dependency, necessitating re-evaluation of drug treatment goals. In these 
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circumstances, medications intended to have long-term preventative effects such as 
lipid-lowering drugs, anti-diabetic agents and cognitive enhancing drugs may no 
longer be appropriate. This is well recognised by doctors and patients. However, 
polypharmacy and inappropriate prescribing (IP) remain highly prevalent in this 
patient population (195, 196), placing these individuals at an increased risk of 
adverse drug reactions (ADRs), hospitalisation and death. Accordingly, appropriate 
deprescribing of medications needs to be considered in frailer, multi-morbid patients 
with a poor survival prognosis. 
 
 5.1.1 Deprescribing in frail older adults 
Deprescribing is defined as “the process of withdrawal of an inappropriate 
medication, supervised by a health care professional with the goal of managing 
polypharmacy and improving outcomes” (131). It involves (i) reviewing all 
medications prescribed, (ii) identifying those medications that are inappropriate, (iii) 
deciding when and how these medications should be tapered, reduced or stopped 
and (iv) arranging adequate monitoring and follow-up (132). Healthcare 
professionals, patients and their relatives all acknowledge the burden of 
polypharmacy for older frail adults, yet all groups display passivity towards 
deprescribing (133). There are many barriers to deprescribing, which are listed in 
Table 5.1 (132-134, 197, 198). As a consequence of these challenges, less than half 
of attending clinicians use a consistent approach to deprescribing (134) and many 
clinicians avoid it completely. 
 
 
197 
 
Table 5.1 Barriers to deprescribing 
Patient factors 
 
Patients’ preference/resistance to change 
Patients’ communication ability 
 
Organisational factors 
 
Time constraints 
Access and maintenance of medical and pharmacy records 
Inter-professional relationships/prescribers from multiple specialties 
Limited training of nursing staff 
Nursing preferences/resistance to change 
Co-ordinating and involving all relevant personnel e.g. pharmacists 
 
Physician factors 
 
Deficiency of knowledge  
Fear of causing adverse events 
Fear of litigation 
Ease of following the “path of least resistance” 
Concern that it may initiate end of life/life expectancy discussions 
Lack of motivation 
 
Research factors 
 
Lack of deprescribing guidelines 
Lack of evidence based research on deprescribing 
Single-disease guidelines driving prescribing and hindering deprescribing 
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The growing burden of polypharmacy and IP has promoted national bodies in the UK 
and Ireland such as the National Institute for health and Care Excellence (NICE) (199-
201) and Health Information Quality Authority (HIQA) (202, 203), to offer guidance 
on deprescribing. NICE recommends annual medication reviews for care home 
residents, during which appropriateness of medications should be optimised and 
medications deprescribed where necessary (199). Similarly they recommend review 
of medications for community dwelling older adults with chronic diseases, however 
no time frame is suggested (200, 201). Despite this, to date, no explicit guidelines 
exist for deprescribing in frailer older adults with poor one year survival prognosis, 
other than NORGEP-NH criteria, which are specific to the nursing home population 
(135).  
 
5.1.2 Objectives 
There is an accepted need for deprescribing in the frailer older population and a clear 
associated need for specific explicit criteria to guide the prescriber. With these 
considerations in mind, the principal objective of this research was to devise and 
validate an explicit set of criteria, using the Delphi technique, aimed at assisting 
physicians with the challenging task of deprescribing medications in older frail adults 
with limited life expectancy. It was envisaged that this tool could be used in all 
healthcare settings where such patients are encountered. The work undertaken in 
this chapter, including study design, data collection and statistical analysis, is entirely 
my own. 
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5.2 METHODS 
The study timeline is detailed in Figure 5.1. This study involved four phases: (i) local 
development of draft criteria; (ii) comprehensive literature review to support the 
inclusion of draft criteria; (iii), use of Delphi consensus methodology and selection of 
expert review panel and (iv) determination of content validity of the criteria using 
the aforementioned technique. Each of these phases are described below. 
Figure 5.1 Delphi consensus method of validation 
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 5.2.1 Local development of draft criteria  
Prof. Denis O’Mahony (senior academic consultant/geriatrician, University College 
Cork), Dr. Paul Gallagher (senior academic consultant/geriatrician, University College 
Cork), Dr. Carole Parsons (academic pharmacist, Queen’s University Belfast), all of 
whom have recognised expertise in geriatric pharmacotherapy, and I were involved 
in the original development of the deprescribing tool.  It was decided that the tool 
should: (i) have an appropriate name to reflect its purpose, (ii) include a clear 
definition of the target patient population, (iii) incorporate common instances of PIM 
encountered in clinical practice in frail older people with poor survival prognosis, (iv) 
be concise and lend itself to be time-efficient and easy to use, and (v) be based on 
the most current up to date evidence available. Medication appropriateness would 
be assessed according to the risk-benefit definition i.e. it is appropriate to prescribe 
an indicated medication if its potential benefit outweighs its’ potential risk of harm, 
while considering patients’ comorbidities, co-prescribed medications and altered 
physiology associated with ageing and disease progression. These five components 
were considered to be mandatory for development of a deprescribing tool that could 
easily be used in both the clinical and research setting.  
 The deprescribing tool was named STOPPFrail (Screening Tool of Older 
Person’s potentially inappropriate Prescriptions in Frail adults with limited life 
expectancy), in an attempt to highlight the proposed appropriate target 
subpopulation of older people. Similar to STOPP/START criteria (36, 37), the initial 
draft of STOPPFrail indicators was arranged according to physiological systems. For 
patients to be suitable for medication review according to STOPPFrail criteria, four 
eligibility criteria were proposed (Table 5.2). Since the most consistent predictors of 
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mortality are the number and severity of co-morbid conditions and associated 
functional impairment (140), our definition of patients in whom deprescribing would 
be appropriate or desirable according to STOPPFrail criteria was based on these 
essential indicators, rather than the presence of specific diseases, such as dementia 
or cancer. In addition, relevant challenges associated with medication use in this 
population, such as administration time and physical discomfort were proposed for 
incorporation into the tool, as these issues have been reported by healthcare 
professionals, patients and their families to be of concern in frail older adults (133).   
 It was envisaged that STOPPFrail criteria would be used by all physicians who 
come in contact with frailer older adults with a limited life expectancy, regardless of 
their own specialty and the location of the assessment (acute hospital, primary care 
or long-term residential units). However, in order to apply the STOPPFrail tool, 
physicians would need to have access to patients’ diagnoses, and medication lists, as 
well as their measured cognitive and functional status details.  
 
Table 5.2 Proposed definition of target population 
 
STOPPFrail is a list of potentially inappropriate prescribing indicators designed to assist 
physicians with stopping such medications in older patients (≥ 65 years) who meet ALL 
of the criteria listed below: 
 
 
End-stage  irreversible pathology 
Poor one-year survival prognosis 
Severe functional impairment or severe cognitive impairment or both 
Symptom control is the priority rather than prevention of disease progression 
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 5.2.2 Comprehensive literature review to support draft criteria inclusion  
The evidence base to support the use of each drug or drug class in frailer older 
patients with limited life expectancy was checked using the British National 
Formulary and an extensive literature review, limited to the last 20 years. Drugs and 
drug classes were selected based on clinical judgement of the authors as well as 
available data on inappropriate prescribing in patients with limited life expectancy. 
Literature searches of the PubMed, Cinahl and Google Scholar databases were 
undertaken. Searches included the drug in question combined with key words i.e. 
“life expectancy”, “frailty”, “older adults”, “poor prognosis”, “deprescribing”, 
“inappropriate prescribing”, “adverse drug reactions” and “adverse drug events”. 
Randomised control trials (RCTs), systematic reviews and up-to-date guidelines were 
included. Where none of the above was found, observational studies were reviewed. 
Articles had to be written in the English language and include older adults. The panel 
was provided with an electronic repository containing supporting references for the 
proposed STOPPFrail criteria.  
 
 5.2.3. Use of Delphi consensus methodology and selection of expert panel 
The Delphi consensus method was used for this research. It is a well-established 
method that aims to gather information from persons in the domain of their relevant 
expertise, with the goal of reaching a group consensus on a complex subject where 
information is lacking. In this instance, the complex subject in question is potentially 
inappropriate medication use in older frailer adults with poor survival prognosis. 
Delphi panellists must have expertise in the topic under consideration and the panel 
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as a whole should represent all relevant parties concerned with the topic. Anonymity 
should be maintained throughout the process to avoid counterproductive argument 
and confrontation between panellists. Discussion outside of the process is generally 
discouraged during the process, although face-to-face panel discussion at the end of 
the process when reaching conclusions is not unusual. This technique has been used 
for the successful development of other explicit prescribing criteria in the past e.g. 
Beers criteria (63-67) and STOPP/START criteria (36, 37). The Delphi consensus 
method is illustrated in figure 5.1. It was the chosen methodology for this research 
due to the paucity of randomised controlled clinical trial evidence supporting the 
long term benefits of preventive drugs in frailer older adults with complex co-
morbidities and limited life expectancy. Such patients are commonly excluded from 
clinical trials of drug therapies (51).  
 In March 2015, twenty five experts, were invited to participate in the Delphi 
process. Panellists were selected on the basis of their recognised academic 
credentials, clinical practice, experience and geographical diversity. After the study 
design and aims were explained to each participant, seventeen of the twenty five 
agreed to participate. The eight individuals who declined were spread across the 
participating specialties (Table 5.3). The final panel consisted of academic consultant 
geriatricians (n=6), clinical pharmacologists (n=3), psychiatrists of old age (n=1), 
palliative medicine physicians (n=3), senior academic primary care physicians (n=2) 
and clinical pharmacists with an interest in geriatric pharmacotherapy (n=2) (Table 
5.4). All of the panellists were affiliated with Irish university teaching hospitals and 
two were practicing in Northern Ireland. Panellists competed the Delphi process 
between May 2015 and April 2016.  
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Table 5.3 Description of the Delphi assessment panel according to occupation 
Specialty Invited Participated 
   
 
Physicians in Geriatric Medicine 
 
8 
 
6 
Clinical pharmacologists 4 3 
Palliative care physicians 6 3 
General Practitioners 3 2 
Old age psychiatrists 2 1 
Clinical pharmacists 2 2 
 
Table 5.4: Expert panellists who participated in Delphi validation of STOPPFrail 
 Name Discipline Place of practice 
 
1 
 
Prof. Joe Harbison 
 
Geriatric Medicine 
 
St James’s Hospital, Dublin 
2 Prof. Lorraine Kyne Geriatric Medicine Mater Misericordiae, Dublin 
3 Prof. Riona Mulcahy Geriatric Medicine University Hospital Waterford 
4 Prof. Sean O’Keeffe Geriatric Medicine University College Hospital Galway 
5 Prof. Peter Passmore Geriatric Medicine Queen’s University Belfast 
6 Dr. Suzanne Timmons Geriatric Medicine Mercy University Hospital, Cork 
7 Prof. Michael Barry Clinical Pharmacology St James’s Hospital, Dublin 
8 Prof. John Stinson Clinical Pharmacology Trinity College, Dublin 
9 Prof. David Williams Clinical Pharmacology Beaumont Hospital, Dublin 
10 Dr. Brian Creedon Palliative care University Hospital Waterford 
11 Prof. Tony O’Brien Palliative care Marymount & Cork University Hospital 
12 Prof. Max Watson Palliative care Northern Ireland Hospice, Belfast 
13 Prof. Tom O’Dowd General Practice Trinity College, Dublin 
14 Prof. Henry Smithson General Practice University College Cork 
15 Prof. Brian Lawlor Psychiatry of Old Age St James’s Hospital, Dublin 
16 Prof. Stephen Byrne Clinical Pharmacy University College Cork, Cork 
17 Dr. Cristin Ryan Clinical Pharmacy Royal College of Surgeons of Ireland 
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 5.2.4 Determination of content validity of the criteria 
Each round was sent to the panellists using an online survey [SurveyMonkey®]. The 
first Delphi round consisted of 30 proposed criteria with each criterion presented in 
a standardized format i.e. a drug or drug class deemed potentially inappropriate 
followed by an explanatory sentence (see Appendix 10). An example of such a 
statement is displayed in Figure 5.2. Panellists rated their agreement with each 
statement on a 5-point Likert scale, where 5 = strongly agree, 4 = agree, 3 = neutral, 
2 = disagree, 1 = strongly disagree, 0 = unable to offer an opinion (204). In round 1, 
panellists were also asked to offer suggestions or comments (including new drugs) as 
appropriate on the proposed criteria.  
 For each statement, consensus was based on the median Likert scale 
response and interquartile range. A median value of 4 or 5 with a 25th centile of ≥4 
was accepted for inclusion in the tool i.e. only statements with at least 75% of 
respondents agreeing or strongly agreeing were included. Proposed criteria with a 
median value of ≤3 were rejected: those with a median value of 4 or 5 and a 25th 
centile of < 4 were rephrased in accordance with panellists’ suggestions and included 
in the next Delphi round. Statistical analysis was performed using IBM SPSS® Statistics 
version 22. 
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Figure 5.2: Sample question from round 1 of the Delphi consensus survey 
Cardiovascular System: 
 
STOPPFrail is a list of potentially inappropriate prescribing indicators designed to assist 
physicians with stopping such medications in older patients (≥ 65 years) who meet ALL of the 
criteria listed below. 
- End-stage irreversible pathology 
- Poor one year survival prognosis 
- Severe functional impairment or severe cognitive impairment or both 
- Symptom control is the priority rather than prevention of disease progression. 
 
The decision to prescribe/not to prescribed medications to the patients, should also be 
influences by the following issues: 
- Risk of the medication outweighing the benefit 
- Administration of the medication is challenging 
- Monitoring of the medication effect is challenging 
- Drug adherence/compliance is difficult 
 
The following prescriptions are potentially inappropriate for patients who meet the 
inclusion criteria above. Please select one response per statement: 
 
B1: Lipid lowering therapies (statins, ezetimibe, bile acid sequestrans, fibrates, nicotinic 
acid, acipimox). These medications needs to be prescribed for a long duration to be of 
benefit. For short term use ADE risk outweighs the potential benefit. 
 
Strongly agree     
Agree  
Neutral  
Disagree  
Strongly disagree  
Don’t know  
 
Additional comments:  
 
 
B2: alpha blockers for hypertension. Stringent blood pressure control is not required in very 
frail people. Alpha blockers in particular cause marked vasodilation, which can result in 
marked symptomatic postural hypotension, falls and injuries. 
 
Strongly agree     
Agree  
Neutral  
Disagree  
Strongly disagree  
Don’t know  
 
Additional comments:  
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5.3 RESULTS 
All panellists completed the Delphi validation process in three rounds; 27 criteria 
comprise the final STOPPFrail tool (for summary, see Figure 5.3).  
Figure 5.3: Flow chart of Delphi process 
 
  
 5.3.1 Round 1 
Round 1 draft criteria were prepared and sent to panellists. The draft criteria, the 
responses received and their outcomes are displayed in Table 5.5.  
 
 
 
 
 
 
 
 
 
Final STOPPFrail criteria
27 criteria listed according to physiological system
Round 3 (2 criteria)
1 accepted 0 rejected 1 remained inconclusive
Round 2 (8 criteria)
6 accepted 0 rejected 2 prepared for round 3
Round 1 (30 criteria)
20 accepted 2 rejected 8 prepared for round 2
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Table 5.5: Round 1 results 
STOPPFrail is a list of potentially inappropriate prescribing indicators designed to assist physicians with 
stopping such medications in older patients (≥ 65 years) who meet ALL of the criteria listed below:  
 End-stage irreversible pathology  
 Poor Prognosis  
 Severe functional impairment or severe cognitive impairment or both 
 Symptom control is the priority rather than prevention of disease progression 
The decision to prescribe/not prescribe medications to the patient, should also be influenced by the 
following issues:  
 Risk of the medication outweighing the benefit  
 Administration of the medication is challenging 
 Monitoring of the medication effect is challenging 
 Drug adherence/compliance is difficult 
 Med IQR Outcome 
Section A: General 
A1. Any drug that the patient persistently fails to comply with for any 
reason 
 
4.0 
 
3.5-5 
 
Inconclusive 
A2. Any drug without clear clinical indication 5.0 5.0-5.0 
 
Accepted 
Section B: Cardiology System 
 
   
B1. Lipid lowering therapies (statins, ezetimibe, bile acid 
sequestrans, fibrates, nicotinic acid and acipimox) These 
medications need to be prescribed for a long duration to be of 
benefit. For short-term use, the risk of adverse drug events 
outweighs the potential benefits 
5.0 4.0-5.0  Accepted 
B2. Alpha-blockers for hypertension Stringent blood pressure 
control is not required in very frail older people. Alpha blockers in 
particular can cause marked vasodilatation, which can result in 
marked postural hypotension, falls and injuries 
5.0 
 
4.0-5.0 Accepted 
Section C: Coagulation System 
 
   
C1. Anticoagulants (warfarin/novel oral anticoagulants) 
Anticoagulation as a preventative measure (e.g. with atrial 
fibrillation) as distinct from treatment of acute venous 
thromboembolic (VTE) disease 
3.0 2.0-4.0 Rejected 
 
C2. Anti-platelet agents No role for anti-platelet agents in primary 
cardiovascular prevention, only beneficial for secondary 
cardiovascular prevention, therefore discontinue unless there is a 
previous history of ischaemic heart disease, cerebrovascular disease 
or arterial stent insertion 
4.0 3.0-5.0 Inconclusive 
Section D: Central Nervous System 
 
   
D1. Memantine Discontinue unless it has been prescribed for 
behavioural and psychological symptoms of dementia (BPSD) in 
patients with Alzheimer’s disease and has been shown to improve 
symptoms  
4.0 2.25-5.0 Inconclusive  
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D2. Acetylcholinesterase inhibitors There is no significant clinical 
benefit from continuation of these drugs in those with advanced 
Alzheimer’s disease (Mini-Mental State Examination score <10/30 
and functionally dependent). No role in other dementia syndromes 
in the advanced stages. 
 
 
 
4.0 
 
3.25-5.0 
 
Inconclusive 
D3. Anti-depressants There is no proven role for anti-depressants in 
advanced dementia (MMSE <10/30 and functionally dependent) 
 
3.0 
 
2.0-4.0 
 
Rejected 
 
D4. Neuroleptic antipsychotics Aim to reduce dose and discontinue 
these drugs in patients taking them for longer than 12 weeks if there 
are no current clinical features of behavioural and psychiatric 
symptoms of dementia (BPSD) 
 
5.0 
 
4.0-5.0 
 
Accepted 
Section E: Gastrointestinal System 
 
   
E1. Proton Pump Inhibitors Proton Pump Inhibitors at full 
therapeutic dose ≥ 8/52, unless persistent dyspeptic symptoms at 
lower maintenance dose. 
 
4.0 
 
4.0-5.0 
 
Accepted  
E2. H2 Receptor Antagonists H2 Receptor Antagonists at full 
therapeutic dose for ≥ 8/52, unless persistent dyspeptic symptoms 
or symptoms reoccur after discontinuation  
4.0 3.5-5.0 Inconclusive 
E3. Gastrointestinal antispasmodics Regular daily prescription of 
gastrointestinal antispasmodics agents unless the patient has 
frequent relapse of colic symptoms because of high risk of anti-
cholinergic side effects 
 
4.0 4.0-5.0 Accepted 
Section F: Respiratory System 
 
   
F1. Theophylline This drug has a narrow therapeutic index, requires 
monitoring of serum levels and interacts with other commonly 
prescribed drugs putting patients at an increased risk of adverse 
drug events (ADEs) 
5.0 4.0-5.0 Accepted 
F2. Leukotriene antagonists (Montelukast, Zafirlukast) These drugs 
have no proven role in COPD, they are indicated only in asthma. 
5.0 4.0-5.0 Accepted 
Section G: Musculoskeletal System 
 
   
G1. Calcium and vitamin D supplementation Unlikely to be of any 
benefit in the short term 
4.0 3.0-5.0 Inconclusive  
G2. Anti-resorptive/bone anabolic drugs for osteoporosis 
(bisphosphonates, strontium, teriparatide, denosumab) Benefits 
unlikely to be achieved within 1 year, increased short-intermediate 
term risk of associated adverse drug events 
4.0 3.0-5.0 Inconclusive 
 
G3. Selective Estrogen Receptor Modulators (SERMs) for 
osteoporosis Benefits unlikely to be achieved within 1 year, 
increased short-intermediate term risk of associated ADEs 
particularly venous thromboembolism and stroke. 
 
5.0 4.0-5.0 Accepted 
G4. Long-term oral NSAIDs Increased risk of side effects (peptic ulcer 
disease, bleeding, worsening heart failure etc.) when taken regularly 
for ≥ 2 months 
 
5.0 4.0-5.0 Accepted 
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G5. Long-term oral steroids Increased risk of side effects (peptic 
ulcer disease etc.) when taken regularly for ≥ 2 months. Consider 
careful dose reduction and discontinuation 
5.0 4.0-5.0 Accepted 
Section H: Urogenital System 
H1. 5-alpha reductase inhibitors No benefit with long term urinary 
bladder catheterisation 
 
5.0 
 
4.0-5.0 
 
Accepted 
H2. Alpha blockers with urinary catheter No benefit with long term 
urinary bladder catheterisation 
5.0 4.0-5.0 Accepted 
H3. Muscarinic antagonists No benefit with long term urinary 
bladder catheterisation, unless clear history of painful detrusor 
hyperactivity 
5.0 4.0-5.0 Accepted 
Section I: Endocrine System 
 
   
I1. Diabetic oral agents Aim for monotherapy. Target of HbA1c 
<8%/64mmol/mol. Stringent glycaemic control is unnecessary 
4.0 4.0-4.5 Accepted 
 
I2. ACE-Inhibitors for diabetes Stop where prescribed only for 
prevention and treatment of diabetic nephropathy. There is no clear 
benefit in older people with advanced frailty with poor survival 
prognosis 
4.0 4.0-5.0 Accepted 
I3. Angiotensin Receptor Blockers (ARBs) Stop where prescribed 
only for prevention and treatment of diabetic nephropathy. There is 
no clear benefit in older people with advanced frailty with poor 
survival prognosis 
4.0 4.0-5.0 Accepted 
I4. Systemic oestrogens for menopausal symptoms Increases risk of 
stroke and VTE disease. Discontinue and only consider 
recommencing if recurrence of symptoms 
4.0 4.0-5.0 Accepted 
Section J: Miscellaneous 
 
   
J1. Multi-vitamin combination supplements Discontinue when 
prescribed for prophylaxis rather than treatment 
5.0 4.0-5.0 
 
Accepted 
 
J2. Nutritional supplements (other than vitamins) Discontinue when 
prescribed for prophylaxis rather than treatment 
5.0 
 
4.0-5.0 
 
Accepted 
 
J3. Prophylactic antibiotics No firm evidence for a role for 
prophylactic antibiotics for recurrent cellulitis or recurrent UTI 
4.0 3.0-5.0 Inconclusive 
    
*Legend: Med = median; IQR = inter-quartile range; ADE=adverse drug event 
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5.3.1.1  Criteria accepted for inclusion after round 1  
In round 1, twenty criteria were accepted (Table 5.5). The first proposed criterion 
included in STOPPFrail was a general statement that any drug prescribed without a 
clinical indication should be discontinued. The remaining 19 criteria accepted 
included deprescribing of lipid-lowering agents, alpha-blockers for hypertension, 
neuroleptics, proton pump inhibitors, theophylline, leukotriene receptor 
antagonists, selective oestrogen receptor modulators, non-steroidal anti-
inflammatories, steroids, 5-alpha reductase inhibitors and alpha-blockers in 
catheterised patients, muscarinic antagonists, diabetic oral agents, Ace-inhibitors, 
angiotensin receptor antagonists, multivitamins and nutritional supplements.  
 
5.3.1.2  Criteria rejected for inclusion after round 1 
Two criteria were rejected in round 1 (Table 5.5). See Table 5.6 for the comments 
received by panellists. 
 
(i) Anticoagulants as a preventative measure. 
Our research group proposed discontinuation of anticoagulation because bleeding 
risk and cost of treatment outweighed the potential benefits to patients in whom 
cognition and activities of daily living function were poor. Panellists agreed that in 
the majority of people meeting the inclusion criteria for STOPPFrail, anticoagulants 
should be stopped. However, this criterion was rejected due to the panel’s concern 
over the minority of patients in whom stopping anticoagulants could be potentially 
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inappropriate. Specifically, the majority of panel members considered that, 
regardless of frailty and life expectancy, stroke or systemic embolism was an 
unfavourable outcome in patients with atrial fibrillation deprived of anticoagulant 
therapy. The panellists and authors agreed that individual clinical judgement should 
be applied based on individual clinician and patient preferences and individual 
priorities with regard to anti-coagulation therapy. In recent years, anticoagulation 
has become easier, safer and more efficient due to the development of direct oral 
anticoagulants i.e. apixaban, rivaroxaban, edoxaban and dabigatran. Therefore 
panellists felt that in patients receiving anti-coagulants with a good indication and 
incurring minimal or no side-effects, continuation was reasonable.  
 
(ii) Use of anti-depressants in patients with advanced dementia 
Reasons for rejection of this proposed criterion included possible benefits outside of 
anti-depressant effects, such as analgesic effects, appetite stimulation and anxiolytic 
properties. Panellist feedback suggested that cessation of antidepressants in patients 
with severe dementia was a generally reasonable approach, but not in all such 
patients with limited life expectancy as a general rule. Panellists feared that 
antidepressant therapy could be stopped in patients who derived benefit from 
treatment that was not measureable because of the communication problems 
associated with severe dementia and that overall, the risk of relapse of symptoms 
outweighed the potential benefit of discontinuation. 
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Table 5.6: Comments received from panellists for criteria rejected in round 1 
Criterion Med IQR Outcome 
C1. Anticoagulants (warfarin/novel oral anticoagulants) 
Anticoagulation as a preventative measure (e.g. with atrial 
fibrillation) as distinct from treatment of acute venous 
thromboembolic (VTE) disease 
3.0 2.0-4.0 Rejected 
 
 
“This must be balanced with how you will respond to a patient if they have an A.fib-related stroke” 
“Depends on vascular risk.  Having a stroke not a good way to go ...” 
“Good evidence from BAFTA that there may be some benefit. Suggestive evidence from AVERROES.” 
“It does depend on the individual case but the majority will gain no benefit. The poor cost benefit of 
the NAOC drugs should make them only a rare second line” 
“Suppose strong history of previous TIAs or small strokes, and A fib, and can take a NOAC- not very 
burdensome to continue this despite poor prognosis - would not like to see a stroke on top of the 
other disease, even if frail” 
“In general I strongly agree. As before easier to use these indicators to justify not starting 
anticoagulants, rather than stopping. The DOACs do seem to have less issues with administration 
and monitoring than warfarin, but renal impairment causes many problems with them” 
“Must assess each individual patient in respect of risk/benefit. It may be reasonable to continue for 
example in a hyper-coaguable patient with distressing symptoms” 
Criterion Med IQR Outcome 
D3. Anti-depressants There is no proven role for anti-depressants in 
advanced dementia (MMSE <10/30 and functionally dependent) 
3.0 
 
2.0-4.0 
 
Rejected 
 
 
“No proof agreed, but if BPSD troublesome and seems related to depression use” 
“Anti-depressants have uses outside depression, e.g. analgesia, appetite stimulation” 
“suggest to clarify wording; is it for patients who meet the frailty criteria or just advanced dementia” 
“I would not stop antidepressants in people with limited life expectancy until end of life - may not 
be of proven benefit in advanced dementia / functionally dependent people, but that doesn't mean 
they don't work. Lots of end of life care we use all the time has NO proven benefit!   Also, would not 
withdraw in a person with previous severe depression and relapse on previous withdrawal” 
“my only comment here is that some anti-depressants have good anxiolytic effects, can be helpful” 
“Needs careful individual clinical assessment. TCADs for example are commonly used in neuropathic 
pain or may be used to reduce oro-pharyngeal secretions” 
*Legend: Med = median; IQR = inter-quartile range 
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5.3.1.3  Criteria deemed inconclusive after round 1 
Eight criteria were deemed inconclusive after round 1 (Table 5.5). The first was a 
general criterion of deprescribing any drug with which patients fail to comply. 
Feedback suggested that the explanatory sentence should remind users to try all 
appropriate measures to improve medication adherence before deprescribing; this 
criterion was rephrased accordingly for round 2. Other drugs for which there was 
uncertainty among the panel were anti-platelet agents, memantine, 
acetylcholinesterase inhibitors, H2-receptor antagonists, calcium and vitamin D 
supplements, bone anti-resorptive/anabolic agents and prophylactic antibiotics. See 
Table 5.7 for the comments received from panellists. Feedback was incorporated into 
rephrasing the criteria for round 2.  
Table 5.7: Comments from panellists for criteria found to be inconclusive 
Criterion Med IQR Outcome 
A1. Any drug that the patient persistently fails to comply with for 
any reason 
4.0 3.5-5 Inconclusive 
 
“Obviously the patient compliance issues will need to be explored to rule out a misunderstanding 
from the individual patient's perspective.” 
“Provided appropriate measures have been taken to enhance compliance.” 
“Depends on clinical situation and whether symptomatic as the situation may change although they 
may not admit to this.” 
“The reason why the patient fails to comply would need to be clarified.” 
“If it helps symptoms, efforts should be made to find a way to improve compliance or find 
alternative administration route -stopping may not be the best result.” 
“As you state ""potentially inappropriate"" I can strongly agree. If you had stated ""inappropriate"" 
alone, I would have ticked agree.” 
“Having spoken to the patient to clarify his / her reasons for non-compliance if possible.” 
Criterion Med IQR Outcome 
C2. Anti-platelet agents No role for anti-platelet agents in 
primary cardiovascular prevention, only beneficial for secondary 
cardiovascular prevention, therefore discontinue unless there is a 
4.0 3.0-5.0 Inconclusive 
215 
 
previous history of ischaemic heart disease, cerebrovascular 
disease or arterial stent insertion. 
 
“Would not stop if symptomatic ischaemic heart disease until last days of life - agree with the 
wording used” 
“I think 75 mg aspirin is still useful in most elderly patients requiring secondary prevention....” 
Criterion Med IQR Outcome 
D1. Memantine Discontinue unless it has been prescribed for 
behavioural and psychological symptoms of dementia (BPSD) in 
patients with Alzheimer’s disease and has been shown to 
improve symptoms. 
4.0 2.25-
5.0 
Inconclusive 
 
“As per previous comments, patients (& families) can have a sense of "I must take this drug to help.” 
“Don't know this one.” 
“Agree totally unless the indication was behavioural symptoms/ hallucinations and these responded 
well to memantine - would then be reluctant to rock the boat. Would not limit to AD however- we 
use for PDD also when intolerant of AChI due to tremor.” 
“Must always explain rationale to patient and family.” 
Criterion Med IQR Outcome 
D”. Acetylcholinesterase inhibitors There is no significant clinical 
benefit from continuation of these drugs in those with advanced 
Alzheimer’s disease (Mini-Mental State Examination score < 
10/30 and functionally dependent). No role in other dementia 
syndromes in the advanced stages. 
4.0 3.25-
5.0 
Inconclusive 
 
“No experience with this one.” 
“Again, unless for hallucinations in PD dementia -would NOT stop in this case as definitely provokes 
return of symptoms.” 
Criterion Med IQR Outcome 
E2. H2 Receptor Antagonists H2 Receptor Antagonists at full 
therapeutic dose for ≥ 8/52, unless persistent dyspeptic 
symptoms or symptoms reoccur after discontinuation. 
4.0 3.5-5.0 Inconclusive 
 
“Hardly ever use these now.” 
Criterion Med IQR Outcome 
G1. Calcium and vitamin D supplementation Unlikely to be of 
any benefit in the short term. 
4.0 3.0-5.0 Inconclusive  
 
“Would not initiate, but less definite about stopping altogether. Bone fractures cause 
symptoms........” 
Criterion Med IQR Outcome 
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G2. Anti-resorptive/bone anabolic drugs for osteoporosis 
(bisphosphonates, strontium, teriparatide, denosumab) Benefits 
unlikely to be achieved within 1 year, increased short-
intermediate term risk of associated adverse drug events. 
4.0 3.0-5.0 Inconclusive 
 
 
“More inclined to stop these due to ADEs, and administration challenges are greater.....” 
“Then indication is the important consideration. May be used in symptomatic hypercalcaemia of 
malignancy for example.” 
Criterion Med IQR Outcome 
J3. Prophylactic antibiotics No firm evidence for a role for 
prophylactic antibiotics for recurrent cellulitis or recurrent UTI. 
4.0 3.0-5.0 Inconclusive 
 
“Act on advice from microbiology.” 
*Legend: Med = median; IQR = inter-quartile range; ADEs = adverse drug events 
 
Panellists agreed with the inclusion of anti-platelet agents, but raised concerns over 
their cessation when their indication was secondary prevention. Similar to the 
feedback for anti-coagulants, panellists were concerned about the minority of 
patients in whom deprescribing of anti-platelet agents may be inappropriate. It was 
felt that secondary prevention of conditions such as ischaemic heart disease, 
peripheral vascular disease and stroke should incorporate bespoke judgement, and 
that a general statement would therefore not be appropriate in relation to anti-
platelet therapy. Hence, it was decided that primary prevention should be the focus 
of this criterion i.e. anti-platelet agents for primary cardiovascular prevention (as 
distinct from secondary prevention) in this category of patient is probably 
inappropriate.  
 Panellists welcomed the inclusion of calcium supplementation and anti-
resorptive therapy in STOPPFrail, but asked for clarity around the explanatory 
sentence i.e. cessation where the indication was osteoporosis and not malignancy or 
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hypercalcaemia. Evidence is lacking on whether long term use of calcium is beneficial 
due to methodological flaws in studies and high dropout rates (205). Patient 
compliance with calcium supplements is generally poor (31); those patients most 
likely to be non-compliant usually have a history of smoking, poor mobility and 
previous fractures (206). Anti-resorptive medications may be challenging to 
administer, have a less favourable side-effect profile and in some cases have been 
shown to have ongoing clinical benefits after cessation e.g. bisphosphonates. For 
these reasons the panellists agreed to cessation in those with limited life expectancy. 
 
 5.3.2 Round 2 
Round 2 draft criteria were prepared, incorporating suggestions and comments 
received and sent to panellists. The draft criteria, the responses received and their 
outcomes are displayed in Table 5.8. Consensus could not be reached on two criteria 
after round 2 i.e. cessation of (i) memantine and (ii) acetylcholinesterase inhibitors 
in advanced dementia. Table 5.9 displays the comments received by the panellists.  
A third Delphi round was therefore prepared for circulation. 
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Table 5.8: Round 2 results 
STOPPFrail is a list of potentially inappropriate prescribing indicators designed to assist physicians with 
stopping such medications in older patients (≥ 65 years) who meet ALL of the criteria listed below:  
 End-stage irreversible pathology  
 Poor Prognosis  
 Severe functional impairment or severe cognitive impairment or both 
 Symptom control is the priority rather than prevention of disease progression 
The decision to prescribe/not prescribe medications to the patient, should also be influenced by the 
following issues:  
 Risk of the medication outweighing the benefit  
 Administration of the medication is challenging 
 Monitoring of the medication effect is challenging 
 Drug adherence/compliance is difficult 
 Med IQR Outcome 
Section A: General 
 
   
A1. Any drug that the patient persistently fails to take or tolerate 
despite adequate education and consideration of all appropriate 
formulations 
 
5.0 4.0-5.0 Accepted 
Section C: Coagulation System 
 
   
C2. Anti-platelet agents Avoid anti-platelet agents for primary (as 
distinct from secondary) cardiovascular prevention (no evidence of 
benefit). 
5.0 4.0-5.0  Accepted 
Section D: Central Nervous System 
 
   
D1. Memantine Discontinue and monitor in patients with moderate 
to severe dementia, unless memantine has clearly improved BPSD  
4.0 3.5-5.0 Inconclusive 
D2. Acetylcholinesterase inhibitors Discontinue and monitor in 
patients with severe dementia. 
4.0 3.0-5.0 Inconclusive 
Section E: Gastrointestinal System 
 
   
E2. H2 Receptor Antagonists H2 Receptor Antagonists at full 
therapeutic dose for ≥ 8/52, unless persistent dyspeptic symptoms 
at lower maintenance dose. 
4.0 4.0-5.0 Accepted 
Section G: Musculoskeletal System 
 
   
G1. Calcium supplementation Unlikely to be of any benefit in the 
short term.   
5.0 4.0-5.0 Accepted 
G2. Anti-resorptive/bone anabolic drugs FOR OSTEOPOROSIS 
(bisphosphonates, strontium, tereparatide, denosumab)  
4.0 4.0-5.0 Accepted 
 
 
Section J: Miscellaneous    
J3. Prophylactic antibiotics No firm evidence for prophylactic 
antibiotics to prevent recurrent cellulitis or UTI.   
4.0 4.0-5.0 Accepted 
 
 
*Legend: Med = median; IQR = inter-quartile range; BPSD = Behavioural and psychological symptoms of 
dementia 
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Table 5.9: Comments received from panellists for criteria rejected in round 2 
Criterion Med IQR Outcome 
D1. Memantine Discontinue and monitor in patients with 
moderate to severe dementia, unless memantine has clearly 
improved BPSD. 
4.0 3.5-5.0 Inconclusive 
 
“there is a study in palliative care where memantine was stopped and quite a percentage of 
patients rebounded in terms of behaviours. it does depend as you say on the behavioural 
responses before to the drug” (this person agreed). 
“If patient has moderate-severe dementia and is tolerating memantine, I see no reason to 
discontinue. It may have benefits that are not recognised until it is stopped” (this person agreed). 
Criterion Med IQR Outcome 
D2. Acetylcholinesterase inhibitors Discontinue and monitor 
in patients with severe dementia. 
4.0 3.0-5.0 Inconclusive 
 
“Would not stop if tolerated. May have unrecognised benefits (this person agreed).  
*Legend: Med = median; IQR = inter-quartile range; BPSD = Behavioural and psychological symptoms 
of dementia 
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 5.3.3  Round 3 
Round 3 draft criteria were prepared and sent to panellists. The draft criteria, the 
responses received and their outcomes are displayed in Table 5.10.  
Table 5.10 Round 3 Results 
STOPP frail is a list of potentially inappropriate prescribing indicators designed to assist physicians 
with stopping such medications in older patients (≥ 65 years) who meet ALL of the criteria listed 
below:  
 End-stage irreversible pathology  
 Poor Prognosis  
 Severe functional impairment or severe cognitive impairment or both 
 Symptom control is the priority rather than prevention of disease progression 
The decision to prescribe/not prescribe medications to the patient, should also be influenced by the 
following issues:  
 Risk of the medication outweighing the benefit  
 Administration of the medication is challenging 
 Monitoring of the medication effect is challenging 
 Drug adherence/compliance is difficult 
 Med IQR  Outcome 
Section D: Central Nervous System    
D1: Memantine Discontinue and monitor in patients with moderate 
to severe dementia, unless memantine has clearly improved 
behavioural and psychological symptoms of dementia (BPSD) 
(specifically in frail patients who meet the criteria above). 
4.0 4.0-5.0 Accepted 
D2. Acetylcholinesterase inhibitors Discontinue and monitor in 
patients with severe dementia (specifically in frail patients who meet 
the criteria above). 
4.0 3.25-5.0 Inconclusive 
*Legend: Med = median; IQR = inter-quartile range, BPSD = Behavioural and psychological symptoms 
of dementia 
 
In this round, consensus was obtained for memantine and it was included in the 
STOPPFrail tool. Consensus was not achieved for acetylcholinesterase inhibitors 
(AChEI’s) with no clear trend towards acceptance (Table 5.11). Table 5.12 displays 
the comments received from the panellists. Panellists reported that the evidence 
base for acetylcholinesterase inhibitors in advanced dementia was still developing 
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and the possibility that unrecognised benefits existed could not be dismissed. The 
DOMINO-AD trial was cited to support their argument in favour of retaining AChEI’s 
(207, 208).  This trial suggests that in patients where AChEI’s are stopped, the 
admission rate to nursing homes in the year following cessation is significantly 
increased compared to those patients who continue to receive AChEI’s. However, 
this difference is only seen in the first year following cessation. 
 After three Delphi rounds, no additional concerns were raised by the panel 
and it was decided by the authors not to proceed to a fourth Delphi round as it was 
deemed unnecessary. The final consensus STOPPFrail criteria are presented in Table 
5.13. 
Table 5.11: Acetyl Cholinesterase Inhibitors Delphi Results 
Acetyl Cholinesterase Inhibitor 
 Round 1 Round 2 Round 3 
Median 4.000 4.000 4.000 
25th centile 3.250 3.000 3.250 
 
Table 5.12: Comments received from panellists for criteria rejected 
Criterion Med IQR Outcome 
D2. Acetylcholinesterase inhibitors Discontinue and monitor 
in patients with severe dementia (specifically in frail patients 
who meet the criteria above). 
4.0 3.25-5.0 Inconclusive 
 
“ if very late then yes but the DOMINO study in NEJM would indicate that inpeople with MMSE 5-13, 
Donepezil al least should be continued for a year. I feel that the definition above is probably not 
concise enough.” 
“Evidence that in severe dementia, stopping acetyl cholinesterase inhibitors is detrimental. If no 
adverse events, I would continue for symptomaic benefit (DOMINO-AD).” 
“Patients (and more over family memebers) may place an over significance in the stopping of this 
medications.” 
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Table 5.13 Final STOPPFrail criteria 
STOPPFrail is a list of potentially inappropriate prescribing indicators 
designed to assist physicians with stopping such medications in older 
patients (≥ 65 years) who meet ALL of the criteria listed below: 
 
1. End-stage irreversible pathology 
2. Poor one-year survival prognosis 
3. Severe functional impairment or severe cognitive impairment 
or both 
4. Symptom control is the priority rather than prevention of 
disease progression 
The decision to prescribe/not prescribe medications to the patients, should 
also be influenced by the following issues: 
 
1. Risk of the medications outweighing the benefit 
2. Administration of the medication is challenging 
3. Monitoring of the medication effect is challenging 
4. Drug adherence/compliance is difficult 
Section A: General 
A1: Any drug that the patient persistently fails to take or tolerate 
despite adequate education and consideration of all appropriate 
information 
A2: Any drug without clear clinical indication 
 
Section B: Cardiovascular 
B1. Lipid lowering therapies [statins, ezetimibe, bile acid 
sequestrants, fibrates, nicotinic acid and acipimox] 
These medications need to be prescribed for a long duration to 
be of benefit. For short-term use, the risk of adverse drug events 
[ADEs] outweighs the potential benefits (209-211) 
B2. Alpha-blockers for hypertension 
Stringent blood pressure control is not required in very frail older 
people. Alpha blockers in particular can cause marked 
vasodilatation, which can result in marked postural hypotension, 
falls and injuries (212) 
 
Section C: Coagulation system 
C1: Anti-platelets 
Avoid anti-platelet agents for primary [as distinct from secondary] 
cardiovascular prevention [no evidence of benefit] (213) 
 
Section D: Central Nervous System 
D1. Neuroleptic antipsychotics 
Aim to reduce dose and gradually discontinue these drugs in 
patients taking them for longer than 12 weeks if there are no 
current clinical features of behavioural and psychiatric symptoms 
of dementia [BPSD] (214-219) 
D2: Memantine 
Discontinue and monitor in patients with moderate to severe 
dementia, unless memantine has clearly improved behavioural 
and psychological symptoms of dementia [BPSD] [specifically in 
frail patients who meet the criteria above] (219-222) 
 
Section E: Gastrointestinal System 
E1. Proton Pump Inhibitors 
Proton Pump Inhibitors at full therapeutic dose ≥ 8/52, unless 
persistent dyspeptic symptoms at lower maintenance dose (190) 
E2: H2 receptor antagonist 
H2 receptor antagonist at full therapeutic dose for ≥ 8/52, unless 
persistent dyspeptic symptoms at lower maintenance dose (190) 
E3. Gastrointestinal antispasmodics 
Regular daily prescription of gastrointestinal antispasmodics 
agents unless the patient has frequent relapse of colic symptoms 
because of high risk of anti-cholinergic side effects (190) 
 
Section F: Respiratory System 
F1. Theophylline 
This drug has a narrow therapeutic index, requires monitoring of 
serum levels and interacts with other commonly prescribed drugs 
putting patients at an increased risk of ADEs (223-226)   
F2. Leukotriene antagonists [Montelukast, Zafirlukast] 
These drugs have no proven role in COPD, they are indicated only 
in asthma (226) 
 
Section G: Musculoskeletal System 
G1: Calcium supplementation 
Unlikely to be of any benefit in the short term 
G2: Anti-resorptive/bone anabolic drugs FOR OSTEOPOROSIS 
(bisphosphonates, strontium, teriparatide, denosumab) 
Unlikely to be of any benefit in the short term 
G3: Selective Estrogen Receptor Modulators [SERMs] for 
osteoporosis 
Benefits unlikely to be achieved within 1 year, increased short-
intermediate term risk of associated ADEs particularly venous 
thromboembolism and stroke (190) 
G4: Long-term oral NSAIDs 
Increased risk of side effects [peptic ulcer disease, bleeding, 
worsening heart failure etc.] when taken regularly for ≥ 2 months 
(227-229) 
G5: Long-term oral steroids 
Increased risk of side effects [peptic ulcer disease etc.] when taken 
regularly for ≥ 2 months. Consider careful dose reduction and 
gradual discontinuation (230) 
 
Section H: Urogenital System 
H1. 5-alpha reductase inhibitors 
No benefit with long term urinary bladder catheterisation (231, 232) 
H2. Alpha blockers 
No benefit with long term urinary bladder catheterisation (231, 232) 
H3. Muscarinic antagonists  
No benefit with long term urinary bladder catheterisation, unless 
clear history of painful detrusor hyperactivity (231, 232) 
 
Section I: Endocrine System 
I1. Diabetic oral agents 
Aim for monotherapy. Target of HbA1c <8%/64mmol/mol. Stringent 
glycaemic control is unnecessary (233) 
I2. ACE-Inhibitors for diabetes 
Stop where prescribed only for prevention and treatment of diabetic 
nephropathy. There is no clear benefit in older people with 
advanced frailty with poor survival prognosis (234) 
I3. Angiotensin Receptor Blockers [ARBs] 
Stop where prescribed only for prevention and treatment of diabetic 
nephropathy. There is no clear benefit in older people with 
advanced frailty with poor survival prognosis (234) 
I4. Systemic oestrogens for menopausal symptoms  
Increases risk of stroke and VTE disease. Discontinue and only 
consider recommencing if recurrence of symptoms (190) 
 
Section J: Miscellaneous 
J1. Multi-vitamin combination supplements 
Discontinue when prescribed for prophylaxis rather than treatment 
J2. Nutritional supplements [other than vitamins] 
Discontinue when prescribed for prophylaxis rather than treatment 
(235) 
J3: Prophylactic Antibiotics 
No firm evidence for prophylactic antibiotics to prevent recurrent 
cellulitis or UTIs (236-238)) 
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5.4  DISCUSSION 
The final STOPPFrail criteria is an explicit list of 27 PIMs in older frail adults with 
limited life expectancy, arranged according to physiological systems.  Each criterion 
is presented in the same manner i.e. a drug/drug class followed up by an explanatory 
sentence to support and guide deprescribing. This list of PIMs was developed and 
validated using the Delphi technique. Delphi panellists included a variety of 
specialists with expertise in geriatric pharmacotherapy. The first two criteria 
recommend deprescribing medications without indication or where compliance is 
poor. The remaining 25 criteria include lipid-lowering therapies, alpha-blockers for 
hypertension, anti-platelets, neuroleptics, memantine, proton-pump inhibitors, H2-
receptor antagonists, anti-spasmodic agents, theophylline, leukotriene antagonists, 
calcium supplements, bone anti-resorptive therapy, selective oestrogen receptor 
modulators, non-steroidal anti-inflammatories, corticosteroids, 5-alpha-reductase 
inhibitors, alpha-1-selective blockers, muscarinic antagonists, oral diabetic agents, 
ACE-inhibitors, angiotensin receptor blockers, systemic oestrogens, multivitamins, 
nutritional supplements and prophylactic antibiotics. Consensus could not be 
reached on the inclusion of acetylcholinesterase inhibitors. Full consensus was 
reached on the exclusion of anticoagulants and antidepressants from the list. 
 The criteria are not designed to replace clinical judgement, but rather to assist 
clinicians with medication reviews and assessment of treatment goals in this specific 
patient population. Recognition of those patients in whom STOPPFrail criteria are 
applicable may be challenging for less experienced physicians; in these 
circumstances, the use of simple mortality predictive tools may be helpful to guide 
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life expectancy e.g. the Walter Index (139) or the Cumulative Illness Rating Scale 
adapted for geriatric patients (CIRS-G) (239). However, one anticipates that the 
majority of clinicians who use STOPPFrail will be experienced in recognising patients 
who are appropriate for deprescribing i.e. general practitioners who regularly attend 
nursing home patients and hospital specialists with prognostic knowledge of the 
diseases in older patients that they manage on a regular basis. In the interest of 
simplicity and user-friendliness, we did not want STOPPFrail criteria to be contingent 
on the use of another tool to determine eligibility. 
 Unnecessary or potentially harmful polypharmacy is a well described problem 
in frailer older people with limited life expectancy. This research aims to put a 
framework on the guiding principle of deprescribing in late life i.e. that the benefits 
of many preventive medications are unlikely to be realised in those with a limited life 
expectancy. Although many IP explicit tools exist (71), there is an unmet need for a 
concise explicit tool to assist deprescribing in this specific patient population. 
STOPPFrail is a concise deprescribing assistive tool, focusing on 27 specific indicators, 
suggesting that it will be easy to use, time efficient and therefore more likely to be 
implemented in routine clinical practice. Like STOPP/START criteria (36, 37), 
STOPPFrail criteria are listed according to physiological systems, thereby allowing 
users to structure their approach to deprescribing. We aimed for a concise set of 
criteria that can be easily deployed in paper and electronic format.   
 Developing this tool required discussion of many controversial treatments in 
frail, end-stage older patients e.g. hypertension. The Delphi panellists agreed that a 
generalised statement about discontinuing all anti-hypertensives would be 
225 
 
contentious. Therefore, it was decided to focus on the drug class least likely to be 
prescribed as a first line agent and most likely to cause orthostatic hypotension and 
falls in an older cohort i.e. alpha-1 receptor blockers. 
 Appropriate use of STOPPFrail criteria may have pharmacoeconomic benefits. 
Older frailer adults with a poor survival prognosis account for a growing proportion 
of the population and a disproportionately high level of medication consumption. 
Implementation of safe, evidence-based deprescribing in this population, may 
improve patients’ quality of life through reduced adverse drug reactions, related 
hospitalisations and mortality. Before the true value of STOPPFrail can be used as a 
measure of prescribing appropriateness in older frailer patients with poor one year 
survival prognosis or tested by means of RCTs, its inter-rater reliability needs to be 
evaluated. This is the subject of chapter 6 of this thesis. Following on from this, the 
prevalence of PIMs according to STOPPFrail criteria need to be assessed. This is the 
subject of chapter 7.  
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CHAPTER 6 
Inter-rater reliability of STOPPFrail criteria amongst physicians from three clinical 
specialty services 
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6.1 INTRODUCTION  
The development and validation of STOPPFrail criteria was described in Chapter 5. In 
brief, STOPPFrail criteria were validated using a Delphi consensus methodology to 
highlight commonly encountered instances of potentially inappropriate medication 
(PIM) use in frail older adults with limited life expectancy. The primary goal of 
STOPPFrail is to assist clinicians with the decision to deprescribe medications that are 
of limited value or appropriateness in this population (240). However, before the 
STOPPFrail tool can be used in clinical practice, its reliability between clinical 
practitioners and generalizability between specialist disciplines must be 
demonstrated.  
 
 6.1.1. Objectives 
The objective of this study is to determine the inter-rater reliability (IRR) of 
STOPPFrail criteria between physicians practising in different clinical specialties. The 
work undertaken in this chapter, including study design, data collection and 
statistical analysis, is entirely my own. 
 
6.2 METHODS 
 6.2.1 Clinical case histories 
Twenty detailed clinical case histories were collated by Dr. Paul Gallagher (Consultant 
Geriatrician / Senior Lecturer, University College Cork) (PG) and I (AL), modified from 
real world anonymised clinical cases. These clinical cases were obtained from a 
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sample of participants enrolled in the prevalence study described in Chapter 3. 
Recorded data included the participant’s co-morbid illnesses, concurrent medication 
use and cognitive and functional abilities. . The Structured History of Medication use 
(SHiM) was employed to accurately capture concurrent medications, including 
medication adherence (241). Case details were amended, where necessary, to 
ensure, the 20 clinical cases described frail multi-morbid patients with an appreciable 
incidence of potentially inappropriate prescriptions (PIPs), according to STOPPFrail 
criteria. Each clinical case history was presented in a standardized format and 
included the patient’s age, gender, co-morbidities, a detailed medication history, 
medication allergies, and cognitive status and activities of daily living (ADL) functional 
status. 
 The participants featured in the 20 clinical cases had a mean (± standard 
deviation) age of 79.3 (± 5.68) years, twelve were female. The total number of 
prescribed medications was 181, median 9 (IQR 7-11). The median number of 
conditions was 7 (IQR 4-8). Eighteen of the twenty clinical cases (90%) were eligible 
for the application of STOPPFrail criteria i.e. end stage irreversible pathology, a poor 
one year survival prognosis, severe cognitive or functional impairment or both and 
symptom management was the priority. The irreversible diagnoses for the 18 cases 
meeting STOPPFrail inclusion criteria were severe dementia (n=6), advanced 
metastatic cancer (n=4), severe disabling stroke (n=2), stage IV chronic obstructive 
pulmonary disease (COPD) (n=2), advanced Parkinson’s disease with associated 
dementia (n=1), motor neuron disease (n=1), stage 4 congestive cardiac failure (n=1) 
and rheumatoid arthritis with dementia (n=1). 
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 6.2.2 Expert Gold Standard Assessment of PIM use according to  
  STOPPFrail criteria 
For each of the 20 clinical cases, two physicians (AL and PG), with expertise in 
geriatric pharmacotherapy, first determined if the patient described in the clinical 
case was eligible for application of STOPPFrail criteria. STOPPFrail criteria were then 
applied to identify potentially inappropriate medications that could be deprescribed. 
Complete agreement between the two expert assessors was reached in terms of 
prescribing appropriateness according to STOPPFrail criteria. This combined level of 
agreement (labelled “rater 1”) was set as the gold standard [GS], against which other 
physicians’ ratings were compared.  
 
 6.2.3 Physician recruitment  
Twelve physicians were invited to participate; 6 geriatricians (3 consultant 
geriatricians and 3 specialist registrars in geriatric medicine), 3 general practitioners 
(GPs) (2 qualified GPs and 1 specialist trainee in general practice) and 3 palliative care 
physicians (Appendix 11). This was a convenience sample with an optimum 
proportion of raters to subjects. It was anticipated that raters would agree 80% of 
the time with a relative error of 30%, thus a minimum of 17 cases was required for 
review (242). Invited participants had no prior knowledge of STOPPFrail criteria and 
did not routinely use other IP tools.  
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The study’s objectives were explained to each invited physician. Subsequently, all 
physicians agreed to participate. Physicians independently completed the exercise 
between January and February 2017. Each physician was supplied, in paper format, 
(i) the STOPPFrail criteria (Chapter 5, Table 5.13 page 222) (ii) the 20 clinical cases 
(Appendix 12) and (iii) an answer booklet with clear instructions (Appendix 13). 
Participants were asked to decide, for each individual clinical case, (i) if the patient 
was eligible for application of STOPPFrail criteria (ii) for the cases that were eligible, 
to identify PIPs listed in STOPPFrail criteria and (iii) suggest which ones, in theory, 
could be deprescribed, but only if they deemed it clinically appropriate to do so. 
Participants were asked, after they had familiarised themselves with STOPPFrail 
criteria, to measure the time taken to apply STOPPFrail criteria in each case.  
 For criterion A1 (any drug that the patient persistently fails to take or tolerate 
despite adequate education and consideration of all formulations), raters were 
instructed to assume that all formulations and delivery mechanisms had been tried 
without success, unless stated otherwise. For criterion A2 (drugs with no clear 
indication), raters were asked to base this on the known indications of the 
medications, as per the summary of product characteristics (SPC) of the medicine, 
the British National Formulary (BNF) and/or their clinical judgement. 
 Physicians were allocated the following rater numbers: consultant 
geriatricians [raters 2, 3, 4], specialist registrars in geriatric medicine [raters 5, 6, 7], 
general practitioners [raters 8, 9], specialist trainee in general practice [rater 10] and 
palliative care physicians [raters 11, 12, 13].   
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 6.2.4 Statistical analysis 
Physician responses were dichotomized into whether each STOPPFrail indicator was 
applied or not. Some criteria could be relevant to more than one drug e.g. criterion 
A2 advises deprescribing any drug which does not have a clear indication. The 
response of raters 2 -13 were cross-tabulated with those of the gold standard (GS) 
assessment. Statistical analysis was performed using IBM SPSS® Statistics version 22. 
Cohen’s Kappa Statistic was used to determine the level of agreement between each 
rater and the GS. This is a chance-corrected measure of agreement on how raters 
classify individual items into the same category, in this instance the presence or 
absence of a potentially inappropriate prescription according to STOPPFrail criteria. 
The Fleiss Kappa statistic was used to determine the overall mean kappa statistics 
between subgroups of raters (geriatricians, GPs and palliative care physicians) and 
the GS. The calculation of the kappa statistic is detailed in Figure 6.1. The kappa 
statistic was interpreted as poor if ≤0.2, fair if 0.21–0.40, moderate if 0.51–0.6, 
substantial if 0.61–0.8 and good if 0.81–1.00 (153). 
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Figure 6.1: Calculation of the kappa statistic and proportions of positive and 
negative agreement between raters 1 and 2 
 
 
Kappa co-efficient = (observed agreement – chance agreement) / (1 – chance 
agreement) 
Observed agreement = (438 + 86) / 573 = 0.92 
Chance agreement = (0.785 * 0.829 ) + (0.171 * 0.215 ) = 0.68 
Kappa = (0.91 – 0.68 ) / (1 – 0.68) = 0.73 
Proportion of positive agreement (ppos) = 2 (438) / (573 + 438 – 86) = 0.95 
Proportion of negative agreement (pneg) = 2 (86) / (573 - 438 + 86) = 0.78 
     
    STOPPFrail criteria 
 
Rater 1 (GS)  
Appropriate     Inappropriate Total 
 
Rater 2 
Appropriate 438 (76.4%) 12 (2.1%) 450 (78.5%) 
Inappropriate 37 (6.5%) 86 (15%) 123 (21.5%) 
Total 475 (82.9%) 98 (17.1%) 573 
 
 
6.3 RESULTS 
 
 6.3.1. Identification of clinical cases eligible for STOPPFrail criteria  
  application 
Of the 12 independent raters, 9 raters identified all 18 cases that met STOPPFrail 
inclusion criteria. Two GPs identified 16 cases and one consultant geriatrician 
identified 17 cases as being eligible for the application of the STOPPFrail tool. No 
rater incorrectly identified the two cases which did not meet STOPPFrail eligibility 
criteria, as doing so. 
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 6.3.2 Time taken to deploy the criteria 
Geriatricians, GPs and Palliative Medicine physicians took an average of 2.33, 3.41 
and 2.7 minutes respectively to apply STOPPFrail criteria to each clinical case, a 
combined overall mean (± standard deviation) of 2.7 (0.94) minutes. During this time 
the physician read the clinical case in question and applied STOPPFrail accordingly. 
This time did not include the time taken for participants to read the instruction 
manual and familiarise themselves with the STOPPFrail tool.  
 
 6.3.3 Medications identified for deprescribing 
Of the 165 medications prescribed to 18 patients, the gold standard (GS) determined 
that 91 medications were potentially inappropriate according to STOPPFrail criteria 
and should be deprescribed. Table 6.1 displays the kappa statistics for each rater 
compared to the GS. Columns A, B, C and D indicate the status of agreement between 
raters and the GS. For example, rater 1 (GS) and rater 3 agreed that STOPPFrail 
criteria were not identified in 471 instances (column A). In 27 instances, rater 1 did 
not identify a STOPPFrail criterion but rater 3 did (column B). There were 20 instances 
where rater 3 identified a STOPPFrail criterion that rater 1 did not (column C). In 83 
instances, both rater 1 and rater 3 identified a STOPPFrail criterion (column D). The 
Fleiss kappa co-efficient between all 12 raters and the GS was 0.76 (SD 0.059). The 
Fleiss kappa co-efficient between the GS and geriatricians, GPs and palliative care 
physicians were 0.80 (SD0.6), 0.77 (SD0.9) and 0.75 (SD0.1) respectively, with no 
significant difference noted between groups or between participants within groups, 
as determined by one way ANOVA (df (2, 9) = 0.712, p=0.516).  
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Table 6.1: Level of agreement in numbers of STOPPFrail criteria applied and numbers of drugs recommended for deprescribing 
  
Rater Combination 
 
A 
 
B 
 
C 
 
D 
 
ppos 
 
pneg 
 
Kappa 
 
IP (n) 
 
Consultant Geriatricians vs 
GS 
Rater 1 * Rater 2 461    
438 
37      
37 
17      
12 
86     
86 
0.94 
0.95 
0.76 
0.78 
0.71                  
(*0.73) 
116 
 Rater 1 * Rater 3 471 27 20 83 0.95 0.78 0.73 102 
 Rater 1 * Rater 4 477 21 14 89 0.96 0.84 0.80 108 
Specialist registrars geriatric 
medicine vs GS 
Rater 1 * Rater 5 483 15 12 91 0.97 0.87 0.84 94 
 Rater 1 * Rater 6 486 12 10 93 0.98 0.89 0.87 96 
 Rater 1 * Rater 7 494 4 27 76 0.97 0.83 0.80 80 
GP Registrars vs GS Rater 1 * Rater 8 485 13 11 92 0.98 0.88 0.86 100 
 Rater 1 * Rater 9 484    
435 
14     
14 
41    
31 
62    
62 
0.95  
0.95 
0.69  
0.73 
0.64                   
(*0.69) 
84 
 Rater 1 * Rater 10 491    
442 
7        
7 
37    
27 
66    
66 
0.96      
0.96 
0.77  
0.80 
0.71                   
(*0.76) 
74 
Pall Care vs GS Rater 1 * Rater 11 488 10 30 73 0.96 0.79 0.75 77 
 Rater 1 * Rater 12 479 19 25 78 0.96 0.78 0.74 94 
 Rater 1 * Rater 13 490 8 30 73 0.96 0.79 0.76 77 
 Mean (SD)       0.76 (SD0.059)  
Legend: A = Both raters agreed criterion not fulfilled; B = Rater 1 scored criterion as being not fulfilled, rater 2 scored criterion as being fulfilled; C = Rater 1 score 
criterion as fulfilled, rater 2 scored criterion as not fulfilled; D = Both raters scored criterion fulfilled; ppos = proportion of positive agreement; pneg = proportion 
of negative agreement; IQR = interquartile range; *adjusted for cases not identified by raters as meeting the inclusion criteria for STOPPFrail. 
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 6.3.4  Variations between raters 
Total agreement between all raters and the GS was observed for 4 STOPPFrail 
criteria. Minor variations (defined as the identification or omission of up to 2 
STOPPFrail criteria by a rater other than the gold standard rater) were observed for 
16 STOPPFrail criteria. Major variations (defined as the identification or omission of 
≥3 STOPPFrail criteria by a rater other than the gold standard rater) were observed 
for 7 STOPPFrail criteria. These rater variations are detailed in Tables 6.2. The reasons 
for variations of each STOPPFrail observation according to each rater is shown in 
Table 6.3. The breakdown of variations between each rater and the GS and for each 
case is presented in Table 6.4. 
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Table 6.2: Criteria where total agreement, minor variations or most variations were 
noted 
Total Agreement (n=4) 
 
D2 
E3  
I4  
J3  
 
Memantine. 
Gastrointestinal antispasmodics. 
Systemic oestrogens for menopausal symptoms. 
Prophylactic Antibiotics. 
 
Minor Variations (n=16) 
(Defined as the identification or omission of up to 2 STOPPFrail criteria by a rater other than the 
gold standard rater) 
 
B1 
B2  
C1  
D1  
E2  
F1  
F2  
G3  
G4  
G5  
H1  
H2  
H3  
I2  
I3  
J2  
 
Lipid lowering therapies. 
Alpha-blockers for hypertension. 
Anti-platelets. 
Neuroleptic antipsychotics. 
H2 receptor antagonist. 
Theophylline. 
Leukotriene antagonists. 
Selective Estrogen Receptor Modulators [SERMs] for osteoporosis. 
Long-term oral NSAIDs. 
Long-term oral steroids. 
5-alpha reductase inhibitors. 
Alpha blockers. 
Muscarinic antagonists. 
ACE-Inhibitors for diabetes. 
Angiotensin Receptor Blockers. 
Nutritional supplements. 
 
Major Variations (n=7) 
(Defined as the identification or omission of ≥3 STOPPFrail criteria by a rater other than the gold 
standard rater) 
 
A1 
 
A2 
E1 
G1 
G2 
I1 
J1 
 
 
Any drug that the patient persistently fails to take or tolerate despite adequate 
education and consideration of all appropriate information. 
Any drug without clear clinical indication. 
Proton Pump Inhibitors. 
Calcium supplementation. 
Anti-resorptive/bone anabolic drugs for Osteoporosis. 
Diabetic oral agents. 
Multi-vitamin combination supplements. 
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Table 6.3: Reasons for major variations in identification of STOPPFrail indicators 
Major Variation (n=7) 
(Defined as the identification or omission of ≥3 STOPPFrail criteria by a rater other than the gold 
standard rater) 
STOPPFrail criterion Reasons for variations 
 
A1: Any drug that the patient persistently 
fails to take or tolerate despite adequate 
education and consideration of all 
appropriate information. 
 
A2: Any drug without clear clinical 
indication 
 
 
 
E1: Proton Pump Inhibitors (PPI) 
 
 
G1: Calcium supplementation 
 
 
G2: Anti-resorptive/bone anabolic drugs for 
Osteoporosis 
 
I1: Diabetic oral agents 
 
 
 
J1: Multi-vitamin combination supplements 
 
 
For 1 or more cases, 10 physicians overlooked that 
patients were having difficulty with medication 
adherence. 
 
Senior consultant geriatricians and those involved 
in caring for nursing home patients more 
frequently suggested discontinuation of warfarin, 
benzodiazepines and acetyl cholinesterase 
inhibitors due to the lack of an ongoing clear 
indication. 
This criterion suggests reducing high dose PPIs to a 
lower dose; 7 physicians suggested 
discontinuation of the lower dose. 
 
This criterion suggestion stopping calcium alone; 3 
physicians suggested discontinuation of vitamin D 
with calcium. 
This criterion suggests stopping anti-resorptive 
therapy in patients with osteoporosis; 6 physicians 
suggested discontinuation in patients with 
metastatic cancer. 
When ≥1 diabetic oral agent was prescribed, 
physicians differed in their approach to 
deprescribing; some suggested discontinuing one 
agent alone whereas others suggested 
discontinuation of all oral diabetic agents. 
Three physicians suggested discontinuing folic acid 
and vitamin b12 supplementation as part of this 
criterion. Other physicians either continued these 
medications or suggested discontinuing them as 
part of criterion A2 i.e. no clear indication. 
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Table 6.4: Frequency of STOPPFrail observations according to each rater 
Criterion  Raters (n)  
GS 2 3 4 5 6 7 8 9 10 11 12 13 
A1: Any drug the patient persistently fails to take/tolerate  11 11 6 6 10 11 2 9 9 2 5 4 5 
A2: Drugs with no clear indication 21 41 23 18 17 16 9 21 8 11 11 14 20 
B1: Lipid lowering therapies 13 14 13 14 14 14 13 14 12 12 14 14 14 
B2: Alpha blockers for HTN 2 2 2 2 2 2 2 2 2 2 1 2 1 
C1: Anti-platelets 1 3 0 1 1 1 1 0 0 1 1 1 1 
D1: Neuroleptics 2 1 2 2 2 2 2 1 2 1 0 0 0 
D2: Memantine 2 2 2 2 2 2 2 2 2 2 2 2 2 
E1: Proton pump inhibitors 4 8 5 7 4 5 4 9 7 5 5 8 4 
E2: H2 Receptor Antagonists 0 1 1 1 1 1 0 1 1 1 1 1 1 
E3: Gastrointestinal antispasmodics 0 0 0 0 0 0 0 0 0 0 0 0 0 
F1: Theophylline 1 1 1 1 1 1 1 1 1 1 0 1 0 
F2: Leukotriene antagonists 1 0 1 1 1 1 0 1 1 1 1 1 1 
G1: Calcium supplementation 6 6 9 6 12 11 6 6 6 5 6 6 6 
G2: Anti-resorptive/Bone anabolic drugs for Osteoporosis 2 2 4 4 3 3 0 1 2 1 3 1 3 
G3: SERMs for Osteoporosis 1 1 1 1 1 0 1 1 0 0 1 1 1 
G4: Long term oral NSAIDs 3 2 3 2 2 3 3 2 3 2 3 3 3 
G5: Long term oral steroids 1 0 1 1 1 1 1 1 0 0 0 0 0 
H1: 5 alpha reductase inhibitors 1 1 1 3 1 1 1 1 1 1 1 1 1 
H2: alpha blockers 3 3 3 5 3 2 3 3 3 3 3 3 3 
H3: Muscarinic antagonists 0 0 0 1 0 1 0 0 0 0 1 1 1 
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I1: Diabetic oral agents 5 4 4 6 5 5 5 5 5 3 2 8 2 
I2: Ace inhibitors for Diabetes Mellitus 0 1 0 0 0 0 0 0 0 0 0 0 0 
I3: Angiotensin receptor blockers [ARBs] for Diabetes Mellitus 1 0 1 1 1 0 0 2 0 1 0 1 0 
I4: Systemic oestrogens for menopausal symptoms 0 0 0 0 0 0 0 0 0 0 0 0 0 
J1: Multivitamin combination tablets 3 3 8 3 3 3 4 3 6 2 3 3 3 
J2: Nutritional Supplements 13 10 11 16 13 13 14 12 1 11 13 14 13 
J3: Prophylactic Antibiotics 5 5 5 5 5 5 5 5 5 5 5 5 5 
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 6.3.5  Criteria with major variations 
The criteria where most variations between raters were observed are listed in Table 
6.3. Differences in opinion regarding drug indication was identified for warfarin, 
benzodiazepines and acetyl cholinesterase inhibitors. Two Consultant Geriatricians 
and one GP with experience in attending patients in residential care units were more 
likely to identify these prescriptions as being potentially inappropriate. Ten raters did 
not observe that patients were having difficulty with medication adherence for all 
cases. Seven raters identified the lower dose of a proton pump inhibitor (PPI) as being 
inappropriate as part of criterion E1; this criterion suggests reducing the higher dose 
to a lower dose. Three raters suggested Vitamin D was inappropriate as part of 
criterion G1. However, this criterion suggests stopping calcium alone i.e. it does not 
mention Vitamin D. When three diabetic oral agents were prescribed, raters’ opinion 
on appropriateness varied. Raters either identified that one agent alone was 
inappropriate and suggested that deprescribing should occur in a staggered fashion 
i.e. one agent at a time. Others identified all diabetic oral agents as inappropriate and 
suggested that they could, in theory, be deprescribed all at the one time. For 3 raters, 
folic acid and vitamin b12 supplementation were identified as inappropriate as part 
of STOPPFrail criterion J1 (combination multivitamins) criterion. Other raters either 
deemed these drugs appropriate and suggested continuation or else deemed them 
inappropriate as part of criterion A2 i.e. prescription of a medication without a clear 
indication.  
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6.4 DISCUSSION 
The Inter-rater reliability of STOPPFrail criteria is substantial to good (mean 0.76 (SD 
0.059)), when tested between multiple physicians practising across three different 
specialities, despite physicians having no prior knowledge of the tool or experience 
of using it. It takes approximately 3 minutes to apply STOPPFrail criteria to one clinical 
case. No discrepancies in its application were identified for 4 STOPPFrail criteria. 
Minor variations were identified for 16 criteria and major variations were identified 
for 7 criteria. There was no difference between the three different physician groups, 
or between the participants within each group, in their ability to apply STOPPFrail 
criteria (df (2, 9) = 0.712, p=0.516). 
 The strength of this study is the robust methodology employed. Three groups 
of physicians, all of whom had no experience in using IP criteria and who were given 
the same clear instructions, participated in this research. The clinical cases used were 
based on real patients and therefore reflected common clinical practice. However, 
there were limitations. Firstly, this was a theoretical exercise i.e. physicians assessed 
the suitability of STOPPFrail criteria according to a clinical case history presented to 
them in a structured format and identified IP accordingly. Assessments were not 
completed on patients in person and medications were not actually deprescribed. It 
could be suggested that physicians are more conservative when dealing with real life 
patients rather than theoretical cases. However, it could be also be suggested that 
the IRR could be under-estimated here. Where there is perceived ambiguity in the 
information provided and patients are not there to clarify information, physicians 
could also assume medications are appropriate.  
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 Efficient and safe deprescribing depends on the quality of the available 
clinical data. The more comprehensive the clinical information, the more accurate IP 
criteria can be applied leading to higher levels of IRR (243). However, ambiguity is 
often present in clinical practice due to incomplete records (244, 245), and 
consequently, physicians often make decisions based on limited information. 
Therefore, these cases, in this theoretical exercise, do reflect common clinical 
scenarios.  
 Major variations, found in 7 STOPPFrail criteria, were as a result of (i) 
differences in physician opinion regarding clinical indications, (ii) criteria mis-
interpretation and (iii) failure to acknowledge problems with medication adherence. 
Differing opinions on clinical indication for medications could be as a consequence of 
physician specialty and/or physician level of training e.g. Consultant Geriatricians 
deemed acetyl-cholinesterase inhibitors inappropriate in late stage dementia more 
frequently than their trainee geriatricians or GP colleagues. Mis-interpretation of 
criteria was identified for the prescription of Vitamin D and low dose PPIs. The 
identification of both these prescriptions as inappropriate was not necessarily 
incorrect, however for the purpose of this exercise, they were deemed incorrect as 
they were not specifically listed as PIP in STOPPFrail criteria. STOPPFrail criteria was 
developed and validated to guide physicians on deprescribing, as well as open 
dialogue around the appropriateness of all medications and in doing so encourage 
medication review in its entirety, thus these variations seen here cannot be assumed 
to be inappropriate.  
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 Despite clear documentation of medication adherence in the clinical cases, 
physicians did not observe this every time. This was probably the result of a reading 
error and once not identified in one case, was unlikely to be identified in other cases. 
This is a challenge with a theoretical exercise as participants rely on their ability to 
assess the clinical information as it is presented to them, rather than confirming 
medications and adherence with a patient directly. This could also be explained by 
user fatigue as the exercise progressed and the process became repetitive.   
 Physicians are frequently under time pressure where completing medication 
reviews and using criteria like STOPPFrail can encourage identification of medications 
that can potentially be deprescribed in a time-efficient structured fashion. Explicit 
criteria that require time to deploy often do not translate to clinical practice and 
inevitably are used primarily as research tools (19). STOPPFrail criteria has shown 
itself here to, not only assist physicians with identifying inappropriate medications in 
frailer older adults with a poor survival prognosis, but to also do this in a time efficient 
manner, which suggests it will translate across to clinical practise, where it hopefully, 
will have impact. 
 Deprescribing requires a culture change for many physicians, particularly 
physicians wherein contact with frail older adults with a poor one year survival 
prognosis comprises a small part of their everyday clinical practice. Deprescribing 
requires extensive knowledge around disease trajectory, pharmacological actions of 
medications and the likely risks involved with their use. Deprescribing in patients with 
a poor survival prognosis is more challenging than deprescribing specific drugs for 
specific reasons in older adults as this process can often initiate a more extensive 
244 
 
discussion around end of life care. Future studies, using STOPPFrail criteria, will be 
needed to ascertain the extent of PIP in this population cohort. The substantial to 
good IRR demonstrated in this study, indicates that prevalence studies of PIP, 
according to STOPPFrail criteria, will be comparable between researchers and across 
research centres. Following this, randomised controlled trials can be planned to 
assess whether deprescribing in this population can affect patient outcomes and 
provide the evidence required to support physicians undertaking deprescribing. Our 
data suggests that STOPPFrail provides reliable explicit guidance for any clinician 
undertaking routine medication review in frailer older patients with poor one year 
survival prognosis. 
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CHAPTER 7: 
Prevalence of potentially inappropriate prescribing as determined by 
STOPPFrail criteria in a representative population of older patients 
undergoing assessment for long term nursing home placement and of older 
adults presenting with acute illness to hospital.  
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7.1  INTRODUCTION 
STOPPFrail criteria were devised to highlight instances of potentially inappropriate 
prescribing practices in frail older adults with a poor one year survival prognosis. 
Their content was validated by Delphi consensus methodology, in which 17 senior 
academic clinicians participated (240). As demonstrated in Chapter 6, the inter-rater 
reliability (IRR) of STOPPFrail criteria was good when deployed by physicians 
practising in different specialties (246).  
 The prevalence of potentially inappropriate prescribing in older frail adults 
with a poor survival prognosis is unknown. One population of older adults with such 
functional impairment are those who require long term nursing home admission. 
Such patients are often very frail (16), with multiple co-morbidities (17), carry a high 
burden of medication (195) and often have a very poor survival prognosis (247).  
 In Ireland, the Health Service Executive (HSE) operates the Nursing Home 
Support Scheme (NHSS) to provide assessment and subsequently financial support 
to older adults requiring long term nursing home care. Prior to nursing home 
application, a care needs assessment must be performed by appropriate healthcare 
professionals. Through this assessment, applicants’ medical, functional and cognitive 
status details are established. The completion of this comprehensive report is 
overseen by a consultant in Geriatric Medicine or Old Age Psychiatry, who provides 
a detailed clinical assessment and confirms that long term nursing care is required 
for the person. This application document contains a large amount of relevant clinical 
information on frail older adults suitable for long term care. For this reason, it was 
deemed a reliable source of relevant information on this population of older people. 
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 In Ireland, older frailer people with a poor one year survival prognosis are 
commonly referred to hospital with acute illness. As pointed out previously, these 
patients are commonly exposed to major polypharmacy as a result of multi-morbid 
illness. The extent to which such patients are exposed to medications that are likely 
not appropriate for them is unknown. 
 
 7.1.1 Objectives 
The objectives of this study were: 
(i) To determine the proportion of older adults requiring long-term nursing 
care eligible for the application of STOPPFrail criteria. 
(ii) To determine the prevalence of potentially inappropriate prescribing 
using STOPPFrail criteria, and the risk factors for prescription of 
STOPPFrail medications. 
(iii) To determine the proportion of older adults presenting to hospital with 
an acute illness to hospital (see Chapter 3) who are eligible for the 
application of STOPPFrail criteria. 
(iv) To determine the prevalence of potentially inappropriate prescribing 
using STOPPFrail criteria in this acutely ill hospitalised cohort. 
 
The work undertaken in this chapter, including study design, data collection and 
statistical analysis, is entirely my own. 
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7.2  METHODS 
 7.2.1 Study population  
Using an estimated prevalence of ≥ 1 potentially inappropriate medication of 20%, a 
margin of error of 5% and a 95% level of confidence, a minimum sample of 246 
patients was required for this study (Figure 7.1). 
Figure 7.1: Same size calculation 
 
Formula 
n = Z2 x P (1 – P) 
D2 
n = sample size 
Z = Z statistic for the level of confidence (1.96) 
P = Expected prevalence (20% or 0.20) 
D = margin of error (5% or 0.05)  
 
n = (1.96)2 x (0.20) (1 – 0.2) = 246 
0.052 
 
 
 7.2.2 Cork City and County Local Placement Forum and the Common  
  Summary Assessment Report 
All patients applying for nursing home or long-term residential placement through 
the Irish Nursing Home Support Scheme (248) must undergo a comprehensive 
multidisciplinary assessment of their illnesses, ADL function, cognition and personal 
care needs. The results of this assessment are presented in the form of a Common 
Summary Assessment Report (CSAR) (appendix 14) which is reviewed and discussed 
by a multidisciplinary panel each fortnight.  
 The CSAR contains details on patients’ co-morbid illnesses, concurrent 
medications and doses, Barthel Index (157) score and cognitive status using either a 
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Mini-mental state examination (MMSE) (158) or the Montreal cognitive assessment 
(MoCA) (162). The Barthel Index and the MMSE have been described in detail in 
Chapter 3. The MoCA is a 30-point cognitive assessment tool, which has been 
validated in patients with mild cognitive impairment and dementia (Appendix 15). It 
assesses several cognitive domains including short-term memory, visuospatial 
abilities, executive function, language, attention, concentration, abstract thinking 
and orientation. 
 
 7.2.3 Study period 
All CSARs submitted as part of the applications for long term nursing home or 
residential facility care to the Cork Nursing Home Support Scheme office, between 
Jan 1st and June 30th 2016, were retrospectively reviewed. The local Clinical Research 
Ethics Committee approved the study protocol (appendix 16). 
 
 7.2.4 Data Collection 
The following data were transferred from the CSARs onto an excel spreadsheet: (i) 
standard demographic details, (ii) medical diagnoses, (iii) concurrent medications 
and doses, (iv) functional ability (Barthel Index score) (157), (vi) cognitive ability 
(MMSE (158) or MOCA score (162), and (vii) frailty using the Rockwood clinical frailty 
scale category (163). Where available, supplementary clinical information was 
obtained from case records. 
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 Recorded medications were those prescribed at the time of nursing home 
application. Short term medications documented on the CSAR were excluded from 
evaluation e.g. heparinoids for deep vein thrombosis prophylaxis. Co-morbidities 
were quantified according to the Cumulative Illness Rating Scale (CIRS) (156). Details 
of both the Clinical Frailty Scale and CIRS have been described in Chapter 3. 
 
 7.2.5 Determination of potentially inappropriate prescribing practices  
  using STOPPFrail criteria 
STOPPFrail criteria for potentially inappropriate prescriptions were applied to 
patients who meet STOPPFrail eligibility criteria i.e. the presence of an end-stage 
irreversible pathology, a poor one year survival prognosis, severe cognitive or 
functional impairment or both and patients in whom symptom management was the 
overriding priority, as opposed to long-term prevention.  
 The presence or absence of a potentially inappropriate medication (PIM) was 
categorised as a dichotomous variable i.e. a medication was either potentially 
inappropriate according to STOPPFrail criteria or not.  Some prescriptions could 
pertain to 1 or more STOPPFrail criteria (e.g. a drug may have no clear indication and 
also be listed elsewhere in the criteria as being inappropriate) but for the purpose of 
this study the identification of one drug was categorised as being inappropriate, 
regardless of whether or not it fulfilled one or more STOPPFrail criteria i.e. the 
potentially inappropriate drug was the unit of measurement, not the numbers of 
STOPPFrail criteria it breached. Uncertainty regarding the appropriateness of a 
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prescription was treated conservatively i.e. the prescribing decision was deemed to 
be appropriate in such circumstances. 
 
 7.2.6 Statistical analysis 
Statistical analysis was performed using SPSS© version 22. Descriptive data were 
reported using the mean and standard deviation (SD) for variables normally 
distributed and median and interquartile range (IQR) for non-parametric variables.  
Differences in the distribution of categorical variables were compared using the 
Pearson Chi-square (Χ2) test and continuous variables using the independent t-test. 
The Mann Whitney U and Kruskal-Wallis tests were used to determine independence 
of two or more non-parametric variables respectively. Multivariable logistic 
regression was used to examine the influence of gender, age, presence of dementia, 
the number of medical conditions and the number of medications on the presence 
of potentially inappropriate prescribing practices. The Hosmer & Lemeshow statistic 
was used to test the goodness-of-fit of the regression model. A probability value of < 
0.05 was considered statistically significant. 
 
 
 
 
 
252 
 
7.3. RESULTS 
7.3.1 Screening 
Four hundred and sixty four CSARs were retrospectively reviewed, of which 38 were 
excluded due to incomplete information (Figure 7.2). Two hundred and seventy four 
patients (59.1%) met STOPPFrail eligibility criteria, thus comfortably fulfilling the 
study power calculation requirement to evaluate at least 246 patients. All patients, 
those that met STOPPFrail eligibility criteria and those that did not, were evaluated 
in this study. 
Figure 7.2: Participant screening, exclusion and enrolment 
 
STOPPFrail eligibility criteria: 
End-stage irreversible 
pathology. 
 
Poor one year survival 
prognosis. 
 
Severe functional impairment 
or severe cognitive 
impairment or both. 
 
Symptom control is the 
priority rather than 
prevention of disease 
progression. 
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 7.3.2 Population characteristics (n = 426) 
Fifty five percent (n=233) of the 426 study patients were female (Table 7.1). The 
median (IQR) age was 83 (77.2 – 88) years, with an overall range of 40 to 99 years. 
Thirty three patients (7.7%) were < 65 years old. Approximately two thirds of patients 
(64.1%) requiring long term care resided in hospital at the time of nursing home 
application; 15.7% were already in emergency nursing home accommodation. The 
remainder of patients were at home (19.7%), in hospice care (0.2%) or in temporary 
hostel accommodation (0.2%). 
 
 7.3.3 Characteristics of patients who were eligible for the application of 
  STOPPFrail criteria 
Differences between older adults that met STOPPFrail eligibility criteria and those 
that did not are displayed in Table 7.1.Two hundred and eighty four (66.7%) of adults 
had a MMSE score available, whereas 58 (13.6%) adults had a MOCA score only. 
Older adults who met STOPPFrail eligibility criteria were older (83.5 (IQR78.75 – 88) 
vs 80 (70.25 – 86) years, U = 15940, p<0.001), had lower mean MMSE scores (14.6 
(SD7) vs 21 (5.6) t248.48 =7.47, p<0.001) and had lower mean Barthel Index scores (7.6 
(SD4.3) vs 12 (3.9) t341.281 =10.86, p=0.03) compared to older patients who did not 
meet STOPPFrail criteria. 
 Older adults meeting STOPPFrail eligibility criteria had a higher level of frailty 
on the Rockwood Clinical Frailty Scale (Χ2 (7) ≥93.616 p=<0.001) (Figure 7.3) than 
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those who did not. Older adults meeting STOPPFrail eligibility criteria more likely to 
be severely frail (68.2% vs 55.3%, Χ2 (1) ≥7.122 p=0.008) or very severely frail (26.3% 
vs 5.3%, Χ2 (1) ≥ 28.305 p ≤0.001) compared to patients who did not meet STOPPFrail 
eligibility criteria. 
Table 7.1: Characteristics of study population  
Variable Eligible for 
application for 
STOPPFrail 
n = 274 
Not eligible for 
application of 
STOPPFrail 
n = 152 
Total  
 
 
n = 426 
P-value 
Female gender 155 (56.6%) 78 (51.3%) 233 (54.7%) 0.297 
 
Age distribution 
    
Median (IQR) 83.50 (78.75-
88) 
80 (70.25-86) 83 (77.25-
88) 
<0.001* 
≤ 64  0 (0%) 33 (21.7%) 33 (7.7%) <0.001* 
65 – 74 37 (13.5%) 11 (7.2%) 48 (11.3%) 0.050* 
75 – 84 109 (39.8%) 60 (39.5%) 169 (39.7%) 0.950 
85 - 94 118 (43.1%) 44 (28.9%) 162 (38%) 0.004* 
≥ 95 10 (3.6%) 4 (2.6%) 14 (3.3%) 0.572 
 
Cognition  
    
Patients completed MMSE (n) 181 (66.1%) 103 (67.8%) 284 (66.7%) 0.721 
Mean (SD) 14.6 (7) 21 (5.6) 16.6 (7) <0.001* 
Normal cognition (24–30) 16 (8.8%) 25 (24.3%) 44 (14.4%) <0.001* 
Mild CI (19–23) 34 (18.8%) 43 (41.7%) 77 (27.1%) <0.001* 
Moderate CI (10-18) 92 (50.8%) 32 (31.1%) 124 (43.7%) 0.001* 
Severe CI (0 – 9) 39 (21.5%) 3 (2.9%) 42 (14.8%) <0.001* 
 
Function (Barthel Index) 
    
Mean (SD) 7.6 (4.3) 12 (3.9) 9.2 (4.7) 0.03* 
Independent (≥ 20) 0 (0%) 4 (2.6%) 4 (0.9%) 0.007* 
Low dependency (16– 19) 9 (3.3%) 27 (17.8%) 36 (8.5%) <0.001* 
Moderate dependency (11 – 
15) 
61 (22.3%) 70 (46.1%) 131 (30.8%) <0.001* 
High dependency (6 – 10) 110 (40.1%) 43 (28.3%) 153 (35.9%) 0.015* 
Maximum dependency (0 – 5) 94 (34.3%) 8 (5.3%) 102 (23.9%) <0.001* 
Legend: IQR = inter-quartile range, MMSE = mini-mental state examination, CI = cognitive 
impairment, SD = standard deviation, p-value pertains to the probability of there being a 
difference between groups in the variable of interest. 
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Figure 7.3: Level of frailty according to STOPPFrail eligibility criteria (n=274) 
 
 
 
 7.3.4 Level of morbidity 
Patients had an average of 7.3 (SD 2.6) conditions, with 3.8 (SD 1.9) illnesses requiring 
regular medications. The prevalence of conditions, in order of frequency, is 
presented in Table 7.2. Patients meeting STOPPFrail eligibility criteria were more 
likely to have a diagnosis of dementia (73.4% vs 42.8%, Χ2 (1) ≥ 9.02, p <0.001), faecal 
incontinence (55.8% vs 30.9%, Χ2 (1) ≥ 24.736, p <0.001), urinary incontinence (81% 
vs 54.6%, Χ2 (1) ≥ 34.385, p <0.001) and osteoporosis (25.2% vs 15.1%, Χ2 (1) ≥ 5.833, 
p <0.016), as well as a higher burden of co-morbid illness, (CIRS scores 13.6 (SD4.4) 
vs 10.9 (SD3.8), t(424) = 6.386, p <0.001) (Figure 7.4) than patients who did not meet 
STOPPFrail eligibility criteria. Anxiety was more prevalent in those ineligible for 
STOPPFrail criteria (11.2% vs 2.9%, Χ2 (1) ≥ 12.088, p <0.001). 
0.0% 10.0% 20.0% 30.0% 40.0% 50.0% 60.0% 70.0% 80.0%
1 (very fit)
2 (well)
3 (managing well)
4 (vulnerable)
5 (mildly frail)
6 (moderately Frail)
7 (severely frail)
8 (very severely frail)
9 (terminally ill)
Eligible for application for STOPPFrail Not eligible for application of STOPPFrail
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Table 7.2: Comparison of patients eligible for STOPPFrail criteria and patients not 
eligible for STOPPFrail criteria in terms of morbidity specific details 
Variable Eligible for 
application of 
STOPPFrail  
n = 274 
Not eligible for 
application of 
STOPPFrail 
n = 152 
Total 
 
 
n = 426 
P-value 
 
Conditions     
Mean (SD) 7.3 (2.6) 6.4 (2.5) 7 (2.6) <0.001* 
 
Conditions requiring regular 
medications 
    
Mean (SD) 4 (2) 3.8 (1.9) 3.9 (2) 0.172 
 
Co-morbid Index (CIRS)     
Mean (SD) 13.6 (4.4) 10.9 (3.8) 12.7 (4.4) <0.001* 
 
Conditions     
Urinary Incontinence 222 (81%) 83 (54.6%) 305 (71.6%) <0.001* 
Faecal Incontinence 153 (55.8%) 47 (30.9%) 200 (46.9%) <0.001* 
Dementia 201 (73.4%) 65 (42.8%) 266 (62.4%) <0.001* 
Hypertension 134 (48.9%) 62 (40.8%) 196 (46%) 0.107 
Constipation 122 (44.5%) 54 (35.5%) 176 (41.3%) 0.071 
Depression 94 (34.3%) 59 (38.8%) 153 (35.9%) 0.353 
Dyslipidaemia 70 (25.5%) 42 (27.6%) 112 (26.3%) 0.640 
Falls 70 (25.5%) 41 (27%) 111 (26.1%) 0.748 
Atrial Fibrillation 64 (23.4%) 36 (23.7%) 100 (23.5%) 0.939 
Osteoporosis 69 (25.2%) 23 (15.1%) 92 (21.6%) 0.016* 
Cancer 60 (21.9%) 25 (16.4%) 85 (20%) 0.178 
Osteoarthritis 52 (19%) 30 (19.7%) 82 (19.2%) 0.849 
Stroke 51 (18.6%) 24 (15.8%) 75 (17.6%) 0.464 
Ischaemic Heart Disease 51 (18.6%) 22 (14.5%) 73 (17.1%) 0.227 
Diabetes Mellitus 42 (15.3%) 29 (19.1%) 71 (16.7%) 0.320 
Previous fracture 47 (17.2%) 19 (12.5%) 66 (15.5%) 0.204 
Hypothyroidism 34 (12.4%) 25 (16.4%) 59 (13.8%) 0.248 
COPD 34 (12.4%) 15 (9.9%) 49 (11.5%) 0.431 
Heart Failure 33 (12%) 11 (7.2%) 44 (10.3%) 0.118 
Chronic kidney disease 23 (8.4%) 15 (9.9%) 38 (8.9%) 0.609 
Benign prostatic hypertrophy 29 (10.6%) 9 (5.9%) 38 (8.9%) 0.106 
Epilepsy 23 (8.4%) 12 (7.9%) 35 (8.2%) 0.857 
Neck of femur fracture 23 (8.4%) 8 (5.3%) 31 (7.3%) 0.233 
Anaemia 22 (8%) 6 (3.9%) 28 (6.6%) 0.103 
Recurrent UTIS 18 (6.6%) 8 (5.3%) 28 (6.6%) 0.997 
Alcohol dependency 14 (5.1%) 13 (8.6%) 27 (6.3%) 0.162 
GORD 13 (4.7%) 12 (7.9%) 25 (5.9%) 0.185 
Anxiety 8 (2.9%) 17 (11.2%) 25 (5.9%) 0.001* 
Glaucoma 17 (6.2%) 6 (3.9%) 23 (5.4%) 0.323 
Parkinson’s Disease 14 (5.1%) 6 (3.9%) 20 (4.7%) 0.587 
Legend: CIRS = Cumulative illness rating scale, SD = standard deviation, COPD = chronic 
pulmonary obstructive disease, UTI = urinary tract infection, p-value pertains to the probability 
of there being a difference between groups in the variable of interest. 
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Figure 7.4: CIRS score according to STOPPFrail eligibility criteria 
 
 
 7.3.5 Prescription medications 
A total of 3765 medications were prescribed to this cohort of 426 patients; 2512 
medications (66.8%) to those eligible for application of STOPPFrail criteria and 1253 
medications (33.2%) to all others. Polypharmacy (≥ 6 medications) and high level 
polypharmacy (≥ 11 medications) were observed in 294 (69%) and 98 (23%) patients 
respectively, with no significant difference noted between groups, (67.1% vs 69%, Χ2 
(1) ≥ 1.425, p = 0.233) and (24.8% vs 19.7%, Χ2 (1) ≥ 0.403, p = 0.526) respectively. 
There was no significant difference in the mean number of medications prescribed 
to those that were eligible for application of STOPPFrail criteria and those that were 
not, a mean of 8.0 (SD 4) vs 7.5 (SD 3.7), t(424) = 1.334, p = 0.183 (Figure 7.5). 
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Table 7.3: Number of prescription medications in 426 patients applying for nursing 
home care 
Variable Eligible for 
application of 
STOPPFrail  
n = 274 
Not eligible for 
application of 
STOPPFrail 
n = 152 
Total 
n = 426 
P-value 
 
 
Medications (regular) 
    
Mean (SD) 8 (4) 7.5 (3.7) 7.8 (3.9) 0.183 
range 0 - 21 0 - 19 0 - 21  
 
Number of patients on 
at least 1 medication 
268 (97.8%) 149 (98%) 417 
(97.9%) 
0.882 
1 – 5 medications 76 (27.7%) 47 (30.9%) 123 
(28.9%) 
0.487 
6 – 10 medications 124 (45.3%) 72 (47.4%) 196 (46%) 0.675 
≥ 11 medications 68 (24.8%) 30 (19.7%) 98 (23%) 0.233 
≥ 6 medications 
 
102 (67.1%) 294 (69%) 294 (69%) 0.526 
Legend: IQR = inter quartile range, p-value pertains to the probability of there being 
a difference between groups in the variable of interest 
 
 
 
Figure 7.5: Numbers of medications according to eligibility for STOPPFrail criteria 
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There was no significant difference between the numbers of medications prescribed 
to those aged ≤ 74 years, those between 75 and 44 years, 75 and those ≥ 85 years (Χ2 
(4) ≥ 5.932, p = 0.204) (Table 7.4). The numbers of prescribed medications increased 
significantly with the number of conditions increasing from ≤ 5 to 6 – 10 but this was 
not the case when the number of conditions increased to ≥ 11 (Χ2 (4) ≥ 102.692, p 
<0.001). 
 
Table 7.4: Number of prescription medications and numbers of co-morbid illnesses 
according to age group 
Variable Number of medications Total 
426 
P-
value 0 - 5 6 - 10 ≥ 11 
 
Age 
     
0.204 
≤ 74 23 (28.4%) 37 (45.7%) 21 (25.9%) 81 (19%)  
75 – 84  45 (26.6%) 79 (46.7%) 45 (26.6%) 169 (39.7%)  
≥ 85 64 (36.4%) 80 (45.4%) 32 (18.2%) 176 (41.3%)  
 
Conditions 
     
<0.001 
0 – 5 75 (56.8%) 46 (23.5%) 5 (5.1%) 126 (29.6%)  
6 – 10 56 (42.4%) 41 (71.9%) 73 (74.5%) 270 (63.4%)  
≥ 11 1 (0.8%) 9 (4.6%) 20 (20.4%) 30 (7%)  
      
Legend: p-value pertains to the probability of there being a difference between 
groups in the variable of interest 
  
 7.3.6 General prescribing trends 
Medication classes prescribed to this cohort are shown in Table 7.5.  
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Table 7.5: Common prescriptions 
Variable Eligible for 
application 
of STOPPFrail  
n = 274 
Not eligible for 
application of 
STOPPFrail 
n = 152 
Total 
n = 426 
P-value 
 
 
Medication 
    
Anti-hypertensives 172 (62.8%) 86 (56.5%) 258 (60.6%) 0.210 
Beta blocker 
Diuretic (loop) 
ACE inhibitor 
Calcium channel 
blocker 
ARBs 
Alpha blockers 
92 (33.6%) 
61 (22.3%) 
38 (13.9%) 
34 (12.4%) 
27 (9.9%) 
23 (8.4%) 
41 (27%) 
26 (17.1%) 
21 (13.8%) 
22 (14.5%) 
11 (7.2%) 
10 (6.6%) 
133 (31.2%) 
87 (20.4%) 
59 (13.8%) 
56 (13.1%) 
38 (8.9%) 
33 (7.7%) 
0.159 
0.206 
0.988 
0.546 
0.364 
0.502 
Aldosterone 
antagonists 
16 (5.8%) 2 (1.3%) 18 (4.2%) 0.026* 
 
Analgesia 
 
134 (48.9%) 
 
70 (46.1%) 
 
204 (47.9%) 
 
0.572 
Paracetamol 
Local anaesthetic 
Opioids (strong) 
Neuropathic agent 
Opioids (weak) 
NSAIDs (oral) 
       NSAIDs (topical) 
110 (40.1%) 
37 (13.5%) 
30 (10.2%) 
19 (6.9%) 
14 (5.1%) 
5 (1.8%) 
5 (1.8%) 
53 (34.9%) 
13 (8.6%) 
20 (13.2%) 
13 (8.6%) 
8 (5.3%) 
2 (1.3%) 
1 (0.7%) 
163 (38.2%) 
50 (11.7%) 
50 (11.7%) 
32 (7.5%) 
22 (5.2%) 
7 (1.6%) 
6 (7%) 
0.283 
0.128 
0.497 
0.544 
0.945 
0.692 
0.328 
 
Proton pump inhibitors 138 (50.4%) 66 (43.4%) 204 (47.9%) 0.169 
     
Laxatives 
Osmotic 
Stimulant 
Enema 
Bulk-forming 
130 (47.7%) 
110 (40.1%) 
71 (25.9%) 
1 (0.4%) 
1 (0.4%) 
51 (33.6%) 
47 (30.9%) 
27 (17.8%) 
2 (1.3%) 
0 (0%) 
181 (42.5%) 
157 (36.9%) 
98 (23%) 
3 (0.7%) 
1 (0.2%) 
0.005* 
0.059 
0.056 
0.261 
0.456 
     
Anti-platelet agents 100 (36.5%) 42 (27.6%) 142 (33.3%) 0.063 
     
Neuroleptics 
 
82 (29.9%) 48 (31.6%) 130 (30.5%) 0.723 
Legend: ACE = angiotensin converting enzyme, ARB = angiotensin receptor 
blocker, NSAID = non-steroidal anti-inflammatory, p-value pertains to the 
probability of there being a difference between groups in the variable of interest 
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Table 7.5: Common prescriptions continued 
Variable Eligible for 
application of 
STOPPFrail  
n = 274 
Not eligible 
for application 
of STOPPFrail 
n = 152 
Total 
n = 426 
P-
value 
 
 
Anti-depressants 
SSRIs 
NASSa 
TCAs 
       SNRIs 
 
76 (27.7%) 
62 (22.6%) 
33 (12%) 
14 (5.1%) 
1 (0.4%) 
 
53 (34.9%) 
39 (25.7%) 
20 (13.2%) 
15 (9.9%) 
1 (0.7%) 
 
129 (30.3%) 
101 (23.7%) 
53 (12.4%) 
29 (6.8%) 
2 (0.5%) 
 
0.125 
0.481 
0.739 
0.062 
0.672 
     
Vitamin D 
supplements 
88 (32.1%) 40 (26.3%) 128 (30%) 0.211 
Calcium 
supplements 
65 (23.7%) 33 (21.7%) 98 (23%) 0.636 
     
Statin 79 (28.8%) 42 (27.6%) 121 (28.4%) 0.792 
     
Anti-dementia drugs 
- Memantine 
- AChEi 
90 (32.8%) 
60 (21.9%) 
52 (19%) 
29 (19.1%) 
17 (11.2%) 
16 (10.5%) 
119 (27.6%) 
77 (18.1%) 
68 (16%) 
0.002* 
0.006* 
0.023* 
     
Nutritional 
supplements 
72 (26.3%) 26 (17.1%) 98 (23%) 0.029* 
     
Benzodiazepines 62 (22.6%) 33 (21.7%) 95 (22.3%) 0.828 
     
Anticoagulants 
- Warfarin 
- DOACs 
41 (15%) 
14 (5.1%) 
27 (9.9%) 
35 (23%) 
6 (3.9%) 
29 (19.1%) 
76 (17.8%) 
20 (4.7%) 
56 (13.1%) 
0.037* 
0.597 
0.007* 
     
Thyroxine 32 (11.7%) 23 (15.1%) 55 (12.9%) 0.309 
     
Z-drug 32 (11.7%) 16 (10.5%) 48 (11.3%) 0.719 
     
Anti-epileptic drugs 32 (11.7%) 14 (9.2%) 46 (10.6%) 0.432 
     
Folic acid  28 (10.2%) 14 (9.2%) 42 (9.9%) 0.738 
Vitamin B1 26 (9.5%) 0 (0%) 42 (9.9%) 0.731 
Legend: SSRI = selective serotonin re-uptake inhibitors, NASSa = nor adrenergic and specific 
serotonergic anti-depressant, TCAs = tricyclic anti-depressants, SNRI = Serotonin-
norepinephrine reuptake inhibitors, AChEi = acetyl cholinesterase inhibitors, DOAC = Direct 
oral anti-coagulants, p-value pertains to the probability of there being a difference 
between groups in the variable of interest 
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The three most commonly prescribed medications were: (i) proton pump inhibitors 
(47.9%), (ii) paracetamol (38.2%) and (iii) osmotic laxatives (36.9%). Opioids were 
prescribed to 17.2% of patients, 30.5% were prescribed neuroleptics, 30.3% were 
prescribed antidepressants and 11.3% of patients were prescribed Z drug hypnotics.  
Patients meeting STOPPFrail eligible criteria were more likely to be prescribed 
aldosterone antagonists (5.8% vs 1.3%), Χ2 (1) ≥ 4.944, p = 0.026), laxatives (40.1% vs 
30.9%, Χ2 (1) ≥ 7.722, p = 0.005) and nutritional supplements (26.3% vs 17.1%, Χ2 (1) 
≥ 4.789, p = 0.029). Consistent with a higher prevalence of dementia in these 
patients, they were also more likely to be prescribed acetyl cholinesterase inhibitors 
(21.9% vs 11.2%, Χ2 (1) ≥ 5.206, p = 0.023) and memantine (19.0% vs. 10.5%, Χ2 (1) ≥ 
7.578, p=0.006). In contrast, anti-coagulants were less frequently prescribed to these 
STOPPFrail eligible patients (15% vs 23%, Χ2 (1) ≥ 7.287, p = 0.037). 
 
7.3.7 Life limiting diagnoses of older adults meeting STOPPFrail eligibility 
criteria 
STOPPFrail eligibility criteria requires a patient to have end-stage irreversible 
pathology with an associated poor one year life expectancy e.g. advanced dementia 
with recurrent infections. Life-limiting conditions for those meeting STOPPFrail 
eligibility criteria are displayed in Figure 7.6. One in two patients (51%) had a 
diagnosis of advanced dementia with major cognitive and functional impairment, a 
further 19% had advanced dementia with another life-limiting diagnosis. Those who 
had dementia as a life-limiting illness were either experiencing recurrent infections 
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or maximum dependency with significant dysphasia. Those classified as “others” 
included end-stage liver disease, multi-system atrophy, motor neuron disease, 
multiple sclerosis and severe peripheral vascular disease. 
Figure 7.6: Life limiting diagnoses in those eligible for STOPPFrail criteria (n = 274) 
 
 
7.3.8 Potentially inappropriate Medication (PIM) use as determined by 
STOPPFrail criteria 
Applying STOPPFrail criteria, 828 of 2512 (33.0%) medicines were potentially 
inappropriate. These were identified in 250 of 274 patients (91.2%) who were eligible 
for STOPPFrail criteria. One PIM was identified in 38 patients (13.9%), 2 PIMs in 55 
patients (20.1%), 3 PIMs in 48 patients (17.5%), 4 PIMs in 50 patients (18.2%), 5 PIMs 
in 34 patients (12.4%), 6 PIMs in 17 patients (6.2%), 7 PIMs in 4 patients (1.5%), 8 
PIMs in 2 patients (0.7%), 10 PIMs in 1 patient (0.4%) and 11 PIMs in 1 patient (0.4%). 
Both males and females were equally likely to be prescribed 1, 2 or ≥ 3 PIMs (Χ2 (3) ≥ 
0.567, p = 0.904) (Figure 7.7). 
58.5%
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Figure 7.7: Numbers of patients on potentially inappropriate medications as 
determined by STOPPFrail criteria (n = 274) 
 
 
The most frequently encountered PIMs identified by STOPPFrail criteria are detailed 
in Table 7.6. These include (i) medications with no clear indication (47.0%), (ii) high 
dose proton pump inhibitors (31.4%), (iii) lipid-lowering therapies (29.6%), (iv) 
nutritional supplements (25.5%) and (v) neuroleptics (24.5%). Females were more 
likely to be inappropriately prescribed medications with no clear indication (52.6% vs 
24.1%, Χ2 (1) ≥ 3.84, p = 0.05), anti-platelets for primary prevention, (23.3% vs 5.5%, 
Χ2 (1) ≥ 9.261, p = 0.002), calcium, (33.5% vs 6%, Χ2 (1) ≥ 20.7, p <0.001) and anti-
resorptive therapy for osteoporosis, (16.3% vs 2.5%, Χ2 (1) ≥ 9.822, p = 0.002). Males 
were more likely to be prescribed alpha blockers for hypertension, (3.5% vs 0.65%, 
Χ2 (1) ≥ 6.514, p = 0.011), and neuroleptics (19.6% vs 18%, Χ2 (1) ≥ 7.884, p = 0.005) 
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and alpha blockers with long term catheterisation (1.5% vs 0%, Χ2 (1) ≥ 3.951, p = 
0.047). 
Table 7.6: Most frequently encountered potentially inappropriate prescriptions 
according to STOPPFrail criteria in 274 eligible patients 
STOPPFrail Criterion Total 
n=274 
A2 No clear indication 182 instances in 129 patients (47%)  
E1 High dose PPI 86 instances in 86 patients (31.4%) 
B1 Lipid lowering therapies 83 instances in 81 patients (29.6%) 
J2 Nutritional Supplements 108 instances in 70 patients (25.5%) 
D1 Neuroleptics 73 instances in 67 patients (24.5%) 
G1 Calcium 64 instances in 64 patients (23.4%) 
D2 Memantine 49 instances in 49 patients (17.9%) 
C1 Anti-platelet for primary 
prevention 
47 instances in 47 patients (17.1%) 
G2 Anti-resorptive therapies for OP 30 instances in 30 patients (10.9%) 
J1 Multivitamins 22 instances in 22 patients (8%) 
I1 Diabetic oral agents 22 instances in 20 patients (7.3%) 
G5 Long term oral steroids 14 instances in 14 patients (5.1%) 
B2 Alpha blockers for HTN 8 instances in 8 patients (2.9%) 
Legend: PPI = proton pump inhibitor; OP = osteoporosis; HTN = hypertension 
 
 7.3.9 Risk factors for being prescribed a PIM as determined by   
  STOPPFrail criteria 
Logistic regression was used to determine the influence of age, gender, dementia, 
number of conditions and number of medications on the risk of receiving a 
potentially inappropriate prescription according to STOPPFrail criteria. The results 
are detailed in Table 7.7. 
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Table 7.7: Risk factors for receiving a PIM as determined by STOPPFrail criteria 
      95% CI for Exp (B) 
Variable  B (SE) df p-value Exp 
(B) 
Lower Upper 
        
Gender Female 0.10 (0.50) 1 .837 1.11 0.42 2.95 
Age 65 – 74  3 .233    
 75 – 84 0.50 (0.72) 1 .490 1.65 0.40 6.76 
 85 – 94 1.14 (0.75) 1 .131 3.12 0.71 13.69 
 ≥ 95 -0.37 (1.04) 1 .724 0.69 0.09 5.34 
Dementia  -0.07 (0.58) 1 .902 0.93 0.30 2.88 
Medications  0.46 (0.09) 1 <0.001* 1.58 1.32 1.89 
Conditions  -0.11 (0.10) 1 .262 0.89 0.73 1.09 
Constant  -0.30 (1.00) 1 .763 0.74   
        
Homer and Lemeshow Χ2 (8) ≥2.795, p=0.947, Model Χ2 = 125.022, Cox and Snell R2 = 0.141, 
Nagelkerke R2 = 0.309, B = beta-value, SE = standard error, df = degrees of freedom, CI = confidence 
interval, Exp (B) = Odds ratio, Medications = number of medications, Conditions = number of 
conditions 
 
 
The number of medications a patient was prescribed was significantly associated 
with an increased risk of receiving a STOPPFrail criteria PIM, controlling for gender, 
age, presence of dementia and the number of medical conditions. For every one 
extra medication prescribed, the odds of receiving a STOPPFrail PIM increased by 
57.9% (Odds ratio 1.579, 95% CI 1.318 – 1.89, P <0.001). 
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7.3.10 Application of STOPPFrail criteria to hospitalised older adults 
In Chapter 3, 240 older patients were studied to determine the prevalence of ADRs 
causing hospitalisation and the prevalence of PIMs according to STOPP/START 
criteria. These patients were retrospectively reviewed to assess their eligibility for 
the application of STOPPFrail criteria; 48 (20%) patients met the STOPPFrail eligibility 
criteria. The differences identified between these patients and those who did not 
meet STOPPFrail eligibility criteria are displayed in Table 7.8. 
 Those who met STOPPFrail eligibility criteria were significantly older (mean 
age 81.4 (SD 6.8) years vs 77.2 (SD 7.6) years, t238 =3.495, p = 0.001), more cognitively 
impaired (median MMSE scores 20 (IQR 11-25) vs 27 (IQR 23.75-28.75), U = 926, p 
<0.001), more functionally impaired (median Barthel Index scores 11 (IQR 7.25) vs 20 
(IQR 18 – 20), U = 519, p <0.001), had a higher burden of co-morbid illness (mean 
CIRS score 20.5 (SD4.5) vs 14 (SD 5.7), t89,454 =5.845, p <0.001), were prescribed a 
higher number of medications (mean 10.8 (SD 4.6) vs 8.2 (SD 4.4), t70,546 =3.696, p = 
0.001) and were significantly frailer on the Rockwood Frailty Scale (Χ2 (8) ≥ 163.627 p 
<0.001) (Figure 7.8) than those that did not. Reasons for both groups not completing 
the MMSE score are displayed in Table 7.9. Those patients who met STOPPFrail 
eligibility criteria were more likely to die during the index admission (14.6% vs 1%, Χ2 
(2) ≥ 18.844, p <0.001) and more likely to die within 6 months of enrolment (39.6% 
vs 3.6%, Χ2 (2) ≥ 50.782 p <0.001) than those who did not meet STOPPFrail eligibility 
criteria.  
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Table 7.8: Characteristics of study population (n=240) 
Variable Eligible for 
application for 
STOPPFrail 
n = 48 
Not eligible for 
application of 
STOPPFrail 
n = 192 
Total  
 
 
n = 240 
P-value 
     
Female 20 (41.7%) 99 (51.6%) 119 (49.6%) 0.220* 
Age, Mean (SD) 81.4 (6.8) 77.2 (7.6) 78 (7.6) 0.001* 
Cognitive ability     
MMSE completed 27 (56.3%) 172 (89.6%) 199 (82.9%) <0.001* 
Median, (IQR) 20 (11-25) 27 (23.25-28.75) 26 (22-28) <0.001* 
Functional ability     
Function (Barthel), med (IQR) 11 (7.25-13) 20 (18-20) 19 (15-20) <0.001* 
Conditions, mean (SD) 11.8 (3.7) 8.2 (3.9) 8 (4.1) <0.001* 
CIRS, mean, (SD) 20.5 (4.5) 14 (5.7) 15.3 (6.1) <0.001* 
Medication use     
Medications, mean (SD) 10.8 (4.6) 8.2 (4.4) 8.7 (4.6) 0.001* 
Number of patients on ≥1 
med 
48 (100%) 188 (97.9%) 236 (98.3%) 0.313 
1 – 5 6 (12.5%) 47 (24.5%) 53 (22.1%) 0.074 
6 – 10 22 (45.8%) 83 (43.2%) 105 (43.8%) 0.745 
≥11 20 (41.7%) 58 (30.2%) 78 (32.5%) 0.130 
≥6 42 (87.5%) 142 (74%) 184 (76.7%) 0.047* 
Follow up data     
Data available on death 38 (79.2%) 146 (76%) 184 (76.7%)  
Death during index admission 7 (14.6%) 2 (1%) 9 (3.8%) <0.001* 
Death within 6 months of 
index admission 
19 (39.6%) 7 (3.6%) 26 (10.8%) <0.001* 
LOS, med (IQR) 9 (5-21.5) 7 (3-12) 8 (3-13.75) 0.022* 
Legend: IQR = inter-quartile range, MMSE = mini-mental state examination, med = median, IQR = 
inter quartile range, SD = standard deviation, CIRS = Cumulative illness rating scale, LOS = length 
of stay, p-value pertains to the probability of there being a difference between groups in the 
variable of interest. 
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Figure 7.8: Clinical Frailty Scale status of patients (n = 240) according to STOPPFrail 
eligibility criteria 
 
 
Table 7.9: Reasons for participants not completing the Mini Mental State 
Examination (MMSE) (n= 41) 
Reasons Eligible for application 
for STOPPFrail 
n =  21 
Not eligible for 
application of STOPPFrail 
n = 20 
   
   
Severe dementia 15 (71.4%) 0 (0%) 
Too delirious/too drowsy 4 (19%) 3 (15%) 
Severe hearing impairment 1(4.8) 2 (10%) 
Patient unable to speak English 0 (0%) 3 (15%) 
Aphasia 1 (4.8%) 1 (5%) 
Declined 0 (0%) 7 (35%) 
Time restraints 0 (0%) 4 (20%) 
   
 
 
0.0% 10.0% 20.0% 30.0% 40.0% 50.0% 60.0% 70.0%
1 (very fit)
2 (well)
3 (managing well)
4 (vulnerable)
5 (mildly frail)
6 (moderately Frail)
7 (severely frail)
8 (very severely frail)
9 (terminally ill)
Eligible for application for STOPPFrail Not eligible for application of STOPPFrail
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STOPPFrail eligibility criteria requires a patient have an end-stage irreversible 
pathology with an associated poor one year life expectancy e.g. advanced dementia 
with recurrent infections. Life-limiting diagnoses among those meeting STOPPFrail 
eligibility criteria are displayed in Figure 7.9. Almost 1 in 2 patients (47.9%) had a 
diagnosis of advanced dementia with major cognitive and/or functional impairment, 
a further 18% of patients had severe chronic lung disease with recurrent 
exacerbations and were requiring long term oxygen. 
Figure 7.9: Life limiting diagnoses in those eligible for STOPPFrail application (n=48) 
 
 
7.3.11 Potentially inappropriate medication (PIM) use as determined by 
STOPPFrail criteria in hospitalised older adults 
According to STOPPFrail criteria, 198 of 519 (38.2%) medicines were potentially 
inappropriate. These were identified in 46 of the 48 patients (95.8%) who were 
47.9%
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eligible for application of STOPPFrail criteria. One PIM was identified in 4 patients 
(8.3%), 2 PIMs in 10 patients (20.8%), 3 PIMs in 5 patients (10.4%), 4 PIMs in 6 
patients (12.5%), 5 PIMs in 8 patients (16.7%), 6 PIMs in 6 patients (12.5%), 7 PIMs in 
3 patients (6.3%), 9 PIMs in 2 patients (4.2%) and 10 PIMs in 2 patients (4.2%). Both 
males and females were equally likely to be prescribed 1, 2 or ≥ 3 PIMs (Χ2 (3) ≥3.360, 
p = 0.339) (Figure 7.10). 
Figure 7.10: Percentage of patients on potentially inappropriate medications as 
determined by STOPPFrail criteria (n = 48) 
 
 
The most frequently encountered PIMs identified by STOPPFrail criteria are detailed 
in Table 7.10. These include: (i) medications with no clear indication (58.3%), (ii) lipid 
lowering therapies (45.8%), (iii) high dose proton pump inhibitors (PPIs) (35.4%), (iv) 
calcium supplementation (31.3%) and (v) neuroleptics (22.9%). There was no 
significant difference in PIM use between men and women.  
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Table 7.10: Most frequently encountered potentially inappropriate prescriptions 
according to STOPPFrail criteria in 48 patients 
STOPPFrail Criterion Total 
n=48 
A2 No clear indication 53 instances in 28 patients (58.3%)  
B1 Lipid lowering therapies 22 instances in 22 patients (45.8%) 
E1 High dose PPI 17 instances in 17 patients (35.4%) 
G1 Calcium supplements 15 instances in 15 patients (31.3%) 
D1 Neuroleptics 12 instances in 11 patients (22.9%) 
J2 Nutritional Supplements 17 instances in 10 patients (20.8%) 
C1 Anti-platelet for primary 
prevention 
8 instances in 8 patients (16.7%) 
D2 Memantine 8 instances in 8 patients (16.7%) 
G5 Long term oral corticosteroids 7 instances in 7 people (14.6%) 
A1 Drugs the patients persistently 
fails to take or tolerate 
13 instances in 6 people (12.5%) 
G2 Anti-resorptive therapies for OP 6 instances in 6 people (12.5%) 
I1 Diabetic oral agents 5 instances in 5 people (10.4%) 
B2 Alpha blockers for HTN 4 instances in 4 people (8.3%) 
I2 ACE inhibitors for Diabetes 
Mellitus 
3 instances in 3 people (6.3%) 
J1 Multivitamins 2 instances in 2 people (4.2%) 
   
Legend: PPI = proton pump inhibitor; OP = osteoporosis; HTN = hypertension, ACE = angiotensin 
converting enzyme 
 
7.4 DISCUSSION 
This study shows that a high proportion of  older adults (59.1%) who apply for nursing 
home long-term care in Ireland meet STOPPFrail eligibility criteria i.e. end stage 
irreversible pathology, poor 1 year survival prognosis, severe functional impairment 
or severe cognitive impairment of both and patients wherein symptoms control is 
the priority rather than prevention of disease progression. In US nursing homes, 65% 
of patients die within one year from the time of admission (247). In the present study, 
as expected, those who met STOPPFrail eligibility criteria were older, had higher 
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levels of cognitive impairment, were more functionally impaired and were 
objectively frailer than those who did not meet STOPPFrail eligibility criteria.  
 Those who met STOPPFrail eligibility criteria had a significantly higher mean 
number of medicated conditions (7.3 (SD 2.6) vs 6.4 (SD 2.5), p <0.001). For patients 
that met STOPPFrail eligibility criteria, the most prevalent life limiting diagnosis was 
advanced dementia, seen in 70% of cases. Dementia was also present, but generally 
in its earlier stages in 42.8% of those not meeting STOPPFrail eligibility criteria.  
 Despite the fact of those who met STOPPFrail eligibility criteria having a poor 
one year survival prognosis, they nevertheless received the same median number of 
daily medications as those patients who did not meet STOPPFrail eligibility criteria (8 
(SD4) vs 7.5 (SD3.7), p = 0.183). Approximately two thirds (69%) of all study 
participants experienced polypharmacy (≥ 6 daily medications) and one quarter 
(23%) experienced high-level polypharmacy (≥ 11 daily medications). No significant 
differences in rates of overall polypharmacy and high-level polypharmacy were 
identified between those that met STOPPFrail eligibility criteria and those that did 
not (67.1% vs 69% p = 0.233 and 24.8% vs 19.7% p = 0.526, respectively). Similar 
prevalence rates of 48.7% and 24.3% for overall polypharmacy (5-9 medications) and 
high-level polypharmacy (≥ 10 medications), have been reported by the SHELTER 
study (195). 
 Nearly two-thirds (60.6%) of patients were prescribed an anti-hypertensive, 
approximately 1 in 2 patients (47.9%) were prescribed a proton pump inhibitor, 
approximately 1 in 3 patients (33.3%) were prescribed an anti-platelet, almost 1 in 3 
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patients (30.5%) were prescribed neuroleptics, over 1 in 4 patients (28.4%) were 
prescribed a statin and almost 1 in 4 (22.3%) were prescribed long-term 
benzodiazepines. The prevalence of neuroleptic prescriptions in nursing homes in the 
US is reported to be approximately 22% to 25% (249, 250). In other countries, varying 
daily neuroleptic prevalence rates have been reported: 11% in Hong Kong, 26-27% in 
Canada, 34% in Switzerland, 38% in Finland (251) and 32.8% in Europe (252). This 
study suggests that the prescription of regular daily anti-psychotic medication often 
precedes nursing home placement in frailer, older people in Ireland. 
 Potentially inappropriate prescribing was highly prevalent in this sample 
population with 1 in 3 prescriptions being potentially inappropriate according to 
STOPPFrail criteria and 90% of patients receiving at least 1 STOPPFrail PIM. 
Approximately 1 in 7 patients (13.9%) received 1 PIM alone, 1 in 5 patients (20.1%) 
received 2 PIMs and 1 in 2 patients (57.7%) received ≥3 PIMs.  Approximately 1 in 2 
of these patients (47%) were prescribed a medication without any clear indication. 
Approximately 1 in 3 of these patients (31.4%) were prescribed a high dose, long-
term proton pump inhibitor without any clear reason. Approximately 1 in 3 (29.6%) 
of these patients were prescribed a statin for long-term cardiovascular prevention. 
The odds of receiving a PIM increased by 57.9% for every extra medication 
prescribed. 
 One in five older adults (20%) presenting to hospital with an acute illness met 
STOPPFrail eligibility criteria. Similar to patients who applied for nursing home 
placement, those that met STOPPFrail eligibility criteria and were being admitted to 
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hospital with acute illness were older, more cognitively impaired, more functionally 
impaired, had a higher burden of co-morbid illness and were frailer than those that 
did not meet STOPPFrail eligibility criteria; they were also prescribed more 
medications. These findings are not surprising, since eligibility for STOPPFrail criteria 
means higher levels of frailty and dependency. Approximately 1 in 7 (14.6%) of those 
who met STOPPFrail eligibility criteria died during the index admission. More than 1 
in 3 (39.6%) patients died within 6 months of enrolment in the study. For nearly half 
(47.9%) of the patients, the life-limiting diagnosis was advanced dementia. For 
approximately 1 in 5 (18%) patients, the life-limiting diagnosis with chronic lung 
disease with recurrent exacerbations and a need for long-term oxygen therapy.  
 For older adults admitted with an acute illness to hospital, nearly all patients 
(95.8%) who met STOPPFrail eligibility criteria were on at least 1 STOPPFrail PIM. The 
most prevalent PIMs were drugs with no clear indication, statins, high dose PPIs, 
calcium supplements and neuroleptics.  
 Clinicians who undertake medication review of multi-morbid older people 
with poor survival prognosis need to be aware of these highly prevalent PIMs, 
particularly at points of care transition, such as hospital discharge and admission to 
nursing homes for long-term care. Given the high prevalence of STOPPFrail PIMs 
identified in the present study, there is potential for STOPPFrail to be beneficial in 
routine medication review in older nursing home residents, both on admission and 
during routine clinical review thereafter. 
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 This study indicates that regardless of poor survival prognosis, IP, according 
to STOPPFrail criteria, is highly prevalent. This suggests that prescribers are either (a) 
failing to identify when patients have a poor survival prognosis, or (b) identifying 
patients with a poor survival prognosis but are not adjusting their prescribing 
practices accordingly. Polypharmacy and IP contribute to ADRs (160), and associated 
increased morbidity and mortality. Older adults who reside in nursing homes are at 
the highest risk from iatrogenic morbidity and mortality (195). 
 Deprescribing of PIMs in this particular population not only has the potential 
to reduce ADRs, but could be economically highly beneficial, given the direct and 
indirect costs associated with STOPPFrail-defined PIMs. Adults aged 85 years and 
older are the fastest growing segment of the population in most developed nations 
(3, 4). Multimorbidity is more prevalent in this population cohort than in any other 
cohort, with prevalence rates of over 80% reported (13), with proportionately high 
levels of polypharmacy and associated IP. Internationally, several studies 
demonstrate the potential magnitude of health budget wastage resulting from ADRs 
(113-116). In addition, the overall expenditure on prescription medications in older 
people is substantial with drug costs being one of the fastest growing areas of all 
healthcare expenditure in general.  In Ireland, Europe and the US the annual 
expenditure on drugs continues to rise in recent years (253-255). STOPPFrail criteria, 
through (i) identifying the correct patient population that would benefit from 
deprescribing and (ii) identifying medications that are potentially inappropriate in a 
systems-based structured fashion, has the potential to guide physicians with 
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deprescribing decisions and consequently to lower costs of drug treatment and 
thereby to have a positive impact on the current healthcare expenditure. 
 Prescribing for the older patients is often complex, particularly prescribing for 
older, frailer multimorbid adults. One continuing challenge is the paucity of clinical 
trial evidence to support prescribing and deprescribing in this group. Older adults 
with multimorbid illness are often excluded from clinical trials and when they are 
included they are, more often than not, under-represented compared to other adult 
age groups (256, 257). Clinical trials often concentrate on reporting on how 
efficaciously a drug works, with very little research focused on the potential impact 
of deprescribing. This observational study is important in the planning of future 
randomised control trials of deprescribing in older frail adults with a poor one year 
survival prognosis. Power calculation in particular will be facilitated by the present 
study as well as the choice of appropriate clinical trial endpoints. 
The global ageing demographic shift also increases the demand for more 
specialist geriatricians than are currently available. Unfortunately, in many countries, 
the proportion of geriatricians to the number of persons aged over 75 is diminishing, 
not rising.  This results in many older complex patients being prescribed for primarily 
by their General Practitioners or hospital specialists who do have specialist training 
in Geriatric Medicine and pharmacotherapy. In this context, explicit tools like 
STOPPFrail criteria, can assist and empower less experienced physicians with 
medication management and deprescribing in complex, multimorbid older patients. 
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CHAPTER 8: 
Summary & Conclusions 
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8.1 Summary of research findings 
In the introduction to this thesis, I reported the demographic changes predicted for 
Ireland, Europe and worldwide i.e. substantial increases in the numbers of older 
frailer patients surviving with complex co-morbid illnesses. I discussed the various 
challenges and considerations when prescribing for such patients. I discussed the role 
of prescribing indicators in identifying potentially inappropriate prescribing in older 
adults and highlighted an important deficiency in the literature, namely the lack of 
an IP screening tool to guide deprescribing in frail multimorbid older adults with poor 
survival prognosis. I subsequently described the negative outcomes associated with 
IP, including ADRs and their associated morbidity, higher mortality and greater 
healthcare costs. I discussed the challenges with current approaches employed by 
researchers and physicians for identifying, classifying and reporting ADRs. I also 
discussed the negative impact these varied methodologies have on the accurate 
ascertainment of ADR prevalence in older adults. I emphasized how such 
heterogeneity in reporting of ADRs results in difficulty with comparing prevalence 
studies in the literature to date.  
 This thesis aimed to contribute to the medical literature by presenting a 
standardized method for identification, assessment and reporting of ADRs in older 
adults. To do this, I reviewed the existing literature relevant to ADR ascertainment, 
including the various ADR definitions and ADR causality tools. The concept of an 
Adverse Event (AE) Trigger List was subsequently developed and validated to assist 
with identification of the most commonly occurring ADRs in older people using a 
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structured and unbiased process. This novel ADR assessment methodology was 
found to have good inter-rater reliability (IRR) amongst physicians chosen from a 
variety of clinical disciplines in everyday clinical practice. This new process of 
evaluating potential ADRs related to commonly encountered AEs was then applied 
to two high risk populations’ i.e. (i) older multimorbid adults attending hospital with 
acute illness and (ii) patients with cancer requiring hospitalisation.  
 In addition, I developed and validated a new explicit prescribing tool, called 
STOPPFrail criteria, through the Delphi consensus technique, to assist deprescribing 
in older frailer multimorbid adults with a poor survival prognosis. This tool was 
designed to aid the deprescription of commonly prescribed pharmacotherapies that 
are unlikely to be beneficial in this particular patient population. The IRR of 
STOPPFrail criteria was then assessed amongst physicians practising across three 
different specialties and subsequently STOPPFrail criteria was applied to two 
representative populations. The principle findings and conclusions of these studies 
are listed below. 
 
 8.1.1 Development and validation of an AE Trigger List 
The newly developed and validated AE Trigger List consists of twelve commonly 
occurring clinical symptoms or syndromes that may be indicative of underlying ADRs 
and thus require investigation using a standardized process to determine if this is the 
case. This AE Trigger List was developed based on the type of ADRs identified in a 
previous robust study of ADR prevalence in older adults (146) and augmented by 
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group consensus. The group consensus involved in the refinement of this AE Trigger 
List comprised co-principal investigators and primary researchers involved in the FP7-
funded SENATOR project which began in 2012 (147). Each AE on the AE Trigger List 
was given a concise definition to remove any ambiguity for the user. 
 This study also aimed to standardise the approach to assessing the morbidity 
associated with ADRs and thus the AE Trigger List was also used to assess the inter-
dependent relationships between symptoms experienced secondary to an ADR; this 
assessment was referred to as Sequence of Events. Not only were all AEs on the 
Trigger List assessed for a drug cause but when a drug cause was found, the 
relationship between AEs was also assessed, allowing the associated morbidity to be 
captured in a structured process. The assessment of AEs on the AE Trigger List was 
then sent to an adjudication committee for review where senior academic clinicians 
with extensive experience in Geriatric Medicine and pharmacotherapy could agree 
or disagree with the assessment undertaken. 
 The IRR of using this AE Trigger List was assessed amongst 21 persons, all of 
whom were principal investigators and primary researchers on the SENATOR project. 
The median IRR was found to be substantial for identifying ADRs. This method of 
evaluating adverse events and determining whether or not they are caused by ADRs 
has been used to determine the principal outcome measure in the SENATOR clinical 
trial which is a large randomised controlled trial to determine the effect of SENATOR 
software on incident ADRs in multimorbid older patients who are hospitalised with 
acute medical and surgical illnesses (147, 150).  
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8.1.2 Prevalence of ADRs causing hospitalisation in older adults  
This is one of the first studies to use a standardized approach to identify, classify and 
report ADRs in older people. The AE Trigger List was applied prospectively to 240 
older adults presenting to hospital with an acute unselected illness. This population 
included many older frailer patients with complex co-morbid illnesses. Of the 
participants studied, 44.2% were aged ≥ 80 years and 84.6% had ≥ 5 conditions. In 
addition, 16.3% had moderate or severe dementia. Using Rockwood’s clinical frailty 
scale, 1 in 4 older adults were severely frail, very severely frail or terminally ill. 
Approximately three quarters of the patients experienced polypharmacy i.e. ≥ 6 daily 
prescription drugs and one third experienced high level polypharmacy i.e. ≥ 11 daily 
prescription drugs.   
 Potentially inappropriate prescribing practices were identified in 67.5% of 
patients using STOPP criteria. Among these patients, 19.2% of prescriptions were 
potentially inappropriate according to STOPP criteria. The most frequently 
encountered PIMs identified by STOPP criteria were: (i) medications prescribed 
beyond a recommended duration (41.3%), (ii) PPI’s for uncomplicated peptic ulcer 
disease/reflux oesophagitis at full therapeutic dosage for > 8 weeks (24.6%), (iii) 
medications prescribed without an evidence-based clinical indication (20%), and (iv) 
use of benzodiazepines for ≥ 4 weeks (17.9%). For every additional medication 
prescribed, the odds of being prescribing a PIM increased by 41.5% (odds ratio 1.415, 
95% CI 1.237 – 1.619, p <0.001). 
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 START criteria for potentially inappropriate prescribing omissions were 
applicable in 170 of the 240 participants (70.8%). For the remaining 70 participants, 
a more palliative approach to pharmacotherapy was appropriate. More than one half 
of participants (52.9%) ≥ 1 PPO. The most common PPOs were: (i) omission of an ACE 
inhibitor in patients with systolic heart failure and/or coronary artery disease 
(12.4%), (ii) omission of bone anti-resorptive or anabolic therapy with osteoporosis 
(8.2%), (iii) omission of vitamin D and calcium with osteoporosis (7.6%) and (iv) 
vitamin D when housebound or experiencing falls (7.6%).  
 ADRs caused or significantly contributed to acute admission in 22.1% of these 
patients. The most common ADRs were bleeding, falls and clinically relevant 
electrolyte disturbances. The AE Trigger List identified 79.3% of these ADRs. Twenty 
nine (54.7%) patients who experienced an ADR had a clear Sequence of Events 
according to the Adverse Event assessment process, with women being more likely 
to experience this phenomenon than men (67.9% vs 40%). The most commonly 
implicated drugs were opioids, direct oral anti-coagulants and benzodiazepines. The 
vast majority of ADRs (85%) were predictable. Using Hallas ADR avoidability criteria, 
45.3% were definitely avoidable and 45.3% possibly avoidable. Those who 
experienced ADRs had a higher burden of co-morbid illness, were prescribed more 
medications and more likely to die during the index admission than patients who did 
not have ADRs. For each additional prescribed medication, the odds of experiencing 
an ADR increased by 10.3% (Odds ratio 1.103, 95% CI 1.006 – 1.210, p <0.001). 
 
284 
 
 
 
8.1.3 Prevalence of ADRs causing hospitalisation in patients with cancer  
This is the first study in Ireland to identify and classify patients with cancer according 
to age, burden of co-morbidity, medication and PIM use. It is also the first study 
internationally to assess ADRs attributable to drugs other than cytotoxic 
chemotherapeutic agents in a comprehensive manner in this population. In this 
prospective study, 34.5% of all patients attending an oncology service were aged ≥ 
70 years and 81.1% of these older patients had ≥ 5 chronic comorbid clinical 
conditions. A higher prevalence of polypharmacy and high level polypharmacy were 
identified in the older patients compared to the younger patients i.e. 63.6% vs 38.4% 
and 19.0% vs 7.4% respectively. In addition, older adults were less likely to be 
prescribed chemotherapy. According to STOPP criteria, 73.1% of patients aged ≥ 65 
years were prescribed at least one PIM and 25.3% were prescribed ≥ 3 PIMs. Similar 
results emerged from application of OncPal criteria; 70.8% of older patients were 
prescribed ≥ 1 PIM and 30.7% were prescribed ≥ 3 PIMs. 
 The 12 point AE Trigger List identified 64% of all ADRs in this population. ADRs 
caused or contributed significantly to 21.5% of all oncology admissions (emergency, 
elective and day unit). ADRs were more prevalent in those patients presenting to 
hospital as an emergency (35.8%). ADRs were equally likely to result from cancer-
specific pharmacotherapy as non-cancer specific pharmacotherapy, with no 
difference in prevalence rates identified between older and younger patients. The 
three most common ADRs in the cohort were: (i) neutropenia with infection, (ii) 
nausea/vomiting and (iii) major constipation. Thirty two (42.7%) of all participants 
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who experienced an ADR had a Sequence of Events. Of the 75 ADRs identified, 67 
(89.3%) were entirely predictable. Using Hallas criteria of avoidability, 29.3% were 
definitely avoidable, 33.3% possibly avoidable and 37.4% were unavoidable. 
Chemotherapeutic agents, opioids, corticosteroids and NSAIDs were the most 
commonly implicated drugs in relation to identified ADRs. 
 
8.1.4 Validation of STOPPFrail criteria  
STOPPFrail is a novel validated list of prescribing indicators for older frailer patients 
with a poor survival prognosis. It is comprised of 27 prescribing indicators designed 
to assist with deprescribing in a structured fashion in this particular patient 
population. STOPPFrail criteria are organised according to physiological systems for 
ease of use and each indicator is accompanied by a concise statement which explains 
why the prescription is potentially inappropriate.  
 Its content validity was established by a Delphi consensus methodology, in 
which a panel of seventeen experts in geriatric pharmacotherapy participated. The 
inter-rater reliability of STOPPFrail application was found to be substantial amongst 
twelve physicians practising in Geriatric Medicine, Palliative Medicine and General 
Practice. 
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8.1.5 Prevalence of potentially inappropriate prescribing as determined 
by STOPPFrail criteria 
STOPPFrail criteria were applied to eligible patients from two study cohorts: (i) older 
adults undergoing comprehensive geriatric assessment when applying for the Irish 
Nursing Home Support Scheme towards long-term nursing home care, and (ii) older 
adults presenting to hospital with an acute unselected illness admitted under the 
care of specialist services other than Geriatric Medicine.  
 Two hundred and seventy four (59.1%) of patients applying for nursing home 
placement were eligible for application of STOPPFrail criteria. Potentially 
inappropriate prescribing according to STOPPFrail criteria was highly prevalent in 
these patients, with 91.2% having ≥ 1 PIM and 33.0% of all prescribed medications 
being potentially inappropriate according to STOPPFrail criteria. The most frequently 
prescribed STOPPFrail PIMs in these frail older patients with a poor one year survival 
prognosis were: (i) medications without a clear clinical indication (47%), (ii) long-
term, high dose proton pump inhibitors without a clinical indication for high-dose 
therapy (31.4%), and (iii) lipid lowering therapies (statins in the great majority) 
(29.4%). 
 Twenty percent of older adults presenting to hospital with an acute illness 
were eligible for the application of STOPPFrail criteria. Potentially inappropriate 
prescribing was highly prevalent in this subgroup of 48 patients, with 46 patients 
(95.8%) being regularly prescribed at ≥ 1 PIM. Over one-third (38.2%) of all 
medications prescribed to these frail older patients with limited life expectancy were 
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potentially inappropriate according to STOPPFrail criteria. The most frequently 
prescribed STOPPFrail PIMs were: (i) medications without a clear indication (58.3%), 
(ii) lipid lowering therapies (45.8%) and (iii) high dose proton pump inhibitors without 
a clinical indication for high-dose therapy (35.4%). The prevalence of PIM use in older 
adults eligible for STOPPFrail criteria was the same in both studies i.e. at the point of 
admission to hospital with acute illness and at the point of consideration for 
transition to long-term nursing home care. Such “transition of care” time points could 
present viable opportunities for application of STOPPFrail criteria and effective 
deprescribing of unnecessary and potentially futile medications in this particular 
older patient population.  
 
8.2 Limitations of these research findings 
All participants who completed the IRR exercise on the assessment of ADRs, using 
the AE Trigger List, were part of the SENATOR project. This research consortium’s 
main purpose is to develop a software engine capable of advising on medication 
appropriateness for older multimorbid patients with polypharmacy. In the second 
phase of this project, which is currently ongoing, a multi-centred RCT is in progress 
investigating whether the use of SENATOR software at the point of admission to 
hospital in older multimorbid adults will reduce incident hospital ADRs compared to 
standard pharmaceutical management in 6 European medical centres. It could be 
argued that because these participants had a good knowledge and background on 
ADR assessment prior to the IRR exercise these results are not generalizable to the 
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average physician, pharmacist or nurse working in hospital setting. However, of the 
21 persons who participated, 15 were junior researchers who were either working 
for their first time on a large research project or were working in the area of Geriatric 
Pharmacotherapy where they hadn’t worked before. Thus, it is likely that with the 
appropriate training, most healthcare staff could learn to use the AE Trigger List 
effectively and identify, assess and report ADRs in a standardized manner. 
Furthermore, if this standardized approach to assessing ADRs were to be used in 
future research studies and RCTs, comparisons between studies would be more 
reliable and determination of ADRs as trial outcomes would consequently be more 
robust. 
 In both prospective observational studies investigating the prevalence of 
ADRs (Chapters 3 and 4), ADR assessments were completed entirely by me. These 
studies could possibly have been strengthened by all AE Trigger List assessments had 
been sent to an adjudication panel to assess whether or not an ADR had occurred.  
This has been done for the SENATOR feasibility study (150) and is currently the 
methodology employed for ADR ascertainment in the SENATOR RCT. In the SENATOR 
feasibility study, 21.6% of all participants experienced an incident ADR during acute 
hospital admission under the care of specialist teams other than Geriatric Medicine 
or Clinical Pharmacology (150). In my study investigating the prevalence of ADRs in 
older patients presenting to hospital, ADRs accounted for 22.1% of all hospital 
admissions, consistent with the SENATOR feasibility study. In previous meta-analyses 
of ADRs causing hospitalisation and ADRs occurring during hospitalisation in older 
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adults, ADR occurrence rates of 10.0% of (83, 144) and 11.5% (84, 144), respectively 
have been reported. This suggests that although under-reporting of ADRs is likely, 
older adults experience ADRs at similar frequency prior to (prevalent ADRs) and 
during hospital admission (incident ADRs). However, more recent studies at Cork 
University Hospital have reported higher rates of 26.3% (45) and 21% (74) for 
prevalence and incident ADRs respectively. My research results presented in this 
thesis concur with these higher ADR prevalence and incidence findings than had been 
reported previously. 
 The use of Delphi Consensus Methodology for the development and 
validation of STOPPFrail criteria has some intrinsic limitations. This approach is not 
based on rigorous scientific evidence, but rather on the informed opinions of experts 
where robust scientific evidence may be lacking.  Methodological concerns have 
been raised regarding the Delphi method, specifically the selection of expert 
panellists and the potential for bias at this stage of the process. Expertise can 
sometimes be overstated and clinical knowledge in a particular area does not 
necessarily equate with expert status. I have tried to be as methodologically robust 
with the Delphi panel selection as possible. Panellists from 5 different and relevant 
clinical practice backgrounds, who were senior academic clinicians regularly dealing 
with the patient cohort in question, were selected. In addition, panellists had to have 
extensive knowledge of the current literature on pharmacotherapy in frail older 
people. In this way, potential bias in the Delphi panel was minimized. 
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 The Delphi consensus technique employs anonymity in each of its assessment 
rounds. This allows panellists to react in an unbiased fashion without influence from 
other panellists when presented with particular items for assessment/judgement.  
Thus each panellist’s opinion carries the same weight and importance as every other 
panellist. Concerns have been raised regarding the true anonymity of this process, 
with some researchers suggesting that anonymity isn’t employed when the 
researcher overseeing the process knows the answers given by each panellists (258). 
To avoid this, I ensured answers were returned to panellists in an anonymous 
fashion. I was aware of panellists’ disciplines and was unaware of which answers 
were given by whom. However, some panellists did know each other and could 
possibly have discussed particular aspects of the research without my knowledge. 
Lack of communication between panellists can be viewed as a strength as well as a 
weakness in a particular Delphi consensus process. However, despite these intrinsic 
limitations, the Delphi technique is a widely recognized and accepted approach to 
achieving consensus when there is a paucity of evidence. It also allows the 
development of tools which can be used to further develop or refine the evidence 
base and reaffirm the original Delphi consensus. Use of the Delphi technique has 
proven beneficial in the development and validation of other IP prescribing tools (36, 
63, 69, 199). 
 STOPPFrail is a novel tool consisting of explicit deprescribing indicators in frail 
older people with a poor one year survival prognosis. Therefore, it does not take into 
consideration the clinical context of the prescribing decision for each individual 
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patient but rather focuses on general prescribing principles. This means that the 
criteria may not be generalizable to all patients in the population that it is designed 
for. However, to minimise this effect we included clinical eligibility criteria that 
patients needed to have for the criteria to be appropriate and applicable. However, 
some clinicians may take the view that not all of the STOPPFrail deprescribing 
indicators are appropriate to all frail older patients with poor one year survival 
prognosis. Nonetheless, STOPPFrail criteria provides explicit guidance and assistance 
to physicians with deprescribing in this population in a structured fashion. As 
guidelines and not dictats, STOPPFrail criteria allow physicians the freedom to refrain 
from deprescribing if they consider that stopping a particular drug it is not in a 
particular patient’s best interest.  
 
8.3 Directions for future research  
This thesis has identified several areas that warrant further investigation. Firstly, the 
AE Trigger List needs to be validated in other patient populations. This method of 
ADR ascertainment could potentially reduce the element of subjectivity in ADR 
identification and reporting in patient populations other than multimorbid older 
people with polypharmacy. If deployed in a standardized process, the AE Trigger List 
has the potential to improve comparison between studies and the accuracy of the 
study results. It would also make it easier for researchers to undertake meta-analyses 
reporting ADR prevalence and incidence in various clinical settings. However, the AE 
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Trigger List process does not identify all potential ADRs and will always require an 
additional ‘unspecified’ adverse event criterion. 
 Patients with cancer frequently have complex co-morbidities, complex 
medication regimes and higher susceptibility to ADRs. Traditionally, these patients 
are managed by specialist oncologists. However, with the increasing complexity of 
prescribing regimes and high prevalence of ADRs from non-cancer pharmacotherapy 
in this cohort, there is a clear role for specialist geriatricians and clinical 
pharmacologists in contributing to the non-cancer therapeutic decisions in this 
vulnerable patient group. The data from my study should be replicated in other 
cancer centres to see if the results are similar and to identify potential areas for 
intervention to reduce the risk of ADRs and related negative outcomes.  Future 
research could also investigate IP and ADRs in patients attending specialist radiation 
oncology services. These patients represented only a small proportion of my study 
population and are likely to comprise a higher number of older frailer patients than 
those hospitalized under the care of medical oncologists. There is a need to 
investigate incident ADRs in this population using this methodology as limited 
research has been completed on this to date. Potential interventional studies could 
examine the role of comprehensive geriatric assessment (CGA), IP screening tools, 
prescriber education, computer-based prescribing/decision support systems and 
clinical pharmacist assessments on reducing ADRs in this population.  
 The prevalence of potentially inappropriate prescribing according to 
STOPPFrail criteria needs to be determined in other patient groups such as those 
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residing in nursing home facilities, those attending specialist palliative care services 
as well as those living in the community attending hospital outpatients. Furthermore, 
the practical value of implementation of STOPPFrail criteria as an intervention needs 
to be tested by way of a randomised controlled trial. Its effect on key health 
outcomes such as ADRs, falls, quality of life, morbidity, mortality, health care 
utilisation and medication cost needs to be investigated. There is the potential for 
this tool to be used in RCTs across different healthcare settings. This would allow the 
evidence base to expand and support physicians with deprescribing. 
 Finally, many IP prescribing tools have been incorporated into electronic 
prescribing decision support systems e.g. STOPP/START criteria in the current 
SENATOR and OPERAM clinical trials. There is the potential for STOPPFrail to be 
incorporated into an electronic prescribing system in a similar manner in both 
primary and secondary care. However, this would require considerable ICT 
developmental work and close collaboration between clinical and ICT experts. 
 Ultimately, this thesis aimed to devise strategies to improve identification, 
classification and reporting of ADRs in older adults who are at particularly high risk 
of serious ADRs. The work described above has also tried to develop strategies to 
improve prescribing in older frailer patients with complex multimorbidity and a 
limited life expectancy. Hopefully, these research findings facilitate better 
prescribing decisions made for these highly vulnerable patient groups in the future. 
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Appendix 3 - Data Collection Sheet  
Study Number: ____________________________________________ 
Hospital Tick type of admission 
CUH  Emergency  
MUH  Elective  
  Day unit  
 
Baseline Characteristics: 
Age  
Gender Male Female 
Smoker (ever) Yes No 
Current Smoker Yes No 
Weekly alcohol Yes No 
Units per week  
Housing (circle) 
   
 
Living in own home  
Living in child’s home  
Sheltered accommodation 
Nursing Home 
Other 
Living arrangements (circle) 
 
Alone 
Spouse 
Spouse and child 
Child/children 
Child and their family 
Living with other relative 
Living with other non-relative 
Supports in place (in the last month) 
PHN Yes No 
Palliative care nurse Yes No 
HSE Home Help/Paid non-relative Yes No 
Paid relative Yes No 
Unpaid Relative Yes No 
Unpaid non-relative Yes No 
Private Home help Yes No 
Did they ever drive Yes No 
Current driving Yes No 
Hearing Impairment Yes No 
Visual impairment Yes No 
Walking Aid 
    
 
Yes 
Walking stick/sticks 
Crutch x 1, Crutch x 2 
Zimmer frame, rollator  
Wheelchair dependent 
No 
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Study ID: ________________________________ 
List Medical Diagnoses (and previous surgeries) 
Name ICD-10 code Name chronic 
disease process 
Treated 
yes/no 
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
 
Cumulative Illness Rating Scale (CIRS) Index 
Body system Score 
Cardiac (heart only) 0  –  1  –  2  –  3  –  4  
Vascular (organ damage is rate separately) 0  –  1  –  2  –  3  –  4  
Haemapoetic (blood, vessel, cells, bone marrow, spleen) 0  –  1  –  2  –  3  –  4  
Respiratory 0  –  1  –  2  –  3  –  4  
ENT (eye, ear, throat, larynx) 0  –  1  –  2  –  3  –  4  
Upper GI 0  –  1  –  2  –  3  –  4  
Lower GI 0  –  1  –  2  –  3  –  4  
Hepatic 0  –  1  –  2  –  3  –  4  
Renal 0  –  1  –  2  –  3  –  4  
Other GU 0  –  1  –  2  –  3  –  4  
Musculoskeletal 0  –  1  –  2  –  3  –  4  
Neurological 0  –  1  –  2  –  3  –  4  
Endocrine-metabolic 0  –  1  –  2  –  3  –  4  
Psychiatric/Behavioural 0  –  1  –  2  –  3  –  4  
Score (range 0 – 56)  
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Study ID: ________________________________ 
 
Medical Card: Yes No 
All prescription medications (regular and PRN) the patient is currently taking (per pharmacy and patient vials) prior to admission to hospital – ring 
pharmacy first to get list and then corroborate with the patient 
Generic 
Name 
What 
Brand dispensed 
Indication Duration 
 
Reg/ 
PRN 
Dose Route Freq Total 
MAI 
STOPP 
(if app) 
OncPal 
(if app) 
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Recent changes to medications  
Antibiotic in the last 2/12; yes or no If yes specify 
 
 
List any other changes/recent courses 
of medications 
 
 
 
 
 
 
 
Previous and current chemotherapy regimens  
Current chemo: 
Name/s: 
 
When received the last cycle: 
 
Cycle number: 
 
Total cycles expected: 
 
Previous chemo: 
Yes or No 
 
Name if known: 
 
 
Previous and current radiotherapy regimens and number of cycles 
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Modified Medications Reconciliation by Structure History of Medications 
1. Are you using your mediation as prescribed (dosage, dose, freq, form) 
 
Check each medication on previous list according to dose, freq, form, time etc 
Yes No 
2. If no list medication/s here and find out reason why not taking as prescribed: 
 
3. What is the reason for deviating (dose, dosage, freq, form) 
or not taking a drug at all (circle) 
List reason/s: 
2. Are you experiencing any side effect (at present, not previously) 
Name: 
Yes No 
4. Are you using any other prescription medication that are not mentioned on 
this list?(view medication containers) (in the last month) 
Name: 
Yes No 
5. Are you using non-prescription meds (in the last month) 
Name: 
Yes No 
6. Are you using homeopathic drugs or herbal remedies (Especially St John’s 
wort) (in the last month) 
Name: 
Yes No 
7. Are you using any drugs belonging to friends or family members (in the last 
month) 
Name: 
Yes No 
8. Are you using ‘as needed drugs’ / on demand drugs (in the last month) 
Name: 
Yes No 
 
9. Are you using drugs that are no long prescribed (in the last month) 
Name: 
Yes No 
10. Are you taking you medications independently 
 
Yes No 
11. 
 
Are you using a dosage system Yes No 
12. 
 
Are you experiencing any problems taking your medication 
 
If yes what: 
Yes No 
13.  Regarding Inhalation therapy what system are you using (circle) Yes using         Not using 
If yes 
Any problems using? 
14 Regarding eye drops. Any difficulties using? (circle) 
 
 
Yes using         Not using 
If yes 
Any problems using? 
15.  Do you ever forget to take you medications 
(this question is N/A if they do not manage their mediations alone) 
- Which medication ________________________ 
- Why________________________________________ 
- What do you do____________________________ 
 
Yes No 
16.  Would you like to comment on or ask a question about your medication?  
 Do you have any allergies 
- Which drug 
- Symptoms 
 
Yes No 
 Do you have any drug intolerances 
- Which drug 
- Symptoms 
 
Yes No 
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Study ID: ________________________________ 
Barthel Index 
Bowels 0 = Incontinent or needs to be given enemas 
1 = Occasional accident (1/wk) 
2 = Continent 
 
Bladder 0 = Incontinent/catheterised and unable to manage 
1= Occasional accident (max 1/24hrs) 
2 = Continent 
 
Grooming 0 = needs help with personal care 
1 =Independent face/hair/teeth/shaving 
 
Toilet Use 0 = dependent 
1= needs some help but can do something alone 
2 =Independent on and off 
 
Feeding 0 = unable 
1 = needs help cutting, spreading butter etc 
2 = independent 
 
Transfer 0 = unable – no sitting balance 
1 = major help (on or two people) can sit 
2 = minor help (verbal or physical) 
3 = independent 
 
Mobility 0 = immobile 
1 = wheelchair independent 
2 = walks with help of one person (verbal or physical) 
3 = Independent (may use any aid) 
 
Dressing 0 = dependent 
1 = needs help but can do about half unaided 
2 = Independent (including buttons, zips etc) 
 
Stairs 0 = unable 
1 = needs help (verbal, physical, carrying aid) 
2 = independent up and down 
 
Bathing 0 = dependent 
1 = Independent (or in shower) 
 
 SCORE  
 
 
Clinical frailty scale (score 1 – 9) 
 
 
  
MMSE 
Potential Score Patients Score Questions 
5  What is the year? Season? Date? Day? Month? 
5  Where are we now: Country? County? Town/city? Hospital? 
President?” 
3  Recall (Ball, Flag Tree) 
5  DLROW 
5  Serial Sevens 
3  Recall: Name the three objects 
2  Name two objects 
1  Repetition: ‘No ifs ands or buts’ 
3  Three step command 
1  Close your eye 
1  Write a sentence 
1  Copy this picture 
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Study ID: ____________________________ 
 
Delirium Assessment 
4AT 
(1) Alertness 
- Normal: 0 
- Mild sleepiness for < 10 seconds after waking, then normal: 0 
- Clearly Abnormal: 4 
(2) AMT4 (age, date of birth, hospital, current year) 
- No mistakes: 0 
- 1 mistake: 1 
- 2 or more: 2 
(3) Attention 
- Achieves 7 months: 0 
- Starts but scores less than 7 months/refuses: 1 
- Untestable (unwell, drowsy, inattentive): 2 
(4) Acute Change or Fluctuating Course 
- No: 0 
- Yes: 4 
Total: ___________ 
DSM-V (yes to all 5) 
A. A disturbance of attention:   yes   no 
B. The disturbance develops over a short period of time:   yes   no 
C. An additional disturbance in cognition:   yes   no 
D. Disturbances in A and C are not better explained by another pre-existing illness:   yes   no 
E. There is evidence from history, exam, investigations etc that disturbance is a direct consequence of another 
medical condition, intoxication etc:   yes   no 
Delirium:   yes   no 
ECG completed, if yes: 
    Sinus  
    Atrial Fibrillation 
    Bradycardia (<50) 
    First degree heart block 
    Second Degree heart block 
    Complete heart block 
    Prolonged QT (QTc:__________ ) 
Yes 
Yes 
Yes 
Yes 
Yes 
Yes 
Yes 
Yes 
No 
No 
No 
No 
No 
No 
No 
No 
Blood Work up (aim from this admission, if not put date beside) 
Date Blood Result 
 Current Urea  
 Current Creatinine  
 Current eGFR (MDRD)  
 Baseline Urea (in the last year)  
 Baseline Creatinine (in the last year)  
 Baseline eGFR (MDRD)  
 Na  
 K+  
 Ca2+  
 Albumin  
 Alk Phos  
 ALT  
 HbA1c  
 CRP  
 Urate  
 Hb  
 WCC  
 Neuts  
 Plts  
 INR  
 
 
Tfts (only if on levothyroxine)  
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Did any of the following events/processes occur prior to admission: 
Did the process 
occur 
 After filling 
out event 
form was the 
event 
secondary to 
a non-cancer 
drug 
(prob/certain) 
Event 
secondar
y to 
recent 
chemo 
(prob/cer
tain) 
Event 
secondar
y to 
radio-
therapy 
Max 
WHO 
causal-
ity 
Max 
H&S 
Sever-
ity 
Max 
Avoid-
ability 
New onset fall Yes 
No 
Yes           
No  
Yes    
No  
Yes    
No  
   
New onset Gait 
disturbance 
Yes 
No 
Yes           
No  
Yes    
No  
Yes    
No  
   
AKI Yes 
No 
Yes          
No  
Yes    
No  
Yes    
No  
   
New onset OH Yes 
No 
Yes          
No  
Yes    
No  
Yes    
No  
   
Major 
electrolyte 
derangement 
Yes 
No 
Yes          
No  
Yes    
No  
Yes    
No  
   
Symptomatic 
bradycardia 
Yes 
No 
Yes          
No  
Yes    
No  
Yes    
No  
   
New onset 
major 
constipation 
Yes 
No 
Yes          
No  
Yes    
No  
Yes    
No  
   
Acute bleeding Yes 
No 
Yes          
No  
Yes    
No  
Yes    
No  
   
Acute dyspepsia Yes 
No 
Yes          
No  
Yes    
No  
Yes    
No  
   
Acute diarrheoa Yes 
No 
Yes          
No  
Yes    
No  
Yes    
No  
   
Delirium Yes 
No 
Yes          
No  
Yes    
No  
Yes    
No  
   
Symptomatic 
hypogylcaemia 
Yes 
No 
Yes          
No  
Yes    
No  
Yes    
No  
   
Other (e.g. 
anaphylaxis, 
neutropenia, 
liver failure) 
Yes 
No 
Yes          
No  
Yes    
No  
Yes    
No  
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Appendix 4 -  Barthel Index Appendix 5 – Mini Mental State Examination (MMSE) 
Bowels 0 = Incontinent or needs to be given enemas 
1 = Occasional accident (1/wk) 
2 = Continent 
 
Bladder 0 = Incontinent/catheterised and unable to manage 
1= Occasional accident (max 1/24hrs) 
2 = Continent 
 
Grooming 0 = needs help with personal care 
1 =Independent face/hair/teeth/shaving 
 
Toilet Use 0 = dependent 
1= needs some help but can do something alone 
2 =Independent on and off 
 
Feeding 0 = unable 
1 = needs help cutting, spreading butter etc 
2 = independent 
 
Transfer 0 = unable – no sitting balance 
1 = major help (on or two people) can sit 
2 = minor help (verbal or physical) 
3 = independent 
 
Mobility 0 = immobile 
1 = wheelchair independent 
2 = walks with help of one person (verbal or physical) 
3 = Independent (may use any aid) 
 
Dressing 0 = dependent 
1 = needs help but can do about half unaided 
2 = Independent (including buttons, zips etc) 
 
Stairs 0 = unable 
1 = needs help (verbal, physical, carrying aid) 
2 = independent up and down 
 
Bathing 0 = dependent 
1 = Independent (or in shower) 
 
 SCORE  
 
 
Potential 
Score 
Patients 
Score 
Questions 
5  What is the year? Season? Date? Day? Month? 
5  Where are we now: Country? County? Town/city? 
Hospital? President?” 
3  Recall (Ball, Flag Tree) 
5  DLROW 
5  Serial Sevens 
3  Recall: Name the three objects 
2  Name two objects 
1  Repetition: ‘No ifs ands or buts’ 
3  Three step command 
1  Close your eye 
1  Write a sentence 
1  Copy this picture 
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Appendix 6 -  Structured History of Medication Use 
Questionnaire (SHiM) 
Appendix 7 – Rockwood’s Clinical Frailty Scale 
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Appendix 8 -  STOPP/START criteria version 2 
Screening Tool of Older Persons’ Prescriptions (STOPP) version 2 
The following prescriptions are potentially inappropriate to use in patients aged ≥ 65 and older. 
Section A: Indication of medication 
1. Any drug prescribed without an evidence-based clinical indication. 
2. Any drug prescribed beyond the recommended duration, where treatment duration is well 
defined. 
3. Any duplicate drug class prescription e.g. two concurrent NSAIDs, SSRIs, loop diuretics, ACE 
inhibitors, anticoagulants (optimisation of monotherapy within a single drug class should be 
observed prior to considering a new agent). 
 
Section B: Cardiovascular System 
1. Digoxin for heart failure with normal systolic ventricular function (no clear evidence of benefit) 
2. Verapamil or diltiazem with NYHA Class III or IV heart failure (may worsen heart failure). 
3. Beta-blocker in combination with verapamil or diltiazem (risk of heart block). 
4. Beta blocker with bradycardia (< 50/min), type II heart block or complete heart block (risk of 
complete heart block, asystole). 
5. Amiodarone as first-line antiarrhythmic therapy in supraventricular tachyarrhythmias (higher risk 
of side-effects than beta-blockers, digoxin, verapamil or diltiazem). 
6. Loop diuretic as first-line treatment for hypertension (safer, more effective alternatives available). 
7. Loop diuretic for dependent ankle oedema without clinical, biochemical evidence or radiological 
evidence of heart failure, liver failure, nephrotic syndrome or renal failure (leg elevation and /or 
compression hosiery usually more appropriate). 
8. Thiazide diuretic with current significant hypokalaemia (i.e. serum K+ < 3.0 mmol/l), 
hyponatraemia (i.e. serum Na+ < 130 mmol/l) hypercalcaemia (i.e. corrected serum calcium > 2.65 
mmol/l) or with a history of gout (hypokalaemia, hyponatraemia, hypercalcaemia and gout can be 
precipitated by thiazide diuretic). 
9. Loop diuretic for treatment of hypertension with concurrent urinary incontinence (may 
exacerbate incontinence). 
10. Centrally-acting antihypertensives (e.g. methyldopa, clonidine, moxonidine, rilmenidine, 
guanfacine), unless clear intolerance of, or lack of efficacy with, other classes of antihypertensives 
(centrally-active antihypertensives are generally less well tolerated by older people than younger 
people). 
11. ACE inhibitors or Angiotensin Receptor Blockers in patients with hyperkalaemia. 
12. Aldosterone antagonists (e.g. spironolactone, eplerenone) with concurrent potassium-
conserving  drugs (e.g. ACEI’s, ARB’s, amiloride, triamterene) without monitoring of serum 
potassium (risk of dangerous hyperkalaemia i.e. > 6.0 mmol/l – serum K should be monitored 
regularly, i.e. at least every 6 months). 
13. Phosphodiesterase type-5 inhibitors (e.g. sildenafil, tadalafil, vardenafil) in severe heart failure 
characterised by hypotension i.e. systolic BP < 90 mmHg, or concurrent nitrate therapy for angina 
(risk of cardiovascular collapse). 
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Section C: Antiplatelet/Anticoagulant Drugs 
1. Long-term aspirin at doses greater than 160mg per day (increased risk of bleeding, no evidence 
for increased efficacy). 
2. Aspirin with a past history of peptic ulcer disease without concomitant PPI (risk of recurrent peptic 
ulcer). 
3. Aspirin, clopidogrel, dipyridamole, vitamin K antagonists, direct thrombin inhibitors or factor Xa 
inhibitors with concurrent significant  bleeding risk, i.e. uncontrolled severe hypertension, bleeding 
diathesis, recent non-trivial spontaneous bleeding) (high risk of bleeding). 
4. Aspirin plus clopidogrel as secondary stroke prevention, unless the patient has a coronary stent(s) 
inserted in the previous 12 months or concurrent acute coronary syndrome or has a high grade 
symptomatic carotid arterial stenosis (no evidence of added benefit over clopidogrel monotherapy). 
5. Aspirin in combination with vitamin K antagonist, direct thrombin inhibitor or factor Xa inhibitors 
in patients with chronic atrial fibrillation (no added benefit from aspirin). 
6. Antiplatelet agents with vitamin K antagonist, direct thrombin inhibitor or factor Xa inhibitors in 
patients with stable coronary, cerebrovascular or peripheral arterial disease (No added benefit from 
dual therapy). 
7. Ticlopidine in any circumstances (clopidogrel and prasugrel have similar efficacy, stronger 
evidence and fewer side-effects). 
8. Vitamin K antagonist, direct thrombin inhibitor or factor Xa inhibitors for first deep venous 
thrombosis without continuing provoking risk factors (e.g. thrombophilia) for > 6 months, (no 
proven added benefit). 
9. Vitamin K antagonist, direct thrombin inhibitor or factor Xa inhibitors for first pulmonary embolus 
without continuing provoking risk factors (e.g. thrombophilia)  for > 12 months (no proven added 
benefit). 
10. NSAID and vitamin K antagonist, direct thrombin inhibitor or factor Xa inhibitors in combination 
(risk of major gastrointestinal bleeding). 
11. NSAID with concurrent antiplatelet agent(s) without PPI prophylaxis (increased risk of peptic 
ulcer disease). 
 
Section D: Central Nervous System and Psychotropic Drugs 
1. TriCyclic Antidepressants (TCAs) with dementia, narrow angle glaucoma, cardiac conduction 
abnormalities, prostatism, or prior history of urinary retention (risk of worsening these conditions). 
2. Initiation of TriCyclic Antidepressants (TCAs) as first-line antidepressant treatment (higher risk of 
adverse drug reactions with TCAs than with SSRIs or SNRIs). 
3. Neuroleptics with moderate-marked antimuscarinic/anticholinergic effects (chlorpromazine, 
clozapine, flupenthixol, fluphenzine, pipothiazine, promazine, zuclopenthixol) with a history of 
prostatism or previous urinary retention (high risk of urinary retention). 
4. Selective serotonin re-uptake inhibitors (SSRI’s) with current or recent significant hyponatraemia 
i.e. serum Na+ < 130 mmol/l (risk of exacerbating or precipitating hyponatraemia). 
5. Benzodiazepines for ≥ 4 weeks (no indication for longer treatment; risk of prolonged sedation, 
confusion, impaired balance, falls, road traffic accidents; all benzodiazepines should be withdrawn 
gradually if taken for more than 4 weeks as there is a risk of causing a benzodiazepine withdrawal 
syndrome if stopped abruptly). 
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6.  Antipsychotics (i.e. other than quetiapine or clozapine) in those with parkinsonism or Lewy Body 
Disease (risk of severe extra-pyramidal symptoms). 
7. Anticholinergics/antimuscarinics to treat extra-pyramidal side-effects of neuroleptic medications 
(risk of anticholinergic toxicity). 
8. Anticholinergics/antimuscarinics in patients with delirium or dementia (risk of exacerbation of 
cognitive impairment). 
9. Neuroleptic antipsychotic in patients with behavioural and psychological symptoms of dementia 
(BPSD) unless symptoms are severe and other non-pharmacological treatments have failed 
(increased risk of stroke). 
10. Neuroleptics as hypnotics, unless sleep disorder is due to psychosis or dementia (risk of 
confusion, hypotension, extra-pyramidal side effects, falls). 
11. Acetylcholinesterase inhibitors with a known history of persistent bradycardia (< 60 beats/min.), 
heart block or recurrent unexplained syncope or concurrent treatment with drugs that reduce heart 
rate such as beta-blockers, digoxin, diltiazem, verapamil (risk of cardiac conduction failure, syncope 
and injury). 
12. Phenothiazines as  first-line treatment, since safer and more efficacious alternatives exist 
(phenothiazines are sedative, have significant anti-muscarinic toxicity in older people, with the 
exception of prochlorperazine for nausea/vomiting/vertigo, chlorpromazine for relief of persistent 
hiccoughs and levomepromazine as an anti-emetic in  palliative care). 
13. Levodopa or dopamine agonists for benign essential tremor (no evidence of efficacy). 
14. First-generation antihistamines (safer, less toxic antihistamines now widely available). 
 
Section E: Renal System. The following drugs are potentially inappropriate in older people with 
acute or chronic kidney disease with renal function below particular levels of eGFR (refer to 
summary of product characteristics datasheets and local formulary guidelines) 
1. Digoxin at a long-term dose greater than 125µg/day if eGFR < 30 ml/min/1.73m2 (risk of digoxin 
toxicity if plasma levels not measured).  
2. Direct thrombin inhibitors (e.g. dabigatran) if eGFR < 30 ml/min/1.73m2 (risk of bleeding). 
3. Factor Xa inhibitors (e.g. rivaroxaban, apixaban) if eGFR < 15 ml/min/1.73m2 (risk of bleeding). 
4. NSAID’s if eGFR < 50 ml/min/1.73m2 (risk of deterioration in renal function). 
5. Colchicine if eGFR < 10 ml/min/1.73m2 (risk of colchicine toxicity). 
6. Metformin if eGFR < 30 ml/min/1.73m2 (risk of lactic acidosis). 
 
Section F: Gastrointestinal System 
1. Prochlorperazine or metoclopramide with Parkinsonism (risk of exacerbating Parkinsonian 
symptoms). 
2. PPI for uncomplicated peptic ulcer disease or erosive peptic oesophagitis at full therapeutic 
dosage for > 8 weeks (dose reduction or earlier discontinuation indicated). 
3. Drugs likely to cause constipation (e.g. antimuscarinic/anticholinergic drugs, oral iron, opioids, 
verapamil, aluminium antacids) in patients with chronic constipation where non-constipating 
alternatives are available (risk of exacerbation of constipation). 
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4. Oral elemental iron doses greater than 200 mg daily (e.g. ferrous fumarate> 600 mg/day, ferrous 
sulphate > 600 mg/day, ferrous gluconate> 1800 mg/day; no evidence of enhanced iron absorption 
above these doses). 
 
Section G: Respiratory System 
1. Theophylline as monotherapy for COPD (safer, more effective alternative; risk of adverse effects 
due to narrow therapeutic index). 
2. Systemic corticosteroids instead of inhaled corticosteroids for maintenance therapy in moderate-
severe COPD (unnecessary exposure to long-term side-effects of systemic corticosteroids and 
effective inhaled therapies are available). 
3. Anti-muscarinic bronchodilators (e.g. ipratropium, tiotropium) with a history of narrow angle 
glaucoma (may exacerbate glaucoma) or bladder outflow obstruction (may cause urinary retention). 
4. Benzodiazepines with acute or chronic respiratory failure i.e. pO2 < 8.0 kPa ± pCO2 > 6.5 kPa (risk 
of exacerbation of respiratory failure). 
 
Section H: Musculoskeletal System 
1. Non-steroidal anti-inflammatory drug (NSAID) other than COX-2 selective agents with history of 
peptic ulcer disease or gastrointestinal bleeding, unless with concurrent PPI or H2 antagonist (risk of 
peptic ulcer relapse). 
2. NSAID with severe hypertension (risk of exacerbation of hypertension) or severe heart failure (risk 
of exacerbation of heart failure). 
3. Long-term use of NSAID (>3 months) for symptom relief of osteoarthritis pain where paracetamol 
has not been tried (simple analgesics preferable and usually as effective for pain relief). 
4. Long-term corticosteroids (>3 months) as monotherapy for rheumatoid arthritis (risk of systemic 
corticosteroid side-effects). 
5.  Corticosteroids (other than periodic intra-articular injections for mono-articular pain) for 
osteoarthritis (risk of systemic corticosteroid side-effects). 
6. Long-term NSAID or colchicine (>3 months) for chronic treatment of gout where there is no 
contraindication to a xanthine-oxidase inhibitor (e.g. allopurinol, febuxostat) (xanthine-oxidase 
inhibitors are first choice prophylactic drugs in gout). 
7. COX-2 selective NSAIDs with concurrent cardiovascular disease (increased risk of myocardial 
infarction and stroke). 
8. NSAID with concurrent corticosteroids without PPI prophylaxis (increased risk of peptic ulcer 
disease). 
9. Oral bisphosphonates in patients with a current or recent history of upper gastrointestinal disease 
i.e. dysphagia, oesophagitis, gastritis, duodenitis, or peptic ulcer disease, or upper gastrointestinal 
bleeding (risk of relapse/exacerbation of oesophagitis, oesophageal ulcer, oesophageal stricture). 
 
Section I: Urogenital System 
1. Antimuscarinic drugs with dementia, or chronic cognitive impairment (risk of increased confusion, 
agitation) or narrow-angle glaucoma (risk of acute exacerbation of glaucoma), or chronic prostatism 
(risk of urinary retention). 
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2. Selective alpha-1 selective alpha blockers in those with symptomatic orthostatic hypotension or 
micturition syncope (risk of precipitating recurrent syncope). 
 
Section J. Endocrine System 
1. Sulphonylureas with a long duration of action (e.g. glibenclamide, chlorpropamide, glimepiride) 
with type 2 diabetes mellitus (risk of prolonged hypoglycaemia). 
2. Thiazolidenediones (e.g. rosiglitazone, pioglitazone) in patients with heart failure (risk of 
exacerbation of heart failure). 
3. Beta-blockers in diabetes mellitus with frequent hypoglycaemic episodes (risk of suppressing 
hypoglycaemic symptoms). 
4. Oestrogens with a history of breast cancer or venous thromboembolism (increased risk of 
recurrence). 
5. Oral oestrogens without progestogen in patients with intact uterus (risk of endometrial cancer). 
6. Androgens (male sex hormones) in the absence of primary or secondary hypogonadism (risk of 
androgen toxicity; no proven benefit outside of the hypogonadism indication). 
 
Section K: Drugs that predictably increase the risk of falls in older people 
1. Benzodiazepines (sedative, may cause reduced sensorium, impair balance). 
2. Neuroleptic drugs (may cause gait dyspraxia, Parkinsonism). 
3. Vasodilator drugs (e.g. alpha-1 receptor blockers, calcium channel blockers, long-acting nitrates, 
ACE inhibitors, angiotensin I receptor blockers) with persistent postural hypotension i.e. recurrent 
drop in systolic blood pressure ≥ 20mmHg (risk of syncope, falls). 
4. Hypnotic Z-drugs e.g. zopiclone, zolpidem, zaleplon (may cause protracted daytime sedation, 
ataxia). 
 
Section L: Analgesic Drugs 
1. Use of oral or transdermal strong opioids (morphine, oxycodone, fentanyl, buprenorphine, 
diamorphine, methadone, tramadol, pethidine, pentazocine) as first line therapy for mild pain (WHO 
analgesic ladder not observed). 
2. Use of regular (as distinct from PRN) opioids without concomitant laxative (risk of severe 
constipation). 
3. Long-acting opioids without short-acting opioids for break-through pain (risk of persistence of 
severe pain). 
 
Section N: Antimuscarinic/Anticholinergic Drug Burden 
Concomitant use of two or more drugs with antimuscarinic/anticholinergic properties (e.g. bladder 
antispasmodics, intestinal antispasmodics, tricyclic antidepressants, first generation antihistamines) 
(risk of increased antimuscarinic/anticholinergic toxicity). 
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Screening Tool to Alert to Right Treatment (START), version 2. 
Unless an elderly patient’s clinical status is end-of-life and therefore requiring a more palliative focus 
of pharmacotherapy, the following drug therapies should be considered where omitted for no valid 
clinical reason(s). It is assumed that the prescriber observes all the specific contraindications to 
these drug therapies prior to recommending them to older patients. 
Section A: Cardiovascular System 
1. Vitamin K antagonists or direct thrombin inhibitors or factor Xa inhibitors in the presence of 
chronic atrial fibrillation. 
2. Aspirin (75 mg – 160 mg once daily) in the presence of chronic atrial fibrillation, where Vitamin K 
antagonists or direct thrombin inhibitors or factor Xa inhibitors are contraindicated. 
3. Antiplatelet therapy (aspirin or clopidogrel or prasugrel or ticagrelor) with a documented history 
of coronary, cerebral or peripheral vascular disease. 
4. Antihypertensive therapy where systolic blood pressure consistently > 160 mmHg and/or diastolic 
blood pressure consistently >90 mmHg; if systolic blood pressure > 140 mmHg and /or diastolic 
blood pressure > 90 mmHg, if diabetic. 
5. Statin therapy with a documented history of coronary, cerebral or peripheral vascular disease, 
unless the patient’s status is end-of-life or age is > 85 years. 
6. Angiotensin Converting Enzyme (ACE) inhibitor with systolic heart failure and/or documented 
coronary artery disease. 
7. Beta-blocker with ischaemic heart disease. 
8. Appropriate beta-blocker (bisoprolol, nebivolol, metoprolol or carvedilol) with stable systolic 
heart failure. 
 
Section B: Respiratory System 
1. Regular inhaled 2 agonist or antimuscarinic bronchodilator (e.g. ipratropium, tiotropium) for 
mild to moderate asthma or COPD. 
2. Regular inhaled corticosteroid for moderate-severe asthma or COPD, where FEV1 <50% of 
predicted value and repeated exacerbations requiring treatment with oral corticosteroids. 
3. Home continuous oxygen with documented chronic hypoxaemia (i.e. pO2 < 8.0 kPa or 60 mmHg 
or SaO2 < 89%). 
 
Section C: Central Nervous System& Eyes 
1. L-DOPA or a dopamine agonist in idiopathic Parkinson’s disease with functional impairment and 
resultant disability. 
2. Non-neuro antidepressant drug in the presence of persistent major depressive symptoms. 
3. Acetylcholinesterase inhibitor (e.g. donepezil, rivastigmine, galantamine) for mild-moderate 
Alzheimer’s dementia or Lewy Body dementia (rivastigmine). 
4. Topical prostaglandin, prostamide or beta-blocker for primary open-angle glaucoma. 
5. Selective serotonin reuptake inhibitor (or SNRI or pregabalin if SSRI contraindicated) for persistent 
severe anxiety that interferes with independent functioning. 
6. Dopamine agonist (ropinirole or pramipexole or rotigotine) for Restless Legs Syndrome, once iron 
deficiency and severe renal failure have been excluded. 
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Section D: Gastrointestinal System 
1. Proton Pump Inhibitor with severe gastro-oesophageal reflux disease or peptic stricture requiring 
dilatation. 
2. Fibre supplements (e.g. bran, ispaghula, methylcellulose, sterculia) for diverticulosis with a history 
of constipation. 
 
Section E: Musculoskeletal System 
1. Disease-modifying anti-rheumatic drug (DMARD) with active, disabling rheumatoid disease. 
2. Bisphosphonates and vitamin D and calcium in patients taking long-term systemic corticosteroid 
therapy. 
3. Vitamin D and calcium supplement in patients with known osteoporosis and/or previous fragility 
fracture(s) and/or (Bone Mineral Density T-scores more than -2.5 in multiple sites). 
4. Bone anti-resorptive or anabolic therapy (e.g. bisphosphonate, strontium ranelate, teriparatide, 
denosumab) in patients with documented osteoporosis, where no pharmacological or clinical status 
contraindication exists (Bone Mineral Density T-scores >-2.5 in multiple sites) and/or previous 
history of fragility fracture(s). 
5. Vitamin D supplement in older people who are housebound or experiencing falls or with 
osteopenia (Bone Mineral Density T-score is > -1.0 but < -2.5 in multiple sites). 
6. Xanthine-oxidase inhibitors (e.g. allopurinol, febuxostat) with a history of recurrent episodes of 
gout. 
7. Folic acid supplement in patients taking methotexate. 
 
Section F: Endocrine System 
1. ACE inhibitor or Angiotensin Receptor Blocker (if intolerant of ACE inhibitor) in coa with evidence 
of renal disease i.e. dipstick proteinuria or microalbuminuria (>30mg/24 hours) with or without 
serum biochemical renal impairment. 
 
Section G: Urogenital System 
1. Alpha-1 receptor blocker with symptomatic prostatism, where prostatectomy is not considered 
necessary. 
2. 5-alpha reductase inhibitor with symptomatic prostatism, where prostatectomy is not considered 
necessary. 
3. Topical vaginal oestrogen or vaginal oestrogen pessary for symptomatic atrophic vaginitis. 
 
Section H: Analgesics 
1. High-potency opioids in moderate-severe pain, where paracetamol, NSAIDs or low-potency 
opioids are not appropriate to the pain severity or have been ineffective. 
2. Laxatives in patients receiving opioids regularly. 
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Section I: Vaccines 
1. Seasonal trivalent influenza vaccine annually. 
2. Pneumococcal vaccine at least once after age 65 according to national guidelines. 
  
 
Appendix 9 - OncPal criteria 
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Appendix 10 - STOPPFrail questionnaire on survey monkey 
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Appendix 11 - Physicians who participants in the IRR of STOPPFrail criteria 
 Name Discipline Place of practice 
1 Dr. Norma Harnedy Geriatric Medicine 
(consultant) 
Cork University Hospital, Cork 
2 Dr. Liam Healy Geriatric Medicine 
(consultant) 
Cork University Hospital, Cork 
3 Dr. Rónán O’Caoimh Geriatric Medicine 
(consultant) 
University Hospital Galway 
4 Dr. Mary Buckley Geriatric Medicine 
(specialist registrar) 
Mercy University Hospital, Cork 
5 Dr. Tim Dukelow Geriatric Medicine 
(specialist registrar) 
Mercy University Hospital, Cork 
6 Dr. Bart Daly Geriatric Medicine 
(specialist registrar) 
Cork University hospital, Cork 
7 Dr. Katie Boyle General Practice Cork City Medical Centre, 91 Patrick 
Street, Cork 
8 Dr. Sadhbh Ní Lionáird 
 
General Practice Meadow Park surgery, Ballyvolane, 
Cork. 
9 Dr. Denis O’Donovan General Practice 
(trainee) 
Cork Specialist training Scheme in 
General Practice. 
10 Dr. Fiona Kiely Palliative care 
(consultant) 
Marymount University Hospital & 
Hospice & Cork University Hospital, 
Cork 
11 Dr. Marie Murphy Palliative care 
(consultant) 
Marymount University Hospital & 
Hospice & Cork University Hospital, 
Cork 
12 Dr. Coman Hennelly Palliative care (specialist 
registrar) 
Marymount University Hospital & 
Hospice & Cork University Hospital, 
Cork 
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Appendix 12 - Twenty clinical cases for assessment of STOPPFrail IRR 
 
Case 1 
Age:    78 
Sex:    female 
Current location:                      Acute hospital with pneumonia 
Usual location:  Living at home but has applied for long term care secondary to severe 
functional and cognitive impairment. 24 supervision by family. 
 
Medical History:                      1.      Dementia diagnosed 2009  
2. Diabetes Mellitus type 2 (HbA1c 6%) 
3. Anxiety diagnosed 15 years ago (Currently no objective 
symptoms) 
4. Intracerebral haemorrhage 2012 
5. Orthostatic hypotension 
6. Hypertension 
7. Carotid stenosis 
8. Diverticular disease – constipation on occasion 
9. Urinary incontinence 
 
Medications:  No problems with medication adherence 
1. Calcium carbonate 500mg po bd (> 5 years) 
2. Cholecalciferol 400IU po bd (> 5 years) 
3. Atorvastatin 40mg po od (> 5 years) 
4. Lansoprazole 30mg po od (4 years) 
5. Senna one tablet po od (1 year) 
6. Folic acid 5mg po od (4 years) 
7. Lercandipine 10mg po od (> 5 years) 
8. Valsartan 40mg po od (> 5 years) 
9. Paracetamol 1g po tds (4 years) 
10. Alprazolam 250mcg po od (1 year) 
Social History: 
Cognition:                      MMSE score 8/30 six months ago 
Function:                      Assistance of two for transfers, wheelchair dependent 
   Urinary incontinent 
   Fully dependent in all activities of daily living (ADLs) 
Speech:   Verbalises but cannot express needs of wishes (random words) 
Behaviour:  No behaviour problems 
 
Case 2 
Age:    89 
Sex:    male 
Current location:                      Acute hospital with pneumonia 
Usual location:  Nursing home resident for 1 year 
 
Medical History: 
1. Total anterior circulation stroke 2015 
2. Post stroke epilepsy 2015 
3. Atrial fibrillation (not for anti-coagulation) 
4. Constipation 
5. BPH (long term catheter in situ) 
6. Recurrent infections (LRTIs, UTIs) 
7. Faecal incontinence 
 
Medications:  No problems with medication adherence 
1. Levetiracetam 250mg po bd (1 year) 
2. Fluvastatin 20mg po od (> 5 years) 
3. Lactulose 15ml po tds (1 year) 
4. Digoxin 125mcg po od (1 year) 
5. Fresubin 5kcal (energy + protein + fat) nutritional supplement 
one carton od (1 year) 
6. Trimethoprim 100mg po od (1 year) 
7. Tamsulosin 400mcg po od (> 5 years) 
 
Social History: 
Cognition:                     MMSE untestable (global aphasia) 
Function:                      Hoist transfer 
   Faecal incontinence 
   Fully dependent in all ADLs 
Speech:   Global aphasia 
Behaviour:  No behaviour problems 
 
 
358 
 
 
Case 3 
Age:    80 
Sex:    female 
Current location:                      Acute hospital with acute agitation (delirium) and constipation 
Usual location:  Living at home with 24 hour supervision by her family 
 
Medical History: 
1. Dementia diagnosed 2010 
2. Diabetes Mellitus type 2 (HbA1c 6.3% one month ago) 
3. Dyslipidaemia 
4. Depression 
5. Hypertension 
6. Osteoarthritis 
7. Urinary incontinence 
8. Constipation 
 
Medications:  No problems with medication adherence 
1. Escitalopram 10mg po od (> 5 years) 
2. Esomeprazole 20mg po od (> 5 years) 
3. Rosuvastatin 20mg po od (> 5 years) 
4. Movicol one sachet po bd (2 years) 
5. Rivastigmine patch 9.5mg od (> 5 years) 
6. Gliclazide 60mg po od (> 5 years) 
7. Metformin 500mg po bd (> 5 years) 
8. Sitagliptin 50mg po od (2 years) 
 
Social History:  
Cognition:                      MMSE 10/30 
Function: Walks with rollator 
Poor safety awareness 
Assistance required with all ADLs 
Speech:   Verbalises but cannot express needs of wishes 
Behaviour:  No behaviour problems generally 
 
 
Case 4 
Age:    86 
Sex:    female 
Current location:                      GP surgery for flu vaccination 
Usual location:  Living at home with her husband and daughter 
 
Medical History: 
1. Anaemia 
2. Congestive heart failure 
3. Colorectal cancer – stage 4 – not for further treatment 
4. GORD during previous treatment 
5. Anxiety 
6. Osteoporosis 
7. COAD – GOLD stage 4 
8. Atrial fibrillation 
 
Medications:  Some problems with medication adherence (see each medication) 
1. Ferrous fumarate 305mg po od (Hb 12.8) (1 year) 
2. Warfarin as per INR (recently erratic – difficulty attending to get 
INRs checked) (>5 years) 
3. Furosemide 40mg po bd (>5 years) 
4. Ramipril 5mg po od (>5 years) 
5. Rosuvastatin 10mg po od (>5 years) 
6. Ranitidine 150mg po bd (1 year) 
7. Diazepam 5mg po nocte (1 year) 
8. Calcium carbonate 500mg po bd (>5 years) 
9. Cholecalciferol 400IU po bd (>5 years) 
10. Seretide (fluticasone/salmeterol) 250mcg inhaled bd – difficulty 
using (>5 years) 
11. Theophylline 200mg po od (>5 years) 
12. Centrum multivitamin one tablet od (1 year) 
13. Fortisip (energy + protein + fat) nutritional supplement one 
carton od (1 year) 
 
Social History:  
Cognition:                      MMSE 24/30 
Function:                      Walks with the help of two people very short distances. 
Assistance required with all ADLs 
Increasing frailty 
Speech:   Communicates ok, some repetition  
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Case 5 
Age:    85 
Sex:    female 
Current location:                      GP surgery for flu vaccination 
Usual location:  Living at home with her husband and daughter 
 
Medical History: 
1. Parkinson’s disease diagnosed 2008 
2. Parkinson’s related dementia 2013 
3. Orthostatic hypotension 2014 
4. HTN 
5. Diabetes 
6. Osteoporosis: previous hip fracture 2012 
7. Dyslipidaemia 
 
Medications:  No problems with medication adherence 
1. Betahistidine 16mg po tds (2 years) 
2. Stalevo (levodopa/carbidopa/entacapone) 
150mg/37.5mg/200mg po qds (>5 years) 
3. Doxazosin 4mg po od (>5 years) 
4. Amlodipine 10mg po od (>5 years) 
5. Metformin 500mg po tds (>5 years) 
6. Gliclazide 90mg po od (>5 years) 
7. Sitagliptin 50mg po bd (>5 years) 
8. Calcium carbonate 500mg po bd (4 years) 
9. Cholecalciferol 400IU po bd (4 years) 
10. Pravastatin 10mg po od (>5 years) 
11. Aspirin 75mg po od (>5 years) 
 
Social History:  
Cognition:                      MMSE 10/30 
Function:                      Walks with a rollator and assistance of 1 
Assistance required with all ADLs 
Increasing frailty 
Speech:   Verbalises but cannot express needs of wishes 
 
 
Case 6 
Age:    82 
Sex:    male 
Current location:                      Acute hospital with pneumonia 
Usual location:  Nursing home resident 
 
Medical History: 
1. BPH  (Previous TURP, long term catheter in situ for 1 year) 
2. HTN 
3. Alzheimer’s dementia 2010 
4. Osteoarthritis 
5. GORD 
6. Diverticular disease  
7. Faecal incontinence 
 
Medications:  Some problems with medication adherence (see each medication) 
1. Dutasteride 0.5mg po od (>5 years) 
2. Tamsulosin 0.4mg po od (>5 years) 
3. Ramipril 10mg po od (>5 years) 
4. Amlodipine 10mg po od (>5 years) 
5. Donepezil 10mg po od (>5 years) 
6. Memantine 20mg po od (3 years) 
7. Paracetamol 1g po tds (1 year) 
8. Naproxen 500mg po od (1 year) 
9. Esomeprazole 40mg po od (1 year) 
10. Lactulose 15mls po tds (1 year) 
11. Fresubin 5 kcal (energy + protein + fat) nutritional supplement 
od (1 year) (patient refuses regularly) 
12. Fresubin 2 kcal (energy + protein + fat) nutritional supplement 
od (1 year) (patient refuses regularly) 
 
Social History:  
Cognition:                     MMSE untestable 
Function:                     Bed bound 
   Hoist transfer 
   Faecal incontinence 
   No behavioural problems 
Speech:   Verbalises but cannot express needs of wishes 
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Case 7 
Age:    75 
Sex:    female 
Current location:                      Oncology outpatients 
Usual location:  Living at home with sister 
 
Medical History: 
1. Ulcerative colitis (colostomy in situ for 30 years) 
2. HTN 
3. Dyslipidaemia 
4. Osteoarthritis 
5. Diabetes Mellitus 
6. Angiosarcoma - stage 4 – diagnosed 2015 
 Unresponsive to treatment 
 Bony metastases 
 Prognosis per oncologist 6 months 
7. Anaemia 
 
Medications:  No problems with medication adherence 
1. Gliclazide 60mg po od (>5 years) 
2. Atorvastatin 40mg po od (>5 years) 
3. Morphine sulphate 10mg po od (3 months) 
4. Lercandipine 10mg po od (>5 years) 
5. Diclofenac 50mg po bd (4 months) 
6. Alendronate 70mg po once a week (1 year) 
7. Calcium carbonate 500mg po bd (1 year) 
8. Cholecalciferol 400IU po bd (1 year) 
Social History:  
Cognition:                      MMSE 28/30 
Function:                      Huge deterioration in function in the last 2 months  
   Walks with rollator from bed to bathroom with assistance of 1 
   Fully dependent in all ADLs  
Speech:   No issues 
 
 
 
Case 8 
Age:    80 
Sex:    female 
Current location:                      Geriatric Outpatients 
Usual location:  Living independently 
 
Medical History: 
1. Congestive heart failure (NYHA II) 
2. Anaemia (Hb 12) 
3. Dyslipidaemia 
4. Asthma 
 
Medications:  No problems with medication adherence 
1. Aspirin 75mg po od (3 years) 
2. Perindopril 10mg po od (3 years) 
3. Spironolactone 25mg po od (3 years) 
4. Bisoprolol 10mg po od (3 years) 
5. Ferrous fumarate 305mg po od (6 months) 
6. Atorvastatin 10mg po od (3 years) 
7. Salbutamol inhaler two puffs prn (> 5 years) 
8. Symbicort (budesonide/formeterol) 400/12mcg inhaled bd (> 5 
years) 
9. Centrum multivitamin po od (1 year) 
10. Bumetanide 1mg po bd (1 year) 
 
Social History:  
Cognition:                      MMSE 28/30 
Function:                      Independent of all activities of daily living.  
Speech:   No issues 
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Case 9 
Age:    82 
Sex:    female 
Current location:                      Acute hospital due to recent seizure activity 
Usual location:   Nursing home resident 
 
Medical History: 
1. Dementia 2010 
2. Recurrent UTIs 
3. Seizures secondary to dementia 
4. HTN 
5. GORD 
6. B12 deficiency (current B12 > 1500) 
 
Medications:  Some problems with medication adherence (see each medication) 
1. Donepezil 10mg po od (>5 years) 
2. Memantine 20mg po od (3 years) 
3. Trimethoprim 100mg po od (2 years) 
4. Levetiracetam 500mg po bd (2 years) 
5. Bisoprolol 10mg po od (>5 years) 
6. Perindopril 5mg po od (>5 years) 
7. Ranitidine 150mg po bd (>5 years) 
8. Hydroxycobalamin 1mg IM 3 monthly (2 years) 
9. Fortisip (energy + protein + fat) nutritional supplement 1 carton 
od (patient refuses frequently) (2 years) 
 
Social History:  
Cognition:                      MMSE untestable 
Function:                      Bed bound 
Hoist transfer 
Dependent in all ADLs 
No behavioural problems 
Speech:   mute 
 
 
 
Case 10 
Age:    74 
Sex:    male 
Current location:                      Oncology outpatients 
Usual location:  Home with wife 
 
Medical History: 
1. BPH (no catheter) 
2. Ischaemic heart disease (previous MI and CABG) 
3. Heart failure 
4. COAD 
5. Lung cancer - stage 4, bony metastases 
6. Dyslipidaemia 
7. Atrial fibrillation 
8. Constipation 
9. Chronic kidney disease 
 
Medications:  Some problems with medication adherence (see each medication) 
1. Aspirin 75mg po od (>5 years) 
2. Bisoprolol 10mg po od (>5 years) 
3. Dutasteride 0.5mg po od (>5 years) 
4. Tamsulosin 0.4mg po od (>5 years) 
5. Rosuvastatin 40mg po od (>5 years) 
6. Ultibro (Indacterol/glycopyronium bromide) 85/43mcg inhaled 
od (>5 years) (difficulty using) 
7. Combivent (ipratropium bromide/salbutamol) 500mcg/2.5mg 
nebulised qds (6 months) 
8. Denosumab 120mg sc 4 weekly (6 months) 
9. Movicol (macrogol) 1 sachet bd (6 months) 
10. Fresubin 5 kcal (energy + protein + fat) nutritional supplement 
od (6 months) 
11. Fresubin 2 kcal (energy + protein + fat) nutritional supplement 
od (6 months) 
12. Quinine sulphate 300mg po od (>5 years) 
 
Social History:  
Cognition:                     MMSE 29/30 
Function:                      Increasing frailty over the last 3 months 
   Walks short distance with assistance of 2 indoors 
Dependent in all ADLs, wheelchair dependent outside home 
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Case 11 
Age:    76 
Sex:    male 
Current location:                      Acute hospital with aspiration pneumonia 
Usual location:  Nursing home resident 
 
Medical History: 
1. Stroke: TACS 2014 
2. Post stroke depression 
3. Atrial fibrillation 
4. PE post stroke 
5. Recurrent aspiration pneumonia (increasing frequency over the 
last 6 months) 
6. PEG fed 
7. HTN 
 
Medications:  No problems with medication adherence 
1. Escitalopram 10mg po od (2 years) 
2. Ramipril 10mg po od (2 years) 
3. Apixaban 5mg po bd (2 years) 
4. Atorvastatin 10mg po od (>5 years) 
5. Doxazosin 4mg po od (>5 years) 
6. Lansoprazole 30mg po od (2 years) 
7. Quetiapine 25mg po nocte (4 months) 
8. Centrum B-complex multivitamin po od (2 years) 
 
Social History: 
Cognition:                      MMSE untestable (global aphasia) – no concerns regarding this 
Function:                      Bed bound, Hoist transfer 
   Fully dependent in all ADLs 
   Poor sleep 
Speech:   Global aphasia 
Behaviour:  No behaviour problems 
 
 
Case 12 
Age:    80 
Sex:    female 
Current location:                      Geriatric outpatients for review of anxiety 
Usual location:  Nursing home resident (moved in 4 weeks ago) 
 
Medical History: 
1. Recurrent cellulitis 
 Started prophylactic antibiotics 1 year ago 
 Three episodes per year pre and post antibiotics 
2. Anxiety (new diagnosis) 
3. Osteoarthritis 
4. Constipation 
5. Hypothyroidism 
6. COAD stage 4 (on home oxygen) 
 Recurrent exacerbations 
 4 hospital admission in the last 6 months 
 
Medications:  No problems with medication adherence 
1. Calvepen (penicillin V) 500mg po bd (1 year) 
2. Paracetamol 1g po tds (1 year) 
3. Diclofenac 50mg po bd (4 months) 
4. Lactulose 10ml po tds (1 year) 
5. Senna two tablets od (1 year) 
6. Levothyroxine 75mcg po od (2 years) 
7. Combivent (ipratropium bromide/salbutamol) 500mcg/2.5mg 
nebuliser qds (3 years) 
8. Betahistidine 16mg po tds (1 year) 
9. Folic acid 5mg po od (2 years) 
 
Social History: 
Cognition:                     MMSE 27/30 
Function:                     Assistance of two to stand, restricted by SOB  
   Fully dependent of ADLS 
Speech:   No problems 
Behaviour:  No behaviour problems 
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Case 13 
Age:    78 
Sex:    female 
Current location:                      GP review for depression 
Usual location:  Nursing home resident 
 
Medical History: 
1. HTN 
2. Osteoarthritis 
3. Osteoporosis: hip fracture 2013) 
 
Medications:  No problems with medication adherence 
1. Aspirin 75mg po od (>5 years) 
2. Bisoprolol 2.5mg po od (>5 years) 
3. Alendronate 70mg po once a week (3 years) 
4. Paracetamol 1g po tds (3 years) 
5. Calcium carbonate 500mg po bd (3 years) 
6. Cholecalciferol 400IU po bd (3 years) 
7. Diclofenac 75mg as required (3 months) 
 
Social History: 
Cognition:                      MMSE 30/30 
Function:                      Independent of all ADLS, walks with one stick 
                                                            Moved into the nursing home due to social isolation 
Speech:   No problems 
Behaviour:  No behaviour problems 
 
 
 
 
Case 14 
Age:    77 
Sex:    female 
Current location:                      GP review in nursing to assess for a DNAR order 
Usual location:   Nursing home resident 
 
Medical History: 
1. Rheumatoid arthritis (burnt out disease) 
2. Osteoarthritis 
3. Diabetes Mellitus diagnosed 2012 
4. Dementia  
5. Constipation 
6. GORD 
7. Urinary incontinence (24 hour pads for the last year, no 
awareness) 
 
Medications:  No problems with medication adherence 
1. Prednisolone 5mg po od (2 years) 
2. Paracetamol 1g po tds (>5 years) 
3. Metformin 500mg po tds (4 years) 
4. Gliclazide 60mg po od (4 years) 
5. Valsartan 80mg po od (4 years) 
6. Solifenacin 5mg po od (>5 years) 
7. Esomeprazole 20mg po od (>5 years) 
8. Movicol (macrogol) one sachet bd (1 year) 
9. Fortisip (energy + protein + fat) nutritional supplement one 
carton od (1 year) 
10. Centrum multivitamin one tablet od (1 year) 
11. Denosumab 60 mg sc 6-monthly (2 years) 
 
Social History: 
Cognition:                     MMSE 24/30 
Function:                      Bed bound and hoist transfer due to RA 
   Totally dependent for all ADLs 
Speech:   No problems 
Behaviour:  No behaviour problems 
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Case 15 
Age:    90 
Sex:    male 
Current location:                      Acute hospital with urosepsis 
Usual location:  Nursing home resident 
 
Medical History: 
1. Dementia 2007 
2. BPH – long term catheter in situ 
3. Recurrent UTIS 
 
Medications:  No problems with medication adherence    
1. Donepezil 10mg po od (>5 years) 
2. Memantine 20mg po od (4 years) 
3. Tamsulosin 400mcg po od (>5 years) 
4. Trimethoprim 100mg po od (2 years) 
5. Fortisip (energy + protein + fat) nutritional supplement one 
carton od (2 years) 
 
Social History: 
Cognition:                      MMSE untestable 
Function:                      Bed bound and hoist transfer  
   Totally dependent for all ADLs 
Speech:   Mute 
Behaviour:  No behaviour problems 
 
 
Case 16 
Age:    79 
Sex:    female 
Current location:                      Acute hospital with superior vena cava obstruction (prognosis 30 days) 
Usual location:  Living in own home with family 
 
Medical History: 
1. Breast cancer  - stage 4 (brain and bone metastasis) diagnosed 
2015 
2. PE 
3. Subclinical hypothyroidism 
4. Depression 
5. Constipation 
6. Dyslipidaemia 
7. Low BMI 
8. Recurrent UTIs 
9. GORD 
 
Medications:  No problems with medication adherence  
1. Capecitabine 500mg po tds (1 year) 
2. Tinzaparin 10,000IU sc od (1 day) 
3. Levothyroxine 25mcg po od (1 year) 
4. Escitalopram 10mg po od (1 year) 
5. Senna two tablets nocte (1 year) 
6. Atorvastatin 10mg po od (>5 years) 
7. Trimethoprim 100mg po od (1 year) 
8. Lansoprazole 15mg po od (>5 years) 
9. Fortisip (energy + protein + fat) nutritional supplement one carton 
po od (1 year) 
 
Social History: 
Cognition:                     MMSE 29/30 
Function:                     Independent up until one month ago. 
   Rapid deterioration since 
   Currently dependent for all ADLs 
   Assistance of two to stand up, can only walk one or two steps 
Speech:   No problems 
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Case 17 
Age:    67 
Sex:    male 
Current location:                      Acute hospital with pneumonia 
Usual location:  Living in own home with family 
 
Medical History: 
1. Motor neuron disease diagnosed 6 months earlier (rapid 
deterioration) 
 RIG (radiological insertion gastrostomy) in situ x 3 
months 
2. HTN 
3. GORD 
4. Dyslipidaemia 
 
Medications:  No problems with medication adherence  
1. Lansoprazole 15mg po od (>5 years) 
2. Amlodipine 10mg po od (>5 years) 
3. Rosuvastatin 10mg po od (>5 years) 
 
Social History: 
Cognition:                      MMSE untestable 
Function:                      Bed bound 
   Hoist transfer 
   Dependent for all ADLs 
Speech:   Unable to communicate secondary to motor dysfunction 
 
 
Case 18 
Age:    77 
Sex:    male 
Current location:                      Acute hospital with pneumonia 
Usual location:  Nursing home resident 
 
Medical History: 
1. Lung cancer (stage 4) (on home oxygen) diagnosed 2015 
2. COAD (GOLD stage 4) (on home oxygen) 
3. BPH 
4. Dyslipidaemia 
5. GORD 
6. Depression  
7. Diverticular disease 
 
Medications:  No problems with medication adherence  
1. Montelukast 10mg po od (>5 years) 
2. Seretide (fluticasone/salmeterol) 500mcg mcg inhaled bd (>5 
years) 
3. Ventolin (salbutamol) inh prn (>5 years) 
4. Aspirin 75mg po od (>5 years) 
5. Dutasteride 0.5mg po od (>5 years) 
6. Tamsulosin 0.4mg po od (>5 years) 
7. Rosuvastatin 10mg po od (>5 years) 
8. Esomeprazole 20mg po od (>5 years) 
9. Escitalopram 10mg po od (1 year) 
10. Fresubin 2Kcal (energy + protein + fat) nutritional supplement od 
(1 year) 
11. Fresubin 5kcal (energy + protein + fat) nutritional supplement od 
(1 year) 
 
Social History: 
Cognition:                     MMSE 28/30 
Function:                      Assistance of two to stand 
   Unable to walk 
   Wheelchair dependent 
   Dependent for all ADLs 
Speech:   No problems 
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Case 19 
Age:    81 
Sex:    female 
Current location:                      Geriatric outpatient for pharmacology review 
Usual location:  Nursing home resident 
 
Medical History: 
1. Dementia diagnosed 2009 
2. Osteoporosis 
3. Dyslipidaemia 
4. Urinary incontinence 
 
Medications:  Some problems with medication adherence (see each medication) 
1. Rivastigmine patch 9.5mg transdermal over 24 hours  (>5 years) 
2. Calcium carbonate 500mg po bd (>5 years) (difficulty taking) 
3. Cholecalciferol 400IU po bd (>5 years) (difficulty taking) 
4. Evista (raloxifene) (>5 years) 60mg po od (>5 years) (difficulty 
taking) 
5. Rosuvastatin 10mg po od (>5 years) (difficulty taking) 
6. Fortisip compact (energy + protein + fat) nutritional supplement 
one carton po od (1 year) (refuses regularly) 
7. Quetiapine 50mg po od (1 year) (uses syrup preparation, no 
difficulty taking) 
 
Social History: 
Cognition:                      MMSE 12/30 
Function:                      Assistance of two to stand 
                                                            Unable to walk 
   Wheelchair dependent 
   Dependent for all ADLs 
Speech:   No problems 
Behaviour:  No problems 
 
 
 
 
 
 
Case 20 
Age:    70 
Sex:    male 
Current location:                      Acute hospital with pneumonia 
Usual location:  Nursing home resident 
 
Medical History: 
1. Osteoarthritis 
2. Osteoporosis 
3. Chronic lower back pain 
4. Benign essential tremor 
5. Gastritis 2010 (while on oral nsaids) 
6. Peripheral vascular disease  - Above knee right leg amputation 
7. IHD - MI 2 months ago 
8. Stroke disease 
9. Carotid artery disease 
10. HTN 
11. CCF (NYHA 4) 
12. Anxiety 
13. Smoker 
 
Medications:  No problems with medication adherence  
1. Aspirin 75mg po od (>5 years) 
2. Atorvastatin 10mg po od (>5 years) 
3. Perindopril 10mg po od (>5 years) 
4. Eplerenone 25mg po od (>5 years) 
5. Lansoprazole 30mg po od (>5 years) 
6. Paracetamol 1g po tds (>5 years) 
7. Buprenorphine patch 10micograms/hr (2 years) 
8. Risedronate 35mg per week (4 years) 
9. Calcium carbonate 500mg po bd (4 years) 
10. Cholecalciferol 400IU po bd (4 years) 
11. Sinemet (Levodopa / carbidopa) 125mg bd (1 year) 
12. Flurazepam 30mg po nocte (1 year) 
 
Social History: 
Cognition:                       MMSE 28/30 
Function:                      Hoist, wheelchair dependent, Dependent for all ADLs 
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Appendix 13 - Twenty answer sheets for assessment of STOPPFrail IRR 
Case 1 
 
Does the patient meet the criteria for STOPPFrail to be applicable? 
Criteria to meet:  
End stage irreversible pathology  
Poor one year survival prognosis  
Severe functional impairment OR severe cognitive impairment OR both  
Symptom control is the priority rather than prevention of disease progression  
 
Yes  No  
 
If yes, review the drug list and assess STOPPFrail criteria: 
Drug Tick if this drug meets any 
STOPPFrail criteria AND you 
would stop it. 
List STOPPFrail indicators 
relevant to this drug 
Calcium carbonate 400mf po bd 
 
  
Cholecalciferol 400IU po bb 
 
  
Atorvastatin 40mg po od 
 
  
Lansoprazole 30mg po od 
 
  
Senna one tablet po od 
 
  
Folic acid 5mg po od 
 
  
Lercandipine 10mf po od 
 
  
Valsartan 40mg po od 
 
  
Paracetamol 1g po tds 
 
  
Alprazolam 250mcg po od 
 
  
 
Case 2 
 
Does the patient meet the criteria for STOPPFrail to be applicable? 
Criteria to meet: 
End stage irreversible pathology  
Poor one year survival prognosis  
Severe functional impairment OR severe cognitive impairment OR both  
Symptom control is the priority rather than prevention of disease progression  
 
Yes  No  
 
If yes, review the drug list and assess STOPPFrail criteria: 
Drug Tick if this drug meets any 
STOPPFrail criteria AND you 
would stop it. 
List STOPPFrail indicators 
relevant to this drug 
Levetiracetam 250mg po bd 
 
  
Fluvastatin 20mg po od 
 
  
Lactulose 15ml po tds 
 
  
Digoxin 125mcg po od 
 
  
Fresublin 5kcal one carton od 
 
  
Trimethoprim 100mg po od 
 
  
Tamsulosin 400mcg po od 
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Case 3 
Does the patient meet the criteria for STOPPFrail to be applicable? 
Criteria to meet: 
End stage irreversible pathology  
Poor one year survival prognosis  
Severe functional impairment OR severe cognitive impairment OR both  
Symptom control is the priority rather than prevention of disease progression  
 
Yes  No  
 
If yes, review the drug list and assess STOPPFrail criteria: 
Drug Tick if this drug meets any 
STOPPFrail criteria AND you 
would stop it. 
List STOPPFrail indicators 
relevant to this drug 
Escitalopram 10mg po od 
 
  
Esomeprazole 20mg po od 
 
  
Rosuvastatin 20mg po od 
 
  
Movicol one sachet po bd 
 
  
Rivastigmine patch 9.5mg od 
 
  
Gliclazide 60mg po od 
 
  
Metformin 500mg po bd 
 
  
Sitagliptin 50mg po od 
 
  
 
 
 
 
Case 4 
Does the patient meet the criteria for STOPPFrail to be applicable? 
Criteria to meet: 
End stage irreversible pathology  
Poor one year survival prognosis  
Severe functional impairment OR severe cognitive impairment OR both  
Symptom control is the priority rather than prevention of disease progression  
 
Yes  No  
 
If yes, review the drug list and assess STOPPFrail criteria: 
Drug Tick if this drug meets any 
STOPPFrail criteria AND you 
would stop it. 
List STOPPFrail indicators 
relevant to this drug 
Ferrous fumarate 305mg po od 
 
  
Warfarin as per INR 
 
  
Furosemide 40mg po bd 
 
  
Ramipril 5mg po od 
 
  
Rosuvastatin 10mg po od 
 
  
Diazepam 5mg po nocte 
 
  
Calcium carbonate 400mg po bd 
 
  
Cholecalciferol 400IU po bd 
 
  
Seretide (fluticasone/salmeterol)  
 
  
Theophylline 200mg po od 
 
  
Centrum multivitamin od 
 
  
Fortisip one carton od   
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Case 5 
Does the patient meet the criteria for STOPPFrail to be applicable? 
Criteria to meet: 
End stage irreversible pathology  
Poor one year survival prognosis  
Severe functional impairment OR severe cognitive impairment OR both  
Symptom control is the priority rather than prevention of disease progression  
 
Yes  No  
 
If yes, review the drug list and assess STOPPFrail criteria 
Drug Tick if this drug meets any 
STOPPFrail criteria AND 
you would stop it. 
List STOPPFrail indicators 
relevant to this drug 
Betahistidine 16mg po tds 
 
  
Stalevo(levodopa/carbidopa/entacapone) 
150mg/37.5mg/200mg po qds 
 
  
Doxazosin 400mg po od 
 
  
Amlodipine 10mg po od 
 
  
Metformin 500mg po tds 
 
  
Gliclazide 90mg po od 
 
  
Sitagliptin 50mg po bd 
 
  
Calcium carbonate 400mg po bd 
 
  
Cholecalciferol 400IU po bd 
 
  
Pravastatin 10mg po od 
 
  
Aspirin 75mg po od 
 
  
 
Case 6 
Does the patient meet the criteria for STOPPFrail to be applicable? 
Criteria to meet: 
End stage irreversible pathology  
Poor one year survival prognosis  
Severe functional impairment OR severe cognitive impairment OR both  
Symptom control is the priority rather than prevention of disease progression  
 
Yes  No  
 
If yes, review the drug list and assess STOPPFrail criteria 
Drug Tick if this drug meets any 
STOPPFrail criteria AND you 
would stop it. 
List STOPPFrail indicators 
relevant to this drug 
Dutasteride 0.5mg po od 
 
  
Tamsulosin 0.4mg po od 
 
  
Ramipril 10mg po od 
 
  
Amlodipine 10mg po od 
 
  
Donepezil 10mg po od 
 
  
Memantine 20mg po od 
 
  
Paracetamol 1g po tds 
 
  
Naproxen 500mg po od 
 
  
Esomeprazole 40mg po od 
 
  
Lactulose 15mls po tds 
 
  
Fresubin 5 kcal od 
 
  
Fresubin 2Kcal od   
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Case 7 
Does the patient meet the criteria for STOPPFrail to be applicable? 
Criteria to meet: 
End stage irreversible pathology  
Poor one year survival prognosis  
Severe functional impairment OR severe cognitive impairment OR both  
Symptom control is the priority rather than prevention of disease progression  
 
Yes  No  
 
If yes, review the drug list and assess STOPPFrail criteria 
Drug Tick if this drug meets any 
STOPPFrail criteria AND you 
would stop it. 
List STOPPFrail indicators 
relevant to this drug 
Gliclazide 60mg po od 
 
  
Atorvastatin 40mg po od 
 
  
Morphine sulphate 10mg po od 
 
  
Lercandipine 10mg po od 
 
  
Diclofenac 50mg po bd 
 
  
Alendronate 70mg po once a 
week 
 
  
Calcium carbonate 400mg po 
bd 
 
  
Cholecalciferol 400IU po bd 
 
  
 
Case 8 
Does the patient meet the criteria for STOPPFrail to be applicable? 
Criteria to meet: 
End stage irreversible pathology  
Poor one year survival prognosis  
Severe functional impairment OR severe cognitive impairment OR both  
Symptom control is the priority rather than prevention of disease progression  
 
Yes  No  
 
If yes, review the drug list and assess STOPPFrail criteria 
Drug Tick if this drug meets any 
STOPPFrail criteria AND you 
would stop it. 
List STOPPFrail indicators 
relevant to this drug 
Aspirin 75mg po od 
 
  
Perindopril 10mg po od 
 
  
Spironolactone 25mg po od 
 
  
Bisoprolol 10mg po od 
 
  
Ferrous fumarate 305mg po od 
 
  
Atorvastatin 10mg po od 
 
  
Salbutamol inhaler two puffs prn 
 
  
Symbicort 
(budesonide/formeterol) inh bd 
 
  
Centrum multivitamin po od 
 
  
Bumetanide 1mg po bd 
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Case 9 
Does the patient meet the criteria for STOPPFrail to be applicable? 
Criteria to meet: 
End stage irreversible pathology  
Poor one year survival prognosis  
Severe functional impairment OR severe cognitive impairment OR both  
Symptom control is the priority rather than prevention of disease progression  
 
Yes  No  
 
If yes, review the drug list and assess STOPPFrail criteria 
Drug Tick if this drug meets any 
STOPPFrail criteria AND you 
would stop it. 
List STOPPFrail indicators 
relevant to this drug 
Donepezil 10mg po od 
 
  
Memantine 20mg po od 
 
  
Trimethoprim 100mg po od 
 
  
Levetiracetam 500mg po bd 
 
  
Bisoprolol 10mg po od 
 
  
Perindopril 5mg po od 
 
  
Ranitidine 150mg po bd 
 
  
Hydroxycobalamin 1mg IM 3 
monthly  
 
  
Fortisip 1 carton od 
 
  
 
 
 
 
Case 10 
Does the patient meet the criteria for STOPPFrail to be applicable? 
Criteria to meet: 
End stage irreversible pathology  
Poor one year survival prognosis  
Severe functional impairment OR severe cognitive impairment OR both  
Symptom control is the priority rather than prevention of disease progression  
 
Yes  No  
 
If yes, review the drug list and assess STOPPFrail criteria 
Drug Tick if this drug meets any 
STOPPFrail criteria AND 
you would stop it. 
List STOPPFrail indicators 
relevant to this drug 
Aspirin 75mg po od 
 
  
Bisoprolol 10mg po od 
 
  
Dutasteride 0.5mg po od 
 
  
Tamsulosin 0.4mg po od 
 
  
Rosuvastatin 40mg po od 
 
  
Ultibro (Indacterol/glycopyronium 
bromide) inh od 
  
Combivent (ipratropium 
bromide/salbutamol) nebs inh qds 
  
Denosumab 120mg sc 4 weekly 
 
  
Movicol (macrogol) 1 bd 
 
  
Fresubin 5kcal od 
 
  
Fresubin 2kcal od 
 
  
Quinine sulphate 300mg po od   
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Case 11 
Does the patient meet the criteria for STOPPFrail to be applicable? 
Criteria to meet: 
End stage irreversible pathology  
Poor one year survival prognosis  
Severe functional impairment OR severe cognitive impairment OR both  
Symptom control is the priority rather than prevention of disease progression  
 
Yes  No  
 
If yes, review the drug list and assess STOPPFrail criteria 
Drug Tick if this drug meets any 
STOPPFrail criteria AND you 
would stop it. 
List STOPPFrail indicators 
relevant to this drug 
Escitalopram 10mg po od  
 
  
Ramipril 10mg po od 
 
  
Apixaban 5mg po bd 
 
  
Atorvastatin 10mg po od 
 
  
Doxazosin 4mg po od 
 
  
Lansoprazole 30mg po od 
 
  
Quetiapine 25mg po nocte  
 
  
Centrum multivitamin po od 
 
  
 
 
Case 12 
Does the patient meet the criteria for STOPPFrail to be applicable? 
Criteria to meet: 
End stage irreversible pathology  
Poor one year survival prognosis  
Severe functional impairment OR severe cognitive impairment OR both  
Symptom control is the priority rather than prevention of disease progression  
 
Yes  No  
 
If yes, review the drug list and assess STOPPFrail criteria 
Drug Tick if this drug meets any 
STOPPFrail criteria AND you 
would stop it. 
List STOPPFrail indicators 
relevant to this drug 
Calvopen (penicillin V) 500mg po 
bd 
 
  
Paracetamol 1g po tds 
 
  
Diclofenac 50mg po bd 
 
  
Lactulose 10ml po tds 
 
  
Senna two tablets od 
 
  
Levothyroxine 75mcg po od 
 
  
Combivent (ipratropium 
bromide/salbutamol) nebuliser 
qds 
 
  
Betahistidine 16mg po tds 
 
  
Folic acid 5mg po od 
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Case 13 
Does the patient meet the criteria for STOPPFrail to be applicable? 
Criteria to meet: 
End stage irreversible pathology  
Poor one year survival prognosis  
Severe functional impairment OR severe cognitive impairment OR both  
Symptom control is the priority rather than prevention of disease progression  
 
Yes  No  
 
If yes, review the drug list and assess STOPPFrail criteria 
Drug Tick if this drug meets any 
STOPPFrail criteria AND you 
would stop it. 
List STOPPFrail indicators 
relevant to this drug 
Aspirin 75mg po od 
 
  
Bisoprolol 2.5mg po od 
 
  
Alendronate 70mg po once a 
week 
 
  
Paracetamol 1g po tds 
 
  
Calcium carbonate 400mg po 
bd 
 
  
Cholecalciferol 400IU po bd 
 
  
Diclofenac 75mg as required 
 
  
 
 
 
 
Case 14 
Does the patient meet the criteria for STOPPFrail to be applicable? 
Criteria to meet: 
End stage irreversible pathology  
Poor one year survival prognosis  
Severe functional impairment OR severe cognitive impairment OR both  
Symptom control is the priority rather than prevention of disease progression  
 
Yes  No  
 
If yes, review the drug list and assess STOPPFrail criteria 
Drug Tick if this drug meets any 
STOPPFrail criteria AND you 
would stop it. 
List STOPPFrail indicators 
relevant to this drug 
Prednisolone 5mg po od  
 
  
Paracetamol 1g po tds 
 
  
Metformin 500mg po tds 
 
  
Gliclazide 60mg po od 
 
  
Valsartan 80mg po od 
 
  
Solifenacin 5mg po od 
 
  
Esomeprazole 20mg po od 
 
  
Movicol (macrogol) one sachet 
bd 
 
  
Fortisip one carton od 
 
  
Centrum multivitamin od 
 
  
Denosumab 60mg sc 6 monthly 
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Case 15 
Does the patient meet the criteria for STOPPFrail to be applicable? 
Criteria to meet: 
End stage irreversible pathology  
Poor one year survival prognosis  
Severe functional impairment OR severe cognitive impairment OR both  
Symptom control is the priority rather than prevention of disease progression  
 
Yes  No  
 
If yes, review the drug list and assess STOPPFrail criteria 
Drug Tick if this drug meets any 
STOPPFrail criteria AND you 
would stop it. 
List STOPPFrail indicators 
relevant to this drug 
Donepezil 10mg po od 
 
  
Memantine 20mg po od 
 
  
Tamsulosin 400mcg po od 
 
  
Trimethoprim 100mg po od 
 
  
Fortisip one carton od 
 
  
 
 
 
 
Case 16 
Does the patient meet the criteria for STOPPFrail to be applicable? 
Criteria to meet: 
End stage irreversible pathology  
Poor one year survival prognosis  
Severe functional impairment OR severe cognitive impairment OR both  
Symptom control is the priority rather than prevention of disease progression  
 
Yes  No  
 
If yes, review the drug list and assess STOPPFrail criteria 
Drug Tick if this drug meets any 
STOPPFrail criteria AND you 
would stop it. 
List STOPPFrail indicators 
relevant to this drug 
Cepcitabine 500mg po tds 
 
  
Tinzaparin 10000IU sc od 
 
  
Levothyroxine 25mcg po od 
 
  
Escitalopram 10mg po od 
 
  
Senna two tablets nocte 
 
  
Atorvastatin 10mg po od 
 
  
Trimethoprim 100mg po od 
 
  
Lansoprazole 15mg po od 
 
  
Fortisip one carton po od 
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Case 17 
Does the patient meet the criteria for STOPPFrail to be applicable? 
Criteria to meet: 
End stage irreversible pathology  
Poor one year survival prognosis  
Severe functional impairment OR severe cognitive impairment OR both  
Symptom control is the priority rather than prevention of disease progression  
 
Yes  No  
 
If yes, review the drug list and assess STOPPFrail criteria 
Drug Tick if this drug meets any 
STOPPFrail criteria AND you 
would stop it. 
List STOPPFrail indicators 
relevant to this drug 
Lansoprazole 15mg po od 
 
  
Amlodipine 10mg po od 
 
  
Rosuvastatin 10mg po od  
 
  
 
 
 
 
Case 18 
Does the patient meet the criteria for STOPPFrail to be applicable? 
Criteria to meet: 
End stage irreversible pathology  
Poor one year survival prognosis  
Severe functional impairment OR severe cognitive impairment OR both  
Symptom control is the priority rather than prevention of disease progression  
 
Yes  No  
 
If yes, review the drug list and assess STOPPFrail criteria 
Drug Tick if this drug meets any 
STOPPFrail criteria AND you 
would stop it. 
List STOPPFrail indicators 
relevant to this drug 
Montelukast 10mg po od 
 
  
Seretide (fluticasone/salmeterol) 
inh bd 
 
  
Ventolin (salbutamol) inh prn 
 
  
Aspirin 75mg po od 
 
  
Dutasteride 0.5mg po od 
 
  
Tamsulosin 0.4mg po od 
 
  
Rosuvastatin 10mg po od 
 
  
Esomeprazole 20mg po od 
 
  
Escitalopram 10mg po od 
 
  
Fresubin 2Kcal od 
 
  
Fresubin 5kcal od 
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Case 19 
Does the patient meet the criteria for STOPPFrail to be applicable? 
Criteria to meet: 
End stage irreversible pathology  
Poor one year survival prognosis  
Severe functional impairment OR severe cognitive impairment OR both  
Symptom control is the priority rather than prevention of disease progression  
 
Yes  No  
 
If yes, review the drug list and assess STOPPFrail criteria 
Drug Tick if this drug meets any 
STOPPFrail criteria AND you 
would stop it. 
List STOPPFrail indicators 
relevant to this drug 
Rivastigmine patch 9.5mg 
transdermal over 24 hours  
 
  
Calcium carbonate 400mg po 
bd 
 
  
Cholecalciferol 400IU po bd  
 
  
Evista (raloxifene) 60mg po od 
 
  
Rosuvastatin 10mg po od  
 
  
Fortisip compact one carton po 
od  
 
  
Quetiapine 50mg po od  
 
  
 
 
 
Case 20 
Does the patient meet the criteria for STOPPFrail to be applicable? 
Criteria to meet: 
End stage irreversible pathology  
Poor one year survival prognosis  
Severe functional impairment OR severe cognitive impairment OR both  
Symptom control is the priority rather than prevention of disease progression  
 
Yes  No  
 
If yes, review the drug list and assess STOPPFrail criteria 
Drug Tick if this drug meets any 
STOPPFrail criteria AND you 
would stop it. 
List STOPPFrail indicators 
relevant to this drug 
Aspirin 75mg po od 
 
  
Atorvastatin 10mg po od 
 
  
Perindopril 10mg po od 
 
  
Eplerenone 25mg po od 
 
  
Lansoprazole 30mg po od 
 
  
Paracetamol 1g po tds 
 
  
Buprenorphine patch 10mcg/hr 
 
  
Risedronate 35mg per week 
 
  
Calcium carbonate 400mg po bd  
 
  
Cholecalciferol 400IU po bd  
 
  
Sinemet (Levodopa/carbidopa) 
125mg bd 
  
Flurazepam 30mg po nocte   
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Appendix 14 - Common Summary Assessment Report (CSAR) 
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Appendix 15 - Montreal Cognitive Assessment (MoCA) 
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Appendix 16 - Ethical approval for STOPPFrail observational study 
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